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Abstract 
 
The immune system plays a crucial role in providing the first line of defence 
against invading pathogens such as bacteria, viruses and parasites. It is activated 
when immune cells known as dendritic cells (DCs) detect specific molecules that 
are foreign to the host, and present them to T cells. This in turn causes the 
activation of T cells, which marks the start of an immune response leading to the 
clearance of the invader. The pathogen-derived molecules recognised by the 
immune cells are typically peptides and their role as activators of the immune 
system is well established. While T cells were originally thought to only recognise 
peptide antigens, it is now evident that T cells are also able to recognise non-
peptide antigens. Recognition of non-peptide antigens confers protection against 
pathogens that have cell surfaces that are highly functionalised with carbohydrate 
moieties, such as glycolipids, glycopeptides and polysaccharides.  
 
Specifically, glycosphingolipids (GSLs) can activate invariant Natural Killer T 
(iNKT) cells via their T cell receptor (TCR) when presented by the CD1d 
molecule found on the surface of DCs. α-Galactosylceramide (α-GalCer 1, Figure 
1), a synthetic analogue of a GSL extracted from the marine sponge Agelas 
mauritianus, was discovered to be a potent stimulator of iNKT cells when 
presented by CD1d. 
 
Figure 1. α-GalCer and fluorescent probes. 
 
α-GalCer is currently being used in clinical trials as an adjuvant to boost the 
activation of immune cells during cancer immunotherapy. Although the molecular 
interaction of α-GalCer with CD1d and iNKT cells is well established, it is not 
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fully understood how the glycolipid interacts with different subsets of DCs. 
Greater understanding of the fate of the glycolipid during cancer immunotherapy 
will provide crucial information on how the current therapy can be improved.  
 
In this thesis, the design and synthesis of two fluorescent α-GalCer probes, 
dansyl-α-GalCer (2, Figure 1) and BODIPY-α-GalCer (3, Figure 1) is reported. 
Dansyl-α-GalCer was able to activate DCs and iNKT cells in a similar fashion to 
the parent glycolipid α-GalCer. Its activity was CD1d-dependent and DCs that 
have taken up α-GalCer in vitro can be detected by flow cytometry. 
Unfortunately, the fluorescence of dansyl-α-GalCer was too weak to be detected 
by fluorescent microscopy due to photobleaching of the dye. Accordingly, another 
α-GalCer probe bearing a brighter fluorescent group, BODIPY, was synthesised. 
The α-GalCer probes were made via two synthetic strategies and the benefits and 
shortcomings of each synthetic route are discussed.  
 
Isoglobotrihexosylceramide (4, iGb3, Figure 2) is another GSL known to activate 
iNKT cells. Like α-GalCer, it is presented by DCs in the context of a CD1d 
molecule. iGb3 contains a sphingosine lipid backbone β-linked to a trisaccharide 
head group, which is in contrast to the α-linked phytosphingosine lipid found on 
α-GalCer. Despite the structural difference, iGb3 can stimulate iNKT cells, 
though to a lesser extent than α-GalCer. The intriguing activity of iGb3 provides a 
platform to further investigate the molecular interactions between CD1d, 
glycolipid and TCR of iNKT cell.  
 
The crystal structure of iGb3 in complex with mouse CD1d and TCR of mouse 
iNKT cell show compelling evidence that the terminal galactose moiety is crucial 
for the observed activity and this is attributed to the hydrogen bond between the 
6´´´-OH and Thr159 on the CD1d. To unambiguously determine the importance 
of the hydrogen bond conferred by 6´´´-OH, 6´´´-deoxy-iGb3-sphingosine (5, 
Figure 2) was synthesised. 6´´´-deoxy-iGb3-sphinganine 6 was also synthesised to 
study the role of the double bond on the sphingosine backbone. A novel synthetic 
route for the synthesis of iGb3 analogues was established. This allowed for the 
expedient synthesis of 6´´´-deoxy-iGb3 derivatives that will subsequently be 
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crystallised with CD1d and TCR of iNKT cell, to provide further insight into the 
structural requirements of β-linked GSLs.  
 
Figure 2. iGb3 and 6´´´-deoxy-iGb3 derivatives. 
 
Studies have also revealed that the length and saturation of the N-acyl chain of 
GSLs greatly influences their activity. It is speculated that varying the length of 
the acyl chain affects the processing and loading of the glycolipid onto CD1d and 
also TCR binding affinity.  To this end, the syntheses of a series of acyl chain 
analogues of iGb3, including the shorter chain homologue C12:0 7 (Figure 3) and 
the unsaturated C20:2 derivative 8 are reported. A divergent synthetic route was 
employed, whereby a common intermediate from the synthesis of 6´´´-deoxy-
iGb3 was used. This allowed for efficient syntheses of the acyl chain analogues 
that will facilitate a greater understanding of the structure-activity relationships. 
 
Figure 3. Acyl chain analogues of iGb3. 
 
Taken together, the GSLs synthesised provide crucial insight into how they 
modulate the immune system and will guide future optimisation of cancer 
immunotherapy regimes.  
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Chapter 1.  Introduction 
 
The term cancer refers to a family of diseases characterised by the uncontrolled 
growth and spread of abnormal cells. Cancer can be caused by inherited genetic 
factors or environmental (external) factors and it remains a leading cause of death 
worldwide, claiming 7.6 million lives in 2008.1 In New Zealand, approximately 
21,000 people were diagnosed with cancer in 2010.2 Treatment of cancer by 
surgical removal of the tumour can be traced back to ancient Egyptian times 
(1600 BC), as documented in the Edwin Smith Papyrus,3,4 while radiation therapy 
came into practice after the discovery of X-rays for medical diagnostics in  
1896.5-7 In the 20th century, the need to treat World War I soldiers suffering from 
hematologic malignancies caused by nitrogen mustard gases prompted the 
development of chemical agents to treat cancer – a treatment referred to as 
chemotherapy.8 To this day, surgery, radiotherapy and chemotherapy continue to 
play a major role in the treatment of cancer, however, such practices often fail to 
induce complete tumour remission and are associated with unpleasant side effects.  
 
1.1 Tumour immunology 
 
The immune system plays a key role in homeostasis in the body. It responds in a 
regulated fashion to pathogens, but is trained not to react against self-tissues, a 
phenomenon known as self-tolerance.9 In the 1950s, the scientific community 
generally accepted the theory that lymphocytes that are responsive to self-tissue 
were deleted in prenatal life during the development of the immune system.10 
While self-tolerance is beneficial in the prevention of autoimmune diseases such 
as cystic fibrosis and rheumatoid arthritis, tumours often use this mechanism to 
evade immune recognition, which results in a weak natural protection against 
malignant tumours. In the 1960s, however, it was recognised that tumours, though 
being self-derived, contain tumour-associated antigens (TAAs), which the body’s 
lymphocytes can detect – a concept called immunosurveillance.11 
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The importance of immunosurveillance in maintaining the health of an individual 
can be illustrated in many ways. For example, renal transplant patients receiving 
immunosuppressive treatment to prevent transplant rejection face a greater risk of 
developing skin cancer when exposed to UV rays from the sun.12 Also, the ability 
of the immune system to recognise specific TAAs is demonstrated by the ability 
of mice, which upon treatment of the first tumour challenge, were able to reject a 
second tumour challenge with the same tumour.13-16 Moreover, malignant tumours 
that are highly genetically unstable often generate a vast number of TAAs, which 
have not been seen by the host.17,18 This provides a range of candidate antigens for 
immune recognition. Nonetheless, due to the dynamic ability of cancerous cells to 
mutate and evade immunological checkpoints, the body’s natural immune 
response is rarely robust enough to fight against aggressive tumours.19  
 
1.2 Antigen presentation of tumour-associated peptides 
 
Antigen presenting cells (APCs) patrol the body in the blood circulation and play 
a crucial role in sending signals to other immune cells upon encountering an 
antigen, thereby activating the immune system. There are two classes of APCs; 
professional and non-professional APCs, which are both capable of presenting 
peptide antigens. Professional APCs are very efficient at internalising antigens 
and displaying them on their cell surface. Dendritic cells (DCs) are an example of 
professional APCs and these specialised cells are distinct from non-professional 
APCs because they are capable of activating the immune cells that they present 
the antigen to.20 
 
When an immature DC encounters an antigen, it matures and migrates to a nearby 
lymph node (Figure 1.1). At the lymph node, the DC cross presents the peptide 
antigen on a cell surface receptor, known as Major Histocompatibility Complex I 
(MHC I), to naïve T cells.21,22 These naïve T cells express T cell receptors (TCRs) 
on their cell surface and can recognise the peptide presented by MHC I. The 
interaction between TCR with MHC I and peptide antigen is highly specific and 
marks the initiation of an immune response, whereby naïve T cells become 
activated to produce the cytokine IL-2, causing them to proliferate and 
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differentiate into mature, effector T cells. In addition to the formation of the TCR-
MHC I-peptide trimer, the interaction of co-stimulatory molecules on DCs and 
naïve T cells are also necessary for the maturation of T cells.23,24 The effector T 
cells then migrate from the lymph node to the site of infection and respond by 
eliminating the infection or by releasing other soluble mediators to recruit other 
immune cells. Different classes of T cells play distinct roles in the immune system 
and are often characterised by the expression of cell surface markers. CD8+ T 
cells, also known as cytotoxic T lymphocytes (CTLs), express the cluster of 
differentiation (CD) 8 protein on their surface and represent an important subset 
of T cells because they are capable of directly killing pathogens or tumour cells. 
The induction of CTLs is thus desired in cancer immunotherapy as CTLs are 
highly effective at killing tumour cells by releasing cytotoxic proteins such as 
perforin and granzymes.25  
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1.3 Cancer immunotherapy 
 
Cancer immunotherapy is a promising new type of anti-cancer treatment that 
employs a patient’s own immune system to fight cancers. The strategy for 
immunotherapy is to improve the immune response to tumours with the ultimate 
goal being the induction of a tumour-specific immune response. Although 
William B. Coley pioneered cancer immunotherapy more than 100 years ago by 
giving cancer patients bacterial infections to invoke their immune system,26 this 
method of treatment was subsequently abandoned because his results were not 
reproducible and other treatments for cancer became more mainstream. 
Nonetheless, in the mid-1980s a resurrection of cancer immunotherapy began. 
Since then, a greater understanding of the immune system aided by advances in 
technology has led to a boost in confidence, and the potential of cancer 
immunotherapy has become more widely accepted in the scientific and clinical 
community. The ability of the immune system to react in a very specific manner, 
hence with minimal side effects, makes it a promising treatment for malignant 
diseases. Moreover, the immune system is able to generate long-lasting tumour 
immunity when activated appropriately. 
 
Cancer vaccines can be broadly classified into two types: 
1. Prophylactic (preventive) vaccine: which prevents the onset of cancer in 
healthy people. 
2. Therapeutic vaccine: which treats existing cancers by enhancing immune 
responses in patients. 
In light of the successful immunisation against diseases such as polio and 
smallpox, many researchers are attempting to replicate similar immunisation 
strategies for malignant diseases. This led to the birth of prophylactic cancer 
vaccines effective against the hepatitis B virus (HBV) and the human papilloma 
virus (HPV), which are the causative agents for liver and cervical cancers, 
respectively.27-30 Though it would be ideal to develop prophylactic vaccines 
against all cancers, at present, this is unfeasible because of the vast number of 
rapidly mutating cancers. 
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In addition to preventive vaccinations, various immunotherapy regimes have been 
developed to prime and boost a patient’s immune system so that it can attack 
existing malignant tumours. Some therapeutic vaccination strategies currently 
under investigation include DNA vaccination, monoclonal antibody treatment, 
adoptive cellular therapy, peptide-based immunotherapy and of particular interest 
to us, dendritic cell (DC)-based vaccination.31-43 These are summarised in Table 
1.1. 
 
Table 1.1. Therapeutic vaccinations currently under investigation. 
Vaccination Description 
DNA vaccine Naked DNA that encodes for a tumour antigen (protein) is 
injected intramuscularly or intradermally into a cancer 
patient. Cells in the body temporarily absorb the DNA 
vaccine and produce the protein of interest. This leads to the 
priming of the immune response against the target 
protein.31-33 
Monoclonal 
antibody treatment 
 
A passive immunotherapy regime that involves the 
administration of an antibody that specifically targets 
molecules that are either tumour cell surface markers (e.g. 
CTLA-4 or PD-1) or are directly responsible for tumour 
growth (e.g. endothelial growth factor receptor).34-36 
Adoptive cellular 
therapy 
 
T lymphocytes or tumour-infiltrating lymphocytes are 
harvested from a patient, expanded in vitro with tumour 
antigens and cytokines and readministered to the patient. 
These effector T cells attack tumour cells in the patient.37,38 
Peptide-based 
immunotherapy 
 
Tumour-specific peptide fragments of defined sequence are 
administered to the patient. The immune system mounts a 
response against the peptide vaccine.39-41  
Dendritic cell-
based vaccination 
 
Dendritic cells (DCs) are harvested from the patient, pulsed 
(ie. incubated) with tumour antigens and sometimes 
adjuvants and reinjected into the patient. This effectively 
teaches the DCs to recognise the tumour (Section 1.4).42,43 
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In April 2010, the US Food and Drug Administration (FDA) approved the first 
anti-cancer therapy vaccine, which is a DC-based cancer immunotherapy 
(Provenge) against prostate cancer.44 Shortly after this, a monoclonal antibody 
was developed against a receptor found on the surface of T cells, known as the 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) that is responsible for 
immunosuppression.35,45 Treatment of metastatic melanoma with the anti-CTLA-4 
is highly promising and was approved by the US FDA in 2011, under the name 
ipilimumab. In addition, there are other immunotherapies in the pipeline, such as 
anti-programmed death (PD)-1, which block the molecules expressed on dying T 
cells known as PD-1 and it is currently being tested in clinical trials.36,46-48 Taken 
as a whole, the recent breakthroughs in cancer immunotherapy will pave the way 
for the release of many other immunotherapies into the market in the future.  
 
1.4 DC-based cancer immunotherapy 
 
In a typical DC-based immunotherapy programme, tumour cells are extracted 
from a patient and apoptosis (programmed cell death) is induced (Figure 1.2A). 
As previously discussed, tumour cells aberrantly express proteins which can serve 
as antigens for a T cell mediated anti-tumour immune response.20 At the same 
time, white blood cells containing precursors (peripheral blood mononuclear cells) 
to DCs are obtained from the same patient via a process called leukapheresis. The 
DC precursors are incubated in vitro with tumour cells that have undergone 
apoptosis and a cocktail of activation factors, which leads to DC maturation. The 
primed DCs are then reinjected into the patient to generate a systemic anti-tumour 
response. 
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Figure 1.2. A. Original DC-based immunotherapy regime. B. Improved regime 
incorporating a glycolipid adjuvant. 
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One may ask why the favourable anti-tumour immune response is not generated 
spontaneously in vivo considering that both DCs and tumour antigens are present 
in the body. It has been shown that most DC precursors found in or near 
malignant tissues are poor antigen presenters because they fail to be activated, 
possibly due to the immunosuppressive environment of the tumour.49,50 However, 
if the DC precursors are activated under in vitro culture conditions, they express 
vital co-stimulatory molecules (e.g. CD40, CD80 and CD86) and acquire the 
capacity to present antigens and activate naïve T cells.  
 
Though tumour regression has been observed in a number of patients treated by 
this DC-based immunotherapy regime, the immune response generated can be 
further improved.51 It has been found that the addition of certain glycolipids, 
acting as adjuvants, boosts the immune response to elicit enhanced anti-tumour 
activity.51 Accordingly, an improved DC-based vaccination regime has been 
developed which involves the isolation of tumour cells and immune cells from the 
patient, apoptosis of the tumour cells by radiation, combination of the cells with a 
glycolipid adjuvant and reinjection of this mixture into the patient (Figure 1.2B). 
This leads to the stimulation of an enhanced tumour-specific response.  
 
The original DC vaccination strategy, whereby DCs pulsed with peptide in vitro 
are reinjected into the patient, has been proven to generate a positive outcome in 
melanoma patients.52 The use of glycolipids in cancer immunotherapy has reached 
clinical trials but the glycolipid adjuvant has only ever been administered on its 
own,53 or administered after it was pre-loaded onto DCs.54-58 The improved 
protocol which incorporates the priming of DCs with both the peptide as well as 
the glycolipid adjuvant has yet to be tested in a clinical setting.  
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1.5 DC-based vaccination at the molecular level 
1.5.1 Overview 
 
An explanation of the cancer immunotherapy protocol at the molecular level is 
given in Figure 1.3. Here the peptide antigen from the apoptosised tumour cell is 
presented on the MHC I molecule of the DC (as discussed in Section 1.2) and the 
presented antigen is then recognised by cytotoxic T lymphocytes (CTLs), which 
become activated to release soluble mediators that directly target the tumour, or 
trigger a cascade of immune activation leading to an anti-tumour response.59 This 
anti-tumour immune response can be modulated by the addition of a glycolipid 
adjuvant (for a comprehensive review see Wu et. al.).60 The glycolipid adjuvant is 
also presented on the surface of the DC, this time via another protein called CD1d. 
The CD1d-glycolipid complex in turn is detected by invariant natural killer T 
(iNKT) cells, a subset of T cells that play a crucial role in regulating immune 
responses.60-65 Upon stimulation, iNKT cells release cytokines that can promote 
either a favourable or unfavourable anti-tumour immune response, generally 
termed as T helper (Th) 1 or Th2 response, respectively.66 The ‘Th1’ response is 
characterised by the release of proinflammatory cytokines, such as interferon 
(IFN)-γ and interleukin (IL)-12, which promote CTL and natural killer (NK) cell 
activation and therefore enhance the anti-tumour response. The ‘Th2’ response is 
immunomodulatory and produces cytokines such as IL-4, which are vital to 
prevent autoimmune diseases such as type-I diabetes and multiple sclerosis. 
However, activation of the Th2 response also leads to suppression of T cell 
mediated anti-tumour immunity. Hence, in developing adjuvants for anti-cancer 
immunotherapy, a glycolipid that is capable of selectively inducing a ‘Th1’ 
response is desired.  
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1.5.2 α-Galactosyl ceramide – A potent glycosphingolipid adjuvant 
 
In 1993, the pharmaceutical division of Kirin Breweries isolated a series of novel 
α-galactosyl ceramides from the marine sponge Agelas mauritianus.67,68 Of these 
glycosphingolipids, agelasphin-9b (AGL-9b, 9, Figure 1.4), exhibited potent anti-
tumour activity in in vivo models of several murine tumour cells and later served 
as the parent compound for subsequent analogue syntheses and structure-activity 
studies.69 The term “glycosphingolipid” refers to a class of glycolipids that 
contain the sphingoid base. AGL-9b is a glycosphingolipid that consists of a 
galactosyl moiety α-linked to a ceramide portion that is made up of an N-acylated 
phytosphingosine backbone. During the course of this structure-activity work, 
KRN7000 (1) was found to have similar anti-tumour activity to 9 and, due to its 
easier synthesis, was deemed the more suitable candidate for clinical use. The 
abolishment of both the terminal methyl group on the phytosphingosine backbone 
and the hydroxyl group on the α-position of the acyl chain did not affect the anti-
tumour activity of the glycolipid.  Since then, KRN7000, now widely known as α-
galactosyl ceramide (α-GalCer), has been reported to have potential in the 
treatment of several diseases including cancer, malaria, type-I diabetes, and 
multiple sclerosis. It has been found to exert its therapeutic activity via its ability 
to bind to CD1d and activate iNKT cells.70,71 This discovery was remarkable and 
provided the first evidence that glycolipids, like their protein counterparts, can be 
presented by APCs and recognised by T cells to invoke an immune response. The 
potential for α-GalCer to treat various diseases lies in its potent ability to 
stimulate iNKT cells, which subsequently activates the Th1 and the Th2 response. 
Given the therapeutic potential of α-GalCer, much effort has been spent in 
identifying other ligands that bind to CD1d and activate iNKT cells.60,69,72-80 
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Figure 1.4. Agelasphin 9b 9 and α-GalCer 1. 
 
1.5.3 CD1d  
 
The CD1d protein is a member of a family of transmembrane glycoproteins 
consisting of a heavy chain with three extracellular domains (α1, α2 and α3) non-
covalently linked to a β2-microglobulin (β2m) chain.81 The non-polar amino acids 
in the α1 and α2 chains form two hydrophobic pockets, A´ and F´ that can 
accommodate the long lipid tails of a glycolipid, leaving the sugar head group 
exposed as depicted in Figure 1.5A. The protruding carbohydrate portion is then 
recognised by iNKT cells, via their TCR. The trimolecular interaction between the 
CD1d, α-GalCer and TCR initiates a cascade of intracellular and extracellular 
signalling that results in the activation of iNKT cells. The precise molecular 
interaction of CD1d with glycolipid was elucidated when Rossjohn and co-
workers crystallised a human iNKT cell TCR (blue and yellow) in complex with 
human CD1d (green) loaded with α-GalCer (pink) (Figure 1.5B).82 In addition, 
crystal structures of mouse and human CD1d reveal that this protein is conserved 
across these two species (Figure 1.5C), whereby the human CD1d is shown in 
grey and the mouse CD1d in green.83 
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Given this similarity, it is generally accepted that the murine model is suitable 
when studying the potency of various analogues of α-GalCer, however, 
considering the subtle, but non-negligible variation in DC subsets between mice 
and humans,84 care should be taken, and these glycosphingolipids should always 
be cross-tested against both species. The varying glycosphingolipid activities of 
triglycosyl ceramides such as isoglobotrihexosylceramide (iGb3) are attributed to 
the difference in CD1d structure between mice and humans.85 In contrast, 
differences in activities observed for glycosphingolipids that possess one sugar 
head group (i.e. α-GalCer analogues) have been traced back to the variation in the 
TCR structure rather than the CD1d molecule.86-88  
  
 
 
Figure 1.5. A. Representation of CD1d–glycolipid–TCR interaction during 
glycolipid presentation. B. Crystal structure of human NKT TCR (blue and 
yellow) interacting with CD1d (green)-glycolipid (pink) complex.82 (Adapted by 
permission from Macmillan Publishers Ltd: Nature Immunology, 2007, 448, 44-
49, ©2007) C. Structural comparison of human (grey) and mouse (green) CD1d 
with α-GalCer bound (orange).83 (Adapted by permission from Macmillan 
Publishers Ltd: Nature Immunology, 2005, 6, 819-826, ©2005) 
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1.5.4 iNKT cells 
 
iNKT cells represent less than 1% of the total T cell population in humans and are 
a heterogeneous population of cells that express an invariant TCR and the natural 
killer (NK) 1.1 marker on the cell surface.61,63 They are commonly found in the 
thymus, spleen, liver and bone marrow.89 Unlike CD4+ and CD8+ T cells, which 
recognise peptide antigens, iNKT cells are restricted by the CD1d molecule and 
can only recognise glycolipids presented by CD1d. iNKT cells play an important 
role in bridging innate and adaptive immunity,89 for they not only have a key role 
in the activation of the immediate innate immune response, but also affect the 
subsequent, longer-lasting, adaptive immunity involving B and T cells.90-92 It is 
this unique characteristic that makes iNKT cells such a potent cell type with great 
potential in cancer immunotherapy. Of note, structure activity relationship studies 
and crystal structure analyses, have revealed that subtle differences exist between 
the TCR structures of humans and mice and can sometimes lead to species-
selective activity of glycolipids.86-88  
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1.6 Fluorescent α-GalCer probes to study cellular uptake 
and trafficking 
 
A comprehensive understanding of the effect of the glycosphingolipids on the 
immune system is crucial for the development of an effective DC-based cancer 
immunotherapy utilitising α-GalCer or analogues thereof. The study of these 
glycosphingolipids in terms of their ability to be presented by CD1d molecules on 
DCs and to iNKT cells to produce specific cytokine profiles is important to 
provide information on how the structures of the glycosphingolipids can be 
altered to improve immune responses. In addition, it is important to understand 
the pharmacokinetics of glycosphingolipid adjuvants once they are administered 
as part of a cancer immunotherapy regime.  
 
Within the human body, there are different subsets of DCs, residing in different 
compartments in vivo that play specific and sometimes overlapping roles in the 
immune system.93,94 Studies have shown that targeting of α-GalCer adjuvants to 
these specific subsets of DCs (such as the CD8α+ DCs) can lead to enhanced anti-
tumour responses.95,96 One of the methods to identify and quantify subsets of DCs 
that have taken up glycolipids and are responsible for the observed immune 
activation is by using a fluorescently labelled antibody that binds to the CD1d-
glycolipid complex.97-101 Unfortunately, these monoclonal antibodies are only 
useful in systems where α-GalCer is bound to CD1d and are less applicable when 
trying to study glycolipid trafficking. Therefore, an alternative approach is to tag 
the glycolipid itself with a fluorophore to directly visualise the glycolipid and its 
interaction with different immune cells. As such, a number of α-GalCer-
derivatives containing a fluorophore102-104 or a biotinylated probe103,105,106 have 
been prepared. Though the ability of α-GalCer to bind to CD1d and activate 
iNKT cells has been robustly studied, scant information is available on inter- and 
intracellular lipid trafficking and how this influences CD1d presentation and 
iNKT cell activation.107 Many groups have thus focussed on derivatising the lipid 
portion of α-GalCer with a reporter probe in order to address such issues, as 
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illustrated by syntheses of biotin-labelled α-GalCer 10,105 BODIPY-labelled  
α-GalCer 11102 and 7-nitro-benz-2-oxa-1,3-diazol-(NBD)-functionalised α-
GalCer 12108 (Figure 1.6). 
 
 
Figure 1.6. Lipid derivatised α-GalCer. 
 
However, as CD1d binds lipid chains within deep hydrophobic pockets,109 it has 
been proposed that the addition of a label on the lipid may interfere with α-
GalCer-CD1d association,110 and moreover, may influence intracellular 
trafficking.107,111-113 Conversely, modelling of the CD1d-α-GalCer complex 
suggests that the hydroxyl groups at C-4´ and C-6´ on galactose are not involved 
in complex formation.114 This theory is also supported by the preparation of an α-
GalCer analogue containing an additional α-linked galactose at the C6´ position, 
which was shown to stimulate iNKT cells without the need for processing.115 
Taken as a whole, it is generally accepted that the CD1d-glycolipid-iNKT cell 
TCR interaction tolerates the appendage of small molecules at C6´ and that this is 
an ideal position to attach a fluorescent reporter group. Indeed, this was the 
conclusion made by Zhou et al. who developed a strategy for the preparation of 
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dansylated α-GalCer derivative 2 (Figure 1.7).103 As such, biotin-labelled  
α-GalCer 13103 and BODIPY-labelled α-GalCer 14104 were also synthesised, with 
extensive confocal microscopy studies being performed on the latter to understand 
the intracellular trafficking on this glycolipid between endosomal compartments 
within a cell. These findings illustrate the versatility of using α-GalCer 
derivatives with fluorophores attached on the 6´ position of the carbohydrate 
moiety. Therefore, attachment of small fluorescent groups at the 6´-position of α-
GalCer will provide useful probes to track and visualise these glycolipids in vitro 
and in vivo.  
 
 
Figure 1.7. 6´-labelled α-GalCer. 
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1.7 β-linked glycolipids 
 
In a general sense, the potent activity of exogenous glycolipids that stimulate the 
immune system requires an α-linkage between the sugar moiety and the lipid 
portion. For example, bacterial glycolipids such as α-glucosyldiacylglycerol from 
Streptococcus pneumoniae and α-glycuronosylceramides from Sphingomonas 
spp. have α-linkages and typically, β-analogues of immunoactive bacterial 
glycolipids have significantly lower stimulatory activity compared to their α-
linked couterparts.71,116-119 Indeed, the potent immunostimulatory activity 
attributed to α-GalCer is significantly reduced when the glycosidic linkage is 
converted to give β-GalCer. In spite of this, β-linked glycolipids represent an 
important class of glycolipids because mammalian cells produce β-linked rather 
than α-linked glycolipids.  
 
iNKT cells represent a potent subset of T cells in both the innate and adaptive 
immune response and accordingly, much effort has focused on understanding 
iNKT cell development. The development of iNKT cells occurs in the thymus, 
where a T cell with a TCR that can recognise CD1d bound to a self glycolipid is 
positively selected. Mice lacking in the CD1d molecule (CD1d knockout mice) do 
not have iNKT cells,63,120 while mice with impaired intracellular CD1d trafficking 
have abnormal iNKT cell development.121 Because all endogenous glycolipids in 
mammalian cells are β-linked, this class of glycolipids has been studied 
extensively to understand how they shape the iNKT cell repertoir. That said, the 
exact identity of the self β-glycolipid remains elusive and it is unclear as to 
whether one or more glycolipids are responsible for the positive iNKT cell 
selection in the thymus.61,62  
 
From a structural point of view, in a CD1d-glycolipid complex, the sugar 
headgroup of α-linked monoglycosyl ceramides wraps closely to the α2-helix of 
CD1d in a parallel orientation, whereas the sugar headgroup of β-linked 
monoglycosyl ceramides protrude from CD1d at an angle perpendicular to the α2-
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helix. For example, β-galactosylceramide (β-GalCer), β-glucosylceramide (β-
GlcCer) and isoglobotrihexosylceramide (iGb3) are implicated in the development 
and activity of iNKT cells.122 The ability of the TCR to accommodate this 
difference is a source of fascination for many structural immunologists and much 
research is still underway to accurately determine the extent of their influence on 
iNKT cell biology.  
 
1.7.1 Isoglobotrihexosylceramide  (iGb3) 
 
Isoglobotrihexosylceramide (iGb3, 4 Scheme 1.1) is a glycosphingolipid 
containing a trisaccharide headgroup attached to a sphingosine ceramide via a β-
linkage. The prospect of iGb3 acting as the self antigen responsible for iNKT cell 
development was first reported by Bendelac and co-workers in 2004. Upon 
observing that mice lacking in β-hexosaminidase B have severely reduced number 
of iNKT cells, they synthesised and tested iGb3 to assess if it was indeed the 
endogenous ligand important for iNKT cell development.123 β-Hexosaminidase B 
is the lysosomal enzyme responsible for cleaving terminal β-linked GalNAc 
residues from mammalian glycosphingolipids (GSLs) and one of the substrates, 
iGb4 (15) is converted to iGb3 (4) by this enzyme. While Bendelac and co-
workers did not directly purify and characterise iGb3 from mammalian tissues, 
they were able to show that synthetic iGb3 stimulates the expansion of human 
iNKT cells from peripheral blood mononuclear cells (PBMCs), and the cytokine 
levels (IFN-γ and IL-4) were comparable to that of α-GalCer.123 They suggested 
that iGb3 was the major self glycolipid responsible for the selection of iNKT cells 
in the thymus of mammalian cells.  
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Scheme 1.1. Biosynthetic pathway for iGb3. 
 
However, further studies by Speak et al. revealed that,  iGb3 could not be detected 
in the thymus or in dendritic cells of humans and mice despite an extensive 
assessment using a highly sensitive HPLC assay.124 In addition, mice lacking in 
iGb3 synthase, a key enzyme that makes iGb3 (4) from LacCer (16) did not show 
reduced iNKT cell numbers or function (Scheme 1.1).125 Moreover, it was 
proposed that iGb3 is unlikely to be the self ligand responsible for the 
development of human iNKT cells because humans do not express functional 
iGb3 synthase126 and instead it was suggested that the loss of iNKT cells in β-
hexasominidase B deficient mice was due to defective lysosomal function rather 
than the absence of iGb3.127 These studies, along with others,128 strongly argue 
against iGb3 being the major self glycolipid responsible for the expansion of 
iNKT cells.127 Nonetheless, the fact that both iGb3 and α-GalCer, which are 
structurally very distinct, are able to activate iNKT cells is interesting and points 
towards the unique nature of the iNKT cell TCR to recognise diverse glycolipid 
ligands presented by CD1d.  
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More recent findings by Brennan et al. revealed that β-glucosylceramide (β-
GlcCer, 17, Scheme 1.2) is an important self glycolipid whose expression is 
upregulated upon DC activation.129 During an infection, toll-like receptor (TLR)-
mediated activation of DCs leads to the upregulation of the enzyme 
glucosylceramide synthase that catalyses the synthesis of β-GlcCer (17) while the 
enzyme lactosylceramide synthase that converts β-GlcCer (17) to LacCer (16) is 
downregulated. The increased accumulation and presentation of β-GlcCer (17) by 
CD1d, in combination with the TLR-dependant production of cytokine IL-12, 
stimulates iNKT cells to produce IFN-γ. Brennan et al. also showed that the 
composition of the N-acyl lipid dictates the activity of β-GlcCer (17) and that the 
most abundant form found in mouse lymphoid organs is the C24:1 variant. This 
study, along with others thus illustrates that β-linked self glycolipids exert their 
effect not only during the development of iNKT cells, but that they are also 
responsible for iNKT cell activation during infection.101,130-134 The challenge 
remains to attribute the contribution of self β-linked glycolipids and foreign α-
linked glycolipids on the immunological profile during an infection. 
 
 
 
Scheme 1.2. Biosynthetic pathway for β-GlcCer (17). 
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1.7.2. Analogues of iGb3  
 
Several trisaccharide analogues of CD1d-binding iGb3 have been synthesised to 
probe the structural requirements of CD1d-binding β-linked glycosphingolipids. 
Modifications have been made to both the carbohydrate portion of the 
glycosphingolipid and to the lipid backbone. For example, Xia et al. synthesised 
two iGb3 analogues iGb3-phytosphingosine (18) and iGb3-sphinganine (19), each 
of which contain a modified ceramide backbone (Figure 1.8).135 In subsequent 
studies, they discovered that iGb3-phytosphingosine (18), which bears the same 
lipid backbone as α-GalCer, was better at stimulating iNKT cells compared to the 
parent iGb3 (4) which bears a sphingosine backbone. Drawing from existing 
crystal structure studies of α-GalCer with CD1d, the authors suggested that the  
4-OH in phytosphingosine is able to provide an additional H-bond with the F´ 
pocket of CD1d. However, it is important to note that this higher activity was only 
observed at low concentrations of the glycolipids (10 – 100 ng/mL). In addition, 
iGb3-sphinganine (19) also stimulated iNKT cells efficiently and it was 
rationalised that the absence of the E-alkene reduces the rigidity, of the lipid 
backbone, allowing for easier loading into the F´ pocket of CD1d.135  
 
Savage and co-workers have also synthesised analogues of iGb3 and Gb3 with an 
α-linkage between the proximal sugar and lipid portion, αiGb3 (20) and αGb3 
(21), and showed that akin to other monoglycosyl ceramides, the α-versions were 
able to activate iNKT cells more effectively than their β-counterparts.136  
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Figure 1.8. Analogues of iGb3.135,136 
 
Despite the studies by Xia et. al. and the earlier work by Bendelac and co-
workers,123,135 the ability of iGb3 to stimulate iNKT cells was still surprising as 
most known iNKT cell ligands were monoglycosyl ceramides. While it was 
already known that some diglycosyl ceramides, such as Gal(α1,2)-α-GalCer (22) 
(Figure 1.9) needed to be processed into the monoglycosyl version before iNKT 
cells can be stimulated.123 Here, the terminal galactose moiety of Gal(α1,2)-α-
GalCer (22) is hydrolysed by α-galactosidase A in the lysosomal compartment of 
APCs, to give α-GalCer, which is then loaded onto the CD1d and presented to an 
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iNKT cell. While iGb3 can be processed into smaller fragments such as β-LacCer 
(23) and β-GlcCer (24) and stimulate iNKT cells, iGb3 was found to be able to 
activate iNKT cells in the absence of processing.117,123,137 Interestingly, a 
regioisomer of iGb3 that is found in mammalian cells, globotrihexosyl ceramide 
(Gb3, 25), varying only in the α1,4 linkage of the terminal galactose, was not able 
to stimulate iNKT cells.123,138 This indicated that the linkage of the terminal sugar 
is crucial for the observed activity of iGb3.  
 
 
Figure 1.9. Analogues of iGb3. 
 
To probe the effect of the terminal galactose residue on the activity of iGb3, Chen 
et al. synthesised a series of dehydroxylated analogues of iGb3, whereby the 
hydroxyl groups on the terminal galactose were systematically removed to give 
2´´´-deoxy- (26), 3´´´-deoxy- (27), 4´´´-deoxy- (28) and 6´´´-deoxy-iGb3 (29) 
(Figure 1.10).139 Of note, a phytosphingosine backbone was incorporated instead 
of the sphingosine lipid found on the original iGb3, with the intention of creating 
glycolipids with more potent iNKT cell stimulatory property. Testing of this 
series of iGb3 analogues revealed that the removal of hydroxyl groups at the 4´´´- 
and 6´´´-position did not significantly hamper the ability to stimulate iNKT cells, 
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but the absence of the 2´´´-OH or 3´´´-OH reduced the agonist effect considerably. 
Thus, these studies further confirmed that the terminal sugar is critical for the 
activity of iGb3 and analogues thereof.  
 
  
 
Figure 1.10. Deoxy analogues of iGb3 with phytosphingosine backbones.139  
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1.8 Crystal structures of β-linked glycolipids 
 
Building from their seminal work in solving the crystal structure of α-GalCer 
bound to CD1d, Rossjohn and co-workers solved the crystal structure of a mouse 
iNKT cell TCR in complex with mCD1d-β-GalCer and showed that the TCR 
docked onto the CD1d-β-GalCer complex in a very similar manner to CD1d-α-
GalCer (Figure 1.11).138 It is well established that when the lipid portion of α-
GalCer is embedded within the hydrophobic cavity of CD1d, the sugar headgroup 
that is exposed lies flat (parallel) against the α2-helix of CD1d.82 One could 
anticipate that the sugar headgroup of β-GalCer protrudes out of the CD1d pocket 
so that it is perpendicular to the α2-helix, however, surprisingly, Rossjohn and co-
workers observed that when the iNKT TCR engages with the CD1d-β-GalCer 
complex, the protruding sugar headgroup is “bulldozed” so that it lies flat against 
the α2-helix of CD1d, and hence occupies the space in a manner more similar to 
α-GalCer.138 Of note, the hydrogen bond network between the β-linked galactose 
and the α2-helix of CD1d were analogous to the interactions found between 
CD1d and α-GalCer, and moreover, the interactions between the iNKT TCR and 
CD1d were also conserved. Taken together, these crystal structures provide a 
molecular explanation for the ability of structurally distinct β-linked glycolipids to 
maintain their function as iNKT cell agonists. Nonetheless, the iNKT TCR has a 
lower affinity for β-GalCer compared to α-GalCer, suggesting that an “energetic 
penalty” is imposed for “flattening” the β-linked glycolipid.138 
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Figure 1.11. Crystal structure of mCD1d and TCR of iNKT cell with α-GalCer 
(in green) and β-GalCer (in yellow).138 (Adapted by permission from Macmillan 
Publishers Ltd: Nature Immunology, 2011, 12, 827-833, ©2011)  
 
The crystal structures of β-linked monoglycosyl ceramides formed the foundation 
for further studies of β-linked glycolipids with more than one sugar headgroup. In 
2011, Yu et al. and Rossjohn and co-workers both reported the crystal structure of 
mouse iNKT cell TCR in complex with mCD1d-iGb3 and their results were in 
agreement.137,138 Both groups observed the flattening of the trisaccharide 
headgroup against the α2-helix of CD1d, similar to that observed for β-GalCer 
(Figure 1.12). The proximal glycosidic bond is “contorted” to resemble the α-like 
conformation, with the β-Glc itself forming interactions with both CD1d and the 
iNKT cell TCR. The middle β-Gal also establishes many contacts with CD1d, and 
has some contact with the TCR. The terminal α-Gal moiety, on the other hand, 
only interacts with the α2-helix of CD1d and not the TCR. Here, the terminal 
sugar is anchored by the hydrogen bond between the 6´´´-OH with Thr159 and the 
van der Waals interaction of 4´´´-OH and 6´´´-OH with Met162 of CD1d. In the 
absence of the terminal α-Gal moiety, as in β-LacCer (23), the agonist activity of 
the glycolipid is abolished. In addition, a structural isomer Gb3 (25), does not 
stimulate iNKT cells because the terminal sugar (α1,4-Gal) is oriented away from 
CD1d and does not form the interaction required to stabilise the trisaccharide 
headgroup. The loss of key interactions in the absence of the terminal α1,3-linked 
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galactose results in the compromised avidity of β-LacCer (23) and Gb3 (25). 
Therefore, the engagement of the terminal sugar of iGb3 with CD1d is the 
prerequisite for the formation of a stable glycolipid conformation, giving rise to 
the iNKT cell agonist effect.138 
 
 
Figure 1.12. Crystal structure of mCD1d and TCR of iNKT cell with iGb3.138 
(Adapted by permission from Macmillan Publishers Ltd: Nature Immunology, 
2011, 12, 827-833, ©2011)  
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1.9 The significance of understanding β-linked self 
glycolipids 
 
The ability of iNKT cells to act as potent immune cells both for the innate and the 
adaptive immune response has driven much research to focus on developing 
glycolipid ligands that can invoke their activation. Current knowledge about 
CD1d presentation of glycolipids to iNKT cells and the associated downstream 
effects is largely attributed to the exogenous glycolipid α-GalCer, however there 
is a growing appreciation of the ways in which β-linked self glycolipids modulate 
the immune response. Not only are β-linked self glycolipids responsible for the 
development of iNKT cells in the thymus,128,129 they also act as direct agonists 
during infection.101,131,133,134,140,141 Accordingly, the synergy of structure-activity-
relationship studies and crystal structure analyses will provide a fuller picture of 
how β-linked glycolipids exert their effect on the immune system, with the view 
that this will then allow for the rational design of β-glycolipids for the treatment 
of diseases such as infections, autoimmune diseases and cancer.   
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1.10 Synthetic strategies for iGb3 and related analogues 
 
The first synthesis of trihexosyl ceramides dates back to 1987, when Koike et al. 
synthesised the iGb3 with a C24 N-acyl lipid along with Gb3 also bearing the C24 
lipid (Scheme 1.3, n = 22).142 The key step in this synthetic route was the coupling 
of a trisaccharide donor with a trichloroacetimidate leaving group 31 and the 
ceramide acceptor 32. The trisaccharide donor 31 was in turn obtained by 
coupling galactose donor 34 with a suitably protected lactose acceptor 35. It is 
important to note that the protecting group used at the 2-OH (R1O-) of lactose 
must be one that is capable of participating during the final glycosidation with the 
lipid acceptor 32 to facilitate the formation of the β-anomer. Schmidt and co-
workers subsequently synthesised another iGb3 analogue with the N-palmitoyl 
(C16) lipid (n = 14) using a very similar strategy, except that the trisaccharide 
donor was coupled in a stepwise fashion, first to the sphingosine acceptor, 
followed by functionalisation with the C16 acyl lipid.143 It was not until 2006, two 
years after iGb3 bearing a hexacosanoyl (C26, n = 24) lipid was first reported to 
be an important endogenous glycolipid for iNKT cell biology, that a flurry of 
syntheses of the prototypical iGb3-C26 analogue 4 were reported.144,145 Since 
then, the synthesis of various other derivatives such as the C18 homologue,146 
thio-iGb3,147 6´´´-deoxy analogues 26-29,139 phytosphingosine 18 and 
sphinganine 19 derivatives135 and αiGb3 analogue 20139 have been published.  
Generally, the routes employed involve the coupling of a trisaccharide imidate 
donor with either a full ceramide lipid acceptor 32 or a 2-azido-sphingolipid 
acceptor 33. The alternative approach by first coupling the lactose donor to the 
ceramide backbone, followed by linkage of the terminal sugar has not been 
reported. While complete chemical synthesis of this glycolipid is the most 
common, some have also used enzymatic syntheses either to make the 
trisaccharide,145 or to furnish LacCer with the desired terminal galactose, in a 
highly stereospecific fashion.148  
 
 
 32 
 
Scheme 1.3. Strategies for the synthesis iGb3 and analogues.  
 33 
 
1.11 Thesis outline 
 
The research described in this thesis focuses on the synthesis of 
glycosphingolipids that can modulate the immune response, particularly in a 
cancer setting. To this end, the development of a variety of glycolipid probes 
which can be used as fluorescent tools to track the uptake and trafficking of  
α-GalCer will be discussed, as will the synthesis of iGb3 derivatives that can be 
used in structure-activity studies to better understand the effects of these 
glycosphingolipids on iNKT cell activation. A brief outline of each thesis chapter 
is given below. 
 
Chapter 2 describes the synthesis of the first α-GalCer fluorescent probe, 
Dansyl-α-GalCer 2 (Figure 1.13), which contains the dansyl fluorophore at the 6´-
position of α-GalCer. A new and highly efficient route for the synthesis of this 
probe is presented, and the ability of the probe to activate the immune response, as 
compared to the parent compound α-GalCer, is also discussed. Finally, the ability 
of the probe to act as a fluorescent tool to track the in vitro uptake of the 
glycolipids is also discussed. 
 
 
Figure 1.13. Fluorescent α-GalCer probes 
 
Chapter 3 then continues on with the development of fluorescent α-GalCer 
probes and discusses the synthesis of BODIPY-α-GalCer 3, which contains the 
BODIPY fluorophore at the 6´-position (Figure 1.13). A synthetic strategy, which 
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is different to that used for the synthesis of dansyl-α-GalCer, is presented and it is 
envisioned that the brighter BODIPY fluorophore will extend the range of 
biological experiments that can be undertaken using this probe. Finally, chapter 3 
also discusses some of the limitations of the BODIPY fluorophore, the steps that 
need to be taken to ensure that the BODIPY-α-GalCer 3 probe does not degrade, 
and initial studies into exploring the photo-reactivity of this fluorescent group. 
 
Chapter 4 describes the synthesis of the first series of iGb3 derivatives, namely 
the 6´´´-deoxy analogues with either the sphingosine 5 or sphinganine 6 lipid 
backbone (Figure 1.14). This is the first time that such 6´´´-deoxy homologues of 
iGb3 have been prepared and, in association with our collaborators, the 
subsequent biological evaluation and crystal structure studies using these 
substrates will allow for an assessment of the effect of the 6´´´-OH on the activity 
of iGb3, and also, how the lipid backbone effects glycolipid loading and iNKT 
cell activation. The route chosen for the synthesis of iGb3 sphingosine 5 or 
sphinganine 6 is highly efficient and moreover, allows for a convergent strategy 
that can be used to prepare not only sugar analogues, such as those discussed in 
this chapter, but also N-acyl chain derivatives. This is the first time that such a 
convergent route for the synthesis of iGb3 analogues will be described.  
 
 
 
Figure 1.14. Target 6´´´-deoxy-iGb3 analogues. 
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Chapter 5 describes the synthesis of two acyl chain homologues of iGb3. Key in 
the methodology is the use of a common intermediate presented in Chapter 4, 
which allows for the preparation of two N-acyl derivatives, namely the C12 7 and 
C20:2 8 homologues (Figure 1.15). The challenges and effectiveness of the 
synthetic route are presented, which can then be compared to the route used for 
the 6´´´-deoxy analogues. It is envisioned that the N-acyl analogues, when 
compared to iGb3 itself, will allow for the effect of lipid length and saturation on 
iNKT cell activation to be determined. 
 
 
 
Figure 1.15. Target acyl chain homologues of iGb3. 
 
Finally, Chapter 6 summarises the research performed in this thesis and 
highlights some future directions for each project area. 
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Chapter 2. The synthesis and biological evaluation 
of dansyl α-galactosylceramide as a fluorescent 
probe for the monitoring of glycolipid uptake by 
cells  
 
This chapter is an edited version of the following publication:  
Cheng, J. M. H.; Chee, S. H.; Knight, D. A.; Acha-Orbea, H.; Hermans, I. F.; 
Timmer, M. S. M.; Stocker, B. L. ‘An improved synthesis of dansylated  
α-galactosylceramide and its use as a fluorescent probe for the monitoring of 
glycolipid uptake by cells.’ Carbohydr. Res. 2011, 346, 914-926.  
 
As the principal author, I carried out all the chemical transformations described 
in this paper and the biological testings were performed at the Malaghan Institute 
of Medical Research under the supervision of I. F. H. and D. A. K. and I played a 
major role in the writing this paper.  
 
2.1 Introduction 
 
The potent glycosphingolipid adjuvant, α-galactosylceramide (α-GalCer 1, Figure 
2.1) is a structural analogue of agelasphin-9b (AGL-9b, 9) that was isolated from 
the marine sponge Agelas mauritianus.1-3 α-GalCer is able to activate a subset of 
T cells known as invariant natural killer T (iNKT) cells when it is presented in the 
context of CD1d [a member of the CD1 family of proteins found on the surface of 
antigen presenting cells (APCs)].4-6 iNKT cells represent a potent type of T cell, 
and the ability for glycosphingolipids to modulate their activation makes them 
useful targets for the treatment of several diseases including cancer, malaria,  
type I diabetes, and multiple sclerosis.  
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Figure 2.1. α-Galactosyl ceramide and derivatives. 
 
Given the therapeutic potential of α-GalCer, much effort has been spent in 
developing robust routes for its synthesis.3,7-10 In addition, a number of α-GalCer-
derivatives containing a fluorophore11-13 or a biotinylated probe11,14,15 have been 
prepared with the objective of using these substrates to better understand the 
mechanism of iNKT cell activation by α-GalCer.13,16,17 Though the ability of α-
GalCer to bind to CD1d and activate iNKT cells has been robustly studied, only 
little information is known about lipid trafficking and how this influences 
presentation by CD1d and activation of iNKT cells.18 Accordingly, many groups 
have focussed on modifying the lipid portion of α-GalCer with a reporter probe in 
order to address such issues.12-14 However, as CD1d binds lipid chains within deep 
hydrophobic pockets,19 it has been proposed that the addition of a label on the 
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lipid may interfere with α-GalCer-CD1d association,17 and moreover, may 
influence intracellular trafficking.18,20-22 Conversely, modelling of the CD1d-α-
GalCer complex suggests that the hydroxyl groups at C4´´ and C6´´ on galactose 
are not involved in complex formation.23 This theory is also supported by the 
preparation of an α-GalCer analogue containing an additional α-linked galactose 
at the C6´´ position which was shown to stimulate iNKT cells without the need 
for processing.24 Taken as a whole, it is generally accepted that the CD1d-
glycolipid-NKT cell receptor interaction tolerates the appendage of small 
molecules at C6´´ and that this is an ideal position to attach a fluorescent reporter 
group. Indeed, this was the conclusion made by Zhou et al. who developed a 
strategy for the preparation of dansylated α-GalCer derivative 2.11 
 
Despite there being much interest in α-GalCer, the need for a more efficient 
synthesis of an appropriately labelled fluorescent α-GalCer derivative remains. 
An improved strategy for the synthesis of the dansylated α-GalCer derivative 2 
(Figure 2.1) is needed to facilitate studies of the mechanism by which α-GalCer is 
transferred to resident dendritic cells (DCs) during cancer immunotherapy.25,26 
The objective was to achieve a robust synthesis of 2 with high reaction yields 
throughout, and to assess the ability of 2 to both activate iNKT cells and to serve 
as a fluorescent reporter group. The results of these studies are reported herein. 
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2.2 Synthesis of dansyl α-GalCer 
 
Retrosynthesis  
 
The retrosynthetic analysis for the preparation of dansylated α-GalCer 2 is 
presented in Scheme 2.1. 2 was prepared from the mono-lipidated derivative 36, 
itself formed via the coupling of dansylated galactosyl iodide donor 37 to the 
phytosphingosine backbone 38. Donor 37 and acceptor 38 are in turn both readily 
prepared from D-galactose (39). The reasoning behind these key disconnects are 
two-fold. First, though it is possible to couple the complete ceramide lipid 
backbone to a suitably protected galactose donor, the ceramide is a particularly 
poor acceptor and yields for these glycosylations are typically modest (ca. 25-
55%). This is a general phenomenon largely independent of the type of galactose 
donor used.8,15,27-31 There are also advantages to be gained by incorporating the 
fluorescent dansyl group at an early stage in the synthesis for it has been well 
documented that molecules containing a chromophore are more easily monitored 
by TLC and purified by flash column chromatography.32 Accordingly, in contrast 
to other syntheses of fluorescent α-GalCer probes,11-13 a glycosylation reaction 
involving the use of a fluorescent galactose donor, such as 37 was employed. 
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Scheme 2.1. Retrosynthetic analysis for the preparation of dansylated α-GalCer 2. 
 
Synthesis of phytosphingosine acceptor 6. 
 
With the synthetic strategy in place, the first goal was the preparation of the 
phytosphingosine backbone 38 (Scheme 2.2). Here, synthesis of the lipid portion 
commenced with the selective tritylation of D-galactose (39) at the primary 
position,33 followed by installation of an isopropylidene at the 3- and 4-positions 
to give the diol 40 in 85% (over two steps).34 Diol 40 was then treated with a 
solution of NaIO4 in THF/H2O, which resulted in cleavage of the diol and 
formation of the formate ester 41 in quantitative yield. As a temporary protecting 
group, the formate at the 4-position was a pivotal step in this strategy as it 
prevented cyclisation to the corresponding D-lyxofuranose derivative, which gave 
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only modest yields (50-60%) when subject to the subsequent Wittig reaction. 
Treatment of ester 41 with excess ylide (BuLi, 2.4 equiv., phosphonium bromide, 
2.5 equiv.), however, gave the corresponding alkene 42 in good (78%) yield and 
in an E:Z ratio of approximately 1:10 based on 1H NMR analysis.  
 
 
 
Scheme 2.2. Synthesis of phytosphingosine acceptor 38. 
 
Subsequent conversion of alkene 42 to the required phytosphingosine backbone 
then followed via quantitative hydrogenation, using 1.5 wt% Pd/C, and treatment 
with triflic anhydride to give the intermediate triflate, which was converted to 
azide 43 in situ. During the installation of the azide functionality, it was found that 
the best yields were obtained when the reaction was preformed at -15 °C as higher 
temperatures resulted in the elimination of the triflate and the formation of the 
corresponding olefinic by-product. Selective removal of the trityl ether in the 
presence of the isopropylidene group was then attempted. This transformation has 
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proven problematic in the past,7 and resulted in the authors adopting a 4-step 
deprotection/reprotection strategy to generate a modified 3-O, 4-O-benzylated 
phytosphingosine derivative. In view of the lability of the isopropylidene group, 
azide 43 was treated with TFA and TES, then added 2,2-dimethoxypropane to the 
reaction vessel to reinstall the isopropylidine, should it be cleaved under the acidic 
reaction conditions. Indeed, using this approach, phytosphingosine 38 was 
obtained in a respectable 63% yield. Numerous attempts were then made to 
further optimise the reaction including the addition of MeOH (to scavenge the 
liberated TES cation, which was sometimes found to be present on the 1-position 
of the lipid), however, this did not lead to any improvements in yield. The use of 
boron trichloride or formic acid to cleave the trityl group resulted in a lower yield 
of product. Despite this, in sum, the core phytosphingosine backbone 38 was 
prepared in 7-steps and in a good overall yield of 34%. This represents one of the 
most efficient syntheses of the phytosphingosine backbone to date.35,36 
 
Synthesis of dansylated galactose donor and dansyl-α-GalCer  
 
Having completed the synthesis of the required phytosphingosine lipid, attention 
was turned to the preparation of the dansylated galactose donor. The synthesis of 
the carbohydrate portion commenced with the formation of the common azide 
(45)11 using a modified sequence of reactions that first led to the formation of 
iodide 44 via the selective installation of isopropylidenes at the 1,2 and 3,4 
positions of D-galactose (39), subsequent installation of the iodide at the primary 
position, and then simultaneous cleavage of the isopropylidenes and Fisher 
glycosylation using a 5% solution of AcCl in MeOH (Scheme 2.3). This route 
provided a convenient means by which to prepare gram quantities of iodide 45 in 
excellent overall yield (72%, 3 steps) and without the need for column 
chromatography. The iodide in 44 was then displaced to give the intermediate 
azide, which was subsequently benzylated to give the fully protected azide 45, 
again in excellent overall yield. 
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Scheme 2.3. Synthesis of dansyl-α-GalCer 2. 
 
With the objective of installing the fluorescent group at an early stage in the 
synthesis, the dansyl group was then incorporated onto the galactose residue 45 in 
a two-step one-pot procedure involving the reduction of the azide to an amine 
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using Staudinger conditions10 and subsequent treatment with dansyl chloride in 
the presence of 1M NaOH. Using this strategy, dansylated galactose 46 was 
prepared in excellent (93%) yield. Dansylated galactose 46 is a bright-green oil, 
and as such, is readily identified during flash column chromatography whereby 
the yellow-green band can be followed by eye during the purification process. 
Furthermore, incorporation of the dansyl flurophore also aids in the monitoring of 
the reaction by TLC analysis with 46 glowing bright white under UV light (λ = 
254 nm). Treatment of 46 with a solution of AcOH, Ac2O and H2SO4 at 0 °C for 3 
h then resulted in the quantitative formation of acetate 47. Here, it should be noted 
that in addition to the conversion of the anomeric methoxy to the acetate, the 
amine of the dansyl group was also acetylated. Though not optimal, the over-
acetylation of dansyl groups has been previously reported37 and it was envisaged 
that the superfluous acetyl could be readily removed during a subsequent step of 
the synthesis. A dramatic change in colour was also observed upon monitoring the 
reaction by TLC analysis (λ = 254 nm), with the methyl glycoside 46 fluorescing 
bright white, whilst the corresponding acetate 47 was mauve (see supporting 
information). As with all dansylated compounds prepared, acetate 47 was a 
fluorescent green colour, which allowed for its ready purification by flash column 
chromatography and illustrates the added value of the early incorporation of the 
dansyl-group into the synthetic plan. 
 
Forging ahead, glycosyl donor 47 was converted to the corresponding glycosyl 
iodide via methodology based on seminal work by Gervay-Hague.38-41 Though a 
number of galactosyl donors have been prepared and coupled to the 
phytosphingosine backbone en route to the preparation of α-GalCer,7,9,10,27-29,42-45 
few of these glycosylation reactions have been reported to be both high-yielding 
and highly α-selective.38,46-48 To this end, the glycosyl iodide route of Gervay-
Hague was employed and glycolipid 36 was prepared in 94% yield and as only the 
α-anomer, as determined by a 1H J1,2 coupling constant of 3.2 Hz and a 13C-1H 
(1JCH) coupling of 172.2 Hz.49 
 
With glycolipid 36 in hand, the next step was the installation of the C26 acyl 
chain. First, the acetyl on the sulfonimide was removed using Zemplén 
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conditions50 to give the desired sulfonamide 48 in quantative yield. Both 
glycolipid 36 and sufonamide 48 had identical Rf values (0.40; PE/EA, 2/1, v/v), 
though were different colours when observed via TLC analysis. With glycolipid 
36 being mauve in colour (UV light, λ = 254 nm) and sulfonamide 48 bright 
white, this greatly aided in the monitoring of the reaction. The isopropylidene 
group was then removed and the diol product subjected to hydrogenation 
conditions using Pd(OH)2/C in the presence of HCl in an attempt to 
simultaneously remove the benzyl groups and reduce the azide to an amine. 
Numerous attempts were made to achieve this transformation, yet despite the 
addition of HCl to protonate the resultant amine and prevent poisoning of the 
palladium catalyst, only partial debenzylation was observed. In view of this, an 
alternative strategy was used whereby the azide in 48 was first reduced to the 
amine, using Staudinger methodology, then coupled the product to hexacosanoic 
acid via an EDCI/DMAP condensation protocol to give fully protected dansylated 
α-GalCer 49 in good (68%) overall yield. Removal of the isopropylidene group 
occurred smoothly to give 50 in 74% yield. Finally, global deprotection, again 
using Pd(OH)2/C as the catalyst, gave dansyl α-GalCer 2 in 62% yield, which 
glowed bright white under UV light (λ = 366 nm). Though glycolipids such as 2 
have been reported to be notoriously difficult to solubilise and hence assign,51,52 
using a variety of 2D NMR spectroscopy techniques (COSY, HSQC, HMBC) 
with spectra recorded in pyridine-d5, all 13C and 1H resonances were fully 
assigned. Furthermore, the dansyl group of 2 allowed for the ready detection of 
the compound by way of HPLC analysis (see supporting information). Thus, in 
summary, dansyl α-GalCer 2 was prepared in 14 linear steps from the 
commercially available and inexpensive D-galactose and in 16% overall yield. 
This represents a highly efficient synthesis of this important biological probe and 
is comparable to the work of Zhou et al. whereby the probe was prepared in <10% 
yield from 6-azido-6-deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose.11 
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2.3 The effects of dansyl-α-GalCer on the stimulation of 
iNKT cells in vitro and in vivo  
 
Having developed an efficient synthesis of dansyl α-GalCer 2, the next task was 
to investigate whether 2 could activate iNKT cells in a manner similar to that of 
its parent compound, α-GalCer (1).6,7,9,11,28,30,45 This was achieved by analysing 
levels of the cytokine IL-2 released by the Vα14+ iNKT cell hybridoma4 
DN32.D3 following in vitro stimulation with the glycolipid compounds and by 
examining the expression of the co-stimulatory molecule, CD86, on splenic DC 
and B cells after injection of the compounds into mice.9 The latter assay is based 
on the observation that CD86 is upregulated as a consequence of iNKT cells 
interacting with, and subsequently driving, DC and B cell maturation.53,54  
 
To assess the ability of 2 to stimulate DN32.D3 iNKT cell hybridoma cells, 
titrated amounts of dansyl α-GalCer 2, or α-GalCer 1, were incubated for 24 h 
with the hybridoma cells in the presence of a constant number of murine DCs 
from the immortalised line, DC2114,55 and supernatants were then collected and 
analysed for IL-2. Proliferation of the IL-2-dependent cell line HT-2 was used as a 
read-out of IL-2 levels. As illustrated (Figure 2.2A), both α-GalCer 1 and dansyl 
α-GalCer 2 stimulated release of IL-2 in a dose-dependent manner, with α-GalCer 
1 driving a higher level of this cytokine. This observation is consistent with 
literature precedent for weaker cytokine profiles generated by similar C6´´-
substituted α-GalCer derivatives, but is nonetheless indicative that dansyl α-
GalCer 2 is indeed capable of iNKT cell activation.11,15 The ability of dansyl α-
GalCer 2 to stimulate iNKT cells in vivo was assessed by injecting mice with 200 
ng of dansyl α-GalCer 2 or α-GalCer 1, and then determining the expression of 
the maturation marker CD86 on the surface of splenic B cells and DCs by flow 
cytometry 20 h later. As shown, administration of fluorescent analogue 2 
stimulated the maturation of B cells and DCs (Figure 2.2B) with activities 
resembling that of the parent compound 1. To confirm that this in vivo activity 
was mediated by iNKT cells, the experiment was repeated in CD1d deficient 
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mice. Here, no up-regulation of CD86 was observed on DCs (Figure 2.2C), 
confirming that dansyl α-GalCer 2, like α-GalCer 1, activates APCs by 
stimulating iNKT cells in a CD1d dependent manner.  
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Figure 2.2. Dansyl α-GalCer 2 stimulates iNKT cells in vitro and in vivo. (A). 
Production of IL-2 by iNKT cells (DN32.D3) in the presence of titrated doses of 
α-GalCer 1 or dansyl α-GalCer 2;  (B) Dansyl α-GalCer 2 drives the maturation 
of splenic DCs and B cells in vivo. C57BL/6 mice were injected intravenously 
with 200 ng of α-GalCer 1 (n=3) or dansyl α-GalCer 2 (n=3), and spleens were 
removed 20 h after injection for antibody labelling and flow cytometry. The 
expression of CD86 on CD11c+ dendritic cells and B220 B cells were assessed; 
(C) 200 ng of dansyl α-GalCer 2 was injected intravenously into wild type 
(C57BL/6) and CD1d–/– mice, and spleens were removed 20 h after injection for 
antibody labelling and flow cytometry. The spleen of an untreated wild type 
(C57BL/6) mouse was used as control. The expression of CD86 on CD11c+ 
dendritic cells was assessed. Mean fluorescence intensities (MFI) ± SD are 
presented.  
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2.4 Uptake of α-GalCer by dendritic cells 
 
Having established that dansyl α-GalCer 2 binds to CD1d and activates iNKT 
cells in a manner similar to that of α-GalCer 1, the ability of dansyl α-GalCer 2 to 
function as a fluorescent reporter group was investigated. This has previously not 
been reported. The fluorescence quantum yield of dansyl α-GalCer 2 (φf) was 
found to be 0.22 as determined via a relative method against the standard, quinine 
sulfate (φf = 0.54 in  1M NaOH). The wavelengths of maximum absorbance and 
emission of 2 were determined by spectrofluorimetry to be 343 nm and 510 nm, 
respectively, and these maxima were used in further analyses. The DC cell line, 
DC2114 was incubated with 4 µg of dansyl α-GalCer 2 for 24 h and uptake of the 
fluorescent glycolipid was analysed by flow cytometry (Figure 3). A distinct shift 
in mean fluorescence intensity was observed for cells treated with dansyl α-
GalCer 2, but not for those treated with α-GalCer 1 or controls (untreated and 
vehicle), illustrating the ability of dansyl α-GalCer 2 to be used as a fluorescent 
probe to detect sub-populations of DCs that present the glycolipid. 
 
 
Figure 2.3. Cells that have taken up dansyl α-GalCer 2 can be detected by flow 
cytometry. 1x106 cells (DC2114 cell line) were incubated for 24 h with 4 µg of 
dansyl α-GalCer 2, α-GalCer 1 or vehicle only. Cells were excited with the UV 
laser, and detected by the Hoechst Blue-A detector. 
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2.5 Visualisation of dansyl α-GalCer by fluorescence 
microscopy 
 
Following the successful detection of dendritic cells that have taken up the 
fluorescent glycolipid by flow cytometry, the next objective was to visualise the 
location of glycolipid when incubated with dendritic cells. Initially, the DC2114 
cell line was incubated at a concentration similar to that used for flow cytometry 
(1x106 cells incubated with 4 µg of dansyl α-GalCer 2). Unfortunately, the 
fluorescence could not be detected, despite increasing the concentration of 
glycolipid by two-fold. In addition, two other cell types, bone marrow derived 
dendritic cells (BMDCs) and A20, a murine B lymphoma cell line used in in vivo 
vaccination, were also incubated with dansyl α-GalCer 2 but again the 
fluorescence was no different when compared to the negative control containing 
cells only. When glycolipid concentrations that well exceed what would be 
relevant in in vitro and in vivo experiments were used, slight fluorescence was 
observed, but this rapidly disappeared due to quenching of the dye. Similarly, the 
probe was also quenched too rapidly when cells that have taken up the glycolipid 
was visualised under a confocal microscope. Efforts to amplify the fluorescence 
of dansyl α-GalCer 2 by using the secondary antibody, anti-dansyl antibody was 
also met with little success. Unfortunately, while dansyl α-GalCer 2 behaved in a 
very similar manner to the parent glycolipid α-GalCer 1, it could not be visualised 
at the concentrations typically used in an in vivo setting.  
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2.6 Conclusion 
 
In summary, an efficient synthesis of the biologically important probe, dansyl α-
GalCer 2. En route to the synthesis of this glycolipid, a highly efficient synthesis 
of the phytosphingosine lipid acceptor was developed. In addition, it was found 
that the early incorporation of the fluorescent group greatly aids in the monitoring 
and purification of reaction products. The ability of dansyl α-GalCer 2 to activate 
iNKT cells and to be used as a fluorescent probe for the analysis of glycolipid 
uptake by DCs has also been illustrated. Unfortunately, the fluorophore was too 
weak and underwent photobleaching when subjected to the UV laser of the 
fluorescent microscope.  
 
Given the importance of α-GalCer 1, it is anticipated that similar derivatives with 
a fluorophore attached on the 6´´-position will find wide application as a 
molecular tool to better understand the trafficking of α-GalCer and glycolipid 
presentation by CD1d. Extension of this work is presented in Chapter 3. 
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2.7 Experimental 
 
2.7.1 General procedure 
Unless otherwise stated all reactions were performed under N2. Prior to use, THF 
(Pancreac) was distilled from LiAlH4, pyridine was dried over 4Å molecular 
sieves (4Å MS), acetone (Pure Science) was dried over 3Å MS, DCM (Pancreac) 
was distilled from P2O5, TMSI (Aldrich) was distilled from antimony powder 
(M&B) and stored over Cu(s) powder (Hopkin & Williams), and H2O and 
benzene (Fisher Scientific) were distilled. Trityl chloride (Acros), CuSO4 (Fluka), 
NaIO4 (M&B), anhydrous Et2O (Pancreac), n-BuLi (Aldrich), 1-bromotridecane 
(Aldrich), PPh3 (Merck), Pd/C (Aldrich, 10 wt%), Tf2O (Aldrich), NaN3 (BDH), 
anhydrous DMF (Acros), TFA (Aldrich), triethylsilane (Fluka), Me2C(OMe)2 
(Aldrich), ZnCl2 (Aldrich), H2SO4 (Lab-Scan), I2 (BDH), imidazole (Aldrich), 
AcCl (B&M), BnBr (Fluka), NaH (Avocado Research Chemicals, 60% dispersion 
in mineral oil), PMe3 (Aldrich, 1M in THF), dansyl chloride (Acros), AcOH (Ajax 
Finechem), Ac2O (Peking Reagent), TBAI (Riedel-de Haen), DiPEA (Aldrich), 
NaOMe (Janssen Chimica), C25H51COOH (Acros), EDCI (Aldrich), DMAP 
(Merck), Pd(OH)2/C (Aldrich, 20 wt%), EtOAc (Pancreac), hexanes (Fisher 
Scientific), petroleum ether (Pure Science), MeOH (Pure Science), CHCl3 
(Pancreac), EtOH (absolute, Pure Science), NaOH (Pure Science), NaHCO3 (Pure 
Science), NaCl (Pancreac) were used as received. All solvents were removed by 
evaporation under reduced pressure. Reactions were monitored by TLC-analysis 
on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent 
indicator UV254) with detection by UV-absorption (short wave UV – 254 nm; long 
wave UV – 366 nm), by dipping in 10% H2SO4 in EtOH followed by charring at 
~150 °C, by dipping in I2 in silica, or by dipping into a solution of ninhydrin in 
EtOH followed by charring at ~150 °C. Column chromatography was performed 
on Pure Science silica gel (40-63 micron). AccuBOND II ODS-C18 (Agilent) was 
used for reverse phase chromatography. High-resolution mass spectra were 
recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer using 
postive electro-spray ionisation. Optical rotations were recorded using a Perkin-
Elmer 241 polarimeter or Autopol II (Rudolph Research Analytical) at 589 nm 
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(sodium D-line). Infrared spectra were recorded as thin films using a Bruker 
Tensor 27 FTIR spectrometer equipped with an Attenuated Total Reflectance 
(ATR) sampling accessory and are reported in wave numbers (cm-1). Nuclear 
magnetic resonance spectra were recorded at 20 °C in D2O or CDCl3 using either 
a Varian INOVA operating at 500 MHz or Varian VNMRS operating at 600 
MHz. Chemical shifts are given in ppm (δ) relative to TMS. NMR peak 
assignments were made using COSY, HSQC and HMBC 2D experiments. 
Melting points were obtained using the Gallenkamp Melting Point Apparatus. 
Spectrofluorimetry measurements were carried out on the Horiba Jobin-Yvon 
Fluorolog-3 spectrofluorometer using the three dimensional (3D) scanning mode. 
High-pressure liquid chromatography was performed on Waters 600 liquid 
chromatograph with a photodiode array detector (Waters 2996) and a C-18 
column (Waters Xbridge 5 µm). 
 
3,4-O-Isopropylidene-6-O-triphenylmethyl-D-galactopyranoside (40).  
Trityl chloride (16.4 g, 58.8 mmol) was added to a solution of D-galactose (39) 
(10 g, 55.5 mmol) in pyridine (150 mL). The reaction mixture was stirred at 50 °C 
for 48 h and concentrated in vacuo. The resulting residue was purified by 
chromatography through a short silica column and the tritylated galactose was 
eluted with acetone and crystallised from EtOH to afford the tritylated galactose 
(23.4 g, 55.4 mmol, quant.) [Rf: 0.17 (EtOAc)] as a white powder. To a solution 
of tritylated galactose (15 g, 35.5 mmol) in anhydrous acetone (750 mL) was 
added copper sulfate (60 g, 380 mmol). After stirring the reaction mixture for 3 d 
at room temperature, carbon was then added and the solution filtered through 
celite. The filtrate was concentrated in vacuo and purified by flash column 
chromatography. Elution with 1:1 (v/v) hexanes/EtOAc afforded the title 
compound 40 (13.9 g, 30.1 mmol, 85%, 2 steps) as a clear oil. Rf: 0.65 (EtOAc); 
[α]D20 = +18.0° (c = 1.0, CHCl3); IR (film) 3406, 3059, 3034, 2986, 2936, 1597, 
1491, 1449, 1380, 1219, 1162, 1132, 1079, 1032, 909, 872, 814, 776, 732, 705 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.48–7.46 (m, 6H, CPh3, CH-o), 7.30 (t, Jo,m 
= Jm,p = 7.4 Hz, 6H, CPh3, CH-m), 7.26–7.23 (m, 3H, CPh3, CH-p), 5.23 (t, J1,2 = 
J1,OH = 3.7 Hz, 1H, H-1α), 4.34–4.29 (m, 3H, H-3, H-4, H-5), 3.87–3.85 (m, 1H, 
H-2), 3.02 (dd, J6a, 6b = 9.1 Hz, J6a,5 = 6.4 Hz,1H, H-6a), 3.33 (dd, J6a, 6b = 9.1 Hz, 
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J6b,5 = 6.4 Hz, 1H, H-6a), 3.02 (d, JOH, 1  = 3.6 Hz, 1H, 1-OH), 2.45–2.44 (m, 1H, 
2-OH), 1.44 (s, 3H, CH3 iPr), 1.36 (s, 3H, CH3 iPr); 13C NMR (125 MHz, CDCl3) 
δ 143.9 (C-i, CPh3), 128.8 (C-o, CPh3), 127.8 (C-m, CPh3), 127. 0 (C-p, CPh3), 
109.5 (Cq iPr), 91.2 (C-1), 86.8 (Cq CPh3), 75.4 (C-3), 72.9 (C-4), 69.1 (C-2), 67.9 
(C-5), 62.8 (C-6), 27.4, 25.7 (2 x CH3 iPr); HRMS(ESI) m/z calcd. for 
[C28H30O6+Na]+: 485.1940, obsd.: 485.1949. 
 
4-O-Formyl-2,3-O-isopropylidene-5-O-triphenylmethyl-D-lyxose (41). A 
solution of NaIO4 (0.46 g, 2.14 mmol) in H2O (4 mL) was added to 40 (0.66 g, 
1.42 mmol) dissolved in 4 mL THF at 0 °C. After stirring at room temperature 
overnight, the reaction mixture was diluted with EtOAc (15 mL) and washed with 
water (20 mL), saturated NaHCO3 solution (20 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo to afford the title compound 41 (0.65 
g, 1.42 mmol, quant.) as a clear oil, which was carried through without further 
purification. Rf: 0.48 (PE/EA, 1/1, v/v); IR (film) 3450, 3060, 3025, 2989, 2938, 
2360, 2341, 2252, 1732, 1597, 1491, 1449, 1383, 1218, 1160, 1076, 987, 907, 
764, 729, 701, 648 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.60 (d, J1,2 = 2.4 Hz, 1H, 
H-1), 8.00 (s, 1H, HCO2), 7.44–7.41 (m, 6H, CPh3, CH-o), 7.34–7.30 (m, 6H, 
CPh3, CH-m), 7.27–7.24 (m, 3H, CPh3, CH-p), 5.18 (q, J3,4 = J4,5a = J4,5b = 4.9 Hz, 
1H, H-4), 4.74 (dd, J2,3 = 7.7 Hz, J3,4 = 4.2 Hz, 1H, H-3), 4.31 (dd, J2,3 = 7.7 Hz, 
J1,2 = 2.4 Hz, 1H, H-2), 3.40 (dd, J5a,5b = 9.8 Hz, J4,5a= 5.6 Hz, 1H, H-5a), 3.37 
(dd, J5a,5b = 9.8 Hz, J4,5b= 5.6 Hz, 1H, H-5b), 1.56 (s, 3H, iPr CH3), 1.42 (s, 3H, 
iPr CH3); 13C NMR (125 MHz, CDCl3) δ 201.1 (C-1), 159.7 (C-6), 128.6 (CH-o, 
CPh3), 127.9 (CH-m, CPh3), 127.2 (CH-p, CPh3), 111.1 (Cq iPr), 87.2 (Cq CPh3), 
80.2 (C-2), 77.0 (C-3), 69.5 (C-4), 61.8 (C-5), 26.8, 25.1 (2 x CH3 iPr); 
HRMS(ESI) m/z calcd. for [C28H28O6+Na]+: 483.1784, obsd.: 483.1793. 
   
3,4-O-Isopropylidene-1-O-triphenylmethyl-D-arabino-octadec-5-en-1,2,3,4-
tetraol (42). A mixture of 1-bromotridecane (7.0 mL, 27.4 mmol) and 
triphenylphosphine (7.18 g, 27.4 mmol) was heated at 140 °C under N2 
atmosphere for 5 h. The reaction mixture was allowed to cool to room temperature 
and formed a solid gel. The gel was dissolved in boiling dry acetone (36 mL) and 
dry diethyl ether (87 mL) was added and the compound left to crystalise, which 
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greatly improved in subsequent batches via the use of seed crystals. The crystals 
were filtered under N2 atmosphere to afford BrPh3PC13H27 (11.1 g, 21.1 mol, 
77%) as white needles. n-BuLi (6.6 mL, 13.2 mmol) was added to BrPh3PC13H27 
(7.0 g, 13.7 mmol) dissolved in distilled THF (130 mL) at –78 °C and stirred for 
15 min. To the bright orange mixture, a solution of formate ester 41 (co-
evaporated with dry toluene x 3) in THF (55 mL) was added. The reaction 
mixture was stirred at –78 °C for 1 h, then warmed to room temperature and 
stirred for a further 3.5 h before being quenched with NH4Cl solution (150 mL), 
concentrated, and redissolved in ethyl acetate (100 mL). The organic layer was 
washed with saturated NaHCO3 solution (100 mL), water (100 mL) and brine 
(100 mL), dried (MgSO4), filtered and concentrated in vacuo. The resulting 
residue was purified by silica gel column chromatography and the desired product 
eluted with 8:1 (v/v) petroleum ether/EtOAc to afford alkene 42 as a clear oil 
(2.57 g, 4.29 mmol, 78%) in an approximate E:Z, 1:10. Rf: 0.33 (PE/EA, 5/1, v/v); 
[α]D20 = –22.2° (c = 1.0, CHCl3); IR (film) 3559, 3058, 3023, 2924, 2854, 1598, 
1491, 1449, 1380, 1214, 1162, 1073, 898, 880, 763, 746, 705 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.48–7.44 (m, 6H, CPh3, CH-o), 7.33–7.29 (m, 6H, CPh3, CH-m), 
7.26–7.23 (m, 3H, CPh3, CH-p), 5.59 (dd, J5,6 = 11.3 Hz, J6,7 = 6.0 Hz, 1H, H-6), 
5.55 (dd, J5,6 = 11.3 Hz, J4,5 = 7.7 Hz, 1H, H-5), 4.92 (dd, J4,5  = 7.7 Hz, J3,4 = 6.9 
Hz, 1H, H-4), 4.23 (dd, J3,4 = 6.9 Hz, J2,3 = 4.3 Hz, 1H, H-3), 3.77 (pent, J1,2 = J2,3 
= J2,OH = 5.4 Hz, 1H, H-2), 3.18 (dd, J1a,1b = 9.4 Hz, J1a,2 = 5.0 Hz, 1H, H-1a), 3.13 
(dd, J1a,1b = 9.4 Hz, J1b,2 = 6.4 Hz, 1H, H-1b), 2.03–1.98 (m, 1H, H-7a), 1.82–1.77 
(m, 1H, H-7a), 1.51 (s, 3H, CH3 iPr), 1.41 (s, 3H, CH3 iPr), 1.33–1.23 (m, 20H, H-
8–H-17), 0.90 (t, J17,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) δ 143.9 
(C-i, CPh3), 135.4 (C-6), 128.7 (CH-o, CPh3), 127.8 (CH-m, CPh3), 127.0 (CH-p, 
CPh3), 125.0 (C-5), 108.4 (Cq iPr), 86.7 (Cq CPh3), 77.5 (C-3), 73.0 (C-4), 69.2 
(C-2), 65.0 (C-1), 31.9, 29.70, 29.67, 29.62, 29.52, 29.50, 29.4, 29.3, 27.6, 22.7 
(C-7–C-17), 27.4, 25.1 (2 x CH3 iPr), 14.2 (C-18); HRMS(ESI) m/z calcd. for 
[C40H54O4+Na]+: 621.3920, obsd.: 621.3926. 
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2-Azido-3,4-O-isopropylidene-1-O-triphenylmethyl-D-arabino-octadecane-
1,3,4-triol (43). Pd/C (1.5 wt %) was added to a solution of 42 (2.52 g, 4.21 
mmol) in distilled THF (42 mL) and stirred under H2 (g) overnight at room 
temperature. The reaction mixture was then filtered through celite and 
concentrated to afford 3,4-O-Isopropylidene-1-O-triphenylmethyl-D-arabino-
octadecane-1,2,3,4-tetraol as a clear oil (2.53 g, 4.21 mmol, quant.), which was 
used without further purification. Rf: 0.44 (PE/EA, 5/1, v/v); [α]D20 = –4.0° (c = 
1.0, CHCl3); IR (film) 3560, 3060, 3023, 2923, 2853, 1598, 1491, 1449, 1379, 
1216, 1073, 899, 872, 762, 746, 705 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.47 (d, 
Jo,m = 7.7 Hz, 6H, CPh3, CH-o), 7.31 (t, Jo,m = Jm,p = 7.7 Hz, 6H, CPh3, CH-m), 
7.27–7.23 (m, 3H, CPh3, CH-p), 4.15 (dd, J2,3 = 6.0 Hz, J3,4 = 3.8 Hz, 1H, H-3), 
4.11–4.07 (m, 1H, H-4), 3.74 (dt, J1,2 = 9.5 Hz, J2,3 = 6.0 Hz, 1H, H-2), 3.24–3.19 
(m, 2H, H-1a, H-1b), 2.34 (d, JOH,2 = 5.9 Hz, 1H, OH), 1.71–1.64 (m, 2H, H-5), 
1.51–1.28 (m, 24H, H-6–H-17), 1.46 (s, 3H, iPr CH3), 1.37 (s, 3H, iPr CH3), 0.89 
(t, J17,18 = 6.9 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) δ 143.9 (C-i, CPh3), 
128.7 (CH-o, CPh3), 127.8 (CH-m, CPh3), 127.1 (CH-p, CPh3), 107.7 (Cq iPr), 
86.8 (Cq CPh3), 77.5 (C-4), 77.0 (C-3), 69.0 (C-2), 65.2 (C-1), 31.9, 29.72, 29.68, 
29.63, 29.62, 29.57, 29.39, 26.8, 22.7 (C-5–C-17), 27.4, 25.2 (2 x CH3 iPr), 14.2 
(C-18); HRMS(ESI) m/z calcd. for [C40H56O4+Na]+: 623.4076, obsd.: 623.4080. 
3,4-O-Isopropylidene-1-O-triphenylmethyl-D-arabino-octadecane-1,2,3,4-tetraol 
(1.59 g, 2.65 mmol) was then co-evaporated with dry toluene (x 3), dissolved in a 
mixture of dry DCM (8 mL) and distilled pyridine (0.54 mL) and cooled to –15 
°C. Triflic anhydride (0.67 mL, 3.97 mmol) was added dropwise over 5 mins and 
stirred at –15 °C for 45 mins to afford the triflate intermediate [Rf: 0.56 (PE/EA, 
5/1, v/v)]. Dry DMF (27 mL) was cooled to –15 °C and added to the reaction 
mixture, followed by the addition of sodium azide (0.69 g, 10.61 mmol). The 
reaction mixture was then warmed to room temperature, stirred overnight, and 
quenched by adding ice water (120 mL). The desired product was extracted with 
EtOAc (2 x 150 mL) and the combined organic layers washed with saturated 
NaHCO3 solution (200 mL), water (200 mL) and brine (200 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by silica gel flash 
column chromatography and eluted with 1.5% EtOAc/hexanes to afford the title 
compound 43 (1.35 g, 2.16 mmol, 81%) as an amorphous white solid. Rf: 0.61 
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(PE/EA, 5/1, v/v); [α]D25 = +7.0° (c = 1.0, CHCl3), Lit:58 [α]D26 = +9.0° (c = 1.0, 
CHCl3); IR (film) 3060, 2923, 2853, 2097, 1598, 1491, 1379, 1370, 1246, 1219, 
1156, 1073, 1034, 900, 869, 762, 744, 703 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.51 (d, Jo,m = 7.3 Hz, 6H, CPh3, CH-o), 7.32 (t, Jo,m = Jm,p = 7.6 Hz, 6H, CPh3, 
CH-m), 7.26 (d, Jo,m = 7.1 Hz, 3H, CPh3, CH-p), 4.13–4.09 (m, 1H, H-4), 3.89 
(dd, J2,3 = 9.5 Hz, J3,4 = 5.5 Hz, 1H, H-3), 3.55 (dd, J1a,1b = 9.9 Hz, J1a,2 = 2.5 Hz, 
1H, H-1a), 3.50 (dt, J2,3 = 9.5 Hz, J1a,2 = 2.5 Hz, 1H, H-2), 3.37 (dd, J1a,1b = 9.9 
Hz, J1b,2 = 7.8 Hz, 1H, H-1b), 1.59–1.28 (m, 26H, H-5–H-17), 1.27 (s, 3H, iPr 
CH3), 1.24 (s, 3H, iPr CH3), 0.90 (t, J17,18 = 6.9 Hz, 3H, H-18); 13C NMR (125 
MHz, CDCl3) δ 143.8 (C-i, CPh3), 128.7 (CH-o, CPh3), 127.9 (CH-m, CPh3), 
127.1 (CH-p, CPh3), 108.1 (Cq CPh3), 87.3 (Cq iPr), 77.9 (C-4), 75.9 (C-3), 64.6 
(C-1), 60.8 (C-2), 32.0, 29.73, 29.69, 29.66, 29.64, 29.57, 29.4, 29.3, 26.5, 22.7 
(C-5–C-17), 28.0, 25.7 (2 x CH3 iPr), 14.2 (C-18); HRMS(ESI) m/z calcd. for 
[C40H55 N3O3+Na]+: 648.4141, obsd.: 648.4145. 
 
2-Azido-3,4-O-isopropylidene-D-ribo-octadecane-1,3,4-triol (38). Triethylsilane 
(91.8 µL, 0.58 mmol) was added to a stirred solution of azide 43 (181 mg, 0.289 
mmol) (co-evaporated with dry toluene x 3) in dry DCM (5 mL) at 0 °C. 
Trifluoroacetic acid (TFA) (90 µL, 1.17 mmol) was added very slowly, allowing 
the reaction mixture to return to a colourless solution before adding the next drop. 
After stirring for 2 min, 2,2-dimethoxypropane (7 µL, 0.057 mmol) was added 
and the reaction mixture stirred for a further 1 min before being quenched with 
saturated NaHCO3 solution (50 mL). The product was extracted with DCM (2 x 
50 mL) and the combined organic layers washed with water (80 mL) and brine 
(80 mL), dried (MgSO4), filtered and concentrated in vacuo. The resulting residue 
was purified by silica gel flash column chromatography and eluted with 5:1 (v/v) 
petroleum ether/EtOAc to afford the title compound 38 (69.3 mg, 0.18 mmol, 
63%) as an amorphous white solid. Rf: 0.21 (PE/EA, 5/1, v/v); [α]D20 = +24.0° (c 
= 1.0, CHCl3); IR (film) 3426, 2923, 2853, 2098, 1465, 1370, 1247, 1220, 1170, 
1063, 909, 869, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.21–4.17 (m, J3,4 = 5.7 
Hz, H-4), 4.0 (ddd, J1a,1b = 11.8 Hz, J1a,OH = 5.1 Hz, J1a,2 = 4.4 Hz, 1H, H-1a), 3.97 
(dd, J2,3 = 9.6 Hz, J3,4 = 5.7 Hz, 1H, H-3), 3.87 (ddd, J1a,1b = 11.8 Hz, J1b,OH = 6.6 
Hz, J1b,2 = 5.6 Hz, 1H, H-1b), 3.48 (ddd, J2,3 = 9.6 Hz, J1b,2 = 5.6 Hz, J1a,2 = 4.4 
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Hz, 1H, H-2), 2.20 (dd, J1b,OH = 6.6 Hz, J1a,OH = 5.1 Hz, 1H, OH), 1.63–1.55 (m, 
3H, H-5a, H-5b, H-6a), 1.43 (s, 3H, iPr CH3), 1.34 (s, 3H, iPr CH3), 1.41–1.26 
(m, 23H, H-6b, H-7–H-17), 0.88 (t, J17,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 
MHz, CDCl3) δ 108.4 (Cq iPr), 77.7 (C-4), 76.7 (C-3), 63.9 (C-1), 61.2 (C-2), 
31.9, 29.70, 29.69, 29.68, 29.66, 29.65, 29.60, 29.58, 29.53, 29.39, 29.36, 26.52, 
22.7 (C-5–C-17), 28.0, 25.5 (2 x CH3 iPr), 14.1 (C-18); HRMS(ESI) m/z calcd. for 
[C21H41N3O3+Na]+: 406.3046, obsd.: 406.3049. 
 
Methyl 6-deoxy-6-iodo-α-D-galactopyranoside (44). To a mixture of 1,2:3,4- 
di-O-isopropylidene-α-D-galactopyranose59,60 (2.6 g, 10 mmol), PPh3 (3.93 g, 15 
mmol) and imidazole (1.36 g, 20 mmol) in dry THF (100 mL), was added iodine 
(3.81 g, 15 mmol) in small portions. After refluxing for 1 h, the reaction mixture 
was cooled to room temperature, and quenched by the addition of 10% aq. 
Na2S2O4. The product was extracted with EtOAc, and the combined organic 
layers were washed with brine, dried (MgSO4), filtered and concentrated. 
Distillation of the residue gave 6-deoxy-6-iodo-1,2:3,4-di-O-isopropylidene-α-D-
galactopyranose as a yellow oil (3.14 g, 8.48 mmol, 85%). AcCl (1.8 mL) was 
added dropwise to a mixture of 6-deoxy-6-iodo-1,2:3,4-di-O-isopropylidene-α-D-
galactopyranose (3.14 g, 8.48 mmol) in MeOH (60 mL). After stirring for 2 d, the 
mixture was concentrated in vacuo and the residue crystalised from MeOH, to 
give the title compound 44 (2.37 g, 7.80 mmol, 92%) as white crystals. Mp 
175.0–175.6 °C, Lit:57 162 °C; Rf = 0.43 (MeOH/EtOAc, 1/9, v/v); [α]D21 = 
+129.0° (c = 1.0, H2O), [α]D21 = +122.1° (c = 1.0, MeOH), Lit:57 [α]D22 = +142.0° 
(c = 1.0, H2O); IR (film) 3354, 3227, 3007, 2953, 2935, 2906, 2836, 1454, 1417, 
1360, 1347, 1297, 1257, 1200, 1145, 1132, 1102, 1078, 1026, 999, 935, 886, 854, 
790, 721, 691, 657 cm-1; 1H NMR (500 MHz, D2O) δ 4.69 (d, J1,2 = 3.6 Hz, 1H, 
H-1), 3.97 (dd, J3,4 = 3.3, J4,5 = 1.2 Hz, 1H, H-4), 3.90 (ddd, J4,5 = 1.2 Hz, J5,6a = 
5.3, J5,6b = 8.0 Hz 1H, H-5), 3.75 (dd, J1,2 = 3.6, J2,3 = 10.2 Hz, 1H, H-2), 3.69 
(dd, J2,3 = 10.2, J3,4 = 3.3 Hz, 1H, H-3), 3.46 (s, 3H, OMe), 3.37 (dd, J5,6a = 5.3, 
J6a,6b = 10.2 Hz, 1H, H-6a), 3.33 (dd, J5,6b = 8.0, J6a,6b = 10.2 Hz, 1H, H-6b); 13C 
NMR (125 MHz, D2O) δ 100.2 (C-1), 71.4 (C-5), 70.4 (C-4), 69.9 (C-2), 68.4 (C-
3), 54.6 (OMe), 2.3 (C-6). HRMS(ESI) m/z calcd. for [C7H13IO5+Na]+: 326.9700, 
obsd.: 326.9709. 
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Methyl 6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranoside (45). 
Sodium azide (4.28 g, 0.066 mmol) was added to iodide 44 (5.01 g, 0.016 mmol) 
dissolved in dry DMF (300 mL). After stirring overnight at room temperature, 
MeOH (150 mL) was added and the reaction mixture was concentrated in vacuo. 
The residue was purified by silica gel flash column chromatography and the 
product eluted with 8% MeOH/DCM. The residue was crystallised from methanol 
to afford methyl 6-azido-6-deoxy-α-D-galactopyranoside (2.96 g, 14 mmol, 82%) 
as white crystals. Mp 173.8–174.1 °C, Lit:60 172-173 °C; Rf = 0.43 
(MeOH/EtOAc, 1/9, v/v); [α]D23 = +144.0° (c = 1.0, H2O), Lit:61  [α]D22 = +154.0° 
(c = 0.8, H2O); IR (film) 3371, 3238, 2934, 2091, 1642, 1459, 1349, 1297, 1245, 
1137, 1107, 1080, 1029, 961, 791, 730, 698 cm-1; 1H NMR (500 MHz, CDCl3) δ 
4.73 (d, J1,2 = 3.7 Hz, 1H, H-1), 3.90 (ddd, J5,6a = 8.8 Hz, J5,6b = 4.0 Hz, J4,5 = 1.1 
Hz, 1H, H-5), 3.79 (dd, J3,4 = 3.3 Hz, J4,5 = 1.1 Hz, 1H, H-4), 3.77 (dd, J2,3 = 10.1 
Hz, J1,2 = 3.7 Hz, 1H, H-2), 3.72 (dd, J2,3 = 10.1 Hz, J3,4 = 3.3 Hz, 1H, H-3), 3.58 
(dd, J6a,6b = 12.8 Hz, J5,6a = 8.8 Hz, 1H, H-6a), 3.44 (s, 3H, OCH3), 3.27 (dd, J6a,6b 
= 12.8 Hz, J5,6b = 4.0 Hz, 1H, H-6b); 13C NMR (125 MHz, CDCl3) δ 100.2 (C-1), 
70.0, 69.83, 69.77 (C-3, C-4, C-5), 68.6 (C-2), 54.3 (OCH3), 51.3 (C-6); 
HRMS(ESI) m/z calcd. for [C7H13N3O5+Na]+: 242.0753, obsd.: 242.0749. Methyl 
6-azido-6-deoxy-α-D-galactopyranose (1.53 g, 6.98 mmol) was then co-
evaporated from dry DMF (x 1), dissolved in dry DMF (150 mL) and cooled to 0 
°C. Benzyl bromide (3.3 mL, 27.9 mmol) was added followed by sodium hydride 
(60% in oil suspension) (1.40 g, 34.9 mmol) and the reaction mixture allowed to 
warm to rt. After stirring for 2 h, the reaction was quenched with MeOH (20 mL) 
and concentrated in vacuo. The residue was taken up in EtOAc (100 mL) and the 
mixture was washed with water (100 mL), saturated NaHCO3 solution (100 mL), 
water (100 mL) and brine (100 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by silia gel flash column chromatography and 
eluted with 20:1 (v/v) petroleum ether/EtOAc to afford the title compound 45 
(3.37 g, 6.88 mmol, 99%) as a clear oil. Rf: 0.72 (PE/EA, 1/1, v/v); [α]D20 = +4.6° 
(c = 1.0, CHCl3); IR (film) 2937, 2098, 1453, 1351, 1124, 1094, 1045, 789, 735 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.44–7.31 (m, 15H, Harom), 5.03 (d, Ja,b = 
11.4 Hz, 1H, CH-a, 4-O-Bn), 4.93 (d, Ja,b = 11.7 Hz, 1H, CH-a, 3-O-Bn), 4.87 (d, 
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Ja,b = 12.1 Hz, 1H, CH-a, 2-O-Bn), 4.78 (d, Ja,b = 11.7 Hz, 1H, CH-b, 3-O-Bn), 
4.72 (d, Ja,b = 12.1 Hz, 1H, CH-b, 2-O-Bn), 4.72 (d, J1,2 = 3.7 Hz, 1H, H-1), 5.03 
(d, Ja,b = 11.4 Hz, 1H, CH-b, 4-O-Bn), 4.07 (dd, J2,3 = 10.1 Hz, J1,2 = 3.7 Hz,  1H, 
H-2), 3.96 (dd, J2,3 = 10.1 Hz, J3,4 = 2.6 Hz,  1H, H-3), 3.83 (dd, J5,6a = 8.3 Hz, 
J5,6b = 4.7 Hz, 1H, H-5), 3.80 (d, J3,4 = 2.6 Hz, 1H, H-4), 3.53 (dd, J6a,6b = 12.7 
Hz, J5,6a = 8.3 Hz, 1H, H-6a), 3.43 (s, 3H, OCH3), 2.94 (dd, J6a, 6b = 12.7 Hz, J5,6b 
= 4.7Hz, 1H, H-6b); 13C NMR (125 MHz, CDCl3) δ 138.7 (C-i, 3-O-Bn), 138.4 
(C-i, 2-O-Bn), 138.1 (C-i, 4-O-Bn), 128.52, 128.50, 128.4, 128.1, 128.0, 127.8, 
127.7, 127.6 (8 x CHarom), 98.8 (C-1), 79.0 (C-3), 76.3 (C-2), 75.3 (C-4), 74.6 
(CH2, 4-O-Bn), 73.70, 73.65 (2 x CH2, 2-O-Bn, 3-O-Bn), 69.8 (C-5), 55.5 
(OCH3), 51.5 (C-6); HRMS(ESI) m/z calcd. for [C28H31N3O5+Na]+: 512.2161, 
obsd.: 512.2159. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-[dimethylamino]napth-1-
ylsulfonyl)amido]-α-D-galactopyranoside (46). Trimethylphosphine (1M in 
THF) (10.2 mL, 10.2 mmol) was added to a solution of 45 (1.0 g, 2.04 mmol) (co-
evaporated with toluene x 3) in distilled THF (10 mL) at 0 °C. After stirring for 
15 min at 0 °C and 45 min at rt, the reaction mixture was cooled to 0 °C and 
dansyl chloride (1.38 g, 5.11 mmol) was added followed by the addition of NaOH 
(1M, 8.17 mL, 8.17 mmol) over 10 min. The reaction was then allowed to warm to 
rt and after 6 h, further dansyl chloride (0.83 g, 3.06 mmol) and NaOH (1M, 2.04 
mL, 2.04 mmol) was added. After stirring for a further 16 h, the solution was 
diluted with EtOAc (50 mL), and the organic layer washed with water (50 mL) 
and brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by silica gel flash column chromatography and eluted with 
1:1 (v/v) petroleum ether/EtOAc to afford the title compound 46 (1.32 g, 1.89 
mmol, 93%) as a lime green foam. Rf: 0.61 (PE/EA, 1/1, v/v); Glows white on 
TLC (λ = 254 nm); [α]D19 = +9.2° (c = 1.0, CHCl3); IR (film) 3293, 3063, 3030, 
2988, 2349, 1588, 1574, 1497, 1326, 1200, 1143, 791, 735, 698 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 8.55 (d, JCH-2,CH-3 = 8.8 Hz, 1H, CH-2 Dan), 8.13 (d, JCH-3,CH-
4 = 7.4 Hz, 1H, CH-4 Dan), 8.08 (d, JCH-7,CH-8 = 8.7 Hz, 1H, CH-8 Dan), 7.54 (dd, 
JCH-7,CH-8 = 8.7 Hz, JCH-6,CH-7 = 7.7 Hz, 1H, CH-7 Dan), 7.50 (d, JCH-2,CH-3 = 8.8 
Hz, 1H, CH-8 Dan), 7.38–7.26 (m, 15H, Harom), 7.20–7.17 (m, 3H, Harom, CH-6 
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Dan), 4.84 (d, Ja,b = 11.7 Hz, 1H, CH-a, 4-O-Bn), 4.77 (d, Ja,b = 12.0 Hz, 1H, CH-
a, 2-O-Bn), 4.76 (d, Ja,b = 11.5 Hz, 1H, CH-a, 3-O-Bn),  4.61 (d, Ja,b = 12.0 Hz, 
2H, CH-b, 2-O-Bn, CH-b, 3-O-Bn), 4.47 (d, J1,2 = 3.8 Hz, 1H, H-1), 4.29 (dd, 
JNH,6a = 8.4 Hz, JNH,6b = 4.6 Hz, 1H, NH Dan), 3.86 (dd, J1,2 = 3.8 Hz, J2,3 = 9.4 
Hz,1H, H-2), 3.65 (dd, J2,3 = 9.4 Hz, J3,4 = 2.7 Hz, 1H, H-3), 3.64 (bs, 1H, H-4), 
3.48 (t, J5,6 = 6.6 Hz, 1H, H-5), 3.23 (s, 3H, OCH3), 2.99–2.77 (m, 2H, H-6a, H-
6b), 2.88 (s, 6H, NMe2); 13C NMR (125 MHz, CDCl3) δ 138.5, 138.3 (2 x C-i, 2-
O-Bn, 3-O-Bn), 137.9 (C-i, 4-O-Bn), 134.9 (C-4a Dan), 130.4 (C-2 Dan), 129.5, 
128.9, 128.6, 128.5, 128.4, 128.3, 128.1, 127.8, 127.7, 127.6 (10 x CHarom), 123.4 
(C-3 Dan), 118.9 (C-8 Dan), 115.4 (C-6 Dan), 98.7 (C-1), 79.0 (C-3), 76.1 (C-2), 
74.1 (CH2, 4-O-Bn), 73.7 (C-4), 73.63, 73.59 (2 x CH2, 2-O-Bn, 3-O-Bn), 68.5 
(C-5), 55.4 (OCH3), 45.5 (NMe2), 43.3 (C-6); HRMS(ESI) m/z calcd. for 
[C40H44N2O7S+Na]+: 719.2756, obsd.: 719.2760. 
 
1-O-Acetyl-2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-[dimethylamino]napth-1-
ylsulfonyl)acetimido]-α-D-galactopyranoside (47). Concentrated sulfuric acid 
(63.1 µL, 1.18 mmol) was added dropwise to a solution of 46 (550 mg, 0.79 
mmol) in acetic anhydride (2.4 mL, 25.3 mmol) and acetic acid (0.32 mL, 5.53 
mmol) at 0 °C. After stirring at 0°C for 1 h and at rt for 2 h, the solution was 
diluted with DCM (50 mL) and washed with water (50 mL), saturated NaHCO3 
solution (50 mL) and brine (100 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by silica gel flash column chromatography and 
eluted with 3:1 (v/v) petroleum ether/EtOAc to afford the title compound 47 (605 
mg, 0.79 mmol) as a lime green foam. Rf: 0.66 (PE/EA, 1/1, v/v); Glows mauve 
on TLC (λ = 254 nm); [α]D23 = +65.8° (c = 1.0, CHCl3); IR (film) 3064, 3030, 
2940, 2872, 1750, 1705, 1454, 1342, 1229, 1135, 1102, 1051, 1009, 788, 739, 699 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.64 (bs, 1H, CH-2 Dan), 8.30 (d, JCH-3,CH-4 = 
7.4 Hz, 1H, CH-4 Dan), 7.85 (bs, 1H, CH-8 Dan), 7.58–7.53 (m, 2H, CH-3, CH-7 
Dan), 7.44–7.29 (m, 15H, Harom), 7.23 (bs, 1H, CH-6 Dan), 6.35 (d, J1,2 = 3.7 Hz, 
1H, H-1), 5.11 (d, Ja,b = 11.6 Hz, 1H, CH-a, 4-O-Bn), 4.91 (d, Ja,b = 11.6 Hz, 1H, 
CH-a, 3-O-Bn), 4.82 (d, Ja,b = 11.6 Hz, 1H, CH-b, 3-O-Bn), 4.72 (s, 2H, CH-a, 
CH-b, 2-O-Bn), 4.69 (d, Ja,b = 11.6 Hz, 1H, CH-b, 4-O-Bn), 4.29 (dd, J5,6a = 8.6 
Hz, J5,6b = 2.5 Hz, 1H, H-5), 4.18 (dd, J2,3 = 10.0 Hz, J1,2 = 3.7 Hz, 1H, H-2), 4.10 
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(dd, J6a,6b = 15.2 Hz, J5,6 = 8.6 Hz, 1H, H-6a), 4.07 (bd, J3,4 = 2.6 Hz, 1H, H-4), 
3.96 (dd, J2,3 = 10.0 Hz, J3,4 =  2.6 Hz, 1H, H-3), 3.85 (dd, J6a,6b = 15.2 Hz, J5,6b = 
2.5 Hz, H1, H-6b), 2.93 (s, 6H, NMe2), 2.18 (s, 3H, NAc), 2.15 (s, 3H, OAc); 13C 
NMR (125 MHz, CDCl3) δ 170.9 (C=O NAc), 169.7 (C=O OAc), 138.4 (C-i, 3-
O-Bn), 138.3 (C-i, 4-O-Bn), 137.9 (C-i, 2-O-Bn), 134.7 (C-4a Dan), 131.2 (C-2 
Dan), 129.2 (C-1/C-8a Dan), 128.53, 128.50, 128.45, 128.42, 128.40, 128.38, 
128.01, 127.94, 127.89, 127.86, 127.82, 127.74, 127.72, 127.61, 127.5 (15 x 
CHarom), 123.5 (C-3 Dan), 115.5 (C-6 Dan), 90.2 (C-1), 78.9 (C-3), 75.2 (C-2), 
74.9 (C-4), 74.6 (CH2, 4-O-Bn), 73.5 (CH2, 3-O-Bn), 73.4 (CH2, 2-O-Bn), 72.1 
(C-5), 47.7 (C-6), 45.5 (NMe2), 24.7 (NAc), 21.2 (OAc), HRMS(ESI) m/z calcd. 
for [C43H46N2O9S+Na]+: 789.2822, obsd.: 789.2819.  
 
2-Azido-3,4-O-isopropylidene-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-
[dimethylamino]napth-1-ylsulfonyl)acetimido]-α-D-galactopyranosyl)-D-ribo-
octadecane-1,3,4-triol (36). Iodotrimethylsilane (65.3 µL, 0.46 mmol) was added 
to a solution of 47 (237 mg, 0.31 mmol) (co-evaporated with toluene x 3) in dry 
DCM (2 mL) at 0 °C. After stirring for 1 h at 0 °C, the reaction mixture was 
concentrated in vacuo, azeotroped with toluene (x 3) and redissolved in dry 
benzene (3 mL). In a separate flask, molecular sieves (4Å, 50 mg), TBAI (342 
mg, 0.93 mmol) and DiPEA (53.8 µL, 0.31 mmol) were added to a solution of the 
lipid acceptor 38 (39.1 mg, 0.10 mmol) (co-evaporated from toluene x 3) in dry 
benzene (1 mL) at room temperature. After stirring the reaction mixture at 70 °C 
for 15 min, the glycosyl iodide was cannulated into the flask containing the lipid 
acceptor and stirred at 70 °C for 20 h. The reaction mixture was then diluted with 
EtOAc (10 mL), cooled to 0 °C and filtered. The filtrate was concentrated and the 
resulting residue purified by silica gel flash column chromatography. Elution with 
7:1 (v/v) hexanes/EtOAc afforded the desired glycolipid 36 (103.9 mg, 0.095 
mmol, 94%) as a lime green oil. Rf: 0.40 (PE/EA, 2/1, v/v); Glows mauve on TLC 
(λ = 254 nm); [α]D24 = +40.9° (c = 1.0, CHCl3); IR (film) 3064, 3031, 2923, 2853, 
2789, 2099, 1704, 1572, 1455, 1347, 1231, 1147, 1096, 1045, 787, 735, 697 cm-1; 
1H NMR (500 MHz, CDCl3) δ 8.58 (d, JCH-2,CH-3 = 8.6 Hz, 1H, CH-2 Dan), 8.29 
(d, JCH-3,CH-4 = 7.3 Hz, 1H, CH-4 Dan), 7.75 (d, JCH-7,CH-8 = 8.6 Hz, 1H, CH-8 
Dan), 7.53 (t, JCH-2,CH-3 = JCH-7,CH-8 = 8.6 Hz, 2H, CH-3, CH-7 Dan), 7.43–7.2.8 
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(m, 15H, Harom), 7.19 (d, JCH-6,CH-7 = 7.5 Hz , 1H, CH-6 Dan), 5.11 (d, Ja,b = 11.7 
Hz, 1H, CH-a, 4′-O-Bn), 5.00 (d, J1,2 = 3.2 Hz, 1H, H-1), 4.91 (d, Ja,b = 11.7 Hz, 
1H, CH-a, 2′-O-Bn), 4.80 (d, Ja,b = 12.0 Hz, 1H, CH-a, 3′-O-Bn), 4.79 (d, Ja,b = 
11.7 Hz, 1H, CH-b, 2′-O-Bn), 4.74 (d, Ja,b = 12.0 Hz, 1H, CH-b, 3′-O-Bn), 4.68 
(d, Ja,b = 11.7 Hz, 1H, CH-b, 4′-O-Bn), 4.25–4.18 (m, 3H, H-1a, H-5′, H-3), 4.15–
4.05 (m, 4H, H-6′a, H-4, H-3′, H-2′), 4.00 (bs, 1H, H-4′), 3.85 (dd, J6a′,6b′ = 14.8 
Hz, J5,6b′ = 2.9 Hz, 1H, H-6′b), 3.74 (dd, J1a,1b = 10.8 Hz, J1b,2 = 5.2 Hz, 1H, H-
1b), 3.41 (ddd, J2,3 = 9.5 Hz, J1a,2 = 5.2 Hz, J1b,2 = 2.5 Hz,1H, H-2), 2.89 (s, 6H, 
NMe2), 2.18 (s, 3H, NAc), 1.67–1.54 (m, 4H, H-5, H-6), 1.43 (s, 3H, CH3 iPr), 
1.30 (s, 3H, CH3 iPr), 1.41–1.27 (m, 22H, H-7–H-17), 0.89 (t, J17,18 = 7.0 Hz, 3H, 
H-18); 13C NMR (125 MHz, CDCl3) δ 170.8 (C=O NAc), 152.2 (C-5 Dan), 138.9 
(C-i, 3′-O-Bn), 138.8 (C-i, 2′-O-Bn), 138.6 (C-i, 4′-O-Bn), 134.5 (C-4a Dan), 
131.5 (C-2 Dan), 131.4 (C-4 Dan), 129.9, (C-1 Dan), 129.6 (C-8a Dan), 128.7 (C-
7 Dan), 128.43, 128.40, 128.37, 128.2, 127.7, 127.6, 127.53, 127.52, 127.43 (9 x 
CHarom), 123.1 (C-3 Dan), 117.8 (C-8 Dan), 115.2 (C-6 Dan), 108.1 (Cq iPr), 98.5 
(C-1′), 78.8 (C-2′), 77.8 (C-4), 76.5 (C-3′), 75.5 (C-4′), 75.0 (C-3), 74.5 (CH2, 4′-
O-Bn), 73.7 (CH2, 2′-O-Bn), 72.7 (CH2, 3′-O-Bn), 70.0 (C-5′), 69.2 (C-1), 59.3 
(C-2), 47.8 (C-6′), 45.4 (NMe2), 31.9, 29.71, 29.68, 29.67, 29.66, 29.64, 29.61, 
29.4, 26.6, 22.7 (C-5–C-17), 28.3, 25.8 (2 x CH3 iPr), 24.8 (NAc), 14.1 (C-18); 
HRMS(ESI) m/z calcd. for [C62H83N5O10S+Na]+: 1112.5758, obsd.: 1112.5767. 
 
2-Azido-3,4-O-isopropylidene-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-
[dimethylamino]napth-1-ylsulfonyl)amido]-α-D-galactopyranosyl)-D-ribo-
octadecane-1,3,4-triol (48). Glycolipid 36 (42.5 mg, 0.039 mmol) was dissolved 
in a mixture of methanol/DCM (3:1, v/v) and to this was added NaOMe until the 
solution reached pH 9.0. After stirring at room temperature for 3 d in the dark, 
while maintaining pH 9.0 via the addition of NaOMe. The solution was then 
diluted with EtOAc (15 mL), and washed with saturated NH4Cl solution (20 mL), 
water (20 mL) and brine (20 mL). The organic layer was dried (MgSO4), filtered 
and concentrated in vacuo to afford the title compound 48 (41 mg, quant.) as a 
lime green oil, which was used without further purification. Rf: 0.40 (PE/EA, 2/1, 
v/v); Glows white on TLC (λ = 254 nm); [α]D21 = +10.5° (c = 1.0, CHCl3); IR 
(film) 3309, 3031, 2923, 2853, 2360, 2099, 1574, 1454, 1328, 1220, 1145, 1094, 
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1047, 791, 734, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.55 (d, JCH-2,CH-3 Dan = 
8.4 Hz, 1H, CH-2 Dan), 8.17 (d, JCH-3,CH-4 Dan = 7.3 Hz, 1H, CH-4 Dan), 8.09 (d, 
JCH-7,CH-8 Dan = 8.7 Hz, 1H, CH-8 Dan), 7.56 (dd, JCH-7,CH-8 Dan = 8.7 Hz, JCH-6,CH-7 
Dan = 7.6 Hz, 1H, CH-7 Dan), 7.53 (dd, JCH-2,CH-3 Dan = 8.4 Hz, JCH-3,CH-4 Dan = 7.3 
Hz, 1H, CH-3 Dan),7.38–7.26 (m, 13H, Harom), 7.20–7.18 (m, 3H, Harom, CH-6 
Dan), 4.86 (d, Ja,b = 11.8 Hz, 1H, CH-a, 4′-O-Bn), 4.79 (d, Ja,b = 12.0 Hz, 1H, CH-
a, 3′-O-Bn), 4.77 (d, J1,2 = 3.6 Hz, 1H, H-1′), 4.75 (d, Ja,b = 11.9 Hz, 1H, CH-a, 2-
O-Bn), 4.66 (d, Ja,b = 11.9 Hz, 1H, CH-b, 2-O-Bn), 4.63 (d, Ja,b = 12.0 Hz, 1H, 
CH-b, 3-O-Bn), 4.53 (d, Ja,b = 11.8 Hz, 1H, CH-b, 4-O-Bn), 4.34 (dd, J6′b, NH = 8.3 
Hz, J6′a, NH =  4.5 Hz, 1H, NH), 4.13 (p, J4,5 = 4.2 Hz, 1H, H-4), 4.04 (dd, J2,3 = 9.8 
Hz, J3,4 = 5.4 Hz, 1H, H-3), 3.95 (dd, J1a,1b = 10.6 Hz, J1a, 2 = 2.5 Hz, 1H, H-1a), 
3.91 (dd, J2′,3′ = 10.1 Hz, J1,2= 3.6 Hz, 1H, H-2′), 3.79 (dd, J2′,3′ = 10.1 Hz, J3′, 4′ = 
2.7 Hz, 1H, H-3′), 3.70 (bs, 1H, H-4′), 3.69–3.68 (m, 1H, H-5′), 3.61 (dd, J1a,1b = 
10.6 Hz, J1b, 2 = 6.4 Hz, 1H, H-1b), 3.38 (ddd, J2,3 = 9.8 Hz, J1b,2 = 6.4 Hz, J1a,2 = 
2.5 Hz,1H, H-2), 2.92-2.81 (dd, J5,6′a = 7.1 Hz, J6′a,NH = 4.5 Hz, 1H, H-6′a),  2.83 
(ddd, J6′a, 6′b = 13.6 Hz, J6′b,NH = 8.3 Hz, J5,6′b = 6.1 Hz, 1H, H-6′b), 2.89 (s, 6H, 
NMe2), 1.64–1.27 (m, 26H, H-5–H-17), 1.45 (s, 3H, CH3 iPr), 1.31 (s, 3H, CH3 
iPr),    0.89 (t, J17,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) δ 152.1 
(C-5 Dan), 138.7, 138.6 (2 x C-i, 2′-O-Bn, 3′-O-Bn), 138.0 (C-i, 4′-O-Bn), 134.7 
(C-4a Dan), 130.5 (C-2 Dan), 129.9 (C-1/C-8a Dan), 129.6 (C-4 Dan), 129.5 (C-
1/C-8a Dan), 128.9, 128.6, 128.4 (3 x CHarom) 128.30 (C-7 Dan), 128.25, 128.22, 
127.64, 127.63, 127.54, 127.48 (6 x CHarom), 123.1 (C-3 Dan), 118.8 (C-8 Dan), 
115.2 (C-6 Dan), 108.3 (Cq iPr), 98.5 (C-1′), 78.6 (C-3′), 77.8 (C-4), 76.3 (C-2′), 
75.2 (C-3), 74.1 (CH2, 4′-O-Bn), 73.8 (C-4′), 73.7 (CH2, 3′-O-Bn), 72.9 (CH2, 2′-
O-Bn), 69.5 (C-1), 69.2 (C-5′), 59.5 (C-2), 45.4 (NMe2), 43.3 (C-6′), 31.9, 29.72, 
29.69, 29.68, 29.64, 29.61, 29.4, 29.3, 26.6, 22.7 (C-5–C-17), 28.3, 25.7 (2 x CH3 
iPr), 14.1 (C-18); HRMS(ESI) m/z calcd. for [C60H81N5O9S+Na]+: 1070.5653, 
obsd.: 1070.5657. 
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1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-[dimethylamino]napth-1-
ylsulfonyl)amido]-α-D-galactopyranosyl)-2-hexacosanoylamido-3,4-O-
isopropylidene-D-ribo-octadecane-1,3,4-triol (49). Trimethylphosphine (1M in 
THF) (0.17 mL, 0.17 mmol) was added to a solution of 48 (34.7 mg, 0.033 mmol) 
(co-evaporated with toluene x 3) in distilled THF (0.2 mL) at 0 °C. After stirring 
the reaction mixture for 15 min at 0 °C and 45 min at rt, the solution was cooled 
to 0 °C and 1M NaOH (aq) solution (0.33 mL, 0.33 mmol) added drop wise. The 
reaction mixture was then stirred at rt for 21 h, then diluted with EtOAc (20 mL), 
washed with water (2 x 20 mL) and brine (20 mL), dried (MgSO4) and filtered. 
Concentration in vacuo afforded the amine [Rf: 0.11 (Toluene:EtOAc, 3/2, v/v)] 
as a green oil, which was used without further purification. A solution of 
hexacosanoic acid (33.5 mg, 0.084 mmol), EDCI (16.2 mg, 0.084 mmol), and 
DMAP (0.4 mg, 0.0034 mmol) in dry DCM (1 mL) was added to the amine 
dissolved in dry DCM (1 mL). After stirring at room temperature for 43 h, the 
reaction mixture was diluted with EtOAc (20 mL) and washed with saturated 
NaHCO3 solution (20 mL), water (20 mL) and brine (20 mL), dried (MgSO4) and 
filtered. The filtrate was concentrated in vacuo and the residue was purified by 
silica gel column chromatography. Elution with 5:1 (v/v) hexanes/EtOAc afforded 
the desired product 49 (31.9 mg, 0.023 mmol, 68%) as a lime green oil. Rf: 0.79 
(Toluene/EtOAc, 3/2, v/v); Glows white on TLC (λ = 254 nm); [α]D22 = +4.3° (c 
= 1.0, CHCl3); IR (film)  2923, 2853, 2361, 1650, 1541, 1455, 1330, 1218, 1145, 
1092, 1052, 791, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.55 (d, JCH-2,CH-3 = 7.4 
Hz, 1H, CH-2 Dan), 8.19 (bs, 1H, CH-4 Dan), 8.16 (d, JCH-7,CH-8 = 7.3 Hz, 1H, 
CH-8 Dan), 7.56 (t, JCH-6,CH-7 = JCH-7,CH-8 = 8.1 Hz, 1H, CH-7 Dan), 7.52 (t, JCH-
2,CH-3 = JCH-3,CH-4 = 8.0 Hz, 1H, CH-3 Dan), 7.41–7.23 (m, 15H, Harom), 7.20 (d, 
JCH-6,CH-7 = 7.1 Hz, 1H, CH-6 Dan), 5.89 (d, JNH,2 = 9.5 Hz, 1H, NH C26), 4.92 (bs, 
1H, NH Dan), 4.88 (d, Ja,b = 11.5 Hz, 1H, CH-a, 4′%-O-Bn), 4.89 (d, J1,2 = 3.6 Hz, 
1H, H-1%%), 4.79 (d, Ja,b = 11.4 Hz, 1H, CH-a, 2%%-O-Bn), 4.76 (d, Ja,b = 11.7 Hz, 
1H, CH-a, 3%%-O-Bn), 4.71 (d, Ja,b = 11.7 Hz, 1H, CH-b, 3%%-O-Bn), 4.64 (d, Ja,b = 
11.4 Hz, 1H, CH-b, 2%%-O-Bn), 4.53 (d, Ja,b = 11.5 Hz, 1H, CH-b, 4%%-O-Bn), 4.18–
4.14 (m, 1H, H-2), 4.07 (t, J2,3 = J 3,4 = 6.9 Hz, 1H, H-3), 4.04–4.01 (m, 1H, H-4), 
3.96 (dd, J2´´,3´´ = 10.0 Hz, J1´´,2´´ = 3.6 Hz, 1H, H-2%%), 3.85 (dd, J1a,1b = 11.6 Hz, 
J1a,2 = 4.6 Hz, 1H, H-1a), 3.82 (bs, 1H, H-4%%), 3.77 (dd, J2´´,3´´ = 10.0 Hz, J3´´,4´´ = 
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2.7 Hz, 1H, H-3%%), 3.71 (t, J5´´,6´´a = 6.6 Hz, 1H, H-5%%), 3.59 (dd, J1a,1b = 11.6 Hz, 
J1b,2 = 2.6 Hz, 1H, H-1b), 2.90 (s, 6H, NMe2), 2.87–2.85 (m, 2H, H-6%%a, H-6%%b), 
2.14 (dt, J2´a,2´b = 14.7 Hz, J2´a,3´ = 7.5 Hz, 1H, H-2%a), 2.06 (dt, J2´a,2´b = 14.7 Hz, 
J2´a,3´ = 7.5 Hz, 1H, H-2%b), 1.71 (bs, 2H, CH2, H-5), 1.59 (m, 2H, H-3%), 1.47–1.43 
(m, 68H, CH2, H-6 – H-17, H-4%–H-25%), 1.43 (s, 3H, CH3 iPr), 1.32 (s, 3H, CH3 
iPr), 0.89 (t, J17,18 = J25´,26´ = 7.0 Hz, 6H, H-18, H-26%); 13C NMR (125 MHz, 
CDCl3) δ 172.6 (C=O), 151.8 (C-5 Dan), 138.4 (C-i, 3%%-O-Bn), 138.2 (C-i, 2%%-O-
Bn), 138.1 (C-i, 4%%-O-Bn), 134.7 (C-4a/C-8a Dan), 130.3 (C-2 Dan), 129.8 (C-
4a/C-8a Dan), 129.6 (C-8 Dan), 128.8, 128.72, 128.66, 128.60, 128.56, 128.5, 
128.4, 128.15, 128.1, 128.0, 127.94, 127.88, 127.7, 127.6, 127.5 (15 x CHarom), 
128.21 (C-7 Dan), 123.3 (C-3 Dan), 119.1 (C-1 Dan), 115.2 (C-6 Dan), 107.8 (Cq 
iPr), 99.3 (C-1%%), 79.1 (C-3%%), 77.7 (C-4), 76.6 (C-3), 76.5 (C-2%%), 74.2 (CH2, 4%%-
O-Bn), 73.7 (CH2, 2%%-O-Bn), 73.4 (C-4%%), 73.0 (CH2, 3%%-O-Bn), 69.4 (C-1), 69.1 
(C-5%%), 49.1 (C-2), 45.5 (NMe2), 43.3 (C-6%%), 36.9 (C-2%), 31.95, 31.94, 31.6, 
29.8, 29.73, 29.71, 29.70, 29.67, 29.65, 29.50, 29.47, 29.42, 29.39, 29.37, 28.83, 
26.8, 22.7 (C-5–C-17, C-3%–C-25%), 27.8, 25.73 (2 x CH3 iPr), 25.72 (CH2, C-3%%), 
14.1 (2 x CH3, C-18, C-26%); HRMS(ESI) m/z calcd. for [C86H133N3O10S+Na]+: 
1422.9609, obsd.: 1422.9615. 
 
1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-[N-(5-[dimethylamino]napth-1-
ylsulfonyl)amido]-α-D-galactopyranosyl)-2-hexacosanoylamido-D-ribo-
octadecane-1,3,4-triol (50). Glycolipid 49 (31.9 mg, 0.023 mmol) was dissolved 
in a mixture of 8:4:1 (v/v/v) AcOH/H2O/toluene and stirred at 50 °C for 1 d after 
which analysis by TLC revealed presence of starting material. The reaction 
mixture was concentrated in vacuo (to remove the acetone by product), then 
redissolved in the same mixture of solvents and stirred for a further day. This 
procedure was repeated until all starting material was converted to product as 
indicated by TLC analysis. The reaction mixture was then concentrated in vacuo 
and the residue was purified by silica gel flash column chromatography. Elution 
with 1:2 (v/v) hexanes/EtOAc afforded the diol 50 (23.0 mg, 0.017 mmol, 74%) 
as a lime green oil. Rf: 0.22 (PE/EA, 3/2, v/v); Glows white on TLC (λ = 254 nm); 
[α]D21 = +13.7° (c = 1.0, CHCl3); IR (film) 3357, 3032, 2922, 2852, 2360, 1643, 
1536, 1498, 1312, 1143, 1092, 1050, 909, 789, 733, 697 cm-1; 1H NMR (500 
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MHz, CDCl3) δ 8.54 (d, JCH-2,CH-3 = 8.5 Hz, 1H, CH-2 Dan), 8.10 (d, JCH-3,CH-4 = 
7.4 Hz, 1H, CH-4 Dan), 8.07 (d, JCH-7,CH-8 = 8.6 Hz, 1H, CH-8 Dan), 7.56 (dd, JCH-
7,CH-8 = 8.6 Hz, JCH-6,CH-7 = 7.8 Hz, 1H, CH-7 Dan), 7.51 (dd, JCH-2,CH-3 = 8.5 Hz, 
JCH-3,CH-4 = 7.4 Hz, 1H, CH-3 Dan), 7.41–7.27 (m, 13H, Harom), 7.22–7.18 (m, 3H, 
Harom, CH-6 Dan), 6.31 (d, JNH,2 = 8.3 Hz, 1H, NH C26), 4.88 (d, Ja,b = 11.7 Hz, 
1H, CH-a, 4%%-O-Bn), 4.83 (d, Ja,b = 11.7 Hz, 1H, CH-a, 2%%-O-Bn), 4.81 (d, Ja,b = 
11.2 Hz, 1H, CH-a, 3%%-O-Bn), 4.75 (d, Ja,b = 11.2 Hz, 1H, CH-b, 3%-O-Bn), 4.74 
(d, J1´´,2´´ = 3.7 Hz, 1H, H-1%%), 4.66 (d, Ja,b = 11.7 Hz, 1H, CH-b, 2%%-O-Bn), 4.53 
(d, Ja,b = 11.7 Hz, 1H, CH-b, 4%%-O-Bn), 4.51–4.49 (m, 1H, NH Dan), 4.30 (dd, J2,3 
= 8.1 Hz, J1a/b,2 = 3.7 Hz, 1H, H-2), 3.95 (dd, J2´´,3´´ = 10.0 Hz, J1´´,2´´ = 3.7 Hz, 1H, 
H-2%%), 3.87–3.84 (m, 3H, H-1a, H-4%%, H-5%%), 3.80 (dd, J2´´,3´´ = 10.0 Hz, J3´´,4´´ = 
2.4 Hz, 1H, H-3%%), 3.76 (dd, J1a,1b = 10.5 Hz, J1b,2 = 4.1 Hz, 1H, H-1b), 3.65–3.64 
(m, 1H, 3-OH), 3.54–3.51 (m, 2H, H-3, H-4), 2.89 (s, 6H, NMe2), 2.83 (ddd, 
J6´´a,6´´b = 14.1 Hz, J5,6´´a = 7.1 Hz, J6´´a,NH = 4.4 Hz, 1H, H-6%%a), 2.77 (ddd, J6´´a,6´´b 
= 14.1 Hz, J6´´b,NH = 8.1 Hz, J5,6´´b = 6.1 Hz, 1H, H-6%%b), 2.56–2.55 (m, 1H, 4-
OH), 2.25 (dt, J2´a,2´b = 14.9 Hz, J2´a,3´ = 7.5 Hz, 1H, H-2%a), 2.19 (dt, J2´a,2´b = 14.9 
Hz, J2´b,3´ = 7.5 Hz, 1H, H-2%b), 1.67–1.15 (m, 74H, CH2, H-5–H-17, H-3%–H-25%), 
0.89 (t, J17,18 = J25´,26´ = 7.0 Hz, 6H, H-18, H-26%); 13C NMR (125 MHz, CDCl3) δ 
173.5 (C=O), 152.0 (C-5 Dan), 138.2 (C-i, 3%%-O-Bn), 137.9 (C-i, 4%%-O-Bn), 137.8 
(C-i, 2%%-O-Bn), 134.1 (C-4a Dan), 130.6 (C-2 Dan), 129.9 (C-1 Dan), 129.6 (C-4 
Dan), 129.5 (C-8a Dan), 128.9, 128.6, 128.54, 128.52, 128.2, 128.05, 128.00, 
127.8, 127.5 (9 x CHarom), 128.4 (C-7 Dan), 123.1 (C-3 Dan), 118.8 (C-8 Dan), 
115.2 (C-6 Dan), 98.8 (C-1%%), 79.4 (C-3%%), 76.3 (C-3), 75.9 (C-2%%), 74.2 (CH2, 
4%%-O-Bn), 74.0 (CH2, 2%%-O-Bn), 73.3 (CH2, 3%%-O-Bn), 73.2 (C-4), 73.1 (C-4%%), 
69.6 (C-5%%), 69.2 (C-1), 49.9 (C-2), 45.4 (NMe2), 43.2 (C-6%%), 36.8 (C-2%), 33.5 
(C-5), 31.9, 29.73, 29.71, 29.68, 29.67, 29.6, 29.44, 29.38, 25.9, 25.7, 22.7 (C-6–
C-17, C-3%–C-25%), 14.1 (2 x CH3, C-18, C-26%); HRMS(ESI) m/z calcd. for 
[C83H129N3O10S+Na]+: 1382.9296, obsd.: 1382.9296. 
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1-O-[6-deoxy-6-[N-(5-[dimethylamino]napth-1-ylsulfonyl)amido]-α-D-
galactopyranosyl]-2-hexacosanoylamido-D-ribo-octadecane-1,3,4-triol (2). 
Pd(OH)2/C (2.5 mol %) was added to a solution of diol 50 (9.9 mg, 0.0073 mmol) 
in a mixture of CHCl3/EtOH (1 mL, 3/2, v/v) and the reaction stirred under H2 (g) 
for 17 h at rt. The reaction mixture was then filtered through Celite, the Celite 
washed thoroughly with CHCl3/EtOH (3/2, v/v), and the filtrate concentrated in 
vacuo. The residue was purified by silica gel flash column chromatography (10% 
MeOH/DCM), followed by reverse phase chromatography (ODS-C18 resin, 
product eluted with MeOH), and finally silica gel column chromatography by 
elution with 5% MeOH/DCM. This afforded the target compound 2 (4.9 mg, 4.49 
mmol, 62%) as a yellow oil. Rf: 0.22 (DCM/MeOH, 92/8, v/v); Glows white on 
TLC (λ = 366 nm); [α]D22 = +40.0° (c = 0.1, pyridine); IR (film) 3320, 2918, 
2851, 2359, 1653, 1634, 1560, 1457, 1310, 1144, 1030, 791, 684 cm-1; UV 
λmaxAbs = 343 nm, λmaxEm = 510 nm; 1H NMR (600 MHz, Pyridine-d5) δ 9.04 (d, 
JCH-2,CH-3 = 8.7 Hz, 1H, CH-2 Dan), 8.61–8.57 (m, 2H, NH C26, CH-4 Dan), 8.54 
(d, JCH-7,CH-8 = 8.6 Hz, 1H, CH-8 Dan), 7.54 (dd, JCH-7,CH-8 = 8.6 Hz, JCH-6,CH-7 = 
7.4 Hz, 1H, CH-7 Dan), 7.51 (dd, JCH-2,CH-3 = 8.7 Hz, JCH-3,CH-4 = 7.6 Hz, 1H, CH-
3 Dan), 7.12 (d, JCH-6,CH-7 = 7.4 Hz, 1H, CH-6 Dan), 5.45 (d, J1´´,2´´ = 3.9 Hz, 1H, 
H-1%%), 5.23 (m, 1H, H-2), 4.54 (dd, J1a,1b = 10.9 Hz, J1a,2 = 5.6 Hz, 1H, H-1a), 
4.52 (dd, J2´´,3´´ = 9.9 Hz, J1´´,2´´ = 3.9 Hz, 1H, H-2%%), 4.51 (t, J5,6a = J5,6b = 6.6 Hz, 
1H, H-5%%), 4.35–4.30 (m, 3H, H-3, H-4, H-4%%), 4.26 (dd, J2´´,3´´ = 9.9 Hz, J3´´,4´´ = 
3.3 Hz, 1H, H-3%%), 4.19 (dd, J1a,1b = 10.9 Hz, J1b,2 = 4.8 Hz, 1H, H-1b), 3.85 (bs, 
2H, H-6%%a, H-6%%b), 2.50 (dt, J2´a,2´b = 14.8 Hz, J2´a,3´ = 7.8 Hz, 1H, H-2%a), 2.46 (dt, 
J2´a,2´b = 14.8 Hz, J2´b,3´ = 7.8 Hz, 1H, H-2%b), 2.34–1.24 (m, 72H, CH2, H-5–H-17, 
H-3%–H-25%), 0.86 (t, J17,18 = J25´,26´ = 7.0 Hz, 6H, H-18, H-26%); 13C NMR (150 
MHz, Pyridine-d5) δ 173.7 (C=O), 152.4 (C-5 Dan), 137.8 (C-4a Dan), 130.8 (C-1 
Dan), 130.6 (C-8a Dan), 130.3 (C-8 Dan), 129.3 (C-4 Dan), 128.5 (C-3 Dan), 
123.5 (C-7 Dan), 120.7 (C-2 Dan), 115.9 (C-6 Dan), 101.4 (C-1%%), 76.8 (C-3), 
72.8 (C-4), 71.42 (C-5%%), 71.37 (C-3%%), 71.2 (C-4%%), 70.2 (C-2%%), 68.5 (C-1), 51.5 
(C-2), 45.52 (NMe2), 45.16 (C-6%%), 37.1 (C-2%), 34.6 (C-5), 32.42, 32.41, 30.8, 
30.7, 30.5, 30.4, 30.34, 30.33, 30.32, 30.31, 30.29, 303.27, 30.26, 30.23, 30.21, 
30.19, 30.14, 30.10, 29.92, 29.90, 26.8, 26.7, 23.24, 23.23 (C-6–C-17, C-3%–C-
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25%), 14.6 (2 x CH3, C-18, C-26%); HRMS(ESI) m/z calcd. for 
[C62H111N3O10S+Na]+: 1112.7888, obsd.: 1112.7878. 
 
2.7.2 Materials and methods for cell proliferation (IL-2) assay, in vivo 
DC maturation assay and in vitro treatment of dendritic cells 
 
Mice. Breeding pairs of the inbred strains C57BL/6 were obtained from The 
Jackson Laboratories and from the Animal Resource Centre. All mice were 
maintained in the Biomedical Research Unit of the Malaghan Institute of Medical 
Research. CD1d–/– mice, which are devoid of CD1d-restricted iNKT cells, were 
also used.62 Experiments were approved by the NZ national animal ethics 
committee and performed according to established national guidelines. 
 
Solubilisation of glycolipid. α-GalCer (Industrial Research Ltd, New Zealand) 
and synthesised glycolipids were tested to be endotoxin-free at the sensitivity of 
0.125 EU/mL with an endotoxin kit (Pyrotell, Limulus Amebocyte Lysate). Each 
glycolipid (1 mg) was dissolved in 200 µL of CHCl3/MeOH/H2O (10:10:3), 
heated at 37°C for 15 min followed by sonication for 10 min. The solution was 
then diluted to 200 µg/mL in 0.5% Tween/phosphate-buffered saline (PBS) and 
left to sit at –4 °C overnight. The glycolipid was then heated at 80 °C for 5 min 
followed by sonication for 5 min then cooled at 0 °C for 5 mins (x 2) and left to 
sit at –4 °C overnight.  
 
Cell proliferation (IL-2) assay. Dendritic cells (DC2114;53 2.5x104 cells) and 
murine NKT hybridoma cells (DN32.D3;4 1x105 cells) were incubated with 
various concentration of glycolipid (α-GalCer 1: 583 nM–0.569 nM; Dansyl α-
GalCer 2: 458 nM–0.447 nM in two fold dilution) in 200 µL of complete medium 
consisting of Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 
2 mM glutamine (Invitrogen), 1% penicillin-streptomycin (Invitrogen), 5x10-5 M 
2-mercaptoethanol (Invitrogen) and 5% foetal bovine serum (Sigma-Aldrich) at 
37 °C for 24 h. 100 µL of supernatant was added to 5x103 HT-2 cells in a flat-
bottom 96-well plate, incubated at 37 °C for 24 h and incorporation of 
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[3H]thymidine over the final 6 h was measured with a beta-counter (Wallac). A 
standard curve was constructed by incubating HT-2 cells with known 
concentrations of IL-2 (200–0 U/mL in five fold dilution). Each sample was 
analysed in triplicate. 
 
Antigen presenting cell maturation assay. Glycolipid diluted to 2 µg/mL and 
200 ng (in 100 µL) was administered i.v. to groups of C57BL/6 mice (n = 3) and 
spleens were removed 20 h later. Spleens were teased through a cell strainer, red 
blood cells (RBC) were lysed with RBC lysis buffer followed by antibody 
labelling for CD11c (clone HL3; BD Pharmingen), B220 (clone RA3-6B2 
conjugated to A488; BD Pharmingen), CD86 (clone GL1 conjugated to PE; 
eBioscience) and propidium iodide (BD Pharmingen) and analysis by flow 
cytometry (BD FACSort). The same protocol was used for assessing expression 
of CD86 on CD11c+ dendritic cells by CD1d–/– mice. 
 
Uptake of glycolipid by dendritic cells in vitro. 1x106 DC2114 cells were 
incubated with 4 µg of glycolipid in 1 mL cIMDM in a flat-bottom 6-well plate at 
37°C for 24 h. Cells were resuspended in FACS buffer, stained with viability dye 
(PI; BD Pharmingen) and analysed by flow cytometry (BD LSRII SORP; UV 
laser, filter 525/50, Hoechst Blue detector) 
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Chapter 3. Synthesis of BODIPY-α-
galactosylceramide 
 
3.1 Introduction 
 
Fluorescently labelled α-galactosylceramide (α-GalCer) probes (eg. Dansyl-α-
GalCer 2 and BODIPY-α-GalCer 3, Figure 3.1) are valuable tools that can be 
used to further understand the mechanism of iNKT cell activation by α-GalCer 
(1). While crystal structure analysis and the results from structure activity 
relationships provide a clear understanding of the specific molecular interactions 
between α-GalCer, CD1d and TCR, which gives rise to the activation of iNKT 
cells, little is known about the trafficking of α-GalCer.  
 
 
 
Figure 3.1. α-GalCer 1, dansyl-α-GalCer 2 and BODIPY-α-GalCer 3. 
Tagging α-GalCer with a fluorophore will allow for further understanding about 
the behaviour of the glycolipid during cancer immunotherapy. The value of 
fluorescently labeled α-galactosylceramide has been illustrated in Chapter 2, 
whereby the synthesis and biological evaluation of dansyl-α-GalCer 2 were 
described. While the uptake of dansyl-α-GalCer 2 by dendritic cells (DCs) can be 
monitored by flow cytometry, the dansyl fluorophore is not bright enough to be 
detected by fluorescent and confocal microscopy. This is because the fluorescent 
glycolipid underwent rapid photobleaching when it was subjected under the UV 
laser used to excite the fluorophore. Moreover, it was found that when DCs were 
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isolated from mice injected with dansyl-α-GalCer 2, and analysed, no glycolipid 
could be detected by flow cytometry. Therefore, to meet the need for a brighter 
fluorophore, boron dipyrromethene (BODIPY)-α-GalCer 3 was developed. 
BODIPY is a boron dipyrromethene dye that has a wavelength of maximum 
absorbance at around 500 nm and emits light at 510 nm. It was chosen as a 
fluorophore due to its higher fluorescence quantum yield (Φ = 0.40 – 0.60) 
compared to the dansyl group (Φ = 0.20).1   
 
3.2 Synthesis of BODIPY-α-galactosylceramide 
Retrosynthesis 
To synthesise BODIPY-α-GalCer 3, a strategy that differed to that used for the 
synthesis of dansyl-α-GalCer 2 was undertaken. Instead of the early incorporation 
of the fluorescent group onto the galactose sugar head group, the route was 
designed such that the BODIPY group was introduced at the end of the synthesis, 
by coupling BODIPY-COOH 52 with the fully deprotected glycolipid, 6´-amino-
α-GalCer 51 (Scheme 3.1). It was envisaged that the development of the late stage 
intermediate, 6´-amino-α-GalCer 51 will be useful not only for making BODIPY-
α-GalCer, but also for attaching other functionalities to the 6´-position of α-
GalCer, such as other fluorescent groups, biotin tags, or peptides.2-7 The 
BODIPY-COOH 52 could in turn be synthesised in six steps from terephthalic 
acid 53 and dimethylpyrrole 54 using a strategy developed in the Stocker-Timmer 
group,1,8 while the deprotected glycolipid 51 could be obtained from 6´-azido-α-
GalCer 55 via removal of the ceramide protecting groups with simultaneous 
hydrogenolysis of the benzyl ethers and reduction of the azide to an amine. The 
fully protected glycolipid 55 could be made by coupling galactosyl imidate 56, 
itself obtained from D-galactose 39,9,10 with a suitably protected lipid acceptor 57, 
prepared in a few steps from phytosphingosine 58. In contrast to the synthetic 
route employed for the synthesis of dansyl-α-GalCer 2, the glycosylation strategy 
employed for the preparation of BODIPY-α-GalCer 3 would involve the coupling 
of galactose donor 56 with the complete ceramide acceptor 57. While the yields of 
glycosylations with N-acylated ceramide acceptors are typically lower (ca. 25-
55%) compared to coupling with the ceramide backbone, this strategy is necessary 
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to avoid the presence of two amine groups, which would be difficult to selectively 
acylate after coupling.7 
 
 
 
Scheme 3.1. Retrosynthetic scheme for BODIPY-α-GalCer 3. 
 84 
Synthesis of 6-azido-galactosyl imidate donor 56. 
The synthesis of BODIPY-α-GalCer 3 commenced with the preparation of 
galactosyl imidate donor 56 (Scheme 3.2). Here, methyl 6-azido galactoside 45, a 
convenient intermediate previously described in Chapter 2 (Scheme 2.3), was 
converted to lactol 59 via acid-mediated hydrolysis of the anomeric methyl group. 
The trichloroacetimidate moiety was installed via the treatment of lactol 59 with 
trichloroacetonitrile in the presence of DBU to provide imidate donor 56, as the 
α-anomer only, in 89% yield. Taken together, galactosyl imidate donor 56 was 
made from D-galactose (39) in 33% overall yield over seven steps, which is more 
efficient compared to the route reported by Li et al., which produced the imidate 
donor 56 in 11% overall yield over seven steps, starting from a later stage 
intermediate, 1-S-β-D-galactosyl toluene.10 
 
 
 
Scheme 3.2. Synthesis of 6-azido-galactosyl imidate donor 56. 
 
Synthesis of BODIPY-COOH 52 
 
A robust and efficient route for the synthesis of BODIPY-COOH 52 was 
developed by Ms. Stephanie Chee within the group (Scheme 3.3).11 Briefly, the 
synthesis began with the methylation and partial hydrolysis of terephthalic acid 53 
to give monoester 60 in 85% yield over two steps. Next, the acid chloride 61 was 
generated in the presence of thionyl chloride, followed immediately by 
condensation with dimethylpyrrole 54 to form dipyrrole 62 in 77% yield over two 
steps. The boron functionality was then introduced by reacting dipyrrole 62 with 
BF3.OEt2 to give BODIPY ester 63 in an excellent 98% yield. Finally, hydrolysis 
of the methyl ester under basic conditions afforded BODIPY-COOH 52 in 
quantitative yield. For this thesis, methyl ester 63 was kindly provided by Ms. 
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Stephanie Chee, which upon hydrolysis afforded the desired BODIPY-COOH 52 
in identical yield to that previously reported.11  
 
 
 
Scheme 3.3. Synthesis of BODIPY-COOH 52.11 
 
Synthesis of 3,4-isopropylidene protected ceramide acceptor 65 and 
coupling to galactosyl donor 56 
 
With the sugar building block and BODIPY-COOH in hand, attention then turned 
to the synthesis of the ceramide acceptor. Again, an existing intermediate from the 
established route for the synthesis of dansyl-α-GalCer 2, namely the 2-azido-3,4-
isopropylidene protected phytosphingosine 43 (Chapter 2), was used (Scheme 
3.4).9 The azide functionality in 43 was reduced using trimethylphosphine and 1M 
NaOH and the resultant amine coupled to hexacosanoic acid using an 
EDCI/DMAP-mediated protocol to give the fully protected lipid 64. Next, the 
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selective removal of the trityl group was attempted under acidic conditions, but 
despite the controlled and careful addition of AcOH or TFA, hydrolysis of the 
isopropylidene protecting group could not be prevented. Therefore, a Birch 
reaction was used as an alternative method to selectively cleave the trityl group, 
which yielded the 3,4-isopropylidene protected acceptor 65 in 70% yield. Here, it 
should be noted that the synthesis of acceptor 65 starting from 2-azido 
phytosphingosine, which has previously been described by Schmidt and co-
workers,12,13 is a shorter and more direct route than the one used herein, however 
intermediate 43 was chosen as it was readily available from previous work with 
dansyl-α-GalCer 2.9    
 
 
Scheme 3.4. Synthesis of 3,4-isopropylidene protected ceramide acceptor 65. 
With acceptor 65 in hand, attempts were then made to perform the glycosylation 
reaction using imidate donor 56 and TMSOTf as the promoter. Glycosylation 
reactions with imidate donors using TMSOTf as the activator are typically 
performed at temperatures of 0 °C or lower,14 however, when the coupling was 
attempted with a 2:1 mixture of DCM/THF as the solvent (Table 3.1, Entry 1), the 
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reaction mixture containing both donor and acceptor appeared cloudy, indicating 
poor solubility of the lipid acceptor. As a result, no desired glycolipid was 
observed and instead the hydrolysed donor 59 was obtained upon workup of the 
reaction, along with the recovery of uncoupled acceptor 65.  
 
Table 3.1. Glycosylation reaction between imidate donor 56 and 3,4-
isopropylidene acceptor 65.  
 
Entry Activator Solventb Temperature Productc 
1 TMSOTf  DCM/THF (2/1) 0 °C to rt 59 
2 TMSOTf 
Toluene/DCM/DMF 
(2/1/0.1) 
rt 59 
3 TMSOTf Toluene/DCM (2/1) 30 °C 59 + 66 
4 TMSOTf Et2O/THF (5/1) rt 59 + 66 
5 BF3.OEt2 Et2O/THF (5/1) -20 °C 59 + 66 
a Donor and acceptor were co-evaporated with dry toluene (x3) and dissolved in the solvent and 
stirred with 4Å molecular sieves for 30 mins. Then the reaction was set to the desired temperature 
and the promoter was added slowly. 
b Solvent and ratio (v/v) in parentheses. 
c Uncoupled lipid acceptor 65 was recovered from all unsuccessful coupling reactions. 
 
During co-evaporation of the donor and acceptor prior to the glycosylation 
reactions, it was observed that toluene, which was used as the solvent for 
azeotropic removal of water, was able to dissolve the lipid acceptor well. 
Therefore, the glycosylation was attempted using a mixture of toluene/DCM/DMF 
(2/1/0.1, v/v/v) as the solvent (Entry 2). While the reaction mixture was 
completely clear at room temperature, unfortunately the glycosylation was 
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unsuccessful, presumably because the highly reactive donor was being activated 
at a temperature that was too high. Again only the hydrolysed donor 59 was 
obtained. Similarly, glycosylation with toluene and DCM as a solvent at 30 °C 
was to no avail and gave 1,1´-digalactoside 66 (Entry 3). While all effort was 
made to ensure that dry conditions were used for the sensitive coupling reactions, 
unfortunately the severe unreactivity of the lipid acceptor 65 meant that trace 
amounts of water in the reaction mixture led to the formation of lactol 59, which 
then reacted with another molecule of imidate 56 to form 1,1´-disaccharide 66. A 
diethyl ether/THF solvent system, which is commonly used in coupling reactions 
between lipid acceptors and glycoside donors,15 but again the lipid acceptor was 
only soluble at room temperature and as a result, gave 1,1´-digalactoside 66 
(Entry 4). In accordance with Wong and co-workers’ procedure,15 a milder 
promoter BF3.OEt2 was used with the same solvent system, though 
disappointingly, this also only gave a mixture of lactol 59 and 1,1´-digalactoside 
66 (Entry 5). From this series of glycosylation attempts, it was concluded that the 
solubility of the ceramide acceptor 65, and hence its poor reactivity, was a major 
issue and that even trace amounts of water would thus preferentially react with the 
imidate donor 56 to form the lactol. Here, it should also be noted that although 
Schmidt and co-workers have reported the synthesis of lipid acceptor 65, it has 
not been used directly as a glycosyl acceptor and instead was converted to a 1-
phosphite derivative for the synthesis of glycophosphatidylinositols (GPIs).12,13 
 
Synthesis of benzoyl protected ceramide acceptor 57 and coupling to 
galactosyl donor 56 
 
Due to the poor reactivity of isopropylidene protected lipid acceptor 65, 
alternative protecting groups on the phytosphingosine backbone were evaluated. 
Xia et al. reported on the successful coupling of the lipid acceptor when the 3- and 
4-hydroxyls were protected as either benzyl ethers or benzoate esters (yield 57-
59%).16 It was therefore proposed that a change of protecting groups would aid 
with the solubility of the lipid, and thus the glycosylation reaction. Furthermore, 
Xia et. al. observed that when the 3- and 4- hydroxyls of the phytosphingosine 
backbone were protected with benzyl groups, upon glycosylation with a 
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galactosyl imidate donor, the β-coupled glycolipid was obtained. This was a 
consequence of the high reactivity of the acceptor due to the arming effect of the 
electron-donating benzyl groups. Alternatively, when the secondary alcohols were 
protected as benzoate esters, only the α-isomer was obtained as the major product. 
From the above results, it was therefore proposed that the glycosylation reaction 
would be more successful if a benzoate-protected lipid was used. 
 
To this end, the synthesis of the target N-acylated phytosphingosine lipid began 
with a similar approach to that previously reported, whereby commercially 
available phytosphingosine 58 was first N-acylated at the 2-position with 
hexacosanoic (C26) acid (Scheme 3.5).16,17 Various strategies such as direct 
coupling of the amine 58 and the C26 acid with EDCI18-21 as the coupling agent or 
coupling to the C26 acid chloride20 or the C26-N-hydroxysuccinimidyl ester16,22 
have been employed to obtain the trihydroxy ceramide 67.  
 
Initial attempts to carry out this reaction according to Gervay-Hague and co-
workers’ protocol utilizing EDCI as a coupling agent in the presence of DMAP 
afforded trihydroxy ceramide 67 in 70% yield (Scheme 3.5).18 During the 
reaction, it was observed that the C26 acid was poorly soluble in pyridine solvent 
used. The poor solubility of the lipid leading to its lower reactivity, as well as the 
ability of EDCI to facilitate the formation of both esters and amides were 
suspected to be the reason for this average yield. Therefore, to improve the yield 
of the reaction, an alternative coupling agent selective only for the acylation of 
amines but not alcohols, PyBOP, in the presence of DiPEA and DMF was used. 
Due to the difficulty in monitoring the disappearance of the starting materials, 
phytosphingosine 67 and C26 acid by TLC, two reactions were set up and allowed 
to stir for 1 day or 3 days, which upon purification by crystallisation afforded the 
ceramide 67 in 37% and 73%, respectively. The purity of the lipid was confirmed 
by 1H NMR. It was concluded that the reaction proceeded slowly, and so when it 
was allowed to react for 7 days, the triol 67 was obtained in quantitative yield. 
This is the first report of PyBOP being used as the coupling agent for 
phytosphingosine-based ceramides and has by far the best yield compared to other 
coupling protocols available.16,19-24 
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Next, the primary hydroxyl was regioselectively protected as a trityl ether to give 
diol 68 in 79% yield. Subsequent benzoylation of the secondary hydroxyls, 
followed by the selective removal of the trityl group then afforded the ceramide 
acceptor 57 in 67% over two steps.16,23 This strategy thus allowed for the 
synthesis of the complete ceramide acceptor in an excellent overall yield of 53% 
over four steps.  The results obtained are comparable to Xia and co-workers’ 
route, which began with succinimide-activated acyl lipid (77% and 65% overall 
yield over five steps for the C26 and C8 lipids, respectively)16,17 and Morita  
et al.’s route, which began with 2-azido-tri-O-benzyl-phytosphingosine (42% 
overall yield over 5 steps).23  
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Scheme 3.5. Synthesis of α-GalCer diol 69.  
 
With the benzoate protected lipid acceptor 57 and the galactose donor 56 in hand, 
the glycosylation was then attempted using TMSOTf as the activator. It was found 
that 0 °C was the lowest temperature that could be used for optimal activation of 
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the trichloroacetimidate donor 56, while keeping the highly lipophilic lipid 
acceptor 57 dissolved. Indeed, this afforded the protected 6´-azido glycolipid 55 
in excellent yield (91%) and satisfactory α-selectivity (α:β = 3:1), as confirmed 
by a coupling constant of 3.6 Hz for the anomeric signal in the 1H NMR and a one 
bond coupling (1JCH) of 168.6 Hz for the α-anomer.25 In contrast, the β-anomer  
had an anomeric coupling constant of 7.8 Hz and a one bond CH-coupling of 
159.4 Hz.  Due to the poor solubility of the lipid, glycosylation reactions using the 
complete ceramide acceptor typically result in a modest yield (ca. 40-50%) for the 
α-anomer,16,19 thus the results observed here were encouraging, particularly as the 
α and β-anomers could be isolated in 68% and 23% yields, respectively. The 
removal of the protecting groups on α-linked glycolipid 55 was initially attempted 
with a Birch reduction, which would remove the benzyl groups as well as the 
benzoyl groups upon quenching of the reaction with methanol to form sodium 
methoxide in situ. However, difficulty in isolating the product upon neutralisation 
with Dowex+H+ meant that stepwise deprotection was needed and the 3- and 4-O-
benzoyl groups were first removed under basic conditions to afford the diol 
glycolipid 69 in an excellent yield of 93%.  
 
Next, the simultaneous hydrogenolysis of the three benzyl ethers and the 
reduction of the azide to the amine was carried out using Pearlman’s catalyst with 
the addition of 5% formic acid to prevent catalyst poisoning by the amine that is 
formed during the reaction (Scheme 3.6). While the reaction appeared to proceed 
to completion by TLC analysis, the isolation and purification of amine 51 proved 
difficult. Despite using copious amounts of CHCl3/EtOH/MeOH and pyridine to 
wash the celite plug that was used to filter the catalyst upon completion of the 
reaction, only a small amount of material was recovered. The difficulty in 
isolating the glycolipid from the reaction mixture was attributed to the poor 
solubility of the fully deprotected 6´-amino glycolipid 51 and its affinity for the 
palladium hydroxide on carbon catalyst. Initial attempts to directly couple the 
crude mixture of amine 51 to BODIPY-COOH 52 was unsuccessful, as confirmed 
by the absence of new product when the reaction mixture was analysed by TLC. 
Indeed, both starting materials were re-isolated.  
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Scheme 3.6. Synthesis of BODIPY-α-GalCer 3 using BODIPY-COOH 52. 
 
To understand why the coupling reaction was unsuccessful, some of the crude 
mixture of glycolipid 51 that was used in the coupling reaction was analysed by 
mass spectrometry. The presence of the desired product 6´-amino-α-GalCer 51 
was detected (m/z calcd. for [C50H100N2O8+H]+: 857.7552, obsd.: 857.7533) along 
with an unexpected m/z of 869.7521. Upon careful analysis, this was attributed to 
the formation of cis-decalin E (Scheme 3.7) due to the presence of trace 
formaldehyde present in the methanol that was used to wash, filter and transfer the 
glycolipid (m/z calcd. for [C51H100N2O8+H]+: 869.7552, obsd.: 869.7521). The 
mechanism for the formation of cis-decalin E is depicted in Scheme 3.7, whereby 
the amine 51 attacks a molecule of formaldehyde to form alcohol B, which upon 
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elimination of water gives the iminium intermediate D. Subsequent attack of the 
4-OH on the iminium carbon followed by the loss of H+ generates the cis-decalin 
by-product E.  
 
 
 
Scheme 3.7. Mechanism for the formation of cis-decalin E by-product. 
In an attempt to regenerate the free amine (ie. to hydrolyse the cis-decalin E), the 
crude mixture was co-evaporated with 1M HCl (aq). Though somewhat 
successful, unfortunately, the reaction did not go to completion. Careful 
purification of the mixture of amine 51 and cis-decalin E by silica gel column 
chromatography using a solvent system of DCM, MeOH, EtOH and NH3 was also 
unsuccessful and instead caused the formation of ammonium chloride salt when 
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the ammonia in the eluting solvent reacted with trace HCl from the hydrolysis 
step. Efforts to separate the salt from the glycolipid by reverse phase column 
chromatography were futile as the glycolipid was insoluble in water and had to be 
loaded onto the column with a few drops of pyridine, which caused the product to 
be eluted together with the salts. Removal of the salts by dialysis was also 
attempted, but again proved unviable because the glycolipid was only soluble in a 
mixture of DCM/MeOH/water (2/1/5, v/v/v), which was not compatible with the 
cellulose dialysis tube. Fortunately, most of the ammonium chloride was 
successfully removed by crystallisation from a mixture of warm 30% MeOH in 
DCM and filtered. Due to the challenges in obtaining pure 6´-amino-α-GalCer (ie. 
without salts), it was decided that the semi-pure mixture would be used for the 
subsequent coupling to BODIPY-COOH 52 and the yield for conversion of diol 
69 to fully deprotected amine 51 was estimated at 33%. The identity of amine 51 
was confirmed by HRMS and the 1H NMR data matched that reported by Zhou et 
al.2 The synthetic approach used here is similar to Zhou et al.’s strategy whereby 
a galactosyl donor is coupled to the complete ceramide acceptor leading to the 
generation of the fully deprotected 6´-amino-α-GalCer 51 and subsequent 
functionalisation with a fluorophore. However, the protecting group strategy used 
in the synthesis reported herein allowed for the simultaneous removal of benzyl 
protecting groups and azide reduction leading to the generation of amine 51 in 
comparable overall yield of 21% over 3 steps from the ceramide lipid acceptor. In 
contrast, Zhou et al. reported an overall yield of 19% over 4 steps from the 
ceramide acceptor.2  
 
Next, amine 51 was coupled to BODIPY-COOH 52 using HBTU as the coupling 
agent (Scheme 3.6). The reaction appeared promising based on TLC analysis, 
however, to obtain BODIPY-α-GalCer 3 of sufficient purity and free from the 
coupling reagents and by-products, repeated purification by silica gel flash 
column chromatography was required. Unfortunately, all attempts to purify 
BODIPY-α-GalCer 3 proved futile. Indeed, the more time taken to purify the 
desired product, the more decomposition was observed. 
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As a fluorescent dye, BODIPY has many advantages including its high quantum 
yield and relatively small size.1 It is also fairly inert, although some 
decomposition of the dye has been observed under rather harsh photo-oxidation 
conditions. For example, some early analyses of the dye in the 1970’s revealed 
that complete fragmention can occur when a slow stream of oxygen is allowed to 
bubble through a solution of 3,5,3´,5´-tetramethyl-4,4´-diethyldipyrrylmethene 
exposed to photolysis under a halogen lamp (500W).26,27 Similar photo-oxidation 
was proposed to occur on boron-containing dipyrrylmethenes F (Scheme 3.8).28 
Here, addition of a singlet oxygen species across the double bond at C-7a and C-8 
of the BODIPY core gave dioxetanes G, which subsequently broke down to the 
ring opened intermediates H, which upon hydrolysis of the boron-nitrogen bonds 
produce dimethylketopyrroles I and ketones K. Tautomerisation of 
dimethylketopyrroles I then leads to the formation of lactam J, while further 
oxidation of ketone K produces 3-methylmaleimide M via dealkylation of the 
endoperoxide intermediate L.28,29  
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Scheme 3.8. Proposed mechanism of photo-oxidation of BODIPY core following 
photolysis with halogen lamp and O2 stream.28  
The degradation of the BODIPY dye under more ambient conditions, however, 
has not been previously reported, yet TLC, HRMS and 1H NMR analysis of the 
product mixture following the repeated purification of BODIPY-α-GalCer 3 
revealed the presence of several species. Given the small quantities of material 
available, it was difficult to conclusively prove the structures of the degradation 
products, however, by TLC, all products had very similar Rf values. Notably, 
analysis by HRMS revealed two by-products containing either one or two chlorine 
atoms, as evidenced by characteristic isotopic distributions arising from 35Cl and 
37Cl atoms. Further analysis revealed the [M+H]+ peak of 1241.8541, which 
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correlated to the calculated value of 1241.8565 for C70H117BClF2N4O9+. Thus, it 
has been tentatively proposed that BODIPY-α-GalCer 3 undergoes photo-
oxidation with subsequent addition of Cl-, which is formed from the 
decomposition of the NMR solvent CDCl3, to yield the cholorinated adduct Q 
(Scheme 3.9). In this proposed mechanism, a singlet oxygen species is added 
across C-3 and C-8a of the BODIPY core to give endoperoxide N, which 
subsequently breaks down to give adduct O that is set up for attack by Cl- at the 2-
position. Loss of H2O2 then reinstates the aromaticity of the BODIPY core to 
produce the chlorinated BODIPY-α-GalCer Q. While there is a possibility of 
chlorination at the 3- and 5- methyl carbons of the BODIPY core, this is unlikely 
to be the by-product in this case because halogenation at the 3- and 5-positions 
typically occurs in the presence of a cationic halogen, such as N-
bromosuccinimide, to form a 3-brominated BODIPY core.30  
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Scheme 3.9. Proposed mechanism for the formation of chlorinated BODIPY-α-
GalCer Q. 
To support the assumption that the BODIPY group can be oxidized under 
relatively mild conditions, a small sample of the dye itself, BODIPY-COOH 52, 
was exposed to UV light (12 Watt lamp) for 10 minutes. Analysis by HRMS once 
again revealed an oxidised product (m/z calcd. for [C20H18BF2N2O3]+: 383.1373, 
obsd.: 383.1385). A mechanism, similar to that proposed for the chlorination 
adduct Q, is proposed to explain the formation of this product, whereby attack of 
H2O in intermediate O leads to an alcohol with net addition of atomic oxygen to 
the BODIPY core. 
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In addition to the oxidised chlorinated adduct, which was determined by HRMS, 
1H NMR of the reaction mixture of BODIPY-α-GalCer 3 after repeated 
purification also revealed that the proton signal belonging to H-2 and H-6 of the 
pyrrole ring was significantly reduced compared to the other signals. Upon 
analysis by mass spectrometry, two masses corresponding to the substitution of 
one and two hydrogen(s) with deuterium(s) were detected (Scheme 3.10). This 
increase in mass came about due to the insolubility of the BODIPY-α-GalCer 3 in 
CDCl3 alone, which necessitated the need for a mixture of 10% deuterated 
methanol (CD3OD) in CDCl3 for NMR analyses. Electrophilic aromatic 
subsitution is most likely to occur at the 2- and 6- positions of the BODIPY core, 
giving rise to deuteration at one (→S) or both (→T) of these sites. The protic 
nature of CD3OD means that a D+ is a readily available electrophile. Accordingly, 
it was thus determined that non-protic deuterated solvents, such as pyridine-d5, 
should be used as the NMR solvent for future analyses. 
 
 
 
Scheme 3.10. Deuteration of BODIPY-α-GalCer 3. 
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To circumvent the aforementioned issues and to develop a BODIPY dye that 
would allow for easier purficiation (and thus limit exposure to light and oxygen), 
BODIPY-COOH 52 was derivatised as the N-hydroxysuccimidyl ester 70 
(Scheme 3.11). In this way, only a base, such as DiPEA, would need to be added 
to the reaction vessel, while the cleaved N-hydroxysuccinimide could be more 
readily separated from the desired BODIPY-α-GalCer 3. Indeed, the coupling of 
the amine 51 with BODIPY-NHS 70 proceeded smoothly and the product could 
be readily purified by silica gel flash column chromatography (gradient from 1%  
to 3% MeOH in DCM) to afford BODIPY-α-GalCer 3 as a red solid in 44% yield. 
This compromised yield is largely attributed to the loss of material when purifying 
the fully deprotected amine 51, as the 44% yield obtained is comparable to amide 
couplings performed on the 6´ position of the α-GalCer which typically range 
from 33-53% yield.2,3 Unfortunately, limited quantities of fully protected 6´-
azido-α-GalCer 55 prevented further optimisation of the last two steps of this 
route. Nonetheless, enough quantity of the final target BODIPY-α-GalCer 3 was 
obtained for the purpose of characterisation. The identity of the BODIPY-α-
GalCer 3 was confirmed by 1H and 13C NMR and mass spectrometry analysis 
(m/z calcd. for [C70H117BF2N4O9+H]+: 1207.8954, obsd.: 1207.8958), including 
the characteristic three-bond correlation (HMBC) between H-6´ and carbonyl 
carbon of BODIPY amide, and there was no evidence of oxidized, chlorinated or 
deuterated by-products by NMR or HRMS. BODIPY-α-GalCer 3 has 
subsequently been sent to collaborators Dr. Hans van der Vliet and co-workers for 
use as a fluorescent probe to study DC processing of α-GalCer, and also to 
determine the loading of glycolipids on tumour cells. 
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Scheme 3.11. Synthesis of BODIPY-α-GalCer 3 using BODIPY-NHS 70.
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3.3 Conclusion 
 
In conclusion BODIPY-α-GalCer 3 was successfully synthesised from the fully 
deprotected amine 51 and BODIPY-NHS 70. It was discovered that the solubility 
of the ceramide lipid acceptor 57 was crucial for its reactivity in the glycosylation 
with imidate donor 56. Though the glycosylation yield obtained when using the 
N-acylated ceramide acceptor is generally lower compared to the yields when the 
phytosphingosine acceptor, remarkably a good 68% yield of the desired α-anomer 
was observed. Moreover, the synthetic strategy employed here is more convergent 
and provides the fully deprotected glycolipid 51 bearing a reactive amine on the 
6´-position that can be readily derivatised. The main challenge, however, is the 
purification of the amine glycolipid 51, of which can be optimised with the 
availability of more of the fully protected glycolipid 55. In the course of 
purification of the final product, BODIPY-α-GalCer 3, limitations due to the 
sensitivity of the dye to photo-oxidation were also discovered. Indeed, this is an 
area that is currently undergoing further investigation in the group to provide 
more conclusive evidence for the oxidation products observed. BODIPY-α-
GalCer 3 has been sent to collaborators who will use the probe to study the role of 
α-GalCer in cancer immunotherapy in more depth. 
 
3.4 Experimental 
General procedure 
Unless otherwise stated all reactions were performed under N2. Prior to use, THF 
(Pancreac) was distilled from sodium and benzophenone, pyridine was distilled 
and dried over 4Å molecular sieves (4Å MS), DCM (Pancreac) was distilled from 
P2O5, and H2O and benzene (Fisher Scientific) were distilled. Trityl chloride 
(Acros), anhydrous Et2O (Pancreac), PPh3 (Merck), Pd(OH)2/C (Aldrich, 20 
wt%), anhydrous DMF (Acros), TFA (Aldrich), trichloroacetonitrile (Aldrich), 
triethylsilane (Fluka), TMSOTf (Aldrich), H2SO4 (Lab-Scan), Formic acid 
(Aldrich), AcCl (B&M), BnBr (Fluka), PMe3 (Aldrich, 1M in THF), AcOH (Ajax 
Finechem), Ac2O (Peking Reagent), TMSOTf (Aldrich), DiPEA (Aldrich), 
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NaOMe (Janssen Chimica), phytosphingosine (TCI), C25H51COOH (Acros), BzCl 
(Aldrich, distilled an stored under argon), HBTU (Acros), PyBOP (Aldrich), 
EDCI (Aldrich), DMAP (Merck), sodium (Aldrich), Pd(OH)2/C (Aldrich, 20 
wt%), EtOAc (Pancreac), hexanes (Fisher Scientific), petroleum ether (Pure 
Science), MeOH (Pure Science), CHCl3 (Pancreac), EtOH (absolute, Pure 
Science), NaOH (Pure Science), NaHCO3 (Pure Science), NaCl (Pancreac) were 
used as received. All solvents were removed by evaporation under reduced 
pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica 
gel coated plastic sheets (0.20 mm, with fluorescent indicator UV254) with 
detection by UV-absorption (short wave UV – 254 nm; long wave UV – 366 nm), 
by dipping in 10% H2SO4 in EtOH followed by charring at ~150 °C, by dipping in 
I2 in silica, or by dipping into a solution of ninhydrin in EtOH followed by 
charring at ~150 °C. Column chromatography was performed on Pure Science 
silica gel (40-63 micron). AccuBOND II ODS-C18 (Agilent) was used for reverse 
phase chromatography. Sephadex® LH-20 (Aldrich) was used for size exclusion 
chromatography. Infrared spectra were recorded as thin films using a Bruker 
Tensor 27 FTIR spectrometer equipped with an Attenuated Total Reflectance 
(ATR) sampling accessory and are reported in wave numbers (cm-1). Nuclear 
magnetic resonance spectra were recorded at 20 °C in CD3OD, CDCl3, or 
pyridine-d5 using either a Varian INOVA operating at 500 MHz or Varian 
VNMRS operating at 600 MHz. Chemical shifts are given in ppm (δ) relative to 
TMS. NMR peak assignments were made using COSY, HSQC and HMBC 2D 
experiments.  
 
 6-Azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactose (59) 
Methyl 6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactoside 
452,9 (360 mg, 0.74 mmol) was dissolved in aqueous acetic 
acid (11 mL, 80% v/v) in water followed by the addition of 1M H2SO4 (2.72 mL, 
2.72 mmol). The reaction was stirred at 100 °C for 4.5 h, then 120 °C for a further 
1.5 h. The reaction mixture was poured into ice water and extracted with EtOAc 
(2 x 50 mL) and the combined organic layers were washed with water (100 mL), 
saturated NaHCO3 solution (2 x 100 mL) and brine (100 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by silica gel flash 
O
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column chromatography and eluted with 5:1 (v/v) petroleum ether/EtOAc to 
afford lactol 59 (219 mg, 0.46 mmol, 63%) as a clear oil. Rf: 0.43 (PE/EA, 2:1, 
v/v); [α]D25 = +9.0° (c = 1.0, CHCl3); IR (film) 3410, 3064, 3031, 2871, 2101, 
1497, 1454, 1362, 1281, 1214, 1062, 1027, 912, 736, 697 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.45–7.31 (m, 15H, Harom), 5.31 (t, J1,2 = J1,OH = 2.6 Hz, 1H, H-1), 
5.03 (d, Ja,b = 11.2 Hz, 1H, CH-a, 4-O-Bn), 4.88 (d, Ja,b = 12.0 Hz, 1H, CH-a, 2-
O-Bn), 4.86 (d, Ja,b = 11.8 Hz, 1H, CH-a, 3-O-Bn), 4.81 (d, Ja,b = 12.0 Hz, 1H, 
CH-b, 2-O-Bn), 4.74 (d, Ja,b = 11.8 Hz, 1H, CH-b, 3-O-Bn), 4.64 (d, Ja,b = 11.2 
Hz, 1H, CH-b, 4-O-Bn), 4.08–4.06 (m, 2H, H-2, H-5), 3.97 (dd, J2,3 = 9.9 Hz, J3,4 
= 2.6 Hz, 1H, H-3), 3.86 (bs, 1H, H-4), 3.53 (dd, J6a,6b = 12.5 Hz, J5,6a = 7.6 Hz, 
1H, H-6a), 3.33 (d, J1,OH = 2.6 Hz, 1H, OH), 3.13 (dd, J6a,6b = 12.5 Hz, J5,6b = 5.9 
Hz, 1H, H-6b); 13C NMR (125 MHz, CDCl3) δ 138.5 (C-i, 2-O-Bn), 138.2 (C-i, 4-
O-Bn), 138.1 (C-i, 3-O-Bn), 128.6, 128.53, 128.47, 128.2, 128.1, 128.0, 127.8, 
127.6 (9 x Carom), 91.9 (C-1), 78.6 (C-3), 76.5 (C-2), 74.74 (C-4), 74.67 (CH2, 4-
O-Bn), 73.6 (CH2, 2-O-Bn), 73.3 (CH2, 3-O-Bn), 69.7 (C-5), 51.2 (C-6); 
HRMS(ESI) m/z calcd. for [C27H29N3O5+Na]+: 498.1999, obsd.: 498.2005. 
 
O-(6-Azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactosyl) 
trichloroacetimidate (56) 
Trichloroacetonitrile (448 µL, 4.47 mmol) and DBU (100 
µL, 0.67 mmol) were added to lactol 59 (213 mg, 0.45 
mmol) (co-evaporated with toluene x 3) in dry CH2Cl2 (5 mL). After stirring for 
1.5 h at rt, the reaction mixture was concentrated in vacuo and purified by silica 
gel flash column chromatography (silica gel was pre-washed with 1% 
triethylamine in 20:1 v/v petroleum ether/EtOAc). Elution with 20:1 (v/v) 
petroleum ether/EtOAc afforded imidate 56 (246 mg, 0.40 mmol, 89%) as a clear 
oil. Rf: 0.62 (PE/EA, 2:1, v/v); [α]D24 = +34.0° (c = 1.0, CHCl3); IR (film) 3338, 
3064, 3031, 2916, 2101, 1732, 1672, 1497, 1454, 1351, 1287, 1107, 1071, 1027, 
838, 794, 736, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H, NH), 7.41–
7.29 (m, 15H, Harom), 6.56 (d, J1,2 = 3.3 Hz, 1H, H-1), 5.06 (d, Ja,b = 11.3 Hz, 1H, 
CH-a, 4-O-Bn), 4.91 (d, Ja,b = 11.8 Hz, 1H, CH-a, 3-O-Bn), 4.81 (d, Ja,b = 11.8 Hz, 
1H, CH-b, 3-O-Bn), 4.78 (bs, 2H, CH-a, CH-b, 2-O-Bn), 4.65 (d, Ja,b = 11.3 Hz, 
1H, CH-b, 4-O-Bn), 4.27 (dd, J2,3 = 10.0 Hz, J1,2 = 3.3 Hz, 1H, H-2), 4.06–4.05 
O
BnO
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N3
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NH
 106 
(m, 2H, H-3, H-5), 3.92 (bs, 1H, H-4), 3.53 (dd, J6a,6b = 12.6 Hz, J5,6a = 7.4 Hz, 
1H, H-6a), 3.14 (dd, J6a,6b = 12.6 Hz, J5,6b = 5.8 Hz, 1H, H-6b); 13C NMR (125 
MHz, CDCl3) δ 161.1 (C=NH), 138.4 (C-i, 3-O-Bn), 138.3 (C-i, 2-O-Bn), 138.1 
(C-i, 4-O-Bn), 128.54, 128.52, 128.51 (3 x C-m, 2-O-Bn, 3-O-Bn, 4-O-Bn), 128.4 
(C-o, 4-O-Bn), 127.8 (C-m, 3-O-Bn), 127.6 (C-m, 2-O-Bn), 128.1, 127.9, 127.7 (3 
x C-p, 2-O-Bn, 3-O-Bn, 4-O-Bn), 94.9 (C-1), 78.0 (C-3), 75.8 (C-2), 74.9 (CH2, 
4-O-Bn), 74.7 (C-4), 73.6 (CH2, 3-O-Bn), 73.1 (CH2, 2-O-Bn), 72.4 (C-5), 50.9 
(C-6); HRMS(ESI) m/z calcd. for [C29H29N4O5Cl3+Na]+: 641.1096, obsd.: 
641.1113. 
 
4-(4,4-Difluoro-1,3,5,7-tetramethyl-3a,4a-diaza-4-bora-s-
indacen-8-yl)benzoic acid (52)  
To a solution of the methyl ester 6311 (0.148 g, 0.387 mmol) in 
isopropanol (15 mL) under an argon atmosphere, an aqueous 
solution of 0.1M KOH (15 mL) was added. The reaction 
mixture was stirred at room temperature until complete 
consumption of 63 by TLC analysis was observed. The reaction mixture was then 
acidified with H+ dowex until pH=2-3, filtered and evaporated to dryness in 
vacuo. The residue was purified by silica gel gradient column chromatography 
(CH2Cl2/MeOH, 99:1 to 96:4, v/v) to afford the BODIPY-COOH 52 (0.142 g, 
0.387 mmol, quantitative). The obtained red-brown solid is stored in the dark. Mp 
182.5–182.8 °C; Rf = 0.74 (MeOH/EtOAc, 1/4, v/v); IR (film) 2924, 1723, 1544, 
1510, 1309, 1194, 1157, 983, 739 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.25 (d, 
J14,15 = J17,18 = 8.5 Hz,  8.2 Hz, 2H, H-15, H-17), 7.44 (d, J14,15 = J17,18 = 8.2, 2H, 
H-14, H-18), 6.01 (s, 2H, H-2, H-6), 2.56 (s, 6H, H-9, H-10), 1.37 (s, 6H, H-11, 
H-12); 13C NMR (125 MHz, CDCl3) δ 130.9 (C-15, C-17), 128.5 (C-14, C-18), 
121.5 (C-2), 14.6 (C-9, C-10, C-11, C-12); HRMS(ESI) m/z calcd. for 
[C20H19BF2N2O2Na]+: 391.1405, obsd.: 391.1413. 
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2,5-Dioxopyrrolidin-1-yl-4-(4,4-difluoro-1,3,5,7-
tetramethyl-3a,4a-diaza-4-bora-s-indacen-8-yl)benzoate 
(70)   
To a solution of BODIPY-COOH 52 (60.4 mg, 0.164 
mmol) in CH2Cl2 (6.5 ml) was added NHS (37.8 mg, 0.328 
mmol) and EDCI (62.9 mg, 0.328 mmol) and the solution 
stirred in the dark overnight. After completion of the 
reaction by TLC analysis, the mixture is diluted with distilled water, extracted 
with CH2Cl2 (2 x 25 mL) and washed with brine (1 x 25 mL). The combined 
organic phase was dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. Purification of the crude residue by silica gel gradient column 
chromatography (petroleum ether to CH2Cl2) afforded BODIPY-NHS 70 (76.0 
mg, 0.163 mmol, quantitative) as a red solid.  Rf = 0.83 (MeOH/EtOAc, 1/4, v/v); 
1H NMR (500 MHz, CDCl3) δ 8.29 (d, J14,15 = J17,18 = 8.5 Hz, 2H, H-15, H-17), 
7.51 (d, J14,15 = J17,18 = 8.5, 2H, H-14, H-18), 6.02 (s, 2H, H-2, H-6), 3.50 (s, 4H, 
CH2 NHS x 2), 2.57 (s, 6H, H-9, H-10), 1.39 (s, 6H, H-11, H-12); 13C NMR (125 
MHz, CDCl3) δ 169.2 (C=O NHS), 160.3 (C=O BOD), 156.2 (C-3, C-5), 142.1 
(C-1, C-7), 142.0 (C-13), 139.3 (C-16), 131.3 (C-15, C-17), 131.1 (C-7a, C-8a), 
129.0 (C-14, C-18), 125.8 (C-8), 121.7 (C-2, C-6), 53.4 (CH2 NHS x 2), 14.8 (C-
9, C-10, C-11, C-12); HRMS(ESI) m/z calcd. for [C24H23BF2N3O4]+: 466.1744, 
obsd.: 466.1740. 
 
(2S,3S,4R)-2-Hexacosanoylamido-D-ribo-
octadecane-1,3,4-triol (67) 
Phytosphingosine 58 (200 mg, 0.63 mmol) and 
hexacosanoic acid (275 mg, 0.69 mmol) were co-
evaporated together with toluene (x 3) and dry DMF 
(6.5 mL) was added followed by PyBOP (656 mg, 1.26 mmol) and DiPEA (0.28 
mL, 1.58 mmol). The white suspension was stirred at rt for 7 d, at which time the 
solvent was removed under reduced pressure and the desired product crystallised 
from EtOAc/MeOH (30 mL, 1:1, v/v). The suspension was spun down in a 
centrifuge, the filtrate removed and the white solid washed twice with 
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EtOAc/MeOH, before it was dried in vacuo to afford triol 67 as a white solid (440 
mg, 0.63 mmol, quantitative). Rf: 0.60 (15% MeOH/CHCl3, v/v, charred with 
cerium ammonium molybdate dip); [α]D25 = -2.9° (c = 1.0, pyridine); IR (film) 
3313, 2956, 2917, 2850, 1642, 1543, 1471, 1086, 1036, 981, 717, 573 cm-1; 1H 
NMR (600 MHz, 10% CD3OD in CDCl3) 6.90 (d, JNH,2 = 8.2 Hz, 1H, NH), 3.99 
(dd, JNH,2 = 8.2 Hz, J1a,2 = J1b,2 = 4.5 Hz, 1H, H-2), 3.71 (dd, J1a,1b = 11.4 Hz, J1a,2 
= 4.5 Hz, 1H, H-1a), 3.61 (dd, J1a,1b = 11.4 Hz, J1b,2 = 4.5 Hz, 1H, H-1b), 3.49–
3.42 (m, 2H, H-3, H-4), 2.13 (t, Jα,β= 7.6 Hz, 2H, CH2-α), 1.56–1.51 (m, 2H, 
CH2-β), 1.36–1.30 (m, 2H, H-5), 1.61–1.56 (m, 1H, H-6a), 1.48–1.44 (m, 1H, H-
6b), 1.23–1.81 (m, 66H, H-7–H-17, H-γ–H-(ω−1)), 0.80 (t, J17,18 = Jω−1,ω = 7.0 
Hz, 6H, H-18, H-ω); 13C NMR (150 MHz, 10% CD3OD in CDCl3) δ 174.6 
(HNC=O), 75.6 (C-3), 72.4 (C-4), 61.1 (C-1), 51.9 (C-2), 36.5 (C-α), 33.0 (C-6), 
31.84, 29.64, 29.62, 29.60, 29.57, 29.56, 29.45, 29.30, 29.26, 29.23, 22.58 (C-7–
C-17, C-γ–C-(ω−1)), 25.77, 25.72 (C-5, C-β), 13.9 (C-18, C-ω); HRMS(ESI) m/z 
calcd. for [C44H89NO4+H]+: 696.6864, obsd.: 696.6837. 
 
(2S,3S,4R)-2-Hexacosanoylamido-1-
triphenylmethoxy-octadecane-3,4-diol (68) 
Trityl chloride (213 mg, 0.76 mmol) and DMAP (1.9 
mg, 0.015 mmol) were added to triol 67 (106 mg, 
0.15 mmol) (co-evaporated with toluene x 3) 
dissolved in dry pyridine (1.2 mL). The reaction was stirred for 20 h at rt, at 
which point further trityl chloride (128 mg, 0.46 mmol) and pyridine (0.7 mL) 
were added. Stirring was continued for 4 h, then at 40 °C for 5 h to ensure 
complete conversion as monitored by TLC. The reaction mixture was then diluted 
with warm CHCl3 (50 mL), washed with brine (30 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The residue was purified by silica gel flash column 
chromatography and eluted with 0.3% MeOH/CHCl3 to afford diol 68 (113 mg, 
0.12 mmol, 79%) as a clear oil. Rf: 0.53 (PE/EA, 2:1, v/v); [α]D26 = +17.0° (c = 
1.0, CHCl3); IR (film) 3305, 2918, 2850, 1643, 1536, 1491, 1468, 1449, 1217, 
1071, 900, 760, 704, 633 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.42 (d, JCH-o,CH-m = 
7.3 Hz, 6H, CPh3, CH-o), 7.32 (t, JCH-o,CH-m = JCH-m,CH-p = 7.6 Hz, 6H, CPh3, CH-
m), 7.25 (t, JCH-m,CH-p = 7.2 Hz, 3H, CPh3, CH-p), 6.11 (d, JNH,2 = 8.3 Hz, 1H, 
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NH), 4.36 (dd, JNH,2 = 8.3 Hz, J1a,2 = J1b,2 = 4.1 Hz, 1H, H-2), 3.60–3.59 (m, 1H, 
H-3), 3.51 (dd, J1a,1b = 10.0 Hz, J1a,2 = 4.1 Hz, 1H, H-1a), 3.40–3.36 (m, 1H, H-4), 
3.35 (dd, J1a,1b = 10.0 Hz, J1b,2 = 4.1 Hz, 1H, H-1b), 3.23 (d, J3,3-OH = 8.6 Hz, 1H, 
3-OH), 2.46 (d, J4,4-OH = 4.1 Hz, 1H, 4-OH), 2.15 (t, Jα,β= 7.7 Hz, 2H, CH2-α), 
1.90–1.64 (m, 1H, H-5a), 1.64–1.58 (m, 2H, CH2-β), 1.48–1.38 (m, 3H, H-6, H-
5b), 1.32–1.15 (m, 66H, H-7–H-17, H-γ–H-(ω−1)),  0.89 (t, J17,18 = Jω−1,ω = 6.8 
Hz, 6H, H-18, H-ω); 13C NMR (125 MHz, CDCl3) δ 173.3 (HNC=O), 143.3 (C-i, 
CPh3), 128.6 (C-o, CPh3), 128.2 (C-m, CPh3), 127.5 (C-p, CPh3), 87.8 (Cq CPh3), 
75.8 (C-3), 73.3 (C-4), 63.0 (C-1), 50.5 (C-2), 37.0 (C-α), 33.4 (C-5), 32.1, 29.84, 
20.83, 29.82, 29.80, 29.79, 29.76, 29.6, 29.54, 29.50, 29.49, 29.48, 22.8 (C-7–C-
17, C-γ–C-(ω−1)), 26.0 (C-6), 25.9 (C-β), 14.3 (C-18, C-ω); HRMS(ESI) m/z 
calcd. for [C63H103NO4+Na]+: 960.7779, obsd.: 960.7781. 
 
(2S,3S,4R)-3,4-Dibenzoyloxy-2-
hexacosanoylamido-1-triphenylmethyoxy-
octadecane 
Benzoyl chloride (94 µL, 0.81 mmol) and DMAP 
(1.6 mg, 0.013 mmol) were added to diol 68 (126 
mg, 0.13 mmol) (co-evaporated with toluene x 3) dissolved in dry pyridine (1.3 
mL) and stirred at rt for 15 h. The pyridine was removed in vacuo, the residue 
redissolved in EtOAc (70 mL) and the organic layer then washed with water (70 
mL), saturated NaHCO3 solution (70 mL), brine (70 mL), dried (MgSO4), filtered 
and concentrated in vacuo. This afforded the title compound, which was used 
without further purification. Rf: 0.49 (PE/EA, 5:1, v/v); [α]D26 = +12.0° (c = 1.0, 
CHCl3); IR (film) 2923, 2853, 1719, 1671, 1540, 1450, 1315, 1280, 1109, 1069, 
1027, 757, 707, 632 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.96 (d, JCH-o,CH-m = 7.5 
Hz, 2H, CH-o, 4-O-Bz), 7.89 (d, JCH-o,CH-m = 7.5 Hz, 2H, CH-o, 3-O-Bz), 7.59 (t, 
JCH-m,CH-p = 7.3 Hz, 1H, CH-p, 3-O-Bz), 7.55 (t, JCH-m,CH-p = 7.6 Hz, 1H, CH-p, 4-
O-Bz), 7.42 (t, JCH-o,CH-m = JCH-m,CH-p = 8.3 Hz, 2H, CH-m, 3-O-Bz), 7.41 (t, JCH-
o,CH-m = JCH-m,CH-p = 8.3 Hz, 2H, CH-m, 4-O-Bz), 7.31–7.30 (m, 6H, CPh3, CH-o), 
7.15–7.20 (m, 9H, CPh3, CH-m, CH-p), 6.03 (d, JNH,2 = 9.3 Hz, 1H, NH), 5.81 
(dd, J2,3 = 9.1 Hz, J3,4 = 2.6 Hz, 1H, H-3), 5.35 (dt, J4,5 = 10.1 Hz, J3,4 = 2.6 Hz, 
1H, H-4), 4.59 (tt, J2,NH = J2,3 = 9.3 Hz, J1a,2 = J1b,2 = 3.2 Hz, 1H, H-2), 3.34 (dd, 
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J1a,1b = 9.9 Hz, J1a,2 = 3.2 Hz, 1H, H-1a), 3.29 (dd, J1a,1b = 9.9 Hz, J1b,2 = 3.2 Hz, 
1H, H-1b), 2.18 (dt, Ja,b = 14.5 Hz, Jα,β = 7.7 Hz, 2H, CH2-α), 1.93–1.81 (m, 2H, 
H-5), 1.68–1.58 (m, 2H, CH2-β), 1.40–1.14 (m, 68H, H-6–H-17, H-γ–H-
(ω−1)), 0.89 (t, J17,18 = Jω−1,ω = 7.0 Hz, 6H, H-18, H-ω); 
13C NMR (125 MHz, 
CDCl3) δ 172.8 (HNC=O), 166.4 (C=O, 4-O-Bz), 165.0 (C=O, 3-O-Bz), 143.3 
(C-i, CPh3), 133.1 (C-p, 3-O-Bz), 132.9 (C-p, 4-O-Bz), 130.2 (C-i, 4-O-Bz), 
129.82 (C-i, 3-O-Bz), 129.78 (C-o, 3-O-Bz), 129.75 (C-o, 4-O-Bz), 128.5 (C-o, 
CPh3), 128.40 (C-m, 3-O-Bz), 128.35 (C-m, 4-O-Bz), 127.8 (C-m, CPh3), 127.0 
(C-p, CPh3), 86.8 (Cq CPh3), 74.2 (C-4), 72.7 (C-3), 61.6 (C-1), 48.5 (C-2), 36.9 
(C-α), 31.9, 29.74, 29.73, 29.72, 29.69, 29.68, 29.67, 29.66, 29.63, 29.58, 29.55, 
29.53, 29.45, 29.39, 29.38, 25.72 (C-6–C-17, C-γ–C-(ω−1)), 28.4 (C-5), 25.70 (C-
β), 14.1 (C-18, C-ω); HRMS(ESI) m/z calcd. for [C77H111NO6+Na]+: 1168.8304, 
obsd.: 1168.8302. 
 
(2S,3S,4R)-3,4-Dibenzoyloxy-2-
hexacosanoylamido-octadecan-1-ol (57) 
(2S,3S,4R)-3,4-Dibenzoyloxy-2-hexacosanoylamido-
1-triphenylmethyoxy-octadecane was dissolved in 
1:1 (v/v) MeOH/CH2Cl2 and pTsOH.H2O (7.7 mg, 
0.040 mmol) was added. The reaction was stirred for 20 h at rt, followed by the 
addition of further pTsOH.H2O (7.7 mg, 0.040 mmol), and stirring was 
contiunued for 6 h. The reaction mixture was diluted with EtOAc (70 mL), 
washed with saturated NaHCO3 solution (2 x 70 mL), brine (70 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude mixture was purified by 
silica gel flash column chromatography and eluted with MeOH/CH2Cl2 (3%, v/v) 
to afford the lipid acceptor 57 as an amorphous white solid (81 mg, 0.090 mmol, 
67% over two steps). Rf: 0.25 (PE/EA, 2:1, v/v); [α]D27 = +54.0° (c = 1.0, CHCl3); 
IR (film) 2918, 2850, 1721, 1649, 1541, 1468, 1315, 1280, 1177, 1111, 1070, 
1027, 757, 710 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.05 (d, JCH-o,CH-m = 7.7 Hz, 
2H, CH-o, 3-O-Bz), 7.94 (d, JCH-o,CH-m = 7.5 Hz, 2H, CH-o, 4-O-Bz), 7.63 (t, JCH-
m,CH-p = 7.7 Hz, 1H, CH-p, 3-O-Bz), 7.52 (t, JCH-m,CH-p = 7.5 Hz, 1H, CH-p, 4-O-
Bz), 7.49 (t, JCH-m,CH-p = JCH-o,CH-m = 7.7 Hz, 2H, CH-m, 3-O-Bz), 7.37 (t, JCH-m,CH-
p = JCH-o,CH-m = 7.5 Hz,  2H, CH-m, 4-O-Bz), 6.48 (d, JNH,2 = 9.3 Hz, 1H, NH), 
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5.44 (dd, J2,3 = 9.6 Hz, J3,4 = 2.3 Hz, 1H, H-3), 5.37 (dt, J4,5 = 9.1 Hz, J3,4 = 2.9 
Hz, 1H, H-4), 4.40 (t, J2,3 = 9.6 Hz, 1H, H-2), 3.68–3.59 (m, 2H, H-1a, H-1b), 
2.91 (dd, JOH,1a = 8.5 Hz, JOH,1b = 5.1 Hz, 1H, OH), 2.28 (t, Jα,β = 7.6 Hz, 2H, 
CH2-α), 2.03–2.00 (m, 2H, H-5), 1.72–1.66 (m, 2H, CH2-β), 1.45–1.13 (m, 68H, 
H-6–H-17, H-γ–H-(ω−1)), 0.88 (t, J17,18 = Jω−1,ω = 7.0 Hz, 6H, H-18, H-ω);  
13C NMR (125 MHz, CDCl3) δ 173.3 (HNC=O), 167.1 (C=O, 3-O-Bz), 166.3 
(C=O, 4-O-Bz), 133.8 (C-p, 3-O-Bz), 133.1 (C-p, 4-O-Bz), 130.0 (C-o, 3-O-Bz), 
129.9 (C-i, 4-O-Bz), 129.6 (C-o, 4-O-Bz), 129.1 (C-i, 3-O-Bz), 128.7 (C-m, 3-O-
Bz), 128.4 (C-m, 4-O-Bz), 74.0 (C-4), 73.6 (C-3), 61.6 (C-1), 49.9 (C-2), 36.9 (C-
α), 31.9, 29.73, 29.71, 29.68, 29.66, 29.65, 29.60, 29.58, 29.55, 29.40, 29.37, 
29.34, 25.85, 22.7 (C-6–C-17, C-γ–C-(ω−1)), 28.4 (C-5), 25.75 (C-β), 14.1 (C-18, 
C-ω); HRMS(ESI) m/z calcd. for [C58H97NO6+Na]+: 926.7208, obsd.: 926.7220. 
 
(2S,3S,4R)-3,4-Dibenzoyloxy-1-(2,3,4-tri-
O-benzyl-6-deoxy-6-azido-α-D-
galactopyranosyloxy)-2-
hexacosanoylamido-octadecane (55) 
Imidate donor 56 (88 mg, 0.14 mmol) and 
lipid acceptor 57 (64 mg, 0.071 mmol) were co-evaporated with toluene (x 3), 
dissolved in dry Et2O/THF (2.7 mL, 5:1, v/v) and stirred with activated 4Å 
molecular sieves for 1 h. The reaction mixture was cooled to 0 °C, freshly 
distilled TMSOTf (stock of 0.055M in Et2O, 76.8 µL, 0.0042 mmol) was added 
dropwise and the resulting solution stirred at 0 °C for 1.5 h. The reaction was 
quenched with triethylamine (50 µL, 0.36 mmol), diluted with EtOAc (20 mL), 
filtered through a celite pad and concentrated in vacuo. The residue was first 
purified by size exclusion column chromatography (LH20, CH2Cl2/MeOH, 1:1, 
v/v) to isolate a mixture of α- and β-coupled glycolipid, which was further 
purified by silica gel gradient column chromatography (petroleum ether/EtOAc, 
15:1 to 5:1, v/v) to give the α-coupled glycolipid 55α  as a colourless oil (65.7 
mg, 0.048 mmol, 68%) and the β-coupled glycolipid 55β  (22.6 mg, 0.017 mmol, 
23%) also as a colourless oil. α: Rf: 0.58 (8% EA/Toluene); [α]D27 = –36.0° (c = 
1.0, CHCl3); IR (film) 3063, 3030, 2922, 2852, 2362, 2338, 2102, 1722, 1673, 
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1530, 1453, 1278, 1095, 1068, 1027, 756, 711, 699 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 8.03 (d, JCH-o,CH-m = 7.1 Hz, 2H, CH-o, 3-O-Bz), 7.96 (d, JCH-o,CH-m = 7.0 
Hz, 2H, CH-o, 4-O-Bz), 7.60 (t, JCH-m,CH-p = 7.5 Hz, 1H, CH-p, 3-O-Bz), 7.54 (t, 
JCH-m,CH-p = 7.5 Hz, 1H, CH-p, 4-O-Bz), 7.48–7.19 (m, 19H, Harom), 6.66 (d, JNH,2 
= 9.5 Hz, 1H, NH), 5.64 (dd, J2,3 = 9.3 Hz, J2,3 = 2.7 Hz, 1H, H-3), 5.39–5.36 (m, 
1H, H-4), 4.96 (d, Ja,b = 11.5 Hz, 1H, CH-a, 4´-O-Bn), 4.78 (d, Ja,b = 11.7 Hz, 1H, 
CH-a, 3´-O-Bn), 4.75 (d, J1´,2´ = 3.6 Hz, 1H, H-1´), 4.78 (d, Ja,b = 11.7 Hz, 1H, 
CH-a, 3´-O-Bn), 4.68 (d, Ja,b = 11.7 Hz, 1H, CH-b, 3´-O-Bn), 4.64 (s, 2H, CH-a, 
CH-b, 2´-O-Bn), 4.61 (t, J1,2 = 3.2 Hz, 1H, H-2), 4.57 (d, Ja,b = 11.5 Hz, 1H, CH-
b, 4´-O-Bn), 3.98 (dd, J2´,3´ = 10.1 Hz, J1´,2´ = 3.6 Hz, 1H, H-2´), 3.93 (dd, J5´,6´a = 
8.3 Hz, J5´,6´b = 5.2 Hz, 1H, H-5´), 3.90 (dd, J1a,1b = 11.6 Hz, J1a,2 = 3.2 Hz, 1H, H-
1a), 3.83 (dd, J2´,3´ = 10.1 Hz, J3´,4´ = 2.7 Hz, 1H, H-3´), 3.78 (bs, 1H, H-4´), 3.67 
(dd, J1a,1b = 11.6 Hz, J1b,2 = 3.2 Hz, 1H, H-1b), 3.55 (dd, J6´a,6´b = 12.4 Hz, J5´,6´a = 
8.3 Hz, 1H, H-6´a), 3.04 (dd, J6´a,6´b = 12.4 Hz, J5´,6´b = 5.2 Hz, 1H, H-6´a), 2.20 (t, 
Jα,β = 7.6 Hz, 2H, CH2-α), 1.95–1.90 (m, 2H, H-5), 1.67–1.64 (m, 2H, Hβ), 1.39–
1.21 (m, 68H, H-6–H-17, H-γ–H-(ω−1)), 0.89 (t, J17,18 = Jω−1,ω = 6.9 Hz, 6H, H-
18, H-ω); 13C NMR (125 MHz, CDCl3) δ 173.1 (HNC=O), 166.2 (C=O, 4-O-Bz), 
165.3 (C=O, 3-O-Bz), 138.6 (C-i, 3´-O-Bn), 138.2 (C-i, 2´-O-Bn), 138.0 (C-i, 4´-
O-Bn), 133.3 (C-p, 3-O-Bz), 132.9 (C-p, 4-O-Bz), 130.1, 129.8 (C-i, 3-O-Bz, 4-
O-Bz), 129.8 (C-o, 3-O-Bz), 129.8 (C-o, 4-O-Bz), 128.6, 128.5, 128.42, 128.41, 
128.34, 128.32, 128.1, 128.0, 127.7, 127.62, 127.56 (21 x CHarom), 99.7 (C-1´, 
1JCH = 168.5 Hz), 78.5 (C-3´), 76.4 (C-2´), 74.8 (C-4´), 74.6 (CH2, 4´-O-Bn), 73.8 
(C-4), 73.5 (CH2, 3´-O-Bn), 73.3 (CH2, 2´-O-Bn), 72.4 (C-3), 70.2 (C-5´), 69.7 
(C-1), 51.3 (C-6´), 48.6 (C-2), 36.8 (C-α), 28.3 (C-5), 25.8 (C-β), 31.9, 29.8, 
29.72, 29.70, 29.67, 29.64, 29.61, 29.60, 29.56, 29.50, 29.4, 25.7, 22.7 (C-6–C-
17, C-γ–C-(ω−1)), 14.1 (C-18, C-ω); HRMS(ESI) m/z calcd. for 
[C85H124N4O10+H]+: 1361.9390, obsd.: 1361.9399. 
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(2S,3S,4R)-2-Hexacosanoylamido-
(2,3,4-tri-O-benzyl-6-deoxy-6-azido-α-
D-galactopyranosyloxy)-octadecane-
3,4-diol (69) 
Glycolipid 55α  (66 mg, 0.048 mmol) was 
dissolved in MeOH/CH2Cl2 (3 mL, 2:1 (v/v) and sodium methoxide was added 
until the reaction mixture reached pH 9.0. After stirring for 12 h at rt, the reaction 
was quenched with Dowex-H+, filtered and concentrated under reduced pressure. 
The residue was purified by silica gel gradient column chromatography 
(petroleum ether/EtOAc, 10:1 to 3:1, v/v) to afford glycolipid diol 69 as an 
amorphous white solid (52 mg, 0.045 mmol, 93%). Rf: 0.28 (PE/EA, 2:1, v/v); 
[α]D24 = +6.0° (c = 1.0, CHCl3); IR (film) 3332, 3065, 3032, 2918, 2850, 2100, 
1717, 1636, 1623, 1542, 1469, 1455, 1350, 1284, 1216, 1078, 1041, 909, 757, 696 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.40–7.29 (m, 15H, Harom), 6.29 (d, JNH,2 = 
8.3 Hz, 1H, NH), 4.98 (d, Ja,b = 11.3 Hz, 1H, CH-a, 4´-O-Bn), 4.884 (d, Ja,b = 11.6 
Hz, 1H, CH-a, 2´-O-Bn), 4.885 (d, J1,2 = 3.7 Hz, 1H, H-1´), 4.82 (d, Ja,b = 11.7 Hz, 
1H, CH-a, 3´-O-Bn), 4.78 (d, Ja,b = 11.7 Hz, 1H, CH-b, 3´-O-Bn), 4.70 (d, Ja,b = 
11.7 Hz, 1H, CH-b, 2´-O-Bn), 4.59 (d, Ja,b = 11.3 Hz, 1H, CH-b, 4´-O-Bn), 4.27 
(dd, JNH,2 = 8.3 Hz, J1a,2 = 3.4 Hz, 1H, H-2), 4.05 (dd, J2´,3´ = 10.0 Hz, J1´,2´ = 3.7 
Hz, 1H, H-2´), 3.93 (dd, J1a,1b= 10.4 Hz, J1a,2 = 3.4 Hz, 1H, H-1a), 3.86 (dd, J2´,3´ 
= 10.0 Hz, J3´,4´ = 2.4 Hz, 1H, H-3´), 3.84–3.82 (m, 2H, H-1b, H-4´), 3.73 (t, J5´,6´ 
= 6.6 Hz, 1H, H-5´), 3.52–3.46 (m, 3H, H-4, H-6´a, H-3), 3.03 (dd, J6´a,6´b = 12.6 
Hz, J5´,6´b = 5.5 Hz, 1H, H-6´b), 2.16 (t, Jα,β = 7.6 Hz, 2H, CH2-α), 1.60–1.50 (m, 
3H, CH2-βa, H-5), 1.48–1.21 (m, 69H, H-6–H-17, H-βb–H-(ω−1)), 0.88 (t, J17,18 
= Jω−1,ω = 7.0 Hz, 6H, H-18, H-ω); 
13C NMR (125 MHz, CDCl3) δ 173.9 
(HNC=O), 138.2 (C-i, 3´-O-Bn), 138.0 (C-i, 4´-O-Bn), 137.8 (C-i, 2´-O-Bn), 
128.69, 128.67, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.7 (15 x CHarom), 
99.0 (C-1´), 79.3 (C-3´), 76.3 (C-3), 75.9 (C-2´), 74.8 (CH2, 4´-O-Bn), 74.5 (C-
4´), 74.4 (CH2, 2´-O-Bn), 73.5 (C-4), 73.2 (CH2, 3´-O-Bn), 70.4 (C-5´), 69.9 (C-
1), 51.2 (C-6´), 49.2 (C-2), 37.0 (C-α), 33.5, 32.1, 29.9, 29.85, 29.81, 29.7, 29.6, 
29.51, 29.46, 22.8 (C-6–C-17, C-γ–C-(ω−1)), 26.0, 25.9 (C-5, C-β), 14.3 (C-18, 
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C-ω); HRMS(ESI) m/z calcd. for [C71H117N4O8+H]+: 1153.8866, obsd.: 
1153.8871. 
 
 (2S,3S,4R)-1-(6-Amino-6-deoxy-α-D-
galactopyranosyloxy)-2-hexacosanoylamido-octadecane-3,4-diol (51) 
To a solution of glycolipid diol 69 (25.1 mg, 0.022 mmol) dissolved in 
CHCl3/EtOH (2.5 ml, 3:2, v/v) was added formic acid (0.13 mL, 0.0034 mmol) 
and Pd(OH)2/C (20 wt% loading, 50 wt% H2O, 36 mg, 0.033 mmol) and the 
reaction stirred under H2 (g) for 15 h at rt. The reaction mixture was filtered 
through a celite pad and washed successively with CHCl3/EtOH/MeOH (20 mL, 
3:1:1, v/v/v) and pyridine (10 mL) and concentrated in vacuo. The residue was 
semi-purified by silica gel column chromatography 
(CH2Cl2→CH2Cl2/MeOH/EtOH/NH3 (35% aq)→55:2:2:1→35:2:2:1→15:2:2:1, 
v/v/v/v) to afford amine 51 as an amorphous white solid (6.2 mg, 0.0072 mmol, 
33%). Rf: 0.50 (DCM/MeOH/EtOH/NH3-H2O, 5:2:2:1, v/v/v/v); 1H NMR (500 
MHz, 10% CD3OD in CDCl3) δ 4.84 (d, J1´,2´ = 3.9 Hz, 1H, H-1´), 4.12 (dd, JNH,2 
= 9.1 Hz, J1a,2 = J1b,2 = 4.9 Hz, 1H, H-2), 3.82–3.79 (m, 2H, H-1a, H-4´), 4.74–
4.73 (m, 1H, H-5´), 3.71 (dd, J2´,3´ = 10.1 Hz, J1´,2´ = 3.9 Hz, 1H, H-2´), 3.63 (dd, 
J2´,3´ = 10.1 Hz, J3´,4´ = 3.4 Hz, 1H, H-3´), 3.53 (dd, J1a,1b = 10.6 Hz, J1b,2 = 4.9 Hz, 
1H, H-1b), 3.47–3.42 (m, 2H, H-3, H-4), 3.01 (dd, J6´a, 6´b = 13.0 Hz, J5,6´a = 7.6 
Hz, 1H, H-6´a), 2.85 (dd,  J6´a, 6´b = 13.0 Hz, J5,6´b = 3.6 Hz, 1H, H-6´b), 2.12 (t, 
Jα,β = 7.6 Hz, 2H, CH2-α), 1.63–1.47 (m, 4H, CH2-β, H-5), 1.30–1.06 (m, 68H, 
H-6–H-17, H-γ–H-(ω−1)), 0.80 (t, J17,18 = Jω−1,ω = 6.9 Hz, 6H, H-18, H-ω); 
HRMS(ESI) m/z calcd. for [C50H100N2O8+H]+: 857.7552, obsd.: 857.7533. 
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(2S,3S,4R)-1-(6-Deoxy-6-[4-(4,4-difluoro-
1,3,5,7-tetramethyl-3a,4a-diaza-4-bora-s-
indacen-8-yl)benzylamido])-α-D-
galactopyranosyloxy)-2-
hexacosanoylamido-octadecane-3,4-diol (3) 
Amine 51 (4.1 mg, 0.0048 mmol) was co-
evaporated with DMF (x 3), dissolved in dry 
DMF (0.6 mL) and the solution was warmed 
to 45 °C followed by the addition of DiPEA 
(3.3 µL, 0.019 mmol). BODIPY-NHS 70 (9.2 mg, 0.020 mmol) was co-
evaporated with DMF (x 3) and added as a solution in DMF (0.6 mL) and stirred 
for 1 h at 45 °C, at which point additional BODIPY-NHS 70 (4.6 mg, 0.010 
mmol) in dry CH2Cl2 (0.6 mL) and DiPEA (3.3 µL, 0.019 mmol) was added and 
the reaction mixture stirred for further 14 h at 45 °C. The reaction mixture was 
then concentrated in vacuo and purified immediately by silica gel gradient column 
chromatography (CH2Cl2 to 3% MeOH in CH2Cl2) to afford BODIPY-α-GalCer 3 
as a red solid (2.5 mg, 0.0021 mmol, 44%). Rf: 0.38 (10% MeOH/DCM, v/v); IR 
(film) 3346, 2851, 1642, 1631, 1608, 1547, 1513, 1468, 1450, 1409, 1308, 1192, 
1157, 1071, 1044, 983, 759, 700, 635 cm-1; 1H NMR (600 MHz, pyridine-d5) δ 
9.74 (t, J6´a,NH = J6´b,NH = 5.6 Hz, 1H, NH-BOD), 8.67 (d, J2,NH = 8.5 Hz, 1H, NH-
lipid), 8.46 (d, J14´´,15´´ = J17´´,18´´ = 8.2 Hz, 2H, H-15´´, H-17´´), 7.34 (d, J14´´,15´´ = 
J17´´,18´´ = 8.2 Hz, 2H, H-14´´, H-18´´), 5.99 (s, 2H, H-2´´, H-6´´), 5.57 (d, J1´,2´ = 
3.9 Hz, 1H, H-1´), 5.29–5.27 (m, 1H, H-2), 4.70 (t, J5´,6´a = J5´,6´b = 6.3 Hz, 1H, H-
5´), 4.68–4.65 (2H, H-1a, H-2´), 4.49 (dd, J5´,6´a = 6.3 Hz, J6´a,6´b = 13.4 Hz, 1H, H-
6´a), 4.46 (d, J3´,4´ = 1.3 Hz, 1H, H-4´), 4.40–4.37 (m, 2H, H-1b, H-3´), 4.35–4.23 
(m, 2H, H-3, H-4), 4.22–4.19 (m, 1H, H-6´b), 2.71 (s, 6H, H-9´´, H-10´´), 2.48 (t, 
Jα,β = 5.6 Hz, 2H, CH2-α), 2.30–2.27 (m, 1H, CH2), 1.97–1.91 (m, 3H, H-5, CH2), 
1.85–1.80 (m, 3H, CH2-β, CH2), 1.71–1.69 (m, 2H, CH2), 1.36 (s, 6H, H-11´´, H-
12´´), 1.45–1.17 (m, 63H, H-6–H-17, H-γ–H-(ω-1)), 0.88 (t, 6H, H-18, H-ω); 13C 
NMR (150 MHz, pyridine-d5) δ 173.7 (HNC=O lipid), 168.1 (HNC=O BOD), 
156.2 (C-3´´, C-5´´), 143.7 (C-7a´´, C-8a´´), 141.9 (C-8´´), 138.1 (C-13´´), 136.9 
(C-16´´), 131.8 (C-1´´, C-7´´), 129.3 (C-15´´, C-17´´), 128.8 (C-14´´, C-18´´), 
O
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122.2 (C-2´´, C-6´´), 77.1 (C-3/C-4), 72.9 (C-3/C-4), 71.64 (C-3´), 71.57 (C-4´), 
70.8 (C-5´), 70.4 (C-2´), 69.1 (C-1), 51.8 (C-2), 72.3 (C-6´), 37.2 (C-α), 34.7, 
32.5, 30.8, 30.5, 30.41, 30.40, 30.39, 30.37, 30.36, 30.34, 30.33, 30.29, 30.27, 
30.26, 30.18, 30.14, 29.98, 29.97, 23.29 (C-6–C-17, C-γ–C-(ω−1)), 26.89 (C-5), 
26.79 (C-β), 15.1, 14.9 (C-9´´, C-10´´, C-11´´, C-12´´), 14.6 (C-18, C-
ω); HRMS(ESI) m/z calcd. for [C70H117BF2N4O9+H]+: 1207.8954, obsd.: 
1207.8958. 
 
 117 
 
3.5 References 
 
1. Loudet, A.; Burgess, K., Chem. Rev. 2007, 107, 4891-932. 
2. Zhou, X.; Forestier, C.; Goff, R. D.; Li, C.; Teyton, L.; Bendelac, A.; 
Savage, P. B., Org. Lett. 2002, 4, 1267-1270. 
3. Trappeniers, M.; Van Beneden, K.; Decruy, T.; Hillaert, U.; Linclau, B.; 
Elewaut, D.; Van Calenbergh, S., J. Am. Chem. Soc. 2008, 130, 16468-
16469. 
4. Bai, L.; Sagiv, Y.; Liu, Y.; Freigang, S.; Yu, K. O. A.; Teyton, L.; Porcelli, 
S. A.; Savage, P. B.; Bendelac, A., Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 
10254-10259. 
5. Aspeslagh, S.; Li, Y.; Yu, E. D.; Pauwels, N.; Trappeniers, M.; Girardi, E.; 
Decruy, T.; Van Beneden, K.; Venken, K.; Drennan, M.; Leybaert, L.; 
Wang, J.; Franck, R. W.; Van Calenbergh, S.; Zajonc, D. M.; Elewaut, D., 
EMBO J. 2011, 30, 2294-305. 
6. Pauwels, N.; Aspeslagh, S.; Vanhoenacker, G.; Sandra, K.; Yu, E. D.; 
Zajonc, D. M.; Elewaut, D.; Linclau, B.; Van Calenbergh, S., Org. Biomol. 
Chem. 2011, 9, 8413-8421. 
7. Huang, Y.-C.; Chiang, L.-W.; Chang, K.-S.; Su, W.-C.; Lin, Y.-H.; Jeng, 
K.-C.; Lin, K.-I.; Liao, K.-Y.; Huang, H.-L.; Yu, C.-S., Molecules 2012, 17, 
3058-3081. 
8. Brellier, M.; Duportail, G.; Baati, R., Tetrahedron Lett. 2010, 51, 1269-
1272. 
9. Cheng, J. M. H.; Chee, S. H.; Knight, D. A.; Acha-Orbea, H.; Hermans, I. 
F.; Timmer, M. S. M.; Stocker, B. L., Carbohydr. Res. 2011, 346, 914-26. 
10. Li, C.; Sun, Y.; Zhang, J.; Zhao, Z.; Yu, G.; Guan, H., Carbohydr. Res. 
2013, 376, 15-23. 
11. Chee, S. BODIPY Fluorescent probes to study glycolipid uptake and 
trafficking in cancer immunotherapy. Honours Project, Victoria University 
of Wellington 2012. 
12. Mayer, T.; Kratzer, B.; Schmidt, R., Angew. Chem. Int. Ed. 1994, 33, 2177-
2181. 
13. Kratzer, B.; Mayer, T.; Schmidt, R., Eur J Org Chem 1998, 291-298. 
14. Zhu, X.; Schmidt, R. R., Angew. Chem. Int. Ed. 2009, 48, 1900-34. 
15. Plettenburg, O.; Bodmer-Narkevitch, V.; Wong, C., J. Org. Chem. 2002, 67, 
4559-4564. 
16. Xia, C.; Yao, Q.; Schumann, J.; Rossy, E.; Chen, W.; Zhu, L.; Zhang, W.; 
De Libero, G.; Wang, P., Bioorg. Med. Chem. Lett. 2006, 16, 2195-2199. 
17. Xia, C.; Zhang, W.; Zhang, Y.; Woodward, R. L.; Wang, J.; Wang, P. G., 
Tetrahedron 2009, 65, 6390-6395. 
18. Du, W.; Kulkarni, S. S.; Gervay-Hague, J., Chem. Commun. 2007, 2336-8. 
19. Khaja, S. D.; Kumar, V.; Ahmad, M.; Xue, J.; Matta, K. L., Tetrahedron 
Lett. 2010, 51, 4411-4414. 
20. Ramjit, H. G.; Newton, R.; Guare, J. P., Rapid Commun. Mass Spectrom. 
2005, 19, 1257-1262. 
21. Yen, Y.-F.; Sawant, R.; Luo, S.-Y., Synthesis 2013, 45, 511-517. 
22. Kim, S.; Song, S.; Lee, T.; Jung, S.; Kim, D., Synthesis 2004, 847-850. 
 118 
23. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; 
Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H., J. Med. Chem. 
1995, 38, 2176-2187. 
24. Xarnod, C.; Huang, W.; Ren, R.-G.; Liu, R.-C.; Wei, B.-G., Tetrahedron 
2012, 68, 6688-6695. 
25. Bubb, W. A., Concepts Magn. Reson. 2003, 19A, 1-19. 
26. Lightner, D. A.; Crandall, D. C., Tetrahedron Lett. 1973, 14, 1799-1802. 
27. Norris, R. D.; Lightner, D. A., J. Heterocycl. Chem. 1979, 16, 263-272. 
28. Jones, G.; Klueva, O.; Kumar, S.; Pacheco, D. P., Solid State Lasers X, 
SPIE 2001, 4267, 24-35. 
29. Quistad, G. B.; Lightner, D. A., Tetrahedron Lett. 1971, 12, 4417-4420. 
30. Ulrich, G.; Ziessel, R.; Haefele, A., J. Org. Chem. 2012, 77, 4298-311. 
 
 
 119 
Chapter 4. Synthesis of terminal sugar homologues 
of iGb3 
 
4.1 Introduction 
 
The glycolipid isoglobotrihexosylceramide (iGb3 4, Figure 4.1) is a 
triglycosylated ceramide that can activate iNKT cells when presented by CD1d. 
Structurally, it differs greatly from the prototype potent foreign antigen α-
galactosylceramide in that it contains a trisaccharide head group, possesses a β-
linkage between the proximal sugar and the lipid portion, and contains a 
sphingosine backbone bearing an E-alkene at C4-C5. Despite this structural 
difference, crystal structure studies have revealed that the T cell receptor (TCR) of 
iNKT cells is able to interact with the iGb3 presented on CD1d,1,2 hence 
confirming that the activity observed in iNKT cell stimulation assays was indeed 
exerted by the intact iGb3, rather than truncated versions which may occur after 
lysosomal processing.  
 
 
 
Figure 4.1. Isoglobotrihexosylceramide (iGb3, 4). 
 
The ability of the iNKT cell to accommodate this structural diversity is fascinating 
and it provides a platform to further understand the structural requirements for 
iNKT cell agonists. In 2011, both Rossjohn and co-workers and Yu et al. 
simultaneously reported the crystal structure of the ternary complex, iNKT TCR-
iGb3-CD1d and suggested that the main reason for β-linked glycolipids activating 
iNKT cells in a manner similar to α-linked glycolipids is because the TCR of the 
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iNKT cell is able to “bulldoze” the protruding headgroup so that it sits flat against 
the α2-helix of CD1d.2,3 The internal glycosidic bond is thus forced to resemble 
the α-conformation. Indeed, the crystal structure studies reveal that the terminal 
galactose sugar forms crucial interactions with CD1d. Specifically, the 6´´´-
hydroxyl of iGb3 forms a hydrogen bond with Thr159 of CD1d, and both the 4´´´- 
and 6´´´-hydroxyls partake in van der Waals interactions with Thr159 and Met162 
(Figure 4.2). 
 
 
Figure 4.2. Crystal structure of iNKT cell TCR (blue) in engagement with iGb3 
(yellow) and murine CD1d (purple).2 (Adapted by permission from Macmillan 
Publishers Ltd: Nature Immunology, 2011, 12, 827-833, ©2011) 
 
To unambiguously ascertain the importance of the 6´´´-hydroxyl in iGb3 binding 
and the activation of iNKT cells, the synthesis of 6´´´-deoxy-iGb3-sphingosine 5 
(Figure 4.3) was envisioned so that its activity as an iNKT cell ligand can be 
established. 6´´´-deoxy-iGb3-sphingosine 5 will also allow for crystal structure 
studies to be performed by the groups of Jamie Rossjohn and Dale Godfrey with 
whom we are collaborating. A similar derivative, the 6´´´-deoxy-iGb3-
phytosphingosine,4 which contains the lipid found in α-GalCer, has been 
synthesised by Chen et al. but no crystal structure data was presented. Herein, 
however, it is envisioned that our target 6´´´-deoxy homologue 5, bearing the 
same sphingosine backbone as the parent iGb3, will be a more useful tool to 
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systematically probe the role of the terminal sugar without changing the lipid 
portion.  
 
 
 
Figure 4.3. Target iGb3 analogues, 5 and 6. 
 
In addition to the 6´´´-deoxy homologue 5, the 6´´´-deoxy-iGb3-sphinganine 6 
(Figure 4.3) is also a useful tool to determine if removal of the rigid E-alkene on 
the lipid backbone alters activity of the glycolipid. Hereby, it should also be noted 
that the iGb3-sphinganine analogue (with galactose as the terminal sugar) has 
been synthesised and found to activate iNKT cells more efficiently than the 
original iGb3-sphingosine.5 Various studies have also shown that changes to the 
lipid backbone of a glycolipid can alter the presentation of the sugar head  
group.6-8 Thus, the biological assessment of 6´´´-deoxy-iGb3-sphinganine 6 will 
help determine if the loss of rigidity in the lipid backbone will compensate for the 
loss of H-bond through the 6´´´-hydroxyl of the terminal sugar.  
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4.2 Synthesis of 6´´´-deoxy homologues of iGb3 
 
Retrosynthesis 
 
To synthesise 6´´´-deoxy-iGb3-sphingosine 5 and 6´´´-deoxy-iGb3-sphinganine 6 
a convergent strategy was employed whereby the fully protected 6´´´-deoxy-iGb3-
sphingosine derivative 71 could be selectively deprotected to give either target 
(Scheme 4.1). Here, global deprotection via Birch reduction will afford 
sphingosine 5 with the double bond still intact, while catalytic hydrogenation 
followed by hydrolysis will afford sphinganine 6. The fully protected glycolipid 
71 could in turn be obtained via the glycosylation of lactosylceramide (LacCer) 
acceptor 73 with the D-fucosyl donor 72, itself obtained in several steps from D-
galactose 39. LacCer acceptor 73 could be obtained from lactosyl 2-azido-
sphingosine 74 via coupling with hexacosanoic acid followed by hydrolysis of the 
isopropylidene protecting group and selective acetylation of the 4´´-OH. Lactosyl 
2-azido-sphingosine 74 could be formed by the coupling of lactosyl donor 75 and 
sphingosine acceptor 76. Finally, the lactosyl donor 75 could be prepared from D-
lactose (77) and the sphingosine acceptor 76 from D-arabinose (78) according to 
published procedures.9,10 
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Scheme 4.1. Retrosynthesis of target 6´´´-deoxy-iGb3 sphingosine 5 and 6´´´-
deoxy-iGb3-sphinganine 6. 
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Synthesis of lactosylceramide (LacCer) acceptor 
 
The synthesis of 6´´´-deoxy-iGb3-sphingosine 5 and 6´´´-deoxy-iGb3-sphinganine 
6 began with the preparation of the appropriately protected lactosyl 2-azido 
sphingosine intermediate 74 (Scheme 4.2). To this end, D-lactose (77) was 
peracetylated, followed by the conversion of the anomeric acetate to a thiophenol 
group and removal of the remaining acetate groups under Zemplén conditions to 
give thiolactoside 79 as a crystalline solid according to literature procedure.9,11-14 
Thiolactoside 79 was then subjected to 2,2-dimethoxypropane and a catalytic 
amount of p-toluenesulfonic acid (pTsOH) to afford the selectively protected 
3´,4´-ketal 80. While these conditions generally yield the thermodynamically 
favoured 5-membered 3´,4´-ketal 80, some of the kinetic 4´,6´-derivative 81 was 
also obtained.14-16 Efforts to drive the exclusive formation of the 3´,4´-ketal 80 by 
allowing for a longer reaction time (3 days) was to no avail. Moreover, Xing et al. 
and Chan et al. also showed that performing the reaction at warmer temperatures 
did not increase the yield of the desired product significantly.9,17 Fortunately, the 
3´,4´-O-isopropylidene derivative 80 could be isolated in 56% yield from the 
mixture by crystallisation. Subsequent protection of the free hydroxyl groups as 
benzoate esters afforded the fully protected thioglycoside 82 in 94% yield, again 
as crystalline material. Next, the anomeric thiophenol was hydrolysed with NBS 
in aqueous acetone9,18 followed by the installation of the trichloroacetimidate 
leaving group9,16,19 to give lactosyl imidate donor 75 in 73% yield over the two 
steps. Spectral data of lactosyl imidate donor 75 matched that previously 
reported,9,16 which was obtained from D-lactose (77) via the use of either an 
anomeric p-toluenethiol group9 or an anomeric thexyldimethylsilyl group.16 
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Scheme 4.2. Synthesis of lactosyl 2-azido-sphingosine 74. 
 
With the lactosyl imidate donor 75 in hand, a coupling reaction to sphingosine 
acceptor 76 was then performed (Scheme 4.2), whereby sphingosine acceptor 76 
was prepared from D-arabinose (78), in nine steps using a strategy previously 
developed in our group.10 The glycosylation reaction utilised TMSOTf as a 
promoter and proceeded smoothly to give lactosyl 2-azido sphingosine 74 in 
quantitative yield.9 1H NMR analysis of the resulting glycolipid revealed a 
coupling constant of 7.8 Hz between H-1´ and H-2´, which confirms the β-
selectivity of the reaction. This stereoselectivity was enabled by the participation 
of the benzoyl protecting group at C2. Interestingly, when Xing et al. coupled the 
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identical lactosyl donor to the full ceramide sphingosine acceptor bearing a C18 
acyl lipid under similar activating conditions, the yield was only 60%, presumably 
due to poorer solubility of the dilipid acceptor.9 
 
Following the coupling of the lipid, the azide on the sphingosine backbone was 
reduced with PPh3 to produce the corresponding amine, which was used without 
further purification in the condensation with hexacosanoic acid using an 
EDCI/DMAP-mediated protocol (Scheme 4.3). Under these conditions the fully 
protected LacCer 83 was produced in 54% yield over two steps. The acetonide on 
the 3´´- and 4´´-positions was then removed via hydrolysis under acidic conditions 
to afford diol 84 in an excellent 96% yield. The regioselective protection of the 
4´´-OH was then performed by using trimethyl orthoacetate and camphorsulfonic 
acid to first install a methylorthoacetate protecting group across the 3´´-OH and 
4´´-OH, which subsequently ring opened during an acidic workup to afford the 
LacCer acceptor 73.  
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Scheme 4.3. Synthesis of LacCer acceptor 73. 
 
The position of the acetate ester was confirmed, firstly by the chemical shift of the 
hydrogens at the 3´´ and 4´´-positions. As expected, because of the electron 
withdrawing nature of ester protecting groups, the narrow doublet with a small 
coupling constant (J3´´,4´´ = 3.5 Hz,) characteristic of H-4´´ is located downfield 
(5.22 ppm) compared to the doublet of doublets (J2´´,3´´ = 9.8 Hz, J3´´,4´´ = 3.5 Hz) 
for H-3´´, which is located at 3.82 ppm. Additionally, HMBC correlation between 
the carbonyl carbon of the acetate and the proton at the 4´´-position 
unambiguously confirms the acetylation of the 4´´-OH (Figure 4.4).   
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Figure 4.4. HMBC of LacCer acceptor 73 confirming acetylation at position 4´´. 
 
This versatile approach to acetylate the axial 4-OH over equatorial 3-OH in a cis-
diol system was first reported by Lemieux et al.20 and the selectivity can be 
rationalised by stereoelectronic effects.21,22 During acidic workup, the methoxy 
group of intermediate B is substituted by water (to give tetrahedral intermediate 
C), and subsequent protonation of either the equatorial oxygen at C-3 (D) or the 
axial oxygen at C-4 (E) determines the formation of the 4-OAc (F) or 3-OAc (G) 
product, respectively (Scheme 4.4). The less sterically hindered oxygen at the 
equatorial position is preferentially protonated over the axial oxygen,23 leading to 
the selective acetylation at the 4-position (F), giving rise to LacCer acceptor 73. 
In summary, the LacCer acceptor 73 was prepared in twelve steps from D-lactose 
(77) in 8% overall yield.  
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Scheme 4.4. Regioselective acetylation of the 3,4-cis-diol system of galactose. 
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Synthesis of thioethyl D-fucoside donor 
 
Having successfully prepared the LacCer acceptor 73, the next synthetic target 
was the β-thioethyl fucose donor 90 (Scheme 4.5). Glycosylation reactions 
incorporating both D- or L-fucose donors are notorious for poor reaction yields 
due to the increased acid lability of the α-fucosyl linkage.24-26 Therefore, mild 
activating conditions are required for their glycosidation. It was envisioned that β-
thioethyl fucose donor 90,27,28 which can be activated under milder conditions 
using CuBr2 and Pr4NBr, will circumvent the problem of low yields. This 
glycosidation protocol was previously optimised within the group from Ogawa’s 
method.29 
 
 
 
Scheme 4.5. Synthesis of β-thioethyl fucose donor 90. 
 
The synthesis of the D-fucose donor building block began with peracetylated D-
fucose 86, which can be obtained in quantitative yield by subjecting D-fucose (85) 
to acetic anhydride and pyridine. However, due to the high cost of the starting 
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material D-fucose (85), an alternative route to make the peracetylated D-fucose 
intermediate 86, starting from D-galactose (39) was developed. Iodogalactoside 86 
can be made according to methods described earlier (Chapter 2, Scheme 2.3) 
whereby the 1,2 and 3,4 positions of D-galactose (39) were protected with 
isopropylidenes followed by the installation of an iodide at the primary position 
via a modified Appel reaction.30 Next, reduction of the iodide under conditions 
akin to the Barton-McCombie deoxygenation, whereby the radical initiator AIBN 
and reducing agent tributyltin hydride were used, provided 6-deoxy galactose 88 
in an excellent 97% yield.31 Subsequent hydrolysis of the isopropylidene groups 
under acidic conditions, followed by peracetylation gave D-fucose tetraacetate 86 
in 85% yield over two steps. According to this route, D-fucose tetraacetate 86 was 
made from D-galactose 39 in 65% yield over five steps. The robust methodology 
for the synthesis of D-fucose intermediates, along with the significantly reduced 
cost of D-galactose (60 times cheaper than D-fucose) provides great incentive to 
start with the more readily available D-galactose. 
 
Following this, β-thiofucoside 89 was prepared by converting the anomeric 
acetate to the thioethyl functionality by using boron trifluoride etherate as the 
Lewis acid (72% yield). The remaining acetate protecting groups were then 
hydrolysed under Zemplén conditions and the resultant free hydroxyls benzylated 
to give benzylated β-thiofucoside donor 90 in 83% yield over two steps.  
 
Attempted coupling of thioethyl fucoside 90 donor and LacCer 
acceptor 73 
 
With the thiofucose donor 90 and LacCer acceptor 73 in hand, the coupling 
reaction was attempted by using CuBr2 and Pr4NBr, but to no avail (Scheme 4.6). 
No desired product was observed, instead, the self-coupled donor 1,1´-difucose 
and unreacted acceptor 73 were obtained. It was speculated that perhaps the 
lipophilic acceptor was not as nucleophilic while the activated fucose donor was 
highly reactive, thus leading to the 1,1´-difucose by-product in the presence of 
trace amount of water.  
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Scheme 4.6. Attempted coupling of thioethyl donor 90 and LacCer acceptor 73. 
 
Modification to the trichloroacetimidate donor 72 
 
Therefore, an alternative donor, the trichloroacetimidate was synthesised in two 
steps from the thiofucoside donor 90 (Scheme 4.7). Hydrolysis of the anomeric 
thioethyl group in the presence of NBS and acetone18 afforded the corresponding 
lactol 91 in 93% yield. The anomeric hydroxyl was then converted to a 
trichloroacetimidate group in an excellent 94% yield to afford the desired fucose 
donor 72.32 Here, both α and β anomers were generated in a 2:1 ratio, and they 
were separable by silica gel column chromatography. Of note, due to the 
prevalence of L-fucose in biological systems, only L-fucosyl imidate donors have 
been reported. This work represents the first synthesis of the D-fucosyl imidate. 
As expected, the 1H and 13C NMR data of α-D-fucosyl imidate 72 were identical 
to that of the enantiomer, α-L-fucosyl imidate,33 and the optical rotation was equal 
in value but opposite in magnitude ([α]D23 α-D-fucosyl imidate 72 = +58°; c = 1.0, 
CHCl3; [α]D20 α-L-fucosyl imidate = –60°; c = 1.0, CHCl333) 
 
 
Scheme 4.7. Synthesis of trichloroacetimidate fucose donor 72. 
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Coupling of trichloroacetimidate donor 72 and LacCer acceptor 73 
and global deprotection 
 
Though coupling reactions using either β-L-fucosyl imidate34,35 or α/β mixtures of 
L-fucosyl imidate36 have been reported, only the α-anomer of D-fucosyl imidate 
72 was used in the glycosylation reaction with LacCer acceptor 73 so as to follow 
Schmidt’s original coupling conditions,33 and to eliminate any ambiguity in the 
effects of starting with a mixture of anomers on α/β-selectivity of the coupling 
reaction. 
 
The coupling of α-fucosyl imidate donor 72 and the LacCer acceptor 73 was 
performed with TMSOTf as the catalyst (Scheme 4.8).33 Gratifyingly, this 
reaction proceeded smoothly to afford the fully protected 6´´´-deoxy-iGb3 71 in 
good 69% yield.  
 
 
Scheme 4.8. Total syntheses of 6´´´-deoxy-iGb3-sphingosine 5 and 6´´´-deoxy-
iGb3-sphinganine 6. 
Analysis of the product by 1H NMR revealed that the coupling constant of H-1´´´ 
at the newly formed anomeric centre was 3.5 Hz, confirming the formation of the 
 134 
α-anomer. No β-coupled product was detected and unreacted acceptor 73 was 
recovered. Three bond correlations of key glycosidic bonds from HMBC analysis 
are shown in Figure 4.5. Specifically, the correlation between C-3´´ and H-1´´´ 
confirms the attachment of the terminal fucose moiety to the 3´´ position of 
LacCer.  In addition, an HMBC correlation between H-4´´ and carbonyl carbon of 
the acetate further confirms that the LacCer was glycosylated at the 3´´ (Figure 
4.6).  
 
 
Figure 4.5. HMBC spectrum of 6´´´-deoxy-iGb3 71 confirming the fucosylation 
of LacCer 73 at the 3´´-position.  
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Figure 4.6. HMBC of 6´´´-deoxy-iGb3 71 confirming acetylation at position 4´´. 
 
With the fully protected 6´´´-deoxy-iGb3 71 at hand, global deprotection under 
Birch conditions was performed and this allowed for the removal of all ether and 
ester protecting groups without reducing the alkene. As large amounts of 
ammonium salts are produced in the Birch reduction, purification by a reverse 
phase chromatography on a C18 column was attempted, but to no avail as the 
poor solubility of the amphiphilic glycolipid made the loading of the column 
rather difficult. Fortunately, upon careful purification by silica gel column 
chromatography, the target 6´´´-deoxy-iGb3-sphingosine 5 could be isolated in 
34% yield. While the yield of this final step was modest, limited quantities of the 
fully protected glycolipid 71 prevented further optimisation of this procedure.  
 
Alternatively, hydrogenation with Pearlman’s catalyst followed by the hydrolysis 
of the esters (acetate and benzoates) under Zemplén condition afforded 6´´´-
deoxy-iGb3-sphinganine 6 in 67% yield over two steps. In contrast to the 
sphingosine derivative 5, purification of the fully deprotected sphinganine 
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analogue 6 was more straightforward as the glycolipid could be obtained by 
precipitating the glycolipid with methanol, followed by centrifugation of the 
mixture to form a glycolipid pellet and removal of the sodium methoxide-
containing methanol.  
 
Full characterisation by mass spectrometry, infrared spectroscopy, 1H and 13C 
NMR confirmed the structure and identity of both target glycolipids. Specifically, 
analysis by mass spectrometry confirmed the identity of 6´´´-deoxy-iGb3-
sphingosine 5 (HRMS ESI m/z calcd. for [C62H117NO17+H]+: 1148.8394, obsd.: 
1148.8374) and 6´´´-deoxy-iGb3-sphinganine 6 (m/z calcd. for 
[C62H120NO17+H]+: 1150.8551, obsd.: 1150.8553). The key difference between 
the two target glycolipids is the presence of the E-alkene in sphingosine 5, which 
was confirmed via NMR spectroscopy by the signature doublet of doublets (H-4) 
and doublet of triplets (H-5) at 6.04 ppm and 5.93 ppm, respectively and their 
corresponding carbon signal at 132.6 ppm and 133.0 ppm. 1H and 13C NMR data 
is in agreement with other iGb3 analogues such as the 6´´´-deoxy-iGb3-
phytosphingosine4 and the iGb3-sphinganine analogue.5 
 
4.3 Conclusion 
 
In this work, two analogues of iGb3 were synthesised. An iGb3 derivative lacking 
the 6´´´-OH on the terminal galactose sugar, 6´´´-deoxy-iGb3-sphingosine 5 was 
synthesised in 2% overall yield over 14 steps (longest linear sequence). A further 
derivative, 6´´´-deoxy-iGb3-sphinganine 6, which lacks the alkene on the 
ceramide backbone was made in 4% overall yield over 15 steps (longest linear 
sequence). The highlight of this synthesis was the high yielding coupling between 
lactosyl imidate donor and sphingosine acceptor, which proceeded with excellent 
β-selectivity. The selective acetylation of the 4´´-position of LacCer also allowed 
for the regioselective fucosylation of the 3´´ position, which proceeded smoothly 
when the trichloroacetimidate donor was employed. These 6´´´-deoxy-iGb3 
derivatives will allow for future assessment of their structure activity relationship 
in terms of iNKT cell activation, as well as analysis of structural interaction with 
the TCR of iNKT cells and CD1d by X-ray crystallography.  
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4.4 Experimental 
 
General procedure 
Unless otherwise stated all reactions were performed under argon. Prior to use, 
THF (Pancreac) was distilled from sodium and benzophenone, pyridine was 
distilled and dried over 4Å molecular sieves (4Å MS), DCM (Pancreac) was 
distilled from P2O5, and H2O and benzene (Fisher Scientific) were distilled. SnCl4 
(Aldrich), PhSH (Koch-Light Laboratories), benzaldehyde dimethyl acetal 
(Aldrich), Me2C(OMe)2 (Aldrich), NBS (Aldrich), DBU (Merck), CSA (Acros), 
nBu3SnCl (Aldrich), AIBN (Aldrich), D-fucose (Aldrich), D-lactose (Aldrich), 
trityl chloride (Acros), anhydrous Et2O (Pancreac), PPh3 (Aldrich), Pd(OH)2/C 
(Aldrich, 20 wt%), anhydrous DMF (Acros), TFA (Aldrich), pTsOH (Aldrich), 
TMSOTf (Aldrich), H2SO4 (Lab-Scan), formic acid (Aldrich), AcCl (Aldrich), 
BnBr (Fluka), PMe3 (Aldrich, 1M in THF), AcOH (Ajax Finechem), Ac2O 
(Peking Reagent), TMSOTf (Aldrich), DiPEA (Aldrich), NaOMe (Janssen 
Chimica), trichloroacetonitrile (Aldrich), C25H51COOH (Acros), BzCl (Aldrich, 
distilled an stored under argon), HBTU (Acros), PyBOP (Aldrich), EDCI 
(Aldrich), DMAP (Merck), sodium (Aldrich), trimethyl orthoacetate (Aldrich), 
LiAlH4 (Aldrich), EtOAc (Pancreac), hexanes (Fisher Scientific), petroleum ether 
(Pure Science), MeOH (Pure Science), CHCl3 (Pancreac), EtOH (absolute, Pure 
Science), NaOH (Pure Science), NaHCO3 (Pure Science), NaCl (Pancreac), NH3 
(BOC gasses) were used as received. All solvents were removed by evaporation 
under reduced pressure. Reactions were monitored by TLC-analysis on Macherey-
Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV254) 
with detection by UV-absorption (short wave UV – 254 nm; long wave UV – 366 
nm), by dipping in 10% H2SO4 in EtOH followed by charring at ~150 °C, by 
dipping in I2 in silica, or by dipping into a solution of ninhydrin in EtOH followed 
by charring at ~150 °C. Column chromatography was performed on Pure Science 
silica gel (40-63 micron). AccuBOND II ODS-C18 (Agilent) was used for reverse 
phase chromatography. Infrared spectra were recorded as thin films using a 
Bruker Tensor 27 FTIR spectrometer equipped with an Attenuated Total 
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Reflectance (ATR) sampling accessory and are reported in wave numbers (cm-1). 
Nuclear magnetic resonance spectra were recorded at 20 °C in CD3OD, CDCl3, or 
pyridine-d5 using either a Varian INOVA operating at 500 MHz or Varian 
VNMRS operating at 600 MHz. Chemical shifts are given in ppm (δ) relative to 
TMS. NMR peak assignments were made using COSY, HSQC and HMBC 2D 
experiments. 
 
Phenyl 4-O-(β-D-galactopyranosyl)-1-thio-β-D-glucopyranoside (79) 
A solution of sodium acetate (20 g, 244 mmol) in acetic 
anhydride (100 mL, 1058 mmol) was heated to reflux 
and D-lactose (77) (40 g, 117 mmol) was added in small 
portions over 30 mins. The resulting mixture was refluxed for 2 h, after which it 
was cooled to rt and poured over ice and stirred for 1 h. The white solid was 
filtered and washed with H2O (100 mL). The filtrate was dissolved in Et2O (800 
mL) and the organic layer was washed with H2O (2 x 800 mL), dried (MgSO4), 
filtered and concentrated in vacuo to afford peracetylated D-lactose as a white 
solid (55 g, 81 mmol, 70%). Peracetylated D-lactose (17 g, 25 mmol) was 
dissolved in CH2Cl2 (125 mL) and thiophenol (2.09 mL, 30 mmol) was added. 
The reaction mixture was then cooled to 0 °C, SnCl4 (289 µL, 2.5 mmol) added 
and the resultant mixture stirred at rt for 4 d. The reaction mixture was diluted 
with CH2Cl2 (200 mL), quenched with sat. aq. NaHCO3 (150 mL) and sat. aq. KF 
(150 mL) and the organic layer was isolated from the mixture, and further washed 
with sat. aq. KF (150 mL), sat. aq. NaHCO3 (150 mL), H2O (150 mL), brine (150 
mL) and dried (MgSO4), filtered and concentrated in vacuo. Crystallisation of the 
crude mixture from EtOAc/petroleum ether (9/1, v/v) afforded phenyl 4-O-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-1-thio-β-D-
glucopyranoside as a white solid (11.6 g, 16 mmol, 64%).  Phenyl 4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-1-thio-β-D-
glucopyranoside (5 g, 6.86 mmol) was dissolved in MeOH (55 mL), and NaOMe 
was added until the pH of the reaction mixture reached 9.0. The resulting mixture 
was stirred at rt for 20 h, after which the reaction mixture was neutralised with 
Dowex-H+, filtered and concentrated in vacuo. The residue was crystallised from 
EtOH/MeOH (9.5/0.5, v/v) to afford thiolactoside 7911,12,14,37 (2.8 g, 6.55 mmol, 
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quantitative) as a white solid. Thiolactoside 79 was obtained in 45% overall yield 
in 3 steps from D-lactose (77). Mp 218.2–219.9 °C;11 Rf: 0.02 (DCM/MeOH, 
5.7/1, v/v); [α]D25 = -40.0° (c = 1.0, H2O);11 IR (film) 3360, 2884, 1644, 1583, 
1479, 1439, 1373, 1278, 1117, 1069, 1020, 889, 822, 784, 743, 691 cm-1; 1H 
NMR (600 MHz, D2O) δ 7.55–7.53 (m, 2H, CH-o), 7.39–7.33 (m, 3H, CH-m, 
CH-p), 4.78 (d, J1,2 = 9.1 Hz, 1H, H-1), 4.40 (d, J1´,2´ = 7.8 Hz, 1H, H-1´), 3.91 
(dd, J6a,6b = 12.6 Hz, J5,6a = 1.7 Hz, 1H, H-6a), 3.87 (d, J3´,4´ = 3.4 Hz, 1H, H-4´), 
3.76 (dd, J6a,6b = 12.6 Hz, J5,6b = 5.0 Hz, 1H, H-6b), 3.76–3.70 (m, 2H, H-6´a, H-
6´b), 3.69–3.66 (m, 1H, H-5´), 3.64–3.63 (m, 2H, H-3, H-4), 3.61 (dd, J2´,3´ = 9.9 
Hz, J3´,4´ = 3.4 Hz, 1H, H-3´), 3.59–3.57 (m, 1H, H-5), 3.49 (dd, J2´,3´ = 9.9 Hz, 
J1´,2´ = 8.0 Hz, 1H, H-2´), 3.37 (t, J1,2 = 9.1 Hz, 1H, H-2); 13C NMR (150 MHz, 
D2O) δ 131.9 (C-i), 131.6, 129.3 (C-o, C-m), 128.1 (C-p), 102.8 (C-1´), 87.1 (C-
1), 78.7 (C-5), 77.8 (C-4), 75.8 (C-3), 75.3 (C-5´) 72.5 (C-3´), 71.4 (C-2), 70.9 
(C-2´), 68.5 (C-4´), 61.0 (C-6´), 60.0 (C-6); HRMS(ESI) m/z calcd. for 
[C18H26O10S+Na]+: 457.1139, obsd.: 457.1148.  
 
Phenyl 4-O-(3,4-O-isopropylidene-β-D-galactopyranosyl)-1-thio-β-D-
glucopyranoside (80) 
To a solution of thiolactoside 79 (1.98 g, 4.56 mmol) 
in dry DMF (17 mL) and dry acetone (34 mL), 2,2-
dimethoxypropane (923 µL) and pTsOH (81 mg, 
0.427 mmol) were added and the resulting solution stirred for 3 d at rt. The 
solution was quenched with NEt3 and concentrated under reduced pressure and 
the residue was then crystalised from hot ethanol to give title compound 80 as a 
white crystaline product (1.14 g, 2.40 mmol, 56%). Mp 203.2–203.9 °C Rf: 0.30 
(DCM/MeOH, 9/1, v/v); [α]D25 = -27.0° (c = 1.0, MeOH); IR (film) 3364, 2946, 
2836, 2073, 1653, 1450, 1222, 1119, 1078, 1023, 977, 873, 737 cm-1; 1H NMR 
(500 MHz, CDCl3/CD3OD, 1/1, v/v) δ 7.52–7.51 (m, 2H, CH-o), 7.30–7.23 (m, 
3H, CH-m, CH-p), 4.58 (d, J1,2 = 9.8 Hz, 1H, H-1), 4.31 (d, J1´,2´ = 8.3 Hz, 1H, H-
1´), 4.12 (dd, J3´,4´ = 5.6 Hz, J4´,5´ = 2.2 Hz, 1H, H-4´), 4.03 (dd, J2´,3´ = 7.5 Hz, 
J3´,4´ = 5.6 Hz, 1H, H-3´), 3.91–3.88 (m, 1H, H-5´), 3.86–3.73 (m, 4H, H-6a, H-
6b, H-6´a, H-6´b), 3.57 (t, J2,3 = J3,4 = 8.7 Hz, 1H, H-3), 3.53 (t, J3,4 = J4,5 = 8.7 Hz, 
1H, H-4), 3.46 (t, J2´,3´ = 7.5 Hz, 1H, H-2´), 3.43–3.39 (m, 1H, H-5), 3.33–3.29 
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(m, 1H, H-2), 1.47 (s, 3H, CH3 iPr), 1.31 (s, 3H, CH3 iPr); 13C NMR (125 MHz, 
CDCl3/CD3OD, 1/1, v/v) δ 132.6 (C-i), 131.8, 128.5 (C-o, C-m), 127.3 (C-p), 
109.9 (Cq iPr), 102.7 (C-1´), 87.6 (C-1), 79.7 (C-4), 79.1 (C-3´), 78.5 (C-5), 76.2 
(C-3), 73.9 (C-5´), 73.4 (C-4´), 72.7 (C-2´), 71.7 (C-2), 61.1, 60.9 (C-6/C-6´), 
27.4, 25.6 (2 x CH3 iPr); HRMS(ESI) m/z calcd. for [C21H30O10S+Na]+: 
497.1452, obsd.: 497.1461. Spectral data of 3´,4´-isopropylidene protected 
thiolactoside Error! Reference source not found. matched that previously 
reported.17 
 
Phenyl 4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-
2,3,6-tri-O-benzoyl-1-thio-β-D-glucopyranoside (82) 
 
3´,4´-isopropylidene protected thiolactoside 8014,38 
(1.10 g, 2.31 mmol) was co-evaporated with toluene 
(x3) and dissolved in pyridine (23 mL). Benzoyl chloride (5.9 mL, 50.86 mmol) 
and DMAP (0.14 g, 1.16 mmol) were added and the reaction was stirred at rt for 
15 h. The reaction mixture was diluted with EtOAc (100 mL), washed with sat. 
aq. NaHCO3 (3 x 100 mL), H2O (100 mL) and brine (100 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure. The product was crystallised 
from petroleum ether/EtOAc (2/1, v/v) to give the fully protected lactoside 82 as 
white fluffy crystals (1.98 g, 1.99 mmol, 86%), and the remainder mother liquor 
was purified by silica flash chromatography (petroleum ether/EtOAc, 3/1, v/v) to 
afford more product (0.18 g, 0.18 mmol, 8%). Rf: 0.56 (PE/EA, 1/1, v/v); [α]D25 = 
+40.0° (c = 1.0, CHCl3); IR (film) 3064, 2988, 2941, 1723, 1602, 1451, 1315, 
1265, 1177, 1110, 1083, 1069, 1027, 1000, 753, 708 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 8.07 (d, JCH-o,CH-m = 7.8 Hz, 2H, CH-o, OBz), 8.00 (d, JCH-o,CH-m = 7.8 
Hz, 2H, CH-o, OBz), 7.96 (d, JCH-o,CH-m = 8.0 Hz, 4H, 2 x CH-o, OBz), 7.92 (d, 
JCH-o,CH-m = 7.8 Hz, 2H, CH-o, OBz), 7.62–7.09 (m, 20H, Harom), 5.73 (t, J3,4 = 9.5 
Hz, 1H, H-3), 5.40 (t, J1,2 = 9.9 Hz, 1H, H-2), 5.13 (t, J1´,2´ = 7.6 Hz, 1H, H-2´), 
4.88 (d, J1,2 = 9.9 Hz, 1H, H-1), 4.65 (d, J6a,6b = 12.0 Hz, 1H, H-6a), 4.59 (d, J1´,2´ 
= 7.6 Hz, 1H, H-1´), 4.47 (dd, J6a,6b = 12.0 Hz, J5,6b = 5.1 Hz, 1H, H-6b), 4.26–
4.21 (m, 2H, H-3´, H-6´a), 4.11 (t, J3,4 = 9.5 Hz, 1H, H-4), 4.09 (d, J4´,5´ = 5.8 Hz, 
1H, H-4´), 3.89 (dd, J5,6a =  9.6 Hz, J4,5  = 5.0 Hz, 1H, H-5), 3.83–3.81 (m, 1H, H-
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5´), 3.66 (dd, J6´a,6´b = 11.2 Hz, J6´a,6´b = 7.6 Hz, 1H, H-6´b), 1.52 (s, 3H, CH3 iPr), 
1.25 (s, 3H, CH3 iPr); 13C NMR (125 MHz, CDCl3) δ 166.1 (C=O, 6´-O-Bn), 
166.0 (C=O, 6-O-Bn), 165.7 (C=O, 3-O-Bn), 165.3 (C=O, 2-O-Bn), 165.0 (C=O, 
2´-O-Bn), 133.52, 133.41, 133.30, 133.11, 133.07 (C-p, 5 x OBz), 132.0 (C-i, 
SPh), 130.31, 130.03, 130.00, 129.93 129.86, 129.72, 129.67, 129.47, 129.40, 
128.96, 128.83, 128.63, 128.59, 128.54, 128.53, 128.27, 128.24 (30 x CHarom), 
111.0 (Cq iPr), 100.4 (C-1´), 86.0 (C-1), 77.4 (C-3´), 77.3 (C-5), 75.5 (C-4), 74.0 
(C-3), 73.8 (C-2´), 73.3 (C-4´), 71.5 (C-5´), 70.6 (C-2), 63.0 (C-6), 62.9 (C-6´), 
27.6, 26.3 (2 x CH3 iPr); HRMS(ESI) m/z calcd. for [C56H50O15S+Na]+: 
1017.2763, obsd.: 1017.2774.  
 
 4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl-2,3,6-tri-
O-benzoyl-α-D-glucopyranose (82a) 
 
NBS (1.86 g, 10.45 mmol) was added to fully protected 
lactoside 82 (2.60 g, 2.61 mmol) dissolved in 
acetone/H2O (9/1, v/v, 52 mL), and the mixture was stirred at rt for 50 mins. The 
reaction was quenched with sat. aq. NaHCO3 (10 mL), diluted with EtOAc (80 
mL), washed with sat. aq. Na2S2O3 (100 mL) and brine (100 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude mixture was purified 
by gradient flash chromatography (petroleum ether/EtOAc, 5/1 to 2/1, v/v) to 
afford title compound 82a as a clear oil (1.84 g, 2.04 mmol, 78%). For long term 
storage, the lactol can be crystallised from petroleum ether/EtOAc (2/1, v/v) to 
give white fluffy crystals. Rf: 0.50 (PE/EA, 1/1, v/v); [α]D24 = +71.0° (c = 1.0, 
CHCl3); IR (film) 3064, 1720, 1602, 1452, 1374, 1316, 1265, 1222, 1177, 1109, 
1069,, 999, 755, 687 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.08 (d, JCH-o,CH-m = 7.3 
Hz, 2H, CH-o, OBz), 8.07–7.95 (m, 8H, 4 x CH-o, OBz), 7.62–7.26 (m, 15H, 
Harom), 6.07 (t, J2,3 = J3,4 = 10.0 Hz, 1H, H-3), 5.58 (t, J1,2 = 3.6 Hz, 1H, H-1), 5.19 
(dd, J2,3 = 10.0 Hz, J1,2 = 3.6 Hz, 1H, H-2), 5.16 (t, J1´,2´ = J2´,3´ = 7.2 Hz, 1H, H-
2´), 4.70 (d, J1´,2´ = 7.4 Hz, 1H, H-1´), 4.60 (dd, J6a,6b = 12.2 Hz, J5,6a = 1.6 Hz, 
1H, H-6a), 4.52 (dd, J6a,6b = 12.2 Hz, J5,6b = 3.4 Hz, 1H, H-6b), 4.40–4.38 (m, 1H, 
H-5), 4.32 (dd, J6´a,6´b = 15.3 Hz, J5,6´a = 8.7 Hz, 1H, H-6´a), 4.27 (t, J3´,4´ = 6.1 Hz, 
1H, H-3´), 4.20 (t, J3,4 = 10.0 Hz, 1H, H-4), 4.13–4.11 (m, 1H, H-4´), 3.90–3.85 
O
BzO
BzO
OBzO
BzO
O
OBz
O
OH
O
 142 
(m, 2H, H-5´, H-6´b), 2.90 (d, J1,OH = 3.6 Hz, 1H, OH), 1.51 (s, 3H, CH3 iPr), 
1.26 (s, 3H, CH3 iPr); 13C NMR (125 MHz, CDCl3) δ 166.0, 166.0 (C=O, 6-O-Bn, 
6´-O-Bn), 165.9 (C=O, 2-O-Bn), 165.6 (C=O, 3-O-Bn), 165.0 (C=O, 2´-O-Bn), 
133.4, 133.4, 133.2, 133.1, 132.9 (C-p, 5 x OBz), 130.04, 129.91, 129.77, 129.70, 
129.65, 129.59, 129.52, 129.33, 128.98, 128.60, 128.46, 128.43, 128.36, 128.15 
(25 x CHarom), 110.9 (Cq iPr), 100.0 (C-1´), 90.3 (C-1), 77.1 (C-3´), 75.4 (C-4), 
73.6 (C-2´), 73.6 (C-4´), 72.2 (C-2), 71.3 (C-5´), 69.5 (C-3), 68.6 (C-5), 63.0 (C-
6´), 62.5 (C-6), 27.4, 26.1 (2 x CH3 iPr); HRMS(ESI) m/z calcd. for 
[C50H46O16+Na]+: 925.2678, obsd.: 925.2681. Spectral data of lactol 82a matched 
that previously reported.9 
 
 O-(4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-
tri-O-benzoyl-α-D-glucopyranosyl) trichloroacetimidate (75) 
 
 Lactol 82a was co-evaporated with toluene (x3) 
and dissolved in dry CH2Cl2 (6 mL). 
Trichloroacetonitrile (1.13 mL, 11.30 mmol) and 
DBU (84 µL, 0.56 mmol) were added and the reaction mixture was stirred at rt for 
1 h. Upon completion, the reaction mixture was concentrated and purified 
immediately by flash column chromatography (petroleum 
ether/EtOAc/CH2Cl2/NEt3, 6/1/1/0.08, v/v) to afford imidate 75 as a colourless 
foam (1.08g, 1.03 mmol, 92%). Rf: 0.54 (PE/EA, 1/1, v/v); [α]D24 = +57.0° (c = 
1.0, CHCl3); IR (film) 3336, 3065, 2986, 2938, 1725, 1677, 1452, 1315, 1265, 
1177, 1109, 1070, 1026, 797, 755, 708 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.55 
(s, 1H, NH), 8.07 (d, JCH-o,CH-m = 7.1 Hz, 2H, CH-o, 6´-O-Bz), 8.02 (t, JCH-o,CH-m = 
8.6 Hz, 4H, 2 x CH-o, OBz), 7.95 (t, JCH-o,CH-m = 8.7 Hz, 4H, 2 x CH-o, OBz), 
7.64–7.30 (m, 15H, Harom), 6.69 (d, J1,2 = 3.4 Hz, 1H, H-1), 6.10 (t, J3,4 = 9.2 Hz, 
1H, H-3), 5.50 (dd, J2,3 = 10.2 Hz, J1,2 = 3.4 Hz, 1H, H-2), 5.16 (t, J2´,3´ = 6.9 Hz, 
1H, H-2´), 4.70 (d, J1´,2´ = 7.6 Hz, 1H, H-1´), 4.59 (d, J6a,6b = 11.8 Hz, 1H, H-6a), 
4.52 (d, J6a,6b = 11.8 Hz, 1H, H-6b), 4.31–4.24 (m, 4H, H-4, H-5, H-6´a, H-3´), 
4.11 (d, J3´,4´ = J4´,5´ =4.4 Hz, 1H, H-4´), 3.81–3.78 (m, 2H, H-5´, H-6´b), 1.50 (s, 
3H, CH3 iPr), 1.25 (s, 3H, CH3 iPr); 13C NMR (125 MHz, CDCl3) δ 165.9 (C=O, 
6´-O-Bn), 165.7 (C=O, 6-O-Bn), 165.5 (C=O, 2-O-Bn), 165.4 (C=O, 3-O-Bn), 
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165.0 (C=O, 2´-O-Bn), 160.7 (C=NH), 133.5, 133.4, 133.3, 133.2, 133.1 (C-p, 5 x 
OBz), 130.1, 129.94, 129.86, 129.78, 129.74, 129.54, 129.50, 129.29, 128.68, 
128.63, 128.47, 128.43, 128.41, 128.21 (25 x CHarom), 110.8 (Cq iPr), 100.7 (C-
1´), 93.1 (C-1), 90.7 (CCl3), 77.0 (C-3´), 75.1 (C-4), 73.7 (C-2´), 73.0 (C-4´), 71.4 
(C-5), 71.3 (C-5´), 70.6 (C-2), 70.1 (C-3), 62.8 (C-6´), 62.1 (C-6), 27.3, 26.1 (2 x 
CH3 iPr); HRMS(ESI) m/z calcd. for [C52H46NO16Cl3+H]+: 1046.1955, obsd.: 
1046.1917. Spectral data of lactosyl imidate donor 75 matched that previously 
reported.9,16 
 
 (2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-
octadec-4-ene (74) 
A solution of imidate donor 75 (973 
mg, 0.93 mmol) and lipid acceptor 76 
(300 mg, 0.72 mmol), co-evaporated 
with dry toluene (x3), was dissolved in dry CH2Cl2 (6 mL) and 4 Å molecular 
sieves were added. This mixture was cooled to -20 ºC and a solution of TMSOTf 
in CH2Cl2 (1.38 mmol/mL, 157 µL, 0.22 mmol) was added slowly dropwise, the 
resulting solution was stirred 1.5 h at -20 ºC until TLC analysis showed complete 
consumption of lipid acceptor 76. The solution was quenched with NEt3 (400 µL, 
2.87 mmol) and concentrated under reduced pressure. The resulting oil was 
purified by gradient flash chromatography (petroleum ether/EtOAc, 10/1 to 5/1, 
v/v) to give glycolipid 74 as a colourless oil (936 mg, 0.72 mmol, Quantitative). 
Rf: 0.49 (PE/EA, 2/1, v/v); [α]D25 = +10.0° (c = 1.0, CH2Cl2); IR (film) 3440, 
3297, 3067, 2925, 2854, 2361, 2342, 2101, 1720, 1602, 1452, 1373, 1315, 1264, 
1177, 1109, 1068, 1027, 825, 707 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.10 (d, 
JCH-o,CH-m = 7.3 Hz, 2H, CH-o, OBz), 8.03 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, 
OBz), 8.00 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, OBz), 7.96–7.94 (m, 4H, 2 x CH-o, 
OBz), 7.64–7.19 (m, 20H, Harom), 5.73 (t, J2´,3´ = 9.4 Hz, 1H, H-3´), 5.46–5.39 (m, 
2H, H-2´, H-5), 5.40 (t, J5,6 = 6.7 Hz, 1H, H-5), 5.26 (dd, J4,5 = 15.6 Hz, J3,4 = 8.6 
Hz, 1H, H-4), 5.14 (t, J2´´,3´´ = 7.3 Hz, 1H, H-2´´), 4.68 (d, J1´,2´ = 7.8 Hz, 1H, H-
1´), 4.60–4.58 (m, 2H, H-1´´, H-6´a), 4.47 (dd, J6´a,6´b = 12.3 Hz, J5´,6´b = 4.2 Hz, 
1H, H-6´b), 4.41 (d, Ja,b = 12.0 Hz, 1H, CH-a, 3-O-Bn), 4.25–4.20 (m, 3H, H-4´, 
O
BzO
OBz
OBz
O
BzO
O
OBz
O O
O
C13H27
N3
OBn
 144 
H-3´´, H-6´´a), 4.15 (d, Ja,b =12.0 Hz, 1H, CH-b, 3-O-Bn), 4.07 (dd, J4´´,5´´ = 5.6 
Hz, J3´´,4´´ = 1.9 Hz, 1H, H-4´´), 3.90 (dd, J1a,1b = 10.3 Hz, J1a,2 = 5.7 Hz, 1H, H-
1a), 3.83–3.77 (m, 2H, H-5´, H-5´´), 3.73 (dd, J3,4 = 8.6 Hz, J2,3 = 5.7 Hz, 1H, H-
3), 3.65 (dd, J6´´a,6´´b = 11.5 Hz, J5,6´´b = 7.4 Hz, 1H, H-6´´b), 3.60 (dd, J1,2 = 11.2 
Hz, J2,3 = 5.7 Hz, 1H, H-2), 3.50 (dd, J1a,1b = 10.3 Hz, J1b,2 = 5.7 Hz, 1H, H-1b), 
1.93–1.91 (m, 2H, H-6), 1.52 (s, 3H, CH3 iPr), 1.32–1.26 (m, 25H, CH3 iPr, H-7–
H-17), 0.89 (t, J17,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) δ 166.0 
(C=O, 6´´-O-Bn), 165.9 (C=O, 6´-O-Bn), 165.7 (C=O, 3´-O-Bn), 165.1 (C=O, 2´-
O-Bn), 165.0 (C=O, 2´´-O-Bn), 138.3 (C-5), 138.1 (C-i, 3-O-Bn), 133.4, 133.3, 
133.24, 133.21, 133.0 (C-p, 5 x OBz), 129.88, 129.85, 129.82, 129.8, 129.6, 
129.5, 129.35, 129.28, 128.7, 128.449, 128.44, 128.37, 128.27, 128.17, 127.53, 
127.45, 127.44 (30 x CHarom), 125.4 (C-4), 110.9 (Cq iPr), 101.0 (C-1´), 100.2 (C-
1´´), 79.6 (C-3), 77.0 (C-3´´), 75.3 (C-4´), 73.6 (C-2´´), 73.2 (C-4´´), 73.0 (C-5´), 
72.7 (C-3´), 71.8 (C-2´), 71.3 (C-5´´), 70.0 (CH2, 3-O-Bn), 68.5 (C-1), 63.7 (C-2), 
62.8 (C-6´´), 62.5 (C-6´), 32.3 (C-6), 27.4, 26.2 (2 x CH3 iPr), 31.9, 29.70, 29.69, 
29.68, 29.66, 29.63, 29.42, 29.37, 29.16, 28.9, 22.7 (C-7–C-17), 14.1 (C-18); 
HRMS(ESI) m/z calcd. for [C75H85N3O17+Na]+: 1322.5771, obsd.: 1322.5764. 
 
 (2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-
2-hexacosanoylamido-octadecen-4-ene (83) 
To a solution of glycolipid azide 74 
(100 mg, 0.077 mmol) in toluene (1 
mL) triphenylphosphine (40 mg, 0.15 
mmol), and distilled water (10 drops) were added, the solution was warmed to 80 
ºC and stirred overnight. The reaction mixture was then cooled to room 
temperature, diluted with EtOAc, washed with sat. aq. NH4Cl, dried (MgSO4), 
filtered and concentrated under reduced pressure to give a colourless oil which 
was used without further purification. The oil was co-evaporated twice with dry 
toluene then suspended in DCM (2 mL), EDCI (73 mg, 0.383 mmol), DMAP (30 
mg, 0.246 mmol), and hexacosanoic acid (151 mg, 0.383 mmol) were added and 
the resulting solution stirred over three nights at room temperature. The reaction 
mixture was then purified directly by gradient flash chromatography (petroleum 
O
BzO
OBz
OBzO
BzO
O
OBz
O O
O
C13H27
HN
OBn
C25H51
O
 145 
ether/EtOAc, 10/1 to 2/1, v/v) to give 83 as a colourless oil (92 mg, 0.056 mmol, 
72% over two steps). Rf: 0.55 (PE/EA, 2/1, v/v); [α]D22 = +16.0° (c = 1.0, 
CH2Cl2); IR (film) 3323, 3063, 3034, 2921, 2852, 2361, 2341, 1971, 1724, 1646, 
1602, 1531, 1452, 1267, 1112, 1068, 1027, 707 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 8.09 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, OBz), 8.02 (d, JCH-o,CH-m = 7.3 Hz, 2H, 
CH-o, OBz), 8.00 (d, JCH-o,CH-m = 7.6 Hz, 2H, CH-o, OBz), 7.96 (d, JCH-o,CH-m = 
7.5 Hz, 2H, CH-o, OBz), 7.92 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, OBz), 7.62–7.11 
(m, 20H, Harom), 5.73 (t, J2´,3´ = 9.4 Hz, 1H, H-3´), 5.49 (dt, J4,5 = 15.3 Hz, J5,6 = 
6.9 Hz, 1H, H-5), 5.393 (dd, J2´,3´ = 9.6 Hz, J1´,2´ = 8.0 Hz, 1H, H-2´), 5.392 (d, 
JNH,2 = 9.1 Hz, 1H, NH C26), 5.24 (dd, J4,5 = 15.3 Hz, J3,4 = 8.5 Hz, 1H, H-4), 5.14 
(t, J1´´,2´´ = 7.2 Hz, 1H, H-2´´), 4.60–4.55 (m, 3H, H-1´, H-1´´, H-6´a), 4.48 (dd, 
J6´a,6´b = 12.3 Hz, J5´,6´ = 4.0 Hz, 1H, H-6´b),  4.44 (d, Ja,b = 11.5 Hz, 1H, CH-a, 3-
O-Bn), 4.26–4.19 (m, 5H, H-1a, H-4´, H-3´´, H-6´´a, CH-b, 3-O-Bn), 4.09–4.05 
(m, 2H, H-2, H-4´´), 3.81–3.79 (m, 1H, H-5´´), 3.75–3.69 (m, 3H, H-5´, H-6´´b, 
H-3), 3.47 (dd, J1a,1b = 9.5 Hz, J1b,2 = 3.4 Hz, 1H, H-1b), 1.95–1.92 (m, 2H, H-6), 
1.71–1.61 (m, 2H, CH2-α), 1.52 (s, 3H, CH3 iPr), 1.55–1.03 (m, 71H, H-7–H-17, 
H-β–H-(ω−1), CH3 iPr), 0.88 (t, J17,18 = Jω−1,ω = 6.9 Hz, 6H, H-18, H-ω); 
13C 
NMR (125 MHz, CDCl3) δ 172.4 (HNC=O), 166.0 (C=O, 6´´-O-Bn), 165.8 
(C=O, 6´-O-Bn), 165.6 (C=O, 3´-O-Bn), 165.3 (C=O, 2´-O-Bn), 165.0 (C=O, 2´´-
O-Bn), 138.3 (C-i, 3-O-Bn), 137.0 (C-5), 133.5, 133.4, 133.3, 133.2, 133.1 (C-p, 
5 x OBz), 129.9, 129.81, 129.78, 129.7, 129.6, 129.5, 129.3, 129.1, 128.7, 128.6, 
128.5, 128.4, 128.2, 127.6, 127.4 (30 x CHarom), 127.3 (C-4), 110.9 (Cq iPr), 101.3 
(C-1´), 100.1 (C-1´´), 79.1 (C-3), 77.0 (C-3´´), 75.2 (C-4´), 73.6 (C-2´´), 73.1 (C-
4´´), 73.0 (C-5´), 72.4 (C-3´), 72.3 (C-2´), 71.3 (C-5´´), 70.3 (CH2, 3-O-Bn), 68.3 
(C-1), 62.8 (C-6´´), 62.6 (C-6´), 51.2 (C-2), 36.4 (C-α), 32.2 (C-6), 31.9, 29.75, 
29.73, 29.71, 29.70, 29.66, 29.56, 29.54, 29.40, 29.38, 29.37, 29.27, 29.23, 22.70 
(C-7–C-17, C-γ–C-(ω−1)), 27.4, 26.1 (2 x CH3 iPr), 25.5 (C-β), 14.1 (C-18, C-
ω); HRMS(ESI) m/z calcd. for [C101H137NO18+Na]+: 1674.9728, obsd.: 
1674.9717. 
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 (2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-
benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-hexacosanoylamido-octadec-
4-ene (84) 
 
To a solution of fully protected lactosyl 
ceramide 83 (226 mg, 0.14 mmol) in 
CH2Cl2 (5 mL) was added TFA/H2O 
solution (1/1, v/v, 0.5 mL) and the resulting solution was stirred at room 
temperature for 12 h. The solution was diluted with ethyl acetate and the organic 
layer was then washed with sat. aq. NaHCO3 and brine, dried (MgSO4), filtered 
and concentrated under reduced pressure. The colourless oil was then purified by 
gradient flash chromatography (petroleum ether/EtOAc, 5/1 to 1/1, v/v) to give 
diol 84 as a colourless oil (213 mg, 0.13 mmol, 96%). Rf: 0.08 (PE/EA, 2/1, v/v); 
[α]D25 = +15.0° (c = 1.0, CH2Cl2); IR (film) 3064, 2922, 2852, 2357, 1724, 1512, 
1452, 1267, 1176, 1110, 1068, 1028, 708 cm-1; 1H NMR (500 MHz, CDCl3) δ 
8.07 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, 2´´-O-Bz), 8.00 (t, JCH-o,CH-m = 8.7 Hz, 4H, 
CH-o, OBz), 7.94 (t, JCH-o,CH-m = 8.7 Hz, 4H, 2 x CH-o, OBz), 7.59–7.14 (m, 20H, 
Harom), 5.66 (t, J2´,3´ = J3´,4´ = 9.4 Hz, 1H, H-3´), 5.50 (dt, J4,5 = 15.4 Hz, J5,6 = 6.6 
Hz, 1H, H-5), 5.40–5.36 (m, 2H, H-2´, NH), 5.29 (t, J1´´,2´´ = 7.8 Hz, 1H, H-2´´), 
5.23 (dd, J4,5 = 15.4 Hz, J3,4 = 8.7 Hz, 1H, H-4), 4.59 (d, J1´´,2´´ = 7.8 Hz, 1H, H-
1´´), 4.56 (d, J1´,2´ = 7.8 Hz, 1H, H-1´), 4.53 (bs, 2H, H-6´a, H-6´b), 4.44 (d, Ja,b = 
11.5 Hz, 1H, CH-a, 3-O-Bn), 4.24 (d, Ja,b = 11.5 Hz, 1H, CH-b, 3-O-Bn), 4.23–
4.22 (m, 1H, H-1a), (t, J3´,4´ = 9.4 Hz, 1H, H-4´), 4.08–4.05 (m, 1H, H-2), 4.00 
(dd, J6´´a,6´´b = 11.3 Hz, J5,6´´a = 6.8 Hz, 1H, H-6´´a), 3.81 (bs, 1H, H-4´´), 3.73–
3.67 (m, 3H, H-3, H-5´, H-3´´), 3.63 (dd, J6´´a,6´´b = 11.3 Hz, J5,6´´b = 6.2 Hz, 1H, 
H-6´´b), 3.48–3.47 (m, 2H, H-1b, H-5´´), 1.95–1.92 (m, 2H, H-6), 1.68–1.60 (m, 
2H, CH2-α), 1.37–0.90 (m, 68H, H-7–H-17, H-β–H-(ω−1)), 0.88 (t, J17,18 = Jω,ω+1 
= 6.9 Hz, 6H, H-18, H-ω); 13C NMR (125 MHz, CDCl3) δ 172.4 (HNC=O), 166.4 
(C=O, 2´´-O-Bn), 166.1 (C=O, 6´´-O-Bn), 165.9 (C=O, 6´-O-Bn), 165.8 (C=O, 
3´-O-Bn), 165.3 (C=O, 2´-O-Bn), 138.3 (C-i, 3-O-Bn), 137.0 (C-5), 133.5, 133.4, 
133.3 (C-p, 5 x OBz), 129.9, 129.8, 129.7, 129.64, 129.56, 129.54, 129.47, 129.1, 
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129.0, 128.59, 128.56, 128.51, 128.4, 128.2, 127.6, 127.4 (30 x CHarom), 127.3 (C-
4), 101.1 (C-1´), 100.8 (C-1´´), 79.1 (C-3), 75.9 (C-4´), 73.7 (C-2´´), 73.0 (C-5´), 
72.7 (C-3´), 72.6 (C-3´´), 72.5 (C-5´´), 72.1 (C-2´), 70.3 (CH2, 3-O-Bn), 68.5 (C-
4´´), 68.3 (C-1), 62.6 (C-6´), 61.8 (C-6´´), 51.2 (C-2), 36.4 (C-α), 32.2 (C-6), 
31.9, 29.72, 29.71, 29.68, 29.66, 29.56, 29.54, 29.40, 29.37, 29.27, 29.23, 22.7 
(C-7–C-17, C-γ–C-(ω−1)), 25.5 (C-β), 14.1 (C-18, C-ω); HRMS(ESI) m/z calcd. 
for [C98H134NO18+H]+: 1612.9595, obsd.: 1612.9612. 
 
 (2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-hexacosanoylamido-
octadec-4-ene (73) 
Diol 84 (181 mg, 0.11 mmol) was co-
evaporated with toluene (x3) and 
dissolved in dry CH2Cl2 (1.1 mL). 
Trimethyl orthoacetate (84 µL, 0.67 mmol) and CSA (52 mg, 0.22 mmol) were 
added and the reaction mixture was stirred at rt for 16 h. The reaction mixture was 
diluted with EtOAc (30 mL), washed with 1M HCl solution (3 x 30 mL), sat. aq. 
NaHCO3 (30 mL) and brine (30 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by gradient flash chromatography (petroleum 
ether/EtOAc, 10/1 to 1/1, v/v) to afford acetate 73 as a clear oil (170 mg, 0.26 
mmol, 92%). Rf: 0.24 (PE/EA, 2/1, v/v); [α]D24 = +4.0° (c = 1.0, CH2Cl2); IR 
(film) 3325, 3064, 2923, 2853, 2359, 1966, 1726, 1452, 1372, 1265, 1177, 1108, 
1094, 1069, 1027, 975, 736, 708 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.06 (d, JCH-
o,CH-m = 7.8 Hz, 2H, CH-o, OBz), 8.03 (d, JCH-o,CH-m = 7.6 Hz, 4H, 2 x CH-o, 
OBz), 7.96 (d, JCH-o,CH-m = 7.3 Hz, 2H, CH-o, OBz), 7.96 (d, JCH-o,CH-m = 7.8 Hz, 
2H, CH-o, OBz), 7.60–7.13 (m, 20H, Harom), 5.72 (t, J2´,3´ = J3´,4´ = 9.7 Hz, 1H, H-
3´), 5.50 (dt, J4,5 = 15.6 Hz, J5,6 = 6.6 Hz, 1H, H-5), 5.41 (dd, J1´,2´ = 8.0 Hz, J2´,3´ 
= 9.7 Hz, 1H, H-2´), 5.37 (d, JNH,2´ = 9.3 Hz, 1H, NH), 5.26–5.22 (m, 1H, H-4), 
5.22 (d, J3´´,4´´ = 3.5 Hz, 1H, H-4´´), 5.16 (dd, J2´´,3´´ = 9.8 Hz, J1´´,2´´ = 8.0 Hz, 1H, 
H-2´´), 4.65 (d, J1´´,2´´ = 8.0 Hz, 1H, H-1´´), 4.61 (d, J1´,2´ = 8.0 Hz, 1H, H-1´), 
4.60–4.51 (m, 2H, H-6´a, H-6´b),  4.44 (d, Ja,b = 11.5 Hz, 1H, CH-a, 3-O-Bn), 
4.25 (d, Ja,b = 11.5 Hz, 1H, CH-b, 3-O-Bn), 4.19 (t, J3´,4´ = 9.7 Hz, 1H, H-4´), 4.07 
(m, 1H, H-2), 3.82 (dd, J2´´,3´´ = 9.8 Hz, J3´´,4´´ = 3.5 Hz, 1H, H-3´´), 3.76 (d, J4´,5´ = 
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7.8 Hz, 1H, H-5´), 3.73–3.68 (m, 2H, H-3, H-6´´a), 3.64–3.59 (m, 2H, H-5´´, H-
6´´b), 3.50 (dd, J1a,1b = 9.8 Hz, J1b,2 = 3.5 Hz, 1H, H-1b), 1.99 (s, 3H, OAc), 1.98–
1.92 (m, 2H, H-6), 1.69–1.60 (m, 2H, CH2-α), 1.37–1.03 (m, 68H, H-7–H-17, H-
β–H-(ω−1)), 0.88 (t, J17,18 = Jω−1,ω = 6.9 Hz, 6H, H-18, H-ω); 
13C NMR (125 
MHz, CDCl3) δ 172.4 (HNC=O), 170.6 (C=O, OAc), 166.5 (C=O, 2´´-O-Bn), 
165.9 (C=O, 6´-O-Bn), 165.6 (C=O, 6´´-O-Bn), 165.3 (C=O, 2´-O-Bn), 165.3 
(C=O, 3´-O-Bn), 138.3 (C-i, 3-O-Bn), 137.0 (C-5), 133.6, 133.5, 133.4, 133.2 (C-
p, 5 x OBz), 129.89, 120.82, 129.76, 129.62, 129.51, 129.41, 129.06, 128.9, 
128.6, 128.58, 128.26, 128.19, 127.63, 127.40, 127.30 (30 x CHarom), 101.3 (C-
1´), 100.3 (C-1´´), 79.1 (C-3), 75.3 (C-4´), 73.5 (C-2´´), 73.0 (C-5´), 72.4 (C-3´), 
72.1 (C-2´), 71.5 (C-3´´), 71.1 (C-5´´), 70.3 (CH2, 3-O-Bn), 69.3 (C-4´´), 68.3 (C-
1), 62.5 (C-6´), 61.2 (C-6´´), 21.1 (C-2), 36.4 (C-α), 32.2 (C-6), 31.92, 29.72, 
29.70, 29.68, 29.66, 29.55, 29.54, 29.39, 29.37, 29.36, 29.26, 29.22, 25.45, 22.69 
(C-7–C-17, C-β–C-(ω−1)), 20.6 (OAc), 14.1 (C-18, C-ω); HRMS(ESI) m/z calcd. 
for [C100H135NO19+Na]+: 1676.9521, obsd.: 1676.9526. 
 
 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (88)31 
LiAlH4 (350 mg, 9.22 mmol) was carefully added to a solution of 
Bu3SnCl (3 g, 9.22 mmol) in dry Et2O (20 mL) at 0 °C. The 
reaction mixture was stirred at rt for 3 h, and ice water (10 mL) 
was added and stirred for a further 5 mins. The mixture was 
filtered through a celite pad and the organic layer washed with H2O (2 x 20 mL), 
dried (MgSO4) and concentrated in vacuo to give Bu3SnH as an oil, which was set 
aside for the next step.  
6-Deoxy-6-iodo-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose, 8730,39,40 (1.0 
g, 2.84 mmol) was co-evaporated with toluene (x3) and dissolved in toluene (1.8 
mL). Bu3SnH (1.53 mL, 5.67 mmol) and AIBN (70 mg, 0.43 mmol) were added 
and stirred at 100 °C for 1.5 h, after which the reaction mixture was diluted with 
EtOAc (80 mL), the organic layer washed with water (80 mL) and brine (80 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The resultant oil was purified 
by gradient flash chromatography (petroleum ether to petroleum ether/EtOAc, 
30/1 to 3/1, v/v) to afford 6-deoxy-galactose 88 as a clear oil (672 mg, 2.75 mmol, 
97%). Rf: 0.27 (PE/EA, 10/1, v/v); [α]D25 = -37.0° (c = 1.0, CHCl3); IR (film) 
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3027, 2930, 1369, 1321, 1230, 1170, 1045, 1020, 904, 669  cm-1; 1H NMR (500 
MHz, CDCl3) δ 5.51 (d, J1,2 = 5.1 Hz, 1H, H-1), 4.58 (dd, J3,4 = 8.0 Hz, J2,3 = 2.2 
Hz, 1H, H-3), 4.27 (dd, J1,2 = 5.1 Hz, J2,3 = 2.2 Hz, 1H, H-2), 4.07 (dd, J3,4 = 8.0 
Hz, J4,5 = 1.8 Hz, 1H, H-4), 3.90 (dq, J5,6 = 6.6 Hz, J4,5 = 1.8 Hz, 1H, H-5), 1.51 
(s, 3H, CH3 iPr), 1.45 (s, 3H, CH3 iPr), 1.34 (s, 3H, CH3 iPr), 1.32 (s, 3H, CH3 
iPr), 1.24 (d, J5,6 = 6.5 Hz, 1H, H-6); 13C NMR (125 MHz, CDCl3) δ 108.9 (Cq 
iPr-3,4), 108.2 (Cq iPr-1,2), 96.5 (C-1), 73.5 (C-4), 70.9 (C-3), 70.3 (C-2), 63.4 
(C-5), 26.0 (2 x CH3 iPr), 26.0 (CH3 iPr), 24.9 (CH3 iPr), 17.5 (C-6); HRMS(ESI) 
m/z calcd. for [C12H20O5+NH4]+: 262.1649, obsd.: 262.1655. 
 
 1,2,3,4-Tetra-O-acetyl-6-deoxy-α/β-D-galactopyranose (86) 
α-D-Fucose 85 (250 mg, 1.52 mmol) was dissolved in 
pyridine (7.6 mL) and Ac2O (4.6 mL, 48.6 mmol) was 
added. The reaction was stirred for 14 h at rt and diluted with 
CH2Cl2, washed with H2O (2 x 50 mL), sat. aq. NaHCO3 (50 mL), brine (50 mL) 
and dried over MgSO4. The MgSO4 was filtered off, the filtrate concentrated in 
vacuo and purified by gradient flash chromatography (petroleum ether/EtOAc, 
10:1 to 3:1, v/v) to afford an α/β mixture (1:1.4) of peracetylated D-fucose 86 as a 
clear oil (506 mg, 1.52 mmol, Quantitative).  
 
Alternative method starting from 6-deoxy-1,2:3,4-di-O-isopropylidene-α-D-
galactopyranose, 8831: 
A solution of AcOH/H2O (4/1, v/v, 5 mL) was added to 6-deoxy galactoside 88 
and stirred for 19 h, after which the reaction mixture was warmed to 105 °C and 
stirred for further 2 h. The reaction mixture was concentrated, and the residue co-
evaporated with pyridine (3 x 8 mL), dissolved in pyridine (5 mL) and Ac2O (0.46 
ml, 4.86 mmol). After stirring at rt for 16 h, the reaction mixture was taken up in 
EtOAc (50 mL), washed with 0.5 M HCl solution (50 mL), sat. aq. NaHCO3 (50 
mL), water (50 mL) and brine (50 mL), dried (MgSO4), filtered and concentrated 
in vacuo. Purification by gradient flash chromatography (petroleum ether/EtOAc, 
10:1 to 3:1, v/v) afforded an α/β mixture (1:5) of peracetylated D-fucose 86 as a 
clear oil (273 mg, 0.82 mmol, 85%). Rf: 0.51 (PE/EA, 1/2, v/v); [α]D25 = 59.0° (c 
= 1.0, CHCl3); IR (film) 3027, 2942, 2880, 1746, 1433, 1369, 1321, 1212, 1167, 
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1052, 1023, 904, 668 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.66 (d, J1,2 = 5.7 Hz, 
1H, H-1), 5.29 (t, J2,3 = 10.3 Hz, 1H, H-2), 5.25 (d, J3,4 = 3.2 Hz, 1H, H-4), 5.05 
(dd, J2,3 = 10.3 Hz, J3,4 = 3.2 Hz, 1H, H-3), 3.94 (q, J5,6 = 6.4 Hz, 1H, H-5), 2.17 
(s, 3H, 4-OAc), 2.09 (s, 3H, 1-OAc), 2.02 (s, 3H, 2-OAc), 1.97 (s, 3H, 3-OAc), 
1.20 (d, J5,6 = 6.4 Hz, 1H, H-6); 13C NMR (125 MHz, CDCl3) δ 170.5 (C=O, 4-
OAc), 170.0 (C=O, 3-OAc), 169.5 (C=O, 2-OAc), 169.2 (C=O, 1-OAc), 92.1 (C-
1), 71.2 (C-3), 70.2 (C-5), 69.9 (C-4), 67.9 (C-2), 20.8 (1-OAc), 20.7 (2-OAc), 
20.63 (4-OAc), 20.56 (3-OAc), 15.9 (C-6); HRMS(ESI) m/z calcd. for 
[C14H20O9+NH4]+: 350.1446, obsd.: 350.1450. 
 
Ethyl 2,3,4-tri-O-acetyl-6-deoxy-1-thio-β-D-galactopyranoside (89) 
 Peracetylated D-fucose 86 (620 mg, 1.87 mmol) was co-
evaporated with toluene (x3) and dissolved in dry CH2Cl2 (10 
mL). Ethanethiol (0.41 mL, 5.60 mmol) was added at rt, 
followed by freshly distilled 48% BF3.OEt2 (0.71 mL, 2.80 mmol) and stirred for 
2 h. The reaction mixture was diluted with CH2Cl2 (80 mL) and washed with H2O 
(2 x 50 mL), sat. aq. NaHCO3 (50 mL), brine (50 mL) and dried over MgSO4 and 
filtered. The concentrated filtrate was purified by flash column chromatography 
(petroleum ether/EtOAc, 5:1, v/v) to give β-thiofucoside 89 as a clear oil (452 mg, 
1.35 mmol, 72%). Rf: 0.55 (PE/EA, 1/1, v/v); [α]D25 = +49.0° (c = 1.0, CHCl3); IR 
(film) 3023, 2904, 1746, 1331, 1245, 1218, 1084, 1055, 1020, 863, 749, 667 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.23 (d, J3,4 = 3.5 Hz, 1H, H-4), 5.17 (t, J1,2 = J2,3 = 
10.0 Hz, 1H, H-2), 5.00 (dd, J2,3 = 10.0 Hz, J3,4 = 3.5 Hz, 1H, H-3), 4.42 (d, J1,2 = 
10.0 Hz, 1H, H-1), 3.79 (q, J5,6 = 6.4 Hz, 1H, H-5), 2.75–2.62 (m, 2H, CH2CH3), 
2.13 (s, 3H, 4-OAc), 2.02 (s, 3H, 2-OAc), 1.94 (s, 3H, 3-OAc), 1.23 (t, JCH2,CH3 = 
7.5 Hz, 3H, CH2CH3), 1.17 (d, J5,6 = 6.6 Hz, 3H, H-6); 13C NMR (125 MHz, 
CDCl3) δ 170.6 (C=O, 4-OAc), 170.1 (C=O, 3-OAc), 169.6 (C=O, 2-OAc), 83.5 
(C-1), 73.1 (C-5), 72.3 (C-3), 70.4 (C-4), 67.3 (C-2), 24.1 (CH2CH3), 20.8 (2-
OAc), 20.7 (4-OAc), 20.6 (3-OAc), 16.4 (C-6), 14.7 (CH2CH3); HRMS(ESI) m/z 
calcd. for [C14H22O7S+NH4]+: 352.1424, obsd.: 352.1430. 
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 Ethyl 2,3,4-tri-O-benzyl-6-deoxy-1-thio-β-D-galactopyranoside (90)28 
β-thiofucoside 89 (389 mg, 1.16 mmol) was dissolved in 
methanol and NaOMe was added until the solution reached 
pH 9.0. The reaction mixture was stirred at rt for 1h, 
neutralized with Dowex H+, filtered and concentrated to give the pure triol as a 
colourless oil (242 mg, 1.16 mmol), which was used without further purification. 
The triol (243 mg, 1.16 mmol) was co-evaporated with toluene (x3) and dissolved 
in dry DMF (12 mL) and benzyl bromide (0.55 mL, 4.66 mmol) was added. The 
mixture was cooled to 0 °C and NaH (60% in oil suspension, 233 mg, 5.82 mmol) 
was added. The reaction was stirred for 17 h at rt, quenched with MeOH (5 mL) 
and concentrated to remove the DMF. The crude oil was redissolved in EtOAc (50 
mL), and washed with sat. aq. NaHCO3 (50 mL) and brine (50 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was purified by gradient 
flash chromatography (petroleum ether/EtOAc, 20:1 to 10:1, v/v) to afford 
benzylated thiofucoside 90 as a clear oil (464 mg, 0.97 mmol, 83%). Rf: 0.73 
(PE/EA, 2/1, v/v); [α]D27 = –6.0° (c = 1.0, CHCl3); IR (film) 3064, 2978, 2868, 
1606, 1497, 1454, 1357, 1208, 1124, 1087, 1066, 1047, 875, 745, 732, 697 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.44–7.29 (m, 15H, Harom), 5.03 (d, Ja,b = 11.8 Hz, 
1H, CH-a, 4-O-Bn), 4.93 (d, Ja,b = 10.3 Hz, 1H, CH-a, 2-O-Bn), 4.84 (d, Ja,b = 
10.3 Hz, 1H, CH-b, 2-O-Bn), 4.80 (d, Ja,b = 12.0 Hz, 1H, CH-a, 3-O-Bn), 4.77 (d, 
Ja,b = 12.0 Hz, 1H, CH-b, 3-O-Bn), 4.73 (d, Ja,b = 11.8 Hz, 1H, CH-b, 4-O-Bn), 
4.43 (d, J1,2 = 9.5 Hz, 1H, H-1), 3.86 (t, J1,2 = J2,3 = 9.5 Hz, 1H, H-2), 3.64 (d, J3,4 
= 2.6 Hz, 1H, H-4), 3.60 (dd, J2,3 = 9.5 Hz, J3,4 = 2.6 Hz, 1H, H-3), 3.51 (q, J5,6 = 
6.4 Hz, 1H, H-5), 2.84–2.71 (m,2H, CH2CH3), 1.33 (t, JCH2,CH3 = 7.5 Hz, 2H, 
CH2CH3), 1.24 (d, J5,6 = 6.4 Hz, 1H, H-6); 13C NMR (125 MHz, CDCl3) δ 138.7 
(C-i, 4-O-Bn), 138.5 (C-i, 3-O-Bn), 138.4 (C-i, 2-O-Bn), 128.6, 128.5, 128.34, 
128.29, 128.22, 128.19, 128.0, 127.73, 127.69, 127.59, 127.54 (15 x CHarom), 85.0 
(C-1), 84.5 (C-3), 78.4 (C-2), 76.5 (C-4), 75.7 (CH2, 2-O-Bn), 75.6 (C-5, CH2, 4-
O-Bn), 72.9 (CH2, 3-O-Bn), 24.7 (CH2CH3), 17.3 (C-6), 15.0 (CH2CH3); 
HRMS(ESI) m/z calcd. for [C29H34NO4S+NH4]+: 496.2516, obsd.: 496.2517. 
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 2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranose (91)41 
Thiofucoside 90 (183 mg, 0.38 mmol) was dissolved in 
acetone/H2O (7.6 mL, 9:1, v/v) and NBS (238 mg, 1.34 mmol) 
was added. The reaction mixture was stirred at rt for 10 mins 
and diluted with ethyl acetate (30 mL) and the organic layer was then washed with 
sat. aq. NaHCO3 (30 mL), and brine (30 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure. The residue was purified by gradient flash 
chromatography (petroleum ether/EtOAc, 2:1, v/v) to afford an α/β mixture 
(2.5:1) of lactol 91 as a colourless oil (154 mg, 0.35 mmol, 93%). Rf: 0.16 
(PE/EA, 2/1, v/v); [α]D27 = +18.0° (c = 1.0, CHCl3, value obtained for 2.5:1 α/β 
mixture); IR (film) 3398, 3063, 3030, 2877, 1497, 1454, 1359, 1309, 1211, 1170, 
1091, 1061, 1027, 950, 912, 815, 734, 696, 666 cm-1; α: 1H NMR (500 MHz, 
CDCl3) δ 7.41–7.28 (m, 15H, Harom), 5.27 (d, J1,2 = 3.7 Hz, 1H, H-1), 4.98 (d, Ja,b 
= 11.6 Hz, 1H, CH-a, 4-O-Bn), 4.84 (d, Ja,b = 11.5 Hz, 1H, CH-a, 3-O-Bn), 4.82 
(d, Ja,b = 10.5 Hz, 1H, CH-a, 2-O-Bn), 4.76 (d, Ja,b = 11.5 Hz, 1H, CH-b, 3-O-Bn), 
4.72 (d, Ja,b = 10.5 Hz, 1H, CH-b, 2-O-Bn), 4.67 (d, Ja,b = 11.7 Hz, 1H, CH-b, 4-
O-Bn), 4.10 (q, J5,6 = 6.5 Hz, 1H, H-5), 4.04 (dd, J2,3 = 9.9 Hz, J1,2= 3.7 Hz, 1H, 
H-2), 3.90 (dd, J2,3 = 9.9 Hz, J3,4 = 2.6 Hz, 1H, H-3), 3.67 (bs, 1H, H-4), 1.14 (d, 
J5,6 = 6.5 Hz, 1H, H-6); 13C NMR (125 MHz, CDCl3) δ 138.7 (C-i, 3-O-Bn), 
138.5 (C-i, 4-O-Bn), 138.2 (C-i, 2-O-Bn), 128.47, 128.45, 128.44, 128.35, 128.26, 
128.21, 128.1, 127.8, 127.69, 127.68, 127.62, 127.60, 127.5 (15 x CHarom), 91.9 
(C-1), 79.1 (C-3), 77.4 (C-4), 76.5 (C-2), 74.8 (CH2, 4-O-Bn), 73.5 (CH2, 2-O-
Bn), 73.0 (CH2, 3-O-Bn), 66.7 (C-5), 16.8 (C-6); HRMS(ESI) m/z calcd. for 
[C27H30O5+NH4]+: 452.2431, obsd.: 452.2436. 
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 O-(2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranosyl) trichloroacetimidate 
(72)32,33 
Lactol 91 (153 mg, 0.35 mmol) was co-evaporated with 
toluene (x3) and dissolved in dry CH2Cl2 (3.5 mL). 
DBU (79 µL, 0.53 mmol) and trichloroacetonitrile (353 
µL, 3.52 mmol) were added at rt and the mixture was 
stirred for 1 h. The reaction mixture was concentrated in vacuo and the residue 
purified by gradient flash chromatography (1% NEt3 + petroleum ether to 
petroleum ether/EtOAc, 20:1, v/v). Both the α-isomer 72 (126 mg, 0.22 mmol, 
62%) and the β-isomer (66 mg, 0.11 mmol, 32%) were obtained as clear oils. Rf: 
0.61 (PE/EA, 2/1, v/v); α: [α]D23 = +58.0° (c = 1.0, CHCl3); IR (film) 3343, 
30064, 3030, 2935, 2904, 2874,1731, 1669, 1603, 1497, 1454, 1356, 1293, 1216, 
1103, 1066, 1027, 968, 943, 838, 794, 735, 697, 644 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 8.53 (s, 1H, NH), 7.41–7.29 (m, 15H, Harom), 6.55 (d, J1,2 = 3.4 Hz, 1H, 
H-1), 5.04 (d, Ja,b = 11.5 Hz, 1H, CH-a, 4-O-Bn), 4.89 (d, Ja,b = 11.7 Hz, 1H, CH-
a, 3-O-Bn), 4.80 – 4.78 (m, 3H, CH-b, 3-O-Bn, CH-a, CH-b, 2-O-Bn), 4.71 (d, Ja,b 
= 11.5 Hz, 1H, CH-b, 4-O-Bn), 4.27 (dd, J2,3 = 10.0 Hz, J1,2 = 3.4 Hz, 1H, H-2), 
4.12 (q, J5,6 = 6.4 Hz, 1H, H-5), 4.06 (dd, J2,3 = 10.0 Hz, J3,4 = 2.6 Hz, 1H, H-3), 
3.74 (bs, 1H, H-4), 1.19 (d, J5,6 = 6.4 Hz, 1H, H-6); 13C NMR (125 MHz, CDCl3) 
δ 161.3 (C=NH), 138.6 (C-i, 3-O-Bn), 138.5 (C-i, 2-O-Bn), 138.4 (C-i, 4-O-Bn), 
128.5, 128.42, 128.37, 128.29, 128.26, 127.74, 127.70, 127.6, 127.5 (15 x 
CHarom), 95.3 (C-1), 91.6 (CCl3), 78.3 (C-3), 77.3 (C-4), 75.8 (C-2), 75.0 (CH2, 4-
O-Bn), 73.2 (CH2, 3-O-Bn), 72.9 (CH2, 2-O-Bn), 69.6 (C-5), 16.7 (C-6); 
HRMS(ESI) m/z calcd. for [C29H30NO5Cl3+Na]+: 600.1082, obsd.: 600.1092. 
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 (2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-6-
deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-
glucopyranosyloxy)-3-benzyloxy-2-hexacosanoylamido-octadec-4-ene (71) 
Fucosyl imidate donor 72 (32 
mg, 0.055 mmol) and lactosyl 
ceramide acceptor 73 (44.7 mg, 
0.027 mmol) were co-
evaporated with toluene (x3), dissolved in dry CH2Cl2 (1 mL) and stirred with 
activated 4Å molecular sieves for 3 h. The reaction mixture was cooled to -40 °C, 
and a solution of TMSOTf in CH2Cl2 (0.28 mmol/mL, 9.8 µL, 0.0027 mmol) was 
added and stirred for 1 h. The reaction was warmed to -20 °C and further 
TMSOTf solution (0.28 mmol/mL, 5.9 µL, 0.0016 mmol) was added. The 
reaction mixture was allowed to warm slowly to rt while stirring overnight (20 h), 
upon which it was quenched with NEt3 (40 µL, 0.29 mmol), filtered and 
concentrated in vacuo. The resultant oil was purified by gradient flash 
chromatography (3% to 8 % EtOAc in toluene) to afford the fully protected 
triglycosyl ceramide 71 as a clear oil (38.6 mg, 0.019 mmol, 69%). Rf: 0.49 
(PE/EA, 2/1, v/v); [α]D24 = +12.0° (c = 1.0, CHCl3); IR (film) 3091, 2923, 2853, 
1730, 1672, 1602, 1497, 1453, 1364, 1315, 1267, 1176, 1097, 1069, 1028, 978, 
755, 710, 641 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.02 (d, JCH-o,CH-m = 7.3 Hz, 
2H, CH-o, 6´´-O-Bz), 8.01 (d, JCH-o,CH-m = 7.0 Hz, 2H, CH-o, 3´-O-Bz), 7.98 (d, 
JCH-o,CH-m = 7.1 Hz, 2H, CH-o, 2´-O-Bz), 7.95 (d, JCH-o,CH-m = 7.1 Hz, 2H, CH-o, 
2´´-O-Bz), 7.93 (d, JCH-o,CH-m = 7.1 Hz, 2H, CH-o, 6´-O-Bz), 7.61–7.13 (m, 35H, 
Harom), 5.74 (t, J3´,4´ = 9.6 Hz, 1H, H-3´), 5.49 (dt, J4,5 = 15.3 Hz, J5,6 = 6.7 Hz, 1H, 
H-5), 5.41 (t, J1´,2´ = J2´,3´ = 7.5 Hz, 1H, H-2´), 5.40 (t, J1´´,2´´ = J2´´,3´´ = 7.5 Hz, 1H, 
H-2´´), 5.36 (d, JNH,2´ = 9.1 Hz, 1H, NH), 5.34 (d, J3´´,4´´ = 3.4 Hz, 1H, H-4´´), 5.23 
(dt, J4,5 = 15.3 Hz, J3,4 = 8.8 Hz, 1H, H-4), 4.94 (d, J1´´´,2´´´ = 3.5 Hz, 1H, H-1´´´), 
4.75 (d, Ja,b = 11.3 Hz, 1H, CH-a, 4´´´-O-Bn), 4.72 (d, Ja,b = 11.9 Hz, 1H, CH-a, 
3´´´-O-Bn), 4.60 (d, J1´,2´ = 7.9 Hz, 1H, H-1´), 4.56 (d, J1´´,2´´ = 8.2 Hz, 1H, H-1´´), 
4.58–4.54 (m, 2H, CH-a, CH-b, 2´´´-O-Bn), 4.48 (d, Ja,b = 11.9 Hz, 1H, CH-b, 
3´´´-O-Bn), 4.48–4.47 (m, 2H, H-6´a, H-6´b), 4.44 (d, Ja,b = 11.5 Hz, 1H, CH-a, 3-
O-Bn), 4.34 (d, Ja,b = 11.3 Hz, 1H, CH-b, 4´´´-O-Bn), 4.25 (dd, J1a,1b = 9.8 Hz, 
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J1a,2 = 2.7 Hz, 1H, H-1a), 4.24 (d, Ja,b = 11.5 Hz, 1H, CH-b, 3-O-Bn), 4.17 (t, J3´,4´ 
= 9.6 Hz, 1H, H-4´), 4.09–4.05 (m, 1H, H-2), 3.83 (dd, J2´´´,3´´´ = 10.2 Hz, J1´´´,2´´´ = 
3.5 Hz, 1H, H-2´´´), 3.80 (dd, J2´´,3´´ = 10.3 Hz, J3´´,4´´ = 3.4 Hz, 1H, H-3´´), 3.74–
3.69 (m, 2H, H-5´, H-3), 3.62–3.59 (m, 2H, H-6´´a, H-6´´b), 3.57–3.55 (m, 2H, H-
5´´´, H-3´´´), 3.52 (t, J5´´,6´´ = 6.9 Hz, 1H, H-5´´), 3.48 (dd, J1a,1b = 9.8 Hz, J1a,2 = 
3.7 Hz, 1H, H-1b), 2.90 (d, J3´´´,4´´´ = 0.9 Hz, 1H, H-4´´´), 1.96–1.92 (m, 2H, H-6), 
1.70–1.62 (m, 2H, CH2-α), 1.63 (s, 3H, OAc), 1.31–1.04 (m, 68H, H-7–H-17, H-
β–H-(ω−1)), 0.88 (t, J17,18 = Jω−1,ω = 7.0 Hz, 6H, H-18, H-ω), 0.79 (d, J5´´´,6´´´ = 
6.5 Hz, 3H, H-6´´´); 13C NMR (150 MHz, CDCl3) δ 172.5 (HNC=O), 170.2 
(C=O, OAc), 166.0 (C=O, 6´-O-Bn), 165.8 (C=O, 6´´-O-Bn), 165.5 (C=O, 2´´-O-
Bn), 165.3 (C=O, 3´-O-Bn), 164.5 (C=O, 2´-O-Bn), 139.0 (C-i, 3´´´-O-Bn), 138.7 
(C-i, 2´´´-O-Bn), 138.5 (C-i, 4´´´-O-Bn), 138.4 (C-i, 3-O-Bn), 137.2 (C-5), 133.7, 
133.6, 133.55, 133.52, 133.3 (C-p, 5 x OBz), 129.97, 129.89, 129.87, 129.78, 
129.67, 129.60, 129.48, 129.18, 128.75, 128.71, 128.57, 128.44, 128.34, 128.32, 
128.22, 128.17, 128.09, 128.05, 127.85, 127.76, 127.61, 127.59, 127.57, 127.52, 
127.41 (45 x CHarom), 127.44 (C-4), 101.5 (C-1´), 100.9 (C-1´´), 94.2 (C-1´´´), 
79.2 (C-3), 79.0 (C-3´´´), 77.6 (C-4´´´), 75.4 (C-4´, C-2´´´), 74.9 (CH2, 4´´´-O-
Bn), 73.5 (CH2, 2´´´-O-Bn), 73.3 (CH2, 3´´´-O-Bn), 73.1 (C-5´), 72.5 (C-3´), 72.3 
(C-2´´, C-3´´), 71.4 (C-5´´), 71.1 (C-2´), 70.4 (CH2, 3-O-Bn), 68.5 (C-1), 66.7 (C-
5´´´), 64.4 (C-4´´), 62.5 (C-6´), 61.3 (C-6´´), 51.3 (C-2), 36.6 (C-α), 32.4 (C-6), 
32.07, 30.17, 29.89, 29.87, 29.85, 29.82, 29.80, 29.70, 29.68, 29.53, 29.52, 29.51, 
29.41, 29.39, 29.36, 27.22, 25.58, 22.84 (C-7–C-17, C-β–C-(ω−1)), 20.4 (OAc), 
16.2 (C-6´´´), 14.3 (C-18, C-ω); HRMS(ESI) m/z calcd. for [C127H163NO23+Na]+: 
2093.1508, obsd.: 2093.1463. 
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 (2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-hydroxy-
octadec-4-ene (5) 
 Fully protected triglycosyl 
ceramide 71 (33 mg, 0.016 
mmol) was dissolved in dry THF 
(2 mL) and NH3 (10 mL) was 
condensed into the reaction vessel at -78 °C. Small pieces of Na (s) were added 
carefully until the solution remained deep blue and the reaction mixture was 
stirred for 30 mins. The reaction was then quenched with a few drops of MeOH 
and Na (s) was added again until the deep blue colour persisted, and the reaction 
mixture stirred for a further 30 mins. The reaction was quenched with 10 mL 
MeOH, and the reaction warmed slowly to rt to allow the ammonia to evaporate. 
Trace ammonia was removed with an Ar stream. The reaction mixture was 
quenched to pH 7 with Dowex-H+, filtered and washed with pyridine and 
concentrated in vacuo. The resultant oil was purified by gradient flash 
chromatography (DCM/MeOH, 20/1 to 10/1, v/v) to afford fully deprotected 6´´´-
deoxy-iGb3-sphingosine 5 as an amorphous white solid (6.2 mg, 0.0054 mmol, 
34%). Rf: 0.29 (DCM/MeOH, 5.7/1, v/v); [α]D27 = +37.0° (c = 0.1, pyridine); IR 
(film) 3402, 2922, 1653, 1558, 1541, 1458, 1134, 1099, 1072, 1038, 890, 814, 
791, 694, 648, 633 cm-1; 1H NMR (500 MHz, pyridine-d5) δ 8.45 (d, J2,NH = 8.2 
Hz, 1H, NH), 6.04 (dd, J4,5 = 15.2 Hz, J3,4 = 16.4 Hz, 1H, H-4), 5.93 (dt, J4,5 = 
15.2 Hz, J5,6 = 6.9 Hz, 1H, H-5), 5.59 (d, J1´´´,2´´´ = 3.7 Hz, 1H, H-1´´´), 5.11 (d, 
J1´´,2´´ = 7.9 Hz, 1H, H-1´´), 4.95 (q, J5´´´,6´´´ = 6.7 Hz, 1H, H-5´´´), 4.89 (d, J1´,2´ = 
7.9 Hz, 1H, H-1´), 4.81–4.79 (m, 3H, H-1a, H-2, H-3), 4.66 (dd, J2´´´,3´´´ = 9.9 Hz, 
J1´´´,2´´´ =  3.7 Hz, 1H, H-2´´´), 4.59 (d, J3´´,4´´ = 2.1 Hz, 1H, H-4´´), 4.56–4.53 (m, 
2H, H-2´´, H-3´´´), 4.50–4.44 (m, 3H, H-6´a, H-6´b, H-6´´a), 4.34 (dd, J6´´a,6´´b = 
10.9 Hz, J5´´,6´´b = 3.4 Hz, 1H, H-6´´b), 4.30–4.23 (m, 3H, H-4´, H-3´´, H-3´), 
4.18–4.17 (m, 1H, H-1b), 4.14 (bs, 1H, H-4´´´), 4.10–4.05 (m, 2H, H-5´´, H-2´), 
3.87–3.85 (m, 1H, H-5´), 2.46 (t, Jα,β = 7.4 Hz, 2H, CH2-α), 2.08 (dd, J6,7 = 13.9 
Hz, J5,6 = 6.9 Hz, 2H, H-6), 1.87–1.81 (m, 2H, CH2-β), 1.59 (d, J5´´´,6´´´ = 6.6 Hz, 
3H, H-6´´´), 1.41–1.27 (m, 66H, H-7–H-17, H-γ–H-(ω−1)), 0.90–0.86 (m, 6H, H-
O
HO
OH
OHO
OH
O
OH
O O
HO
C13H27
HN
OH
C25H51
OO
CH3HO
HO
HO
 157 
18, H-ω); 13C NMR (125 MHz, pyridine-d5) δ 173.7 (HNC=O), 133.0 (C-5), 
132.6 (C-4), 105.84, 105.79 (C-1´, C-1´´), 97.9 (C-1´´´), 82.4 (C-4´), 80.4 (C-3´´), 
77.00 (C-3´), 76.95 (C-5´´), 76.8 (C-5´), 75.1 (C-2´), 73.8 (C-4´´´), 73.0 (C-3), 
72.0 (C-3´´´), 70.8 (C-1, C-2´´), 70.4 (C-2´´´), 68.1 (C-5´´´), 66.3 (C-4´´), 62.3 (C-
6´), 62.2 (C-6´´), 55.2 (C-2), 37.3 (C-α), 33.1 (C-6), 26.8 (C-β), 32.48, 32.46, 
30.38, 30.36, 30.33, 30.25, 30.14, 30.07, 29.98, 29.94, 23.29, 23.27 (C-7–C-17, 
C-γ–C-(ω−1)), 17.6 (C-6´´´), 14.6 (C-18, C-ω); HRMS(ESI) m/z calcd. for 
[C62H117NO17+H]+: 1148.8394, obsd.: 1148.8374. 
 
 (2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-hydroxy-
octadecane (6) 
Pd(OH)2/C (2 mol%) was added 
to a solution of fully protected 
triglycosyl ceramide 71 (22 mg, 
0.010 mmol) dissolved in 
CHCl3/EtOH (3/2, v/v). The reaction mixture was stirred under H2 atmosphere for 
4 h, filtered through a celite pad and concentrated under reduced pressure. The 
resultant oil was purified by gradient flash chromatography (2.5% to 5% MeOH 
in DCM) to afford debenzylated 6´´´-deoxy-iGb3-sphinganine (13.4 mg, 0.0078 
mmol, 75%), which was subsequently dissolved in MeOH/DCM (2/1, v/v, 4.5 
mL). NaOMe was added until the reaction mixture reached pH 9 and stirred at rt 
for 17 h. The reaction mixture was warmed to 40 °C and stirred for further 3 h, 
then neutralised to pH 7 with Dowex-H+. The resin was removed by filtration and 
washed successively with pyridine and concentrated under reduced pressure. 
MeOH (5 mL) was added to the crude mixture and cooled to -4 °C to give a 
suspension of glycolipid in solution. The precipitate was collected by centrifuge 
and washed with MeOH (2 x 5 mL), to afford the fully deprotected 6´´´-deoxy-
iGb3-sphinganine 6 as an amorphous white solid (6.1 mg, 0.0053 mmol, 70%). 
More desired product was precipitated from the combined MeOH supernatant (1.7 
mg, 0.0015 mmol, 19%). The total yield of 6´´´-deoxy-iGb3-sphinganine 6 was 
89% (7.8 mg, 0.0068 mmol). Rf: 0.23 (DCM/MeOH, 5/1, v/v); [α]D27 = +42.0° (c 
= 0.1, pyridine); IR (film) 3342, 2919, 2850, 1626, 1551, 1468, 1379, 1165, 1081, 
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1038, 899, 813, 778, 722, 677, 651, 632 cm-1; 1H NMR (500 MHz, pyridine-d5) δ 
8.45 (d, J2,NH = 9.0 Hz, 1H, NH), 7.64 (d, J2´,OH = 3.0 Hz, 1H, H-2´-OH), 7.36 (d, 
J2´´/3´´´,OH = 5.5 Hz, 1H, H-2´´/3´´´-OH), 7.08 (d, J2´´´,OH = 5.5 Hz, 1H, H-2´´´-OH), 
6.68 (d, J6´´,OH = 5.0 Hz, 1H, H-6´´-OH), 6.56 (d, J2´´/3´´´,OH = 5.4 Hz, 1H, H-
2´´/3´´´-OH), 6.48 (d, J6´,OH = 6.2 Hz, 1H, H-6´-OH), 6.30 (d, J3,OH = 6.3 Hz, 1H, 
H-3-OH), 6.26 (d, J4´´´,OH = 3.8 Hz, 1H, H-4´´´-OH), 6.18 (s,1H, H-3´-OH), 5.83 
(s,1H, H-4´´-OH), 5.60 (d, J1´´´,2´´´ = 3.3 Hz, 1H, H-1´´´), 5.10 (d, J1´´,2´´ = 8.0 Hz, 
1H, H-1´´), 4.95 (q, J5´´´,6´´´ = 6.5 Hz, 1H, H-5´´´), 4.89 (d, J1´,2´ = 7.6 Hz, 1H, H-
1´), 4.80 (dd, J1a,1b = 10.4 Hz, J1a,2 = 4.4 Hz, 1H, H-1a), 4.73–4.69 (m, 1H, H-2), 
4.68–4.64 (m, 1H, H-2´´´), 4.59 (bs, 1H. H-4´´), 4.57–4.53 (m, 2H, H-2´´, H-3´´´), 
4.51–4.49 (m, 2H, H-6´a, H-6´b), 4.46 (dd, J6´´a,6´´b = 12.2 Hz, J5,6´´a = 5.6 Hz,1H, 
H-6´´a), 4.37–4.33 (m, 1H, H-6´´b), 4.29–4.21 (m, 4H, H-3´, H-4´, H-3´´, H-3), 
4.18 (dd, J1a,1b = 10.4 Hz, J1b,2 = 3.2 Hz, 1H, H-1b), 4.14 (bs, 1H, H-4´´´), 4.10–
4.06 (m, 2H, H-5´´, H-2´), 4.89–4.87 (m, 1H, H-5´), 2.48 (t, Jα,β = 7.4 Hz, 2H, 
CH2-α), 1.96–1.80 (m, 4H, H-4, CH2-β), 1.60 (d, J5´´´,6´´´ = 6.5 Hz, 3H, H-6´´´), 
1.41–1.27 (m, 70H, H-5–H-17, H-γ–H-(ω−1)), 0.89–0.87 (m, 6H, H-18, H-ω); 13C 
NMR (125 MHz, pyridine-d5) δ 173.6 (HNC=O), 105.9 (C-1´, C-1´´), 98.0 (C-
1´´´), 82.5 (C-4´), 80.5 (C-3´´), 77.1 (C-3´), 77.0 (C-5´´), 76.9 (C-5´), 75.1 (C-2´), 
73.8 (C-4´´´), 72.0 (C-3´´´), 71.7 (C-3), 71.1 (C-1), 70.9 (C-2´´), 70.4 (C-2´´´), 
68.1 (C-5´´´), 66.3 (C-4´), 62.4 (C-6´), 62.2 (C-6´´), 55. 3 (C-2), 37.3 (C-α), 35.3 
(C-4), 26.9 (C-β), 32.49, 32.48, 30.59, 30.48, 30.40, 30.38, 30.30, 30.27, 30.22, 
30.12, 29.99, 29.96, 26.79, 23.30, 23.29 (C-7–C-17, C-γ–C-(ω−1)), 17.6 (C-6´´´), 
14.6 (C-18, C-ω); HRMS(ESI) m/z calcd. for [C62H119NO17+H]+: 1150.8551, 
obsd.: 1150.8553. 
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Chapter 5. Synthesis of acyl chain homologues of 
iGb3 
 
5.1 Introduction 
 
The N-acyl lipids of CD1d-binding glycolipids have been reported to impact 
glycolipid activity by altering the ability of the glycolipids to activate iNKT cells 
and also by affecting the cytokine profile induced.1-6 The acyl lipid lodges itself 
into the hydrophobic A´-pocket of CD1d7,8 and along with the ceramide 
backbone, is responsible for the positioning of the sugar headgroup for 
recognition by the iNKT cell TCR.5 In addition, changes to the lipid portion of α-
GalCer have been suggested to affect its solubility, leading to variations in in vivo 
distribution and pharmacology of the glycolipids.3 This could alter glycolipid 
processing and presentation by various subsets of dendritic cells, ultimately 
resulting in the specific iNKT cell activation. 
 
While the influence of α-GalCer analogues with acyl chains of varying length, 
saturation and substitution patterns have been extensively studied,1,2,4-6,9 no 
systematic analysis has been carried out for N-acyl chain homologues of 
isoglobotrihexosylceramide, iGb3, 4 (Figure 5.1). To date, the short acyl chain 
derivatives of iGb3 4 (i.e. C8 and C18 derivatives), have been used for 
crystallographic analysis, but they have not been compared side-by-side for their 
structure activity relationships. The C26 acyl lipid is notorious for being poorly 
soluble, therefore, in the synthesis of glycosphingolipids, the original C26 acyl 
chain, as found in α-GalCer and iGb3, is often substituted by shorter variants 
(C16, C18, C24). This presumably has the advantage of increasing the yield of the 
amide coupling with the more readily soluble fatty acids, and consequently, of 
improving the solubility of the final glycosphingolipids, which assists with 
purification and characterisation.  
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Figure 5.1. iGb3 (4) and acyl chain homologues, iGb3-C12 (7) and iGb3-C20:2 
(8). 
 
Access to a panel of acyl chain homologues of iGb3 (4) will provide a useful 
means by which to probe the structure activity relationship between iNKT cell 
activation and acyl lipid length and saturation. To this end, the novel iGb3-C12 
analogue 7 will provide a platform to further test how the truncated lipid can 
affect the orientation of the sugar headgroup and hence activity (Figure 5.1). 
While shorter acyl chain homologues of iGb3 such as the C8,10,11 C16,12 C18,13 
and C2414 homologues have previously been made, no systematic structure 
activity relationship studies were performed on this series. In addition, α-GalCer 
with a C20:2 acyl lipid has been found to have superior activity compared to the 
saturated analogue C20, and can skew the immune system towards an anti-
inflammatory (Th2) cytokine response.2,15,16 Accordingly, the unprecedented 
C20:2 derivative of iGb3 8, will be prepared. Through synthesis, subsequent 
structure activity relationship studies and crystal structure analysis, it will thus be 
possible to understand the influence that the unsaturated acyl chain has on the 
presentation of triglycosylceramides. 
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One other point to keep in mind is that while α-GalCer remains the glycolipid 
adjuvant of choice in DC based cancer immunotherapy, the activity of this 
glycolipid is so potent that anergy can be induced.17-20 Thus, while it is a long way 
off, there is also the potential to use iGb3 analogues in cancer immunotherapy or, 
through structural modification and the judicious induction of a different cytokine 
profile, as a therapy for diseases other than cancer, such as infectious diseases and 
autoimmune diseases.21-23 Furthermore, there has been increasing appreciation for 
the role that β-linked glycolipids play in activating iNKT cells, beyond just 
serving as the endogenous ligands responsible for positive selection of iNKT 
cells.24 Brigl et al. convincingly illustrated that in a microbial infection setting, 
iNKT cells were able to respond to inflammatory stimulus in the absence of 
known microbial–derived ligands for iNKT TCR.25 Innate stimulus such as the 
TLR signal stimulates the production of IL-12, causing cytokine-mediated 
activation of iNKT cells, presumably through the activity of endogenous 
glycolipids. While the exact identity of the self-glycolipids remains to be 
determined, β-glucosylceramide (β-GlcCer) was isolated in abundance and was 
shown to accumulate in the lymphoid tissues of mice and humans during 
infection.26 Much remains to be answered about the exact role of β-linked self 
glycolipids, but these findings point towards the possibility of using β-linked 
glycolipids, such as iGb3 analogues, to activate iNKT cells not just for cancer, but 
also for other disease settings.  
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5.2 Synthesis of acyl chain homologues of iGb3 
 
Retrosynthesis 
 
To synthesise the acyl chain homologues of iGb3, iGb3-C12 7 and iGb3-C20:2 8, 
a highly convergent strategy was chosen, whereby both glycolipids 7 and 8 could 
be obtained from the triglycosyl 2-azido-sphingosine intermediate 92 via azide 
reduction, amide coupling with the desired fatty acid, then global deprotection via 
Birch reduction (Scheme 5.1). In turn, azide 92 could be made by the 
glycosylation reaction between galactosyl imidate donor 93 and 
lactosylsphingosine (LacSphing) acceptor 94, while the galactosyl imidate donor 
could be obtained in several steps from D-galactose (39). Finally, the LacSphing 
acceptor 94 could be obtained from lactosyl 2-azido-sphingosine 74, where the 
synthesis of lactosyl 2-azido-sphingosine 74 is described in Chapter 4 (Scheme 
4.2). This strategy differs from the approach used to synthesise 6´´´-deoxy-iGb3, 
in that the complete trisaccharide core is prepared prior to the addition of N-acyl 
chain. The advantage of this approach is that the late stage azide intermediate 92 
could be functionalised with desired fatty acids, followed immediately by global 
deprotection to afford the target iGb3 analogues.  
 
 
 
 
 
 
 165 
 
 
Scheme 5.1. Retrosynthesis of target iGb3 homologues, iGb3-C12 (7) and iGb3-
C20:2 (8). 
 
Synthesis of galactosyl imidate donor 93 
 
The synthesis of target iGb3 homologues 7 and 8 began with the synthesis of 
galactosyl imidate donor 93 (Scheme 5.1).27-30 Here, D-galactose (39) was 
peracetylated, then subjected to the Helferich glycosidation using tin(IV) chloride 
as the Lewis acid,31 and the acetate groups were then removed using sodium 
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methoxide in methanol to afford thiogalactoside 95. Next, the 4- and 6-hydroxyls 
were selectively protected with a benzylidene group, which was previously 
anticipated to favour α-glycosylation,28,32,33 and the remaining hydroxyls were 
then benzylated to afford the fully protected thiogalactoside 96 in 53% yield over 
two steps. Initial attempts at synthesising iGb3 by other members of our group 
using a thiol donor to attach the terminal sugar led to poor yields and a mixture of 
products,34 so accordingly, an imidate donor was chosen. To this end, the 
anomeric thiophenol group in 96 was hydrolysed using NBS in the presence of 
acetone and water to provide lactol 97 in quantitative yield.35 The anomeric 
hydroxyl was then converted into a trichloroacetimidate group to afford galactosyl 
imidate donor 93 as crystalline material in 86% yield. In summary, the galactose 
donor building block 93 was made from D-galactose (39) in seven steps and in an 
overall yield of 45%, which is comparable to Wong and co-workers’ synthesis via 
the 1-S-p-methylphenyl intermediate.28  
 
 
Scheme 5.2. Synthesis of galactosyl imidate donor 93. 
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Triglycosyl 2-azido-sphingosine 92 
 
With the galactose building block in hand, attention was then turned towards the 
synthesis of triglycosyl 2-azido-sphingosine 92, which commenced with lactosyl 
2-azido-sphingosine 74, an intermediate from the synthesis of 6´´´-deoxy-iGb3 
analogues (cf. Chapter 4, Scheme 4.2). Accordingly, the isopropylidene group in 
74 was first hydrolysed in the presence of acid to afford diol 98 in an excellent 
99% yield (Scheme 5.3). Next, the 4´´-OH was regioselectively protected as an 
acetate by employing the same strategy used in Chapter 4, whereby trimethyl 
orthoacetate and camphorsulfonic acid were used to first install a methyl 
orthoacetate protecting group at 3´´-OH and 4´´-OH, which subsequently ring-
opened upon acidic workup. In this way, LacSphing acceptor 94 was prepared in 
an excellent 94% yield. The successful acetylation at the 4´´-position was 
confirmed by a HMBC between the carbonyl carbon of the acetate and H-4´´.  
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Scheme 5.3. Synthesis of triglycosyl 2-azido-sphingosine 92. 
 
Using galactose donor 93 and the LacSphing acceptor 94 a glycosylation reaction 
was then performed with TMSOTf as the promoter. Initially, the reaction was  
carried out at at -40 °C, however this proved unsuccessful and no desired product 
was formed. When the reaction was repeated at warmer temperatures (activation 
at -20 °C followed by stirring from 0 °C to rt over 2.5 h) the desired α-isomer of 
92 was formed (56% yield), however, a significant amount (ca. 40%) of unreacted 
acceptor 94 was also isolated. Despite efforts to push the reaction to completion 
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by sequentially adding more equivalents of the donor to the reaction mixture, the 
glycosylation yield could not be improved. Indeed, the best yields were obtained 
when the donor was added in one portion. The glycosylation at the 3´´ position 
was confirmed by HMBC between C-3´´ and H-1´´´ (Figure 5.2).  
  
 
Figure 5.2. HMBC spectrum of triglycosyl 2-azido-sphingosine 92. 
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Coupling of acyl lipids and global deprotection 
 
Having prepared triglycosyl 2-azido-sphingosine 92, the next step was to 
functionalise the sphingosine backbone with fatty acids bearing the C12 or the 
C20:2 lipid. The reduction of the azide to the amine using triphenylphosphine and 
water was then undertaken according to previously published procedures,36,37 and 
this provided amine 99, which was used without further purification (Scheme 5.4). 
Dodecanoic (C12) acid was coupled to the amine by using an EDCI/DMAP 
coupling protocol to provide the fully protected iGb3-C12 100 in an excellent 
75% yield over two steps. An identical coupling strategy was carried out for the 
C20:2 analogue, whereby azide reduction to the amine 99, followed by immediate 
coupling with 11Z,14Z-eicosadienoic (C20:2) acid afforded the fully protected 
iGb3-C20:2 101 in 28% yield over two steps. The lower yield of this second 
acylation is in part attributed to the poorer solubility of the C20:2 lipid compared 
to the shorter chain C12 variant, which causes it to be less reactive. In addition, it 
has also been reported that skipped dienes are particularly prone to autoxidation to 
form conjugated diene hydroperoxides.38,39 Extensive studies on linoleic (C18:2) 
acid, which has the same unsaturation pattern as the C20:2 acid, have shown that 
1,3-conjugated diene hydroperoxides are formed from the incorporation of 
atmospheric oxygen.39,40 Exposure to oxygen from the atmosphere for too long 
leads to autoxidation products as observed for the starting material C20:2 acid 
whereby m/z corresponding to the 1,3-conjugated diene alcohol (m/z calcd. for 
C20H35O3-: 323.2592, obsd.: 323.2587) and the 1,3-conjugated diene ketone (m/z 
calcd. for C20H33O3-: 321.2435, obsd.: 321.2435) were detected by mass 
spectrometry. Effort to minimise the degradation of the C20:2 glycolipid by 
autoxidation was taken by ensuring that the compounds are always kept under an 
inert, oxygen-free atmosphere. It should also be noted that none of the by-
products were in the purified fractions of the fully protected iGb3-C20:2 101.  
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Scheme 5.4. Coupling of acyl lipid and global deprotection to form iGb3-C12 (7) 
and iGb3-C20:2 (8). 
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Next, the global deprotection of the fully protected iGb3-C12 100 was carried out 
with a Birch reaction to remove all ether and ester protecting groups, but leaving 
the alkene intact. The reaction was performed under standard conditions for 
glycolipids,41,42 yet surprisingly, mass spectrometry analysis of the crude reaction 
mixture before and after quenching with Dowex-H+ revealed the presence the 
desired product iGb3-C12 (7) (m/z calcd. for [C48H89NO18+H]+: 968.6152, obsd.: 
968.6159) along with the hydrolysed by-products LacCer-C12 (m/z calcd. for 
[C42H78NO13+H]+: 806.5624, obsd.: 806.5632), GlcCer-C12 (m/z calcd. for 
[C36H68NO8+H]+: 644.5096, obsd.: 644.5100) and Cer-C12 (m/z calcd. for 
[C30H58NO3+H]+: 482.4568, obsd.: 482.4573). As glycosidic linkages are 
generally considered to be stable under basic conditions, this result was 
surprising. The yields of Birch reactions performed on glycolipids varies,41,42 and 
indeed, others have reported modest yields,41-43 fragmentation under Birch 
conditions has not been widely reported, though the cleavage of β-mannosyl 
glycosidic bonds have been observed by several others.44,45 Further systematic 
studies need to be undertaken to understand why this hydrolysis occurred and it 
would be valuable if others were to comment on observed by-products to assist 
with understanding the mechanisms that are taking place.     
 
Despite the formation of the by-products, purification of the crude residue by 
silica gel column chromatography, followed by reverse phase column 
chromatography afforded the desired target iGb3-C12 7 in 24% yield. GlcCer-
C12 was also isolated (34% yield) along with a mixture of semi-deprotected 
glycolipid (with intact benzylidene and the benzyl protecting groups) as identified 
by mass spectrometry (m/z calcd. for [C76H111NO3+H]+: 1326.7874, obsd.: 
1326.7851). The incomplete deprotection of the ether protecting groups was 
puzzling as the Birch protocol employed involved two rounds of addition of 
sodium, with quenching by methanol in between each addition of sodium, 
however due to the limited availability of the intermediate triglycosyl 2-azido-
sphingosine 92, this reaction was not further optimised. Nonetheless, the desired 
target iGb3-C12 7 was obtained in sufficient quantities for characterisation and 
biological evaluation. 
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The same global deprotection procedure was applied to the fully protected iGb3-
C20:2 101. Again, like the C12 analogue 100, careful mass spectrometry analysis 
of the crude reaction mixture before and after neutralisation with Dowex-H+ 
revealed the presence of the desired product iGb3-C20:2 (8) (m/z calcd. for 
[C56H101NO18+H]+: 1076.7091, obsd.: 1076.7090) along with by-products from 
hydrolysis of the glycosidic linkages, namely LacCer-C20:2 (m/z calcd. for 
[C50H91NO13+H]+: 914.6563, obsd.: 914.6575), GlcCer-C20:2 (m/z calcd. for 
[C44H81NO8+H]+: 752.6035, obsd.: 752.6042) and Cer-C20:2 (m/z calcd. for 
[C38H71NO3+H]+: 590.5507, obsd.:m/z 590.5524). The incompletely deprotected 
intermediate with ether groups intact were not detected. Purification of the crude 
reaction mixture by silica gel column chromatography afforded the desired target 
iGb3-C20:2 (8) in 48% yield. 
 
Having successfully prepared the C12 and C20:2 iGb3 homologues, and in 
Chapter 4 the 6´´´-deoxy derivatives, it would be interesting to compare the 
syntheses. Three key transformations for both routes are the acyl chain coupling, 
the terminal sugar coupling and the formation of the 3´´-OH glycolipid acceptor, 
and as the yields for these key transformations in both strategies are very 
comparable, it is difficult to say whether one of these approaches is better. The 
advantage to the synthetic strategy employed across these two different series of 
iGb3 homologues, however, is the fact that the late stage key intermediate, 
lactosyl 2-azido-sphingosine glycolipid 74, is easily accessible from D-lactose and 
can be functionalised accordingly to obtain both terminal sugar homologues and 
acyl chain homologues from a common intermediate. Taken as a whole, the 
strategy here differs from all other iGb3 syntheses previously reported, whereby a 
trisaccharide donor is coupled directly to either the complete ceramide41,46 or in 
two steps, to the sphingosine backbone followed by N-acylation of the lipid 
backbone.37,47,48 While these reported strategies may be more convergent for the 
synthesis of one target, the route designed in this work is robust and versatile for 
the synthesis of multiple targets of either the terminal sugar or the acyl chain 
series.  
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5.3 Conclusion 
 
In summary, two novel acyl chain homologues of iGb3, iGb3-C12 (7) and iGb3-
C20:2 (8) were synthesised in 2% and 1% overall yield, respectively, over 12 
steps from D-lactose (longest linear sequence). Key to the synthesis is the 
coupling of the terminal galactose sugar donor 93 to the lactosylsphingosine 
(LacSphing) acceptor 94, which proceeded in good selectivity giving only the α-
isomer in 56% yield. Acceptor 94 itself was synthesised from the common 
intermediate lactosyl 2-azido sphingosine 74, which was used for the synthesis of 
6´´´-deoxy-iGb3 analogues described in Chapter 4. In addition, the triglycosyl 
sphingosine intermediate 92 represents a useful intermediate for functionalisation 
with desired acyl chains, as was illustrated in this work, whereby the C12 and 
C20:2 lipids were coupled. It was observed that amide coupling with shorter chain 
homologues (i.e. C12), proceeds more smoothly compared to their longer chain 
counterparts, such as the C20:2, and also the C26 lipid used the Chapter 4. In 
addition, the sensitivity of C20:2 lipid to autoxidation means that extra care had to 
be taken when working with this lipid. From this work, the successful synthesis of 
these two acyl chain homologues will allow for further structure activity 
relationship studies to be performed by our collaborators so that more insight can 
be gained on the influence of lipid length and saturation patterns for iNKT cell 
activity. Moreover, crystal structure studies of these glycolipids in complex with 
CD1d and TCR of iNKT cells will shed light on the favourable or unfavourable 
interactions giving rise to the activity observed.  
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5.4 Experimental 
General procedure 
Unless otherwise stated all reactions were performed under argon. Prior to use, 
THF (Pancreac) was distilled from sodium and benzophenone, pyridine was 
distilled and dried over 4Å molecular sieves (4Å MS), DCM (Pancreac) was 
distilled from P2O5, and H2O and benzene (Fisher Scientific) were distilled. SnCl4 
(Aldrich), PhSH (Koch-Light Laboratories), benzaldehyde dimethyl acetal 
(Aldrich), Me2C(OMe)2 (Aldrich), NBS (Aldrich), DBU (Merck), CSA (Acros), 
nBu3SnCl (Aldrich), AIBN (Aldrich), D-fucose (Aldrich), D-lactose (Aldrich), 
trityl chloride (Acros), anhydrous Et2O (Pancreac), PPh3 (Aldrich), Pd(OH)2/C 
(Aldrich, 20 wt%), anhydrous DMF (Acros), TFA (Aldrich), pTsOH (Aldrich), 
TMSOTf (Aldrich), H2SO4 (Lab-Scan), formic acid (Aldrich), AcCl (Aldrich), 
BnBr (Fluka), PMe3 (Aldrich, 1M in THF), AcOH (Ajax Finechem), Ac2O 
(Peking Reagent), TMSOTf (Aldrich), DiPEA (Aldrich), NaOMe (Janssen 
Chimica), trichloroacetonitrile (Aldrich), lauric acid (Hopkin & Williams), 
11Z,14Z-eicosadienoic acid (Allichem LLC), BzCl (Aldrich, distilled an stored 
under argon), HBTU (Acros), PyBOP (Aldrich), EDCI (Aldrich), DMAP 
(Merck), sodium (Aldrich), trimethyl orthoacetate (Aldrich), LiAlH4 (Aldrich), 
EtOAc (Pancreac), hexanes (Fisher Scientific), petroleum ether (Pure Science), 
MeOH (Pure Science), CHCl3 (Pancreac), EtOH (absolute, Pure Science), NaOH 
(Pure Science), NaHCO3 (Pure Science), NaCl (Pancreac), NH3 (BOC gasses) 
were used as received. All solvents were removed by evaporation under reduced 
pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica 
gel coated plastic sheets (0.20 mm, with fluorescent indicator UV254) with 
detection by UV-absorption (short wave UV – 254 nm; long wave UV – 366 nm), 
by dipping in 10% H2SO4 in EtOH followed by charring at ~150 °C, by dipping in 
I2 in silica, or by dipping into a solution of ninhydrin in EtOH followed by 
charring at ~150 °C. Column chromatography was performed on Pure Science 
silica gel (40-63 micron). AccuBOND II ODS-C18 (Agilent) was used for reverse 
phase chromatography. Infrared spectra were recorded as thin films using a 
Bruker Tensor 27 FTIR spectrometer equipped with an Attenuated Total 
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Reflectance (ATR) sampling accessory and are reported in wave numbers (cm-1). 
Nuclear magnetic resonance spectra were recorded at 20 °C in CD3OD, CDCl3, or 
pyridine-d5 using either a Varian INOVA operating at 500 MHz or Varian 
VNMRS operating at 600 MHz. Chemical shifts are given in ppm (δ) relative to 
TMS. NMR peak assignments were made using COSY, HSQC and HMBC 2D 
experiments. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 
1,2,3,4,6-penta-O-acetyl-β-D-galactopyranose (20 g, 51.24 
mmol) was co-evaporated with toluene (x2), dissolved in 
CH2Cl2 (150 mL) and cooled to 0 °C. Thiophenol (6.3 mL, 
61.42 mmol) and tin(IV) chloride (0.6 mL, 5.12 mmol) was added to the reaction 
mixture under argon and stirred for 3 h. The reaction was quenched with a 3M 
solution of potassium fluoride (100 mL, 6 equiv.) and the organic layer was 
washed with water, saturated sodium bicarbonate solution, brine and dried over 
MgSO4, filtered and concentrated in vacuo. The residue was taken up in ethyl 
acetate and passed through a plug of silica gel to remove residual tin by-products. 
This afforded title compound as a yellow oil (23.9 g). Rf: 0.73 (PE/EA, 1/1, v/v); 
[α]23D = +4.0° (c = 1.0, CHCl3); IR (thin film) 3060, 2917, 2849, 2400, 2000, 
1747, 1583, 1480, 1439, 1369, 1200, 1054, 917, 736, 702 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.51 (m, 2H, CH-o Ph), 7.31 (m, 3H, CH-m Ph), 5.41 (d, 1H, J3,4 
= 3.4 Hz, H-4), 5.24 (t, 1H, J1,2 = J2,3 = 10.0 Hz, H-2), 5.05 (dd, 1H, J2,3 = 10.0 
Hz, J3,4 = 3.4 Hz, H-3), 4.72 (d, 1H, J1,2 = 10.0 Hz, H-1), 4.18 (dd, 1H, J6a,6b = 
11.4 Hz, J5,6a = 7.1 Hz, H-6a), 4.11 (dd, 1H, J6a,6b = 11.4 Hz, J5,6b = 6.2 Hz, H-6b), 
3.94 (t, 1H, J5,6a = 7.1 Hz, J5,6b = 6.2 Hz, H-5), 2.11 (s, 3H, COCH3), 2.09 (s, 3H, 
COCH3), 2.04 (s, 3H, COCH3), 1.97 (s, 3H, COCH3); 13C NMR (500 MHz, 
CDCl3) δ 170.4, 170.2, 170.1, 169.4 (COCH3), 132.5 (CH-o Ph) 132.5 (C-i Ph), 
128.9 (CH-m Ph), 128.2 (CH-p Ph), 86.6 (C-1), 74.4 (C-5), 72.0 (C-3), 67.22, 
67.20 (C-2 and C-4), 61.6 (C-6), 20.8 (COCH3),  20.7 (COCH3), 20.64 (COCH3), 
20.59 (COCH3); HRMS(ESI) m/z calcd. for [C20H24O9S+Na]+: 463.1034, obsd.: 
463.1034. 
O
AcO
AcO
OAc
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Phenyl 1-thio-β-D-galactopyranoside (95) 
Sodium methoxide was added slowly to a suspension of 
phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 
(23.9 g) in methanol (200 mL) until the solution reached pH 
13. The reaction mixture was stirred for 4 h and neutralised with Dowex-H+. The 
resin was removed by filtration and the methanolic solution was concentrated to 
afford 95 as a white solid (13.9 g, 99% over two steps), which was used without 
further purification. Rf: 0.37 (EA/MeOH, 9/1, v/v); [α]21D = -37.0° (c = 0.1, 
MeOH); IR (thin film) 3383, 2895, 1583, 1480, 1439, 1057, 865, 743, 692 cm-1; 
1H NMR (500 MHz, CD3OD) δ 7.56–7.53 (m, 2H, CH-o Ph), 7.31–7.27 (m, 2H, 
CH-m Ph), 7.24–7.22 (m, 1H, CH-p Ph), 4.60 (d, 1H, J1,2 = 9.7 Hz, H-1), 3.91 (bs, 
1H, H-4), 3.77 (dd, 1H, J6a,6b = 11.5 Hz, J5,6a = 7.0 Hz, H-6a), 3.72 (dd, 1H, J6a,6b 
= 11.5 Hz, J5,6b = 5.5 Hz, H-6b), 3.60 (t, 1H, J1,2 = J2,3 = 9.7 Hz, H-2), 3.56 (t, 1H, 
J4,5 = J5,6b = 5.5 Hz, H-5), 3.49 (dd, 1H, J2,3 = 9.5 Hz, J3,4 = 3.0 Hz, H-3); 13C 
NMR (500 MHz, CD3OD) δ 135.9 (Ci SPh) 131.9 (CH-o Ph), 129.8 (CH-m Ph), 
127.9 (CH-p Ph), 90.2 (C-1), 80.5 (C-5), 76.2 (C-3), 70.9 (C-2), 70.3 (C-4), 62.6 
(C-6); HRMS(ESI) m/z calcd. for [C12H16O5S+Na]+: 295.0611, obsd.: 295.0613. 
 
Phenyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside 
Thioglycoside 95 (13.9 g, 51.0 mmol) was co-evaporated with 
dry DMF (x2) and dissolved in dry DMF (180 mL). Under an 
argon atmosphere, benzaldehyde dimethyl acetal (11.5 mL, 
76.6 mmol) was added followed by pTsOH (1.0 g, 5.1 mmol) 
and the reaction mixture was stirred at rt overnight. The 
reaction mixture was neutralised with triethylamine, concentrated in vacuo and 
redissolved in ethyl acetate. The organic layer was washed with water, sat. aq. 
NaHCO3, brine, dried over MgSO4, fillered and concentrated in vacuo. 
Crystallisation from ethyl acetate/petroleum ether (1:2, v/v) afforded title 
compound as fluffy white crystals (12.2 g, 33.8 mmol, 66%). Mp 154–156 °C; Rf: 
0.69 (EA/MeOH, 9/1, v/v); [α]22D = -34.5 ° (c = 1.0, CHCl3); IR (thin film) 3401, 
3061, 2976, 2869, 1583, 1480, 1451, 1439, 1362, 1098, 1070, 1041, 1027, 925, 
898, 866, 734, 696 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.70 (m, 2H, aromatic H), 
7.40-7.29 (m, 8 H, aromatic H), 5.52 (s, 1H, CH-Ph), 4.52 (d, 1H, J1,2 = 9.0 Hz, 
O
HO
HO
OH
SPh
OH
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H-1), 4.40 (d, 1H, J6a,6b = 12.5 Hz, H-6a) 4.22 (d, 1H, J3,4 = 1.5 Hz, H-4), 4.05 
(dd, 1H, J6a,6b = 12.5 Hz, J5,6b = 1.0 Hz, H-6b), 3.71-3.70 (m, 2H, H-2, and H-3), 
3.57 (bs, 1H, H-5), 2.60 (s, 1H, HO-3), 2.58 (d, 1H, J = 8.5 Hz, HO-2); 13C NMR 
(500 MHz, CDCl3) δ 137.5, 130.6 (C-i Ph), 133.8, 129.4, 129.0, 128.3, 126.5 (8 x 
CHarom), 101.4 (PhCHO2), 87.0 (C-1), 75.3 (C-4), 73.8 (C-2), 70.1 (C-5), 69.3 (C-
6), 68.8 (C-3); HRMS(ESI) m/z calcd. for [C19H20O5S+Na]+: 383.0924, obsd.: 
383.0927. 
 
 
Phenyl 2,3-O-benzyl-4,6-benzylidene-1-thio-β-D-galactopyranoside  (96)  
Phenyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside (2 g, 
5.55 mmol) was dissolved in dry DMF (25 mL) and benzyl 
bromide (1.6 mL, 13.3 mmol) was added under nitrogen. The 
reaction mixture was cooled to 0 °C and sodium hydride 
(60% in oil suspension) (0.72 g, 18.0 mmol) was added slowly. The reaction 
mixture was stirred overnight at rt after which time methanol (15 mL) was added 
slowly to quench the reaction. The reaction mixture was diluted with diethyl ether 
and ethyl acetate and washed with water, sat. aq. NaHCO3, brine and dried over 
MgSO4. The organic layer was concentrate in vacuo and the product was 
crystallised from ethyl acetate/petroleum ether to afford 96 as white fluffy crystals 
(2.39 g, 4.42 mmol, 80%). Mp 171.2–171.9 °C; Rf: 0.49 (PE/EA, 3/1, v/v); [α]22D 
= -18.9° (c = 1.0, CHCl3); IR (thin film) 2817, 2849, 1977, 1584, 1453, 1399, 
1092, 1057, 1026, 815, 759, 732, 696 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.73–
7.71 (m, 2H, CH-o PhCHO2), 7.55–7.53 (m, 2H, CH-o SPh), 7.43–7.19 (m, 16H, 
aromatic H), 5.50 (s, 1H, PhCHO2), 4.72 (m, 4H, 2 x CH2Ph), 4.63 (d, 1H, J1,2 = 
9.3 Hz, H-1), 4.39 (d, 1H, J6a,6b = 12.5 Hz, H-6a), 4.17 (d, 1H, J3,4 = 3.4 Hz, H-4), 
4.01 (dd, 1H, J = 1.3, 12.0 Hz, H-6a), 3.91 (t, 1H, J1,2 = J2,3 = 9.3 Hz, H-2), 3.64 
(dd, J2,3 = 9.3 Hz, 1H, J3,4 = 3.4 Hz, H-3), 3.44 (bs, 1H, H-5); 13C NMR (500 
MHz, CDCl3) δ 138.5, 138.1, 137.9 (C-i Ph), 132.8 (CH-o SPh), 132.7, 129.1, 
128.9, 128.4, 128.4, 128.24, 128.19, 127.8, 127.7, 127.5, 126.6 (19 x CHarom), 
101.4 (PhCHO2), 86.5 (C-1), 81.4 (C-3), 75.5 (2-OCH2Ph), 75.4 (C-2), 73.7 (C-
4), 71.9 (3-OCH2Ph), 69.9 (C-5), 69.4 (C-6); HRMS(ESI) m/z calcd. for 
[C19H20O5S+Na]+: 563.1868, obsd.: 563.1871. 
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 2,3-Di-O-benzyl-4,6-O-benzylidene-D-galactose (97)  
NBS (1.73 g, 9.71 mmol) was added to a solution of 
thioglycoside 96 (1.5 g, 2.77 mmol) in acetone (111 mL) and 
water (5.5 mL), and the reaction was stirred at room 
temperature for 10 min. The reaction mixture was diluted 
with EtOAc (80 ml), and washed sat. aq. Na2S2O3 (80 mL), water (80 mL) and 
brine (80 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting oil was purified by gradient flash chromatography 
(Petroleum ether/EtOAc, 5/1 to 0/100, v/v) then crystallised (Petroleum 
ether/EtOAc, 2/1, v/v) to give 97 as fluffy white crystals (1.24 g, 2.76 mmol, 
Quantitative). Rf = 0.08 (PE/EA, 5/1, v/v). Mp = 165.5–166.4 °C; [α]D24 = +41.0 
(c = 1.0, CHCl3). IR (film) 3408, 3064, 3032, 2865, 1454, 1400, 1364, 1249, 
1097, 1052, 1027, 996, 909, 732, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.57–
7.53 (m, 3H, aromatics), 7.43–7.29 (m, 12H, aromatics), 5.50 (s, 1H, CH-
benzylidene), 5.38 (s, 1H, H-1), 4.93–4.86 (m, 1H, CH-a, 2-O-Bn), 4.82–4.76 (m, 
2H, CH-a, CH-b, 3-O-Bn), 4.73–4.69 (m, 1H, CH-a, 2-O-Bn), 4.24 (d, J6a,6b = 
12.5 Hz, 1H, H-6a), 4.23 (s, 1H, H-4), 4.07 (dd, J1,2 = 3.4, J2,3 = 9.7 Hz, 1H, H-2), 
4.03 (d, J6a,6b = 12.5 Hz, 1H, H-6b), 3.98 (dd, J3,4 = 3.4, J2,3 = 9.7 Hz, 1H, H-3), 
3.88 (s, 1H, H-5), 2.90 (s, 1H, 1-OH);  13C NMR (125 MHz, CDCl3) δ 138.5, 
138.2, 137.8, 128.9, 128.7, 128.6, 128.5, 128.45, 128.39, 128.21, 128.18, 128.14, 
128.1, 128.9, 128.8, 128.7, 126.3 (18 x CHarom), 101.1 (PhCHO2), 92.2 (C1), 
75.73 (C2), 75.71 (C3), 74.3 (C4), 73.9 (2-OCH2Ph), 71.8 (3-OCH2Ph), 69.5 
(C6), 62.8 (C5); HRMS(ESI) m/z calcd. for [C27H28O6+Na]+: 471.1778, obsd.: 
471.1774.  
 
 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactosyl trichloroacetimidate (93) 
To a solution of lactol 97 (240 mg, 0.535 mmol, co-
evaporated 3 times dry toluene) in dry CH2Cl2 (5.4 mL) 
was added trichloroacetonitrile (537 µL, 0.77 g, 5.35 
mmol) followed by 1,8-diazabicycloundec-7-ene (120 µL, 
0.12 g, 0.80 mmol) and the resulting brown solution 
stirred 45 min at rt. The solution was concentrated under reduced pressure and 
O
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purified by gradient flash chromatography (Petroleum ether/EtOAc/NEt3, 95/5/1 
to 1/1/0, v/v/v) to give trichloroacetimidate 93 as a colourless oil (273 mg, 0.46 
mmol, 86%). Rf = 0.69 (PE/EA, 1/2, v/v); Mp = 140.8–142.1 °C; [α]D24 = +93.0 
(c = 1.0, CHCl3). IR (film) 3339, 3065, 2907, 2864, 1671, 1497, 1456, 1368, 
1290, 1249, 1175, 1120, 1098, 1027, 968, 846, 794, 738, 697 cm-1. 1H NMR (500 
MHz, CDCl3) δ 8.58 (s, 1H, H-N), 7.55-7.53 (m, 3H, aromatics), 7.40-7.28 (m, 
15H, aromatics), 6.65 (d, J1,2 = 3.4 Hz, 1H, H-1), 5.53 (s, 1H, CH-benzylidene), 
4.84 (d, Ja,b = 11.9 Hz, 1H, CH-a, 3-O-Bn), 4.81 (d, Ja,b = 8.8 Hz, 1H, CH-a, 2-O-
Bn), 4.79 (d, Ja,b = 8.8 Hz, 1H, CH-b, 2-O-Bn), 4.77 (d, Ja,b = 11.9 Hz, 1H, CH-b, 
3-O-Bn), 4.31–4.27 (m, 3H, H-2, H-4 and H-6a), 4.09 (dd, J3,4 = 3.5, J2,3 = 10.0 
Hz, 1H, H-3), 4.02 (dd, J5,6b = 1.5, J6a, 6b = 12.7 Hz, 1H, H-6b), 3.85 (s, 1H, H-5); 
13C NMR (125 MHz, CDCl3) δ 161.0 (C=NH), 138.4, 138.3, 137.6, 129.0, 128.3, 
128.26, 128.2, 128.0, 127.7, 127.5, 127.4, 126.4 (18 x CHarom), 101.1 (CH-
benzylidene), 95.6 (C1), 91.4 (CCl3), 75.1 (C2), 74.7 (C3), 74.5 (C4), 73.1 (2-
OCH2Ph), 72.2 (3-OCH2Ph), 69.1 (C6), 65.3 (C5); HRMS(ESI) m/z calcd. for 
[C29H28NO6Cl3+Na]+: 614.0874, obsd.: 614.0872.  
 
(2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-
O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-octadec-4-ene (98)  
To a solution of lactosyl 2-azid-
sphingosine 74 (144 mg, 0.11 mmol) in 
CH2Cl2 (4 mL) was added TFA/H2O (1/1, 
v/v, 0.4 mL) and the resulting solution was stirred at room temperature for 20 h. 
The solution was diluted with EtOAc and the organic layer was then washed with 
sat. aq. NaHCO3 (x3) and brine, dried (MgSO4), filtered and concentrated under 
reduced pressure. The colourless oil was then purified by gradient flash 
chromatography (petroleum ether/EtOAc, 5/1 to 1/1, v/v) to give diol 98 as a 
colourless oil (139 mg, 0.11 mmol, 99%). Rf: 0.46 (PE/EA, 1/1, v/v); [α]D21 = 
+17.0° (c = 1.0, CHCl3); IR (film) 3448, 3066, 2925, 2854, 2102, 1720, 1602, 
1585, 1452, 1315, 1270, 1177, 1113, 1095, 1069, 1028, 976, 756, 708 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 8.07 (d, JCH-o,CH-m = 7.8 Hz, 2H, CH-o, 2´´-O-Bz), 
8.02–8.00 (m, 4H, 2 x CH-o, OBz), 7.97 (d, JCH-o,CH-m = 7.8 Hz, 2H, CH-o, OBz), 
7.93 (d, JCH-o,CH-m = 7.8 Hz, 2H, CH-o, 2´-O-Bz), 7.61–7.19 (m, 20H, Harom), 5.67 
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(t, J2´,3´ = J3´,4´ = 9.4 Hz, 1H, H-3´), 5.46–5.39 (m, 2H, H-2´, H-5), 5.30–5.23 (m, 
2H, H-2´´, H-4), 4.66 (d, J1´,2´ = 7.8 Hz, 1H, H-1´), 4.60 (d, J1´´,2´´ = 7.8 Hz, 1H, 
H-1´´), 4.59–4.58 (m, 1H, H-6´a), 4.52 (dd, J6´a,6´b = 12.0 Hz, J5´,6´b = 4.4 Hz, 1H, 
H-6´b), 4.40 (d, Ja,b = 11.8 Hz, CH-a, 3-O-Bn), 4.19–4.14 (m, 2H, H-4´, CH-b, 3-
O-Bn), 4.04 (dd, J6´´a,6´´b = 11.4 Hz, J5´´,6´´ = 6.7 Hz, 1H, H-6´´a), 3.90 (dd, J1a,1b = 
10.2 Hz, J1a,2 = 5.8 Hz, 1H, H-1a), 3.82–3.79 (m, 1H, H-5´), 3.77 (d, J3´´,4´´ = 3.3 
Hz, 1H, H-4´´), 3.72 (dd, J3,4 = 8.5 Hz, J2,3 = 5.6 Hz, 1H, H-3), 3.66 (dd, J2´´,3´´ = 
9.8 Hz, J3´´,4´´ = 3.3 Hz, 1H, H-3´´), 3.60–3.56 (m, 2H, H-2, H-6´´b), 3.51 (dd, 
J1a,1b = 10.2 Hz, J1b,2 = 5.4 Hz, 1H, H-1b), 3.46 (t, J5,6= 6.7 Hz, 1H, H-5´´), 1.93–
1.90 (m, 2H, H-6), 1.31–1.25 (m, 22H, H-7–H-17), 0.88 (t, J17,18 = 7.0 Hz, 3H, H-
18); 13C NMR (125 MHz, CDCl3) δ 166.5 (C=O, 2´´-O-Bn), 166.2 (C=O, 6´´-O-
Bn), 166.1 (C=O, 6´-O-Bn), 166.0 (C=O, 3´-O-Bn), 165.2 (C=O, 2´-O-Bn), 138.4 
(C-5), 138.2 (C-i, 3-O-Bn), 133.6, 133.5, 133.4, 133.3 (C-p, 5 x OBz), 130.06, 
129.95, 129.85, 129.79, 129.76, 129.70, 129.68, 129.66, 129.42, 129.22, 128.73, 
128.62, 128.49, 128.39, 127.58 (30 x CHarom), 125.6 (C-4), 101.0 (C-1´, C-1´´), 
79.7 (C-3), 76.2 (C-4´), 73.8 (C-2´´), 73.1 (C-3´, C-5´), 72.7 (C-3´´, C-5´´), 71.7 
(C-2´), 70.1 (CH2, 3-O-Bn), 68.6 (C-1, C-4´´), 63.9 (C-2), 62.7 (C-6´), 61.9 (C-
6´´), 32.4 (C-6), 32.0, 29.83, 29.81, 29.80, 29.79, 29.76, 29.55, 29.49, 29.29, 
29.03, 22.8 (C-7–C-17), 14.3 (C-18); HRMS(ESI) m/z calcd. for 
[C72H81N3O17+Na]+: 1282.5458, obsd.: 1282.5453. 
 
(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyloxy)-2-azido-3-benzyloxy-octadec-4-ene 
(94)  
Diol 98 (62 mg, 0.049 mmol) was co-
evaporated with toluene (x3) and 
dissolved in dry CH2Cl2 (0.8 mL). 
Trimethyl orthoacetate (19 µL, 0.15 mmol) and CSA (5.7 mg, 0.025 mmol) were 
added and the reaction mixture was stirred at rt for 5 h. The reaction mixture was 
diluted with EtOAc (30 mL), washed with 1M HCl (30 mL x 3), sat. aq. NaHCO3 
(30 mL) and brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified by gradient flash chromatography (petroleum 
ether/EtOAc, 10:1 to 3:1, v/v) to afford acetate 94 as a clear oil (59 mg, 0.046 
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mmol, 94%). Rf: 0.63 (PE/EA, 1/1, v/v); [α]D25 = +2.0° (c = 1.0, CHCl3); IR (film) 
3475, 2102, 1727, 1602, 1452, 1371, 1315, 1269, 1177, 1110, 1095, 1070, 1028, 
976, 709 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.06 (d, JCH-o,CH-m = 8.3 Hz, 2H, 
CH-o, 2´´-O-Bz), 8.04–8.02 (m, 4H, 2 x CH-o, 3´-O-Bz, 6´´-O-Bz), 7.98 (d, JCH-
o,CH-m = 7.8 Hz, 2H, CH-o, 6´-O-Bz), 7.95 (d, JCH-o,CH-m = 7.8 Hz, 2H, CH-o, 2´-O-
Bz), 7.62–7.19 (m, 20H, Harom), 5.72 (t, J2´,3´ = J3´,4´ = 9.6 Hz, 1H, H-3´), 5.46 (dd, 
J2´,3´ = 9.6 Hz, J1´,2´ = 7.9 Hz, 1H, H-2´), 5.41 (dt, J4,5 = 15.7 Hz, J5,6 = 6.6 Hz, 1H, 
H-5), 5.26 (dd, J4,5 = 15.7 Hz, J3,4 = 8.6 Hz, 1H, H-4), 5.21 (d, J3´´,4´´ = 3.4 Hz, 1H, 
H-4´´), 5.17 (dd, J2´´,3´´ = 9.8 Hz, J1´´,2´´ = 8.0 Hz, 1H, H-2´´), 4.69 (d, J1´,2´ = 7.9 
Hz, 1H, H-1´), 4.65 (d, J1´´,2´´ = 8.0 Hz, 1H, H-1´´), 4.62 (d, J6´a,6´b = 12.0 Hz, 1H, 
H-6´a), 4.53 (dd, J6´a,6´b = 12.0 Hz, J5,6´b = 4.3 Hz, 1H, H-6´b), 4.41 (d, Ja,b = 11.7 
Hz, 1H, CH-a, 3-O-Bn), 4.21 (t, J3´,4´ = 9.6 Hz, 1H, H-4´), 4.15 (d, Ja,b = 11.7 Hz, 
1H, CH-b, 3-O-Bn), 3.92 (dd, J1a,1b = 10.0 Hz, J1a,2 = 5.9 Hz, 1H, H-1a), 3.83–
3.81 (m, 2H, H-5´, H-3´´), 3.76–3.72 (m, 2H, H-3, H-6´´a), 3.61–3.56 (m, 2H, H-
2, H-5´´), 3.55–3.50 (m, 2H, H-6´´b, H-1b), 2.01 (s, 3H, OAc), 1.98–1.91 (m, 2H, 
H-6), 1.32–1.21 (m, 22H, H-7–H-17), 0.88 (t, J17,18 = 6.9 Hz, 3H, H-18); 13C 
NMR (125 MHz, CDCl3) δ 170.7 (C=O, OAc), 166.6 (C=O, 2´´-O-Bn), 166.1 
(C=O, 6´-O-Bn), 165.8 (C=O, 6´´-O-Bn), 165.5 (C=O, 3´-O-Bn), 165.1 (C=O, 2´-
O-Bn), 138.4 (C-5), 138.2 (C-i, 3-O-Bn), 133.7, 133.6, 133.5, 133.4, 133.3 (C-p, 
5 x OBz), 130.02, 130.30, 129.88, 129.74, 129.67, 129.65, 129.60, 129.43, 
129.02, 128.80, 128.71, 128.70, 128.50, 128.40, 128.37, 127.58 (30 x CHarom), 
125.6 (C-4), 101.2 (C-1´), 100.5 (C-1´´), 79.7 (C-3), 75.6 (C-4´), 73.6 (C-2´´), 
73.1 (C-5´), 72.8 (C-3´), 71.8 (C-2´), 71.7 (C-3´´), 71.3 (C-5´´), 70.1 (CH2, 3-O-
Bn), 69.4 (C-4´´), 68.7 (C-1), 63.9 (C-2), 62.7 (C-6´), 61.3 (C-6´´), 32.4 (C-6), 
32.0, 29.83, 29.81, 29.80, 29.79, 29.76, 29.55, 29.49, 29.29, 29.03, 22.8 (C-7–C-
17), 20.7 (OAc), 14.3 (C-18); HRMS(ESI) m/z calcd. for [C72H83N3O18+NH4]+: 
1319.6010, obsd.: 1319.5966. 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-
benzylidene-α-D-galactopyranosyl)-β-D-galactopyranosyl)-2,3,6-tri-O-
benzoyl-β-D-glucopyranosyloxy)-2-azido-3-benzyloxy-octadec-4-ene (92) 
 
 
 
 
 
 
Galactosyl imidate donor 93 (165 mg, 0.278 mmol) and lactosyl 2-azido-
sphingosine acceptor 94 (145 mg, 0.111 mmol) were co-evaporated with toluene 
(x3), dissolved in dry CH2Cl2 (1 mL) and stirred with activated 4Å molecular 
sieves for 30 mins. The reaction mixture was cooled to -20 °C, and a solution of 
TMSOTf in CH2Cl2 (0.55 mmol/mL, 50 µL, 0.027 mmol) was added and the 
mixture stirred at 0 °C for 2 h. The reaction was warmed to rt and stirred for 
another 30 mins, upon which it was diluted with EtOAc (30 mL), washed with sat. 
aq. NaHCO3 (30 mL) and brine (30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The resultant oil was purified by gradient flash 
chromatography (petroleum ether/EtOAc, 10:1 to 4:1, v/v) to afford the fully 
protected triglycosyl ceramide 92 as a clear oil (109 mg, 0.0629 mmol, 56%). Rf: 
0.82 (PE/EA, 1/1, v/v); [α]D26 = +58.0° (c = 1.0, CHCl3); IR (film)  3089, 3065, 
2925, 2854, 2102, 1731, 1602, 1585, 1452, 1364, 1315, 1268, 1177, 1097, 1069, 
1028, 979, 755, 710 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.05–7.94 (m, 10H, 5 x 
CH-o, 2´-O-Bz, 3´-O-Bz, 6´-O-Bz, 2´´-O-Bz, 6´´-O-Bz), 7.63–7.19 (m, 35H, 
Harom), 5.73 (t, J2´,3´ = J3´,4´ = 9.4 Hz, 1H, H-3´), 5.45 (dd, J2´,3´ = 9.4 Hz, J1´,2´ = 8.0 
Hz, 1H, H-2´), 5.43–5.38 (m, 2H, H-5, H-2´´), 5.35 (d, J3´´,4´´ = 3.1 Hz, 1H, H-
4´´), 5.26 (dd, J4,5 = 15.4 Hz, J3,4 = 8.6 Hz, 1H, H-4), 5.15 (s, 1H, PhCHO2), 5.03 
(d, J4,5 = 3.2 Hz, 1H, H-1´´´), 4.68 (d, J1´,2´ = 8.0 Hz, 1H, H-1´), 4.65 (d, Ja,b = 
11.5 Hz, 1H, CH-a, 2´´´-O-Bn), 4.64 (d, Ja,b = 12.2 Hz, 1H, CH-a, 3´´´-O-Bn), 
4.59 (d, J1´´,2´´ = 8.0 Hz, 1H, H-1´´), 4.55 (d, Ja,b = 11.5 Hz, 1H, CH-b, 2´´´-O-Bn), 
4.52– 4.50 (m, 3H, H-6´a, H-6´b, CH-b, 3´´´-O-Bn), 4.40 (d, Ja,b = 11.7 Hz, 1H, 
CH-a, 3-O-Bn), 4.20–4.14 (m, 2H, H-4´, CH-b, 3-O-Bn), 3.92 (dd, J1a,1b = 10.2 
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Hz, J1a,2 = 5.8 Hz, 1H, H-1a), 3.90–3.88 (m, 2H, H-2´´´, H-6´´´a), 3.81–3.78 (m, 
2H, H-5´, H-3´´), 3.73 (dd, J3,4 = 8.6 Hz, J2,3 = 5.6 Hz, 1H, H-3), 3.67–3.64 (m, 
2H, H-6´´a, H-3´´´), 3.59 (q, J1,2 = J2,3 = 5.5 Hz, 1H, H-2), 3.55–3.49 (m, 3H, H-
1b, H-5´´, H-6´´b), 3.46 (d, J3´´´,4´´´ = 2.9 Hz, 1H, H-4´´´), 3.41 (d, Ja,b = 6.4 Hz, 
1H, H-6´´´b), 3.29 (s, 1H, H-5´´´), 1.93–1.90 (2H, H-6´´), 1.63 (s, 3H, OAc), 
1.26–0.92 (m, 22H, H-7–H-17), 0.89 (t, J17,18 = 6.9 Hz, 3H, H-18); 13C NMR (125 
MHz, CDCl3) δ 170.1 (C=O, OAc), 166.1 (C=O, 6´-O-Bn), 165.8 (C=O, 6´´-O-
Bn), 165.5 (C=O, 3´-O-Bn), 165.2 (C=O, 2´-O-Bn), 164.4 (C=O, 2´´-O-Bn), 
138.9, 138.7 (C-i, 2´´´-O-Bn, 3´´´-O-Bn), 138.4 (C-5), 138.2 (C-i, 3-O-Bn), 137.8 
(C-i, benzylidene), 133.7, 133.58, 133.55, 133.4, 133.3 (C-p, 5 x OBz), 129.97, 
129.86, 129.77, 129.70, 129.68, 129.64, 129.55, 129.44, 129.18, 129.00, 128.90, 
128.80, 218.74, 128.51, 128.39, 128.33, 128.26, 128.21, 128.19, 127.72, 127.59, 
127.57, 127.57, 127.50 (43 x CHarom), 126.4 (C-o, benzylidene), 125.5 (C-4), 
101.2 (C-1´), 101.0 (C-1´´, CH-benzylidene), 95.4 (C-1´´´), 79.7 (C-3), 76.0 (C-
3´´´), 75.6 (C-4´), 74.7 (C-2´´´), 74.4 (C-4´´´), 73.9 (CH2, 2´´´-O-Bn), 73.3 (C-
3´´), 73.1 (C-5´), 72.7 (C-3´), 72.3 (CH2, 3´´´-O-Bn), 71.8 (C-2´), 71.5 (C-5´´), 
71.1 (C-2´´), 70.1 (CH2, 3-O-Bn), 68.9 (C-6´´´), 68.7 (C-1), 64.6 (C-4´´), 63.9 (C-
2), 62.9 (C-5´´´), 62.6 (C-6´), 61.3 (C-6´´), 32.4 (C-6), 32.06, 29.83, 29.82, 29.80, 
29.79, 29.76, 29.55, 29.49, 29.29, 29.04, 22.83 (C-7–C-17), 20.3 (OAc), 14.3 (C-
18); HRMS(ESI) m/z calcd. for [C101H109N3O23+NH4]+: 1749.7790, obsd. 
1749.7802. 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-
benzylidene-α-D-galactopyranosyl)-β-D-galactopyranosyl)-2,3,6-tri-O-
benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-dodecanoylamido-octadec-4-
ene (100) 
 
 
 
 
 
 
To a solution of glycolipid azide 92 (68 mg, 0.039 mmol) in dry benzene (0.8 mL) 
triphenylphosphine (21 mg, 0.078 mmol), and distilled water (30 µL) were added, 
the solution was warmed to 45 ºC and stirred overnight. The reaction mixture was 
then cooled to room temperature, diluted with EtOAc (20 mL), washed with sat. 
aq. NH4Cl, (5 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure to give a colourless oil which was used without further purification. Half 
of the amine intermediate obtained was coupled to the C12 fatty acid as described 
below.  
 
The oil was co-evaporated twice with dry toluene then suspended in DCM (1 mL), 
EDCI (11.3 mg, 0.0589 mmol), DMAP (9.6mg, 0.0785 mmol), and lauric acid 
(11.8 mg, 0.0589 mmol) were added and the resulting solution stirred over 4 days 
at room temperatur, after which it was diluted with EtOAc (30 mL), washed with 
sat. aq. NaHCO3 (30 mL) and brine (30 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The reaction mixture was then purified directly by gradient 
flash chromatography (petroleum ether/EtOAc, 10/1 to 2/1, v/v) to give 100 as a 
colourless oil (28 mg, 0.015 mmol, 75% over two steps). Rf: 0.68 (PE/EA, 1/1, 
v/v); [α]D24 = +62.0° (c = 0.1, CHCl3); IR (film) 2924, 2854, 1733, 1718, 1576, 
1558, 1541, 1473, 1177, 1098, 1070, 1028, 756, 633, 620 cm-1; 1H NMR (500 
MHz, CDCl3) δ 8.04–7.93 (m, 10H, 5 x CH-o, 2´-O-Bz, 3´-O-Bz, 6´-O-Bz, 2´´-O-
Bz, 6´´-O-Bz), 7.56–7.18 (m, 35H, Harom), 5.74 (t, J2´,3´ = J3´,4´ = 9.6 Hz, 1H, H-
3´), 5.49 (dt, J4,5 = 15.2 Hz, J5,6 = 7.0 Hz, 1H, H-5), 5.42–5.38 (m, 3H, H-2´, H-
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2´´, NH), 5.36 (m, 1H, H-4´´), 5.24 (dd, J4,5 = 15.2 Hz, J3,4 = 8.8 Hz, 1H, H-4), 
5.15 (s, 1H, PhCHO2), 5.03 (d, J1´´´,2´´´, = 3.0 Hz, 1H, H-1´´´), 4.64 (d, Ja,b = 11.5 
Hz, 1H, CH-a, 3´´´-O-Bn), 4.63 (d, Ja,b = 12.5 Hz, 1H, CH-a, 2´´´-O-Bn), 4.61 (d, 
J1´,2´ = 8.0 Hz, 1H, H-1´), 4.59 (d, J1´´,2´´ = 8.1 Hz, 1H, H-1´´), 4.51 (d, Ja,b = 11.6 
Hz, 1H, CH-b, 3´´´-O-Bn), 4.49–4.43 (m, 3H, H-6´a, H-6´b, CH-b, 2´´´-O-Bn), 
4.44 (d, Ja,b = 11.6 Hz, 1H, CH-a, 3-O-Bn), 4.26–4.24 (m, 2H, CH-b, 3-O-Bn, H-
1a), 4.17 (t, J2´,3´ = J3´,4´ = 9.6 Hz, 1H, H-4´), 4.09–4.06 (m, 1H, H-2), 3.90–3.88 
(m, 2H, H-2´´´, H-6´´´a), 3.80 (dd, J2´´,3´´ = 10.0 Hz, J3´´,4´´ = 3.3 Hz, 1H, H-3´´), 
3.75–3.70 (m, 2H, H-3, H-5´), 3.65 (dd, J2´´´,3´´´ = 10.0 Hz, J3´´´,4´´´ 3.1 Hz, 1H, H-
3´´´), 3.62 (d, J5´´,6´´ = 6.6 Hz, 2H, H-6´´a, H-6´´b), 3.53–3.48 (m, 2H, H-1b, H-
5´´), 3.46 (d, J3´´´, 4´´´ = 3.0 Hz, 1H, H-4´´´), 3.41 (d, J3´´´, 4´´´ = 12.0 Hz, 1H, H-
6´´´b), 3.29 (s, 1H, H-5´´´), 1.96–1.92 (m, 2H, H-6), 1.68–1.63 (m, 2H, CH2-α), 
1.61 (s, 3H, OAc), 1.29–1.03 (m, 40H, H-7–H-17, H-β–H-(ω−1)), 0.89–0.87 (m, 
6H, H-18, H-ω); 13C NMR (125 MHz, CDCl3) δ 172.5 (HNC=O), 170.1 (C=O, 
OAc), 166.1 (C=O, 6´-O-Bn), 165.8 (C=O, 6´´-O-Bn), 165.5 (C=O, 3´-O-Bn), 
165.4 (C=O, 2´-O-Bn), 164.4 (C=O, 2´´-O-Bn), 138.9, 138.7 (C-i, 2´´´-O-Bn, 
3´´´-O-Bn), 138.5 (C-i, 3-O-Bn), 137.8 (C-i, benzylidene), 137.2 (C-5), 133.8, 
133.6, 133.5, 133.3 (C-p, 5 x OBz), 132.99, 129.97, 129.89, 129.86, 129.78, 
129.69, 129.59, 129.49, 129.20, 129.17, 128.99, 128.91, 128.76, 128.74, 128.34, 
128.31, 128.24, 128.20, 128.18, 127.73, 127.71, 127.58, 127.51, 127.49, 127.44, 
126.37 (45 x CHarom, C-4), 101.5 (C-1´), 101.0 (C-1´´), 100.9 (CH-benzylidene), 
95.4 (C-1´´´), 79.3 (C-3), 76.0 (C-3´´´), 75.5 (C-4´), 74.6 (C-2´´´), 74.4 (C-4´´´), 
73.9 (CH2, 3´´´-O-Bn), 73.3 (C-3´´), 73.1 (C-5´), 72.5 (C-3´), 72.3 (CH2, 2´´´-O-
Bn, C-2´/C-2´´), 71.5 (C-2´/C-2´´), 71.1 (C-5´´), 70.4 (CH2, 3-O-Bn), 68.9 (C-
6´´´), 68.5 (C-1), 64.6 (C-4´´), 62.9 (C-5´´´), 62.6 (C-6´), 61.2 (C-6´´), 51.4 (C-2), 
36.6 (C-α), 32.3 (C-6), 32.05, 29.84, 29.83, 29.83, 29.80, 29.78, 29.66, 29.49, 
29.39, 29.34, 25.69, 25.57, 23.99, 23.96, 22.82 (C-7–C-17, C-β–C-(ω−1)), 20.3 
(OAc), 14.3 (C-18, C-ω); HRMS(ESI) m/z calcd. for [C113H133NO24+H]+: 
1888.9290, obsd. 1888.9282 
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(2S,3R,4E)-2-Dodecanoylamido-1-(4-O-(3-O-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-β-D-glucopyranosyloxy)-3-hydroxy-octadec-4-ene (7) 
 
 
 
Fully protected triglycosyl ceramide 100 (25 mg, 0.0132 mmol) was dissolved in 
dry THF (2 mL) and NH3 (10 mL) was condensed into the reaction vessel at -78 
°C. Small pieces of Na (s) were added carefully until the solution remained deep 
blue and the reaction mixture was stirred for 30 mins. The reaction was then 
quenched with a few drops of MeOH and Na (s) was added again until the deep 
blue colour persisted, and the reaction mixture stirred for a further 30 mins. The 
reaction was quenched with 10 mL MeOH, and the reaction warmed slowly to rt 
to allow the ammonia to evaporate. Trace ammonia was removed with an Ar 
stream. The reaction mixture was quenched to pH 7 with Dowex-H+, filtered and 
washed with pyridine and concentrated in vacuo. The resultant oil was purified by 
gradient flash chromatography (DCM/MeOH, 20/1 to 5/1, v/v) to afford fully 
deprotected iGb3-C12 7 as an amorphous white solid (3.1 mg, 0.0032 mmol, 
24%). Rf: 0.07 (DCM/MeOH, 5/1, v/v); [α]D24 = +29.0° (c = 0.1, pyridine); IR 
(film) 3347, 2956, 2922, 2852, 1641, 1552, 1466, 1377, 1266, 1150, 1076, 1029, 
973, 803, 774, 720, 693, 662 cm-1; 1H NMR (600 MHz, pyridine-d5) δ 8.45 (d, 
J2,NH = 8.4 Hz, 1H, NH), 7.46 (d, J = 5.3 Hz, 1H, OH), 6.78 (d, J4,5 = 4.7 Hz, 1H, 
OH), 6.71, 6.64, 6.56 (3 x bs, 3H, 3 x OH), 6.51–6.49 (m, 1H, OH), 6.19 (bs, 1H, 
OH), 6.03 (dd, J4,5 = 15.4 Hz, J3,4 = 6.6 Hz, 1H, H-4), 5.95–5.90 (m, 1H, H-5), 
5.70 (s, 1H, OH), 5.68 (d, J1´´´,2´´´ = 3.8 Hz, 1H, H-1´´´), 5.11 (d, J1´´, 2´´ = 7.7 Hz, 
1H, H-1´´), 5.08 (t, J5´´´,6´´´ = 6.2 Hz, 1H, H-5´´´), 4.90 (d, J1´, 2´ = 7.9 Hz, 1H, H-
1´), 4.83–4.79 (m, 3H, H-1a, H-2, H-3), 4.75 (dd, J2´´´,3´´´ = 9.6 Hz, J1´´´, 2´´´ = 3.8 
Hz, 1H, H-2´´´), 4.69 (bs, 1H, H-4´´´), 4.59 (bs, 1H, H-4´´), 4.57–4.43 (m, 2H, H-
2´´, H-3´´´), 4.47–4.45 (m, 3H, H-6´´´a, H-6´´´b, H-6´´a), 4.34–4.31 (m, 2H, H-
6´a, H-6´´b), 4.28–4.23 (m, 4H, H-6´b, H-3´, H-4´, H-3´´), 4.17 (dd, J1a,1b = 9.7 
Hz, J1b,2 = 2.9 Hz, 1H, H-1b), 4.08–4.03 (m, 2H, H-2´, H-5´´),  3.88–3.85 (m, 1H, 
O
HO
OH
OH
O
OH
O
OH
O
O
HO
C13H27
HN
OH
O
HO
OH
HO
HO
O
10
 188 
H-5´), 2.45 (t, Jα,β = 7.1 Hz, 2H, CH2-α), 2.07 (dd, J6,7 = 14.3 Hz, J5,6 = 6.6 Hz, 
1H, H-6), 1.88–1.88 (m, 2H, CH2-β), 1.37–1.22 (m, 38H, H-7–H-11, H-γ–H-
(ω−1)), 0.88 (t, J11,12 = Jω−1,ω = 6.6 Hz, 6H, H-12, H-ω); 
13C NMR (125 MHz, 
pyridine-d5) δ 173.7 (HNC=O), 133.0 (C-4), 132.6 (C-5), 105.8 (C-1´, C-1´´), 
98.0 (C-1´´´), 82.4 (C-4´), 80.4 (C-3´´), 77.0 (C-5´), 76.92 (C-3´), 76.85 (C-5´´), 
75.1 (C-2´), 73.2 (C-5´´´), 73.0 (C-3), 72.0 (C-3´´´), 71.2 (C-4´´´), 70.8 (C-1, C-
2´´), 70.7 (C-2´´´), 66.3 (C-4´´), 62.6 (C-6´´´), 62.29 (C-6´´), 62.17 (C-6´), 55.2 
(C-2), 37.3 (C-α), 33.1 (C-6), 32.5, 30.37, 30.34, 30.31, 30.28, 30.25, 30.23, 
30.21, 30.12, 30.07, 29.96, 23.28 (C7–C-11, C-γ–C-(ω−1)), 26.8 (C-β), 14.6 (C-
12, C-ω); HRMS(ESI) m/z calcd. for [C48H89NO18+H]+: 968.6152, obsd.: 
968.6159. 
 
(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-
benzylidene-α-D-galactopyranosyl)-β-D-galactopyranosyl)-2,3,6-tri-O-
benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-(11Z,14Z-
eicosadienoylamido)-octadec-4-ene (101) 
 
 
To a solution of glycolipid azide 92 (23 mg, 0.013 mmol) in dry benzene (0.8 mL) 
triphenylphosphine (7 mg, 0.026 mmol), and distilled water (5 µL) were added, 
the solution was warmed to 45 ºC and stirred overnight. The reaction mixture was 
then cooled to room temperature, diluted with EtOAc (15 mL), washed with sat. 
aq. NH4Cl (5 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure to give a colourless oil which was used without further purification. The 
oil was co-evaporated twice with dry toluene then suspended in DCM (1 mL), 
EDCI (11.3 mg, 0.0589 mmol), DMAP (9.6mg, 0.0785 mmol), and 11Z,14Z-
eicosadienoic acid (11.8 mg, 0.0589 mmol) were added and the resulting solution 
stirred over 2 days at room temperature, after which it was diluted with EtOAc 
(20 mL), washed with sat. aq. NaHCO3 (20 mL) and brine (20 mL), dried 
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(MgSO4), filtered and concentrated in vacuo. The reaction mixture was then 
purified directly by gradient flash chromatography (petroleum ether/EtOAc, 10/1 
to 2/1, v/v) to give 101 as a colourless oil (7.5 mg, 0.0038 mmol, 28% over two 
steps). The product was kept under inert argon atmosphere at all time to prevent 
degradation by autoxidation. Rf: 0.39 (PE/EA, 2/1, v/v); [α]D20 = +40.0° (c = 1.0, 
CHCl3); IR(film) 3062, 30111, 2956, 2926, 1730, 1453, 1438, 1270, 1177, 1119, 
1070, 1028, 998, 754, 711, 634 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.04–7.93 
(m, 10H, 5 x CH-o, 2´-O-Bz, 3´-O-Bz, 6´-O-Bz, 2´´-O-Bz, 6´´-O-Bz), 7.61–7.12 
(m, 35H, Harom), 5.73 (t, J2´,3´ = J3´,4´ = 9.6 Hz, 1H, H-3´), 5.49 (dt, J4,5 = 15.6 Hz, 
J5,6 = 6.7 Hz, 1H, H-5), 5.41–5.30 (m, 4H, H-2´, H-2´´, NH, H-4´´), 5.23 (dd, J4,5 
= 15.3 Hz, J3,4 = 8.6 Hz, 1H, H-4), 5.15 (s, 1H, PhCHO2), 5.03 (d, J1´´´,2´´´, = 3.0 
Hz, 1H, H-1´´´), 4.62 (d, Ja,b = 11.3 Hz, 1H, CH-a, 3´´´-O-Bn), 4.63 (d, Ja,b = 12.4 
Hz, 1H, CH-a, 2´´´-O-Bn), 4.61 (d, J1´,2´ = 8.0 Hz, 1H, H-1´), 4.58 (d, J1´´,2´´ = 8.0 
Hz, 1H, H-1´´), 4.53 (d, Ja,b = 11.8 Hz, 1H, CH-b, 3´´´-O-Bn), 4.49–4.47 (m, 3H, 
H-6´a, H-6´b, CH-b, 2´´´-O-Bn), 4.43 (d, Ja,b = 11.7 Hz, 1H, CH-a, 3-O-Bn), 
4.25–4.24 (m, 2H, CH-b, 3-O-Bn, H-1a), 4.16 (t, J2´,3´ = J3´,4´ = 9.5 Hz, 1H, H-4´), 
4.08–4.05 (m, 1H, H-2), 3.89–3.87 (m, 2H, H-2´´´, H-6´´´a), 3.79 (dd, J2´´,3´´ = 9.9 
Hz, J3´´,4´´ = 3.1 Hz, 1H, H-3´´), 3.74–3.69 (m, 2H, H-3, H-5´), 3.65 (dd, J2´´´,3´´´ = 
10.0 Hz, J3´´´,4´´´ 3.1 Hz, 1H, H-3´´´), 3.61 (d, J5´´,6´´ = 6.6 Hz, 2H, H-6´´a, H-6´´b), 
3.52–3.48 (m, 2H, H-1b, H-5´´), 3.45 (d, J3´´´, 4´´´ = 3.0 Hz, 1H, H-4´´´), 3.40 (d, 
J3´´´, 4´´´ = 12.0 Hz, 1H, H-6´´´b), 3.29 (s, 1H, H-5´´´), 2.77 (t,  J13,14 (fatty acid) = J12,13 
(fatty acid) = 6.9 Hz, 2H, H-13 fatty acid), 2.05 (m, 4H, H-10, H-16 fatty acid), 1.95–
1.92 (m, 2H, H-6), 1.68–1.63 (m, 2H, CH2-α), 1.61 (s, 3H, OAc), 1.35–1.23 (m, 
42H, H-7–H-17, H-β–H-(ω−1)), 0.89–0.86 (m, 6H, H-18, H-ω); 13C NMR (125 
MHz, CDCl3) δ 172.5 (HNC=O), 170.1 (C=O, OAc), 166.1 (C=O, 6´-O-Bn), 
165.8 (C=O, 6´´-O-Bn), 165.5 (C=O, 3´-O-Bn), 165.4 (C=O, 2´-O-Bn), 164.4 
(C=O, 2´´-O-Bn), 138.9, 138.7 (C-i, 2´´´-O-Bn, 3´´´-O-Bn), 138.5 (C-i, 3-O-Bn), 
137.8 (C-i, benzylidene), 137.2 (C-5), 133.8, 133.7, 133.6, 133.5, 133.3 (C-p, 5 x 
OBz), 130.35, 13.27, 129.97, 129.91, 129.88, 129.79, 129.70, 129.67, 129.61, 
129.49, 129.20 ,129.16, 129.02, 128.92, 128.78, 128.76, 128.70, 128.62, 128.40, 
128.36, 128.32, 128.26, 128.22, 128.19, 128.12, 128.06, 127.74, 127.73, 127.61, 
127.53, 127.50, 126.39 (CHarom, C-4, C-11, C-12, C-14, C-15 fatty acid), 101.5 
(C-1´, C-1´´), 100.9 (CH-benzylidene), 95.4 (C-1´´´), 79.3 (C-3), 76.0 (C-3´´´), 
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75.5 (C-4´), 74.6 (C-2´´´), 74.4 (C-4´´´), 73.9 (CH2, 3´´´-O-Bn), 73.3 (C-3´´), 73.1 
(C-5´), 72.5 (C-3´), 72.3 (CH2, 2´´´-O-Bn, C-2´/C-2´´), 71.5 (C-2´/C-2´´), 71.1 (C-
5´´), 70.4 (CH2, 3-O-Bn), 69.0 (C-6´´´), 68.5 (C-1), 64.6 (C-4´´), 62.9 (C-5´´´), 
62.6 (C-6´), 61.2 (C-6´´), 51.4 (C-2), 36.6 (C-2 fatty acid), 32.4 (C-6), 32.07, 
31.66, 29.86, 29.85, 29.82, 29.74, 29.68, 29.66, 29.51, 29.49, 29.39, 29.37, 27.40, 
27.34, 27.23, 25.77, 25.64, 25.58, 25.19, 23.92, 22.84, 22.72, 20.21 (C-7–C-17, 
C-3–C-10 fatty acid, C16–C19 fatty acid), 20.3 (OAc), 14.3 (C-18, C-
20 fatty acid); HRMS(ESI) m/z calcd. for [C121H145NO24+H+NH4]2+: 1007.5284, 
obsd. 1007.5262. 
 
(2S,3R,4E)-2-(11Z,14Z-Eicosadienoylamido)-1-(4-O-(3-O-α-D-
galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-3-hydroxy-
octadec-4-ene (8) 
 
 
Fully protected triglycosyl ceramide 101 (20 mg, 0.010 mmol) was dissolved in 
dry THF (1 mL) and NH3 (10 mL) was condensed into the reaction vessel at -78 
°C. Small pieces of Na (s) were added carefully until the solution remained deep 
blue and the reaction mixture was stirred for 30 mins. The reaction was then 
quenched with a few drops of MeOH and Na (s) was added again until the deep 
blue colour persisted, and the reaction mixture stirred for a further 30 mins. The 
reaction was quenched with 10 mL MeOH, and the reaction warmed slowly to rt 
to allow the ammonia to evaporate. Trace ammonia was removed with an Ar 
stream. The reaction mixture was quenched to pH 7 with Dowex-H+, filtered and 
washed with pyridine and concentrated in vacuo. The resultant oil was purified by 
gradient flash chromatography (DCM/MeOH, 20/1 to 5/1, v/v) to afford fully 
deprotected iGb3-C12 8 as an amorphous white solid (5.2 mg, 0.0048 mmol, 
48%). Rf: 0.13 (DCM/MeOH, 4/1, v/v); [α]D24 = +26.0° (c = 0.1, pyridine); IR 
(film) 3360, 3010, 2923, 2853, 1640, 1548, 1464, 1377, 1255, 1150, 1075, 1030, 
971, 895, 804, 632 cm-1; 1H NMR (600 MHz, pyridine-d5) δ 8.49 (d, J2,NH = 8.3 
Hz, 1H, NH), 6.04 (dd, J4,5 = 15.2 Hz, J3,4 = 6.3 Hz, 1H, H-4), 5.93 (dd, J4,5 = 15.2 
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Hz, J5,6 = 6.7 Hz, H-5), 5.68 (d, J1´´´,2´´´ = 3.6 Hz, 1H, H-1´´´), 5.54–5.48 (m, 4H, 
H-11, H-12, H-14, H-15 fatty acid), 5.09 (d, J1´´, 2´´ = 8.0 Hz, 1H, H-1´´), 5.06 (t, 
J5´´´,6´´´ = 5.9 Hz, 1H, H-5´´´), 4.90 (d, J1´, 2´ = 7.9 Hz, 1H, H-1´), 4.84–4.79 (m, 
3H, H-1a, H-2, H-3), 4.76 (dd, J2´´´,3´´´ = 10.0 Hz, J1´´´, 2´´´ = 3.6 Hz, 1H, H-2´´´), 
4.68 (bs, 1H, H-4´´´), 4.59 (bs, 1H, H-4´´), 4.58–4.52 (m, 2H, H-2´´, H-3´´´), 
4.51–4.43 (m, 3H, H-6´´´a, H-6´´´b, H-6´´a), 4.33 (dd, Ja,b= 10.9 Hz, Ja,b = 4.9 Hz,  
2H, H-6´a, H-6´´b), 4.29–4.24 (m, 4H, H-6´b, H-3´, H-4´, H-3´´), 4.18–4.16 (m, 
1H, H-1b), 4.08–4.03 (m, 2H, H-2´, H-5´´),  3.87–3.85 (m, 1H, H-5´), 2.93 (t, 
J13,14 (fatty acid) = J12,13 (fatty acid) = 5.3 Hz, 2H, H-13 fatty acid), 2.46 (t, Jα,β = 7.6 Hz, 
2H, H-2 fatty acid), 2.15–2.06 (m, 6H, H-10, H-16 fatty acid, H-6), 1.86–1.80 (m, 
2H, CH2-β), 1.36–1.23 (m, 42H, H-3–H-9 fatty acid, H-17–H-19 fatty acid, H7-
17), 0.89–0.86 (m, 6H, H-18, H-20 fatty acid); 13C NMR (125 MHz, pyridine-d5) 
δ 173.7 (HNC=O), 133.0 (C-4), 132.6 (C-5), 130.8, 128.7 (C-11, C-12, C-14, C-
15 fatty acid), 105.8 (C-1´, C-1´´), 98.0 (C-1´´´), 82.3 (C-4´), 80.4 (C-3´´), 76.97 
(C-5´), 76.92 (C-3´), 76.82 (C-5´´), 75.1 (C-2´), 73.2 (C-5´´´), 73.0 (C-3), 72.0 (C-
3´´´), 71.2 (C-4´´´), 70.8 (C-1, C-2´´), 70.7 (C-2´´´), 66.2 (C-4´´), 62.6, 62.2 (C-
6´´´, C-6´´, C-6´), 55.2 (C-2), 37.3 (C-α), 33.1 (C-6), 30.30, 30.27, 30.24, 30.21, 
30.12, 30.05, 29.96, 29.94, 293.92, 29.83, 27.90, 27.79, 27.38, 26.74, 26.37, 
23.27, 23.14 (C7–C-17, C-2–C-10 fatty acid, C16–C19 fatty acid), 14.6, 14.56 (C-
18, C-20 fatty acid); HRMS(ESI) m/z calcd. for [C56H101NO18+H]+: 1076.7091, 
obsd.: 1076.7090). 
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Chapter 6. Summary and future prospects 
 
Glycosphingolipids play a crucial role in modulating the immune response, and in 
particular, the glycolipid adjuvant α-galactosyl ceramide (α-GalCer) is capable of 
enhancing the body’s ability to detect and destroy cancerous cells during dendritic 
cell (DC)-based cancer immunotherapy. In stimulating an anti-cancer immune 
response, α-GalCer is presented by the CD1d molecule found on DCs to the TCR 
of iNKT cells, which was discussed in the introduction (Chapter 1) to this thesis. 
In addition to foreign α-linked glycolipids, β-linked glycosphingolipids, such as 
isoglobotrihexosylceramide (iGb3), can also be recognised by the TCR of NKT 
cells when it is bound to CD1d. Accordingly, iGb3 analogues have much potential 
as immunomodulatory compounds, as was  described in Chapter 1. 
Various analogues of α-GalCer have been synthesised with the aim of fine-tuning 
the immune response generated during DC-based cancer treatment. Hence, a 
comprehensive understanding of how α-GalCer interacts with the immune system 
is crucial in order to guide efforts towards improved vaccination strategies. One of 
the ways to study the uptake and trafficking of α-GalCer in vitro and in vivo is by 
using fluorescent α-GalCer probes. In Chapter 2, the synthesis of the fluorescent 
probe, dansyl-α-GalCer was described. Biological evaluation of dansyl-α-GalCer 
revealed that it was able to activate DCs and iNKT cells in a similar fashion to the 
parent glycolipid α-GalCer and its activity was CD1d-dependent. It was also 
shown that DCs that have taken up dansyl-α-GalCer in vitro were detectable by 
flow cytometry. Unfortunately, the fluorescence of dansyl-α-GalCer was too 
weak to be visualised by fluorescent microscopy due to photobleaching of the 
dye. Accordingly, another α-GalCer probe bearing a brighter fluorescent group, 
BODIPY, was synthesised, as was discussed in Chapter 3. The dansyl-α-GalCer 
and BODIPY-α-GalCer probes were made via two different synthetic strategies, 
which reflects the different chemistries that the respective dyes are compatible 
with. It is envisioned that the brighter BODIPY fluorophore will allow for its use 
in in vivo studies, however, care must be taken to avoid the photo-oxidation of the 
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dye upon prolonged exposure to light and oxygen. Indeed, this photo-oxidation 
under relatively mild conditions has not been previously reported for the BODIPY 
fluorophore and future work will include exploring this phenomenon further. Both 
dansyl-α-GalCer and BODIPY-α-GalCer were sent to our collaborator, Hans van 
der Vliet (VU University Medical Centre, Amsterdam) for further studies to 
understand glycolipid uptake by human DCs. It will be exciting to see the results 
from this work and how the probes have been used to address biological 
questions. 
In Chapter 4 the synthesis of two iGb3 analogues, 6´´´-deoxy-iGb3-sphingosine 
and 6´´´-deoxy-iGb3-sphinganine was described. The highlight of this route was 
the highly efficient synthesis of a lactosyl 2-azido-sphingosine acceptor which, in 
this chapter, was N-acylated then functionalised with a D-fucose moiety. The use 
of two different deprotection strategies performed on the late stage intermediate 
(i.e. the fully protected 6´´´-deoxy-iGb3), allowed for the generation of 6´´´-
deoxy-iGb3 analogues with the sphingosine or the sphinganine lipid backbone. 
6´´´-deoxy-iGb3-sphingosine will be valuable to unambiguously ascertain the 
importance of the 6-hydroxyl group of the terminal sugar in the interaction with 
CD1d. The other analogue, 6´´´-deoxy-iGb3-sphinganine, which has a fully 
saturated lipid backbone, is a valuable glycolipid to determine if the removal of 
the rigid E-alkene on the lipid backbone alters the glycolipid activity. Both 
glycolipids have been sent to our collaborators, Jamie Rossjohn (Monash 
University) and Dale Godfrey (University of Melbourne) for testing in iNKT cell 
assays, as well as crystal structure studies in the context of CD1d and iNKT cells. 
In Chapter 5 the synthesis of two novel iGb3 analogues bearing either the 
dodecanoic acid (iGb3-C12) or the di-unsaturated 11Z,14Z-eicosadienoic acid 
(iGb3-C20:2) was presented. The synthetic route made use of the common 
intermediate lactosyl 2-azido-sphingosine, previously described in Chapter 4. The 
key synthetic steps included the coupling of the terminal galactose sugar, which 
occurred in high yield, followed by functionalisation of the lipid backbone with 
the two desired fatty acids. The iGb3 analogues will allow for the study of 
structure activity relationship and crystal structure analyses, which will provide 
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insight into how lipid chain length and unsaturation can influence glycolipid 
activity. 
Taken together, Chapter 4 and Chapter 5 describe an elegant, robust and 
convergent synthetic route that allows for the generation of two series of iGb3 
analogues; namely the terminal sugar series and the N-acyl chain series. In the 
future, it would be valuable to extend the repertoire of these two series to further 
probe the structure-activity relationships. For the terminal sugar series, it would 
be interesting to attach D-galactose in a β1-3 linkage, instead of the original α1-4 
linkage found in iGb3, to assess if the orientation of the terminal sugar affects 
how it interacts with the CD1d molecule and the TCR of iNKT cells, and 
subsequently the effect that this has on the quality of iNKT cell activation. In 
addition, it would also be valuable to substitute the terminal galactose with an N-
acetyl galactosamine moiety to generate iGb3 analogues that are akin to 
gangliosides, which is another class of biologically important glycosphingolipids 
that contain N-acetylgalactosamine attached to a sialylated lactosylceramide. The 
effect of an N-acetyl group on CD1d binding and subsequent iNKT cell activation 
could potentially lead to an additional series of biologically active 
glycosphingolipids. 
In the future, it would also be interesting to extend the series of acyl chain 
homologues by attaching fatty acids of different lengths. Of particular interest 
would be the saturated C20 acid which, together with the iGb3-C20:2 synthesised 
in Chapter 5, will provide insight into the influence that rigid double bonds have 
on the iNKT cell activity. These are just some of the many glycosphingolipids that 
can be prepared and studied in order to find an optimum glycolipid adjuvant for 
use in the treatment of diseases, such as cancer. 
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O-(4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl)  
trichloroacetimidate (75) 13C NMR, CDCl3, 125 MHz 
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 xlii 
 
 
 
 
 
(2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-
glucopyranosyloxy)-3-benzyloxy-octadec-4-ene (74) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-
glucopyranosyloxy)-3-benzyloxy-octadec-4-ene (74) 13C NMR, CDCl3, 125 MHz 
 
O
BzO
OBz
OBz
O
BzO
O
OBz
O O
O
C13H27
N3
OBn74
 xliv 
 
 
 
 
 
(2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-
benzyloxy-2-hexacosanoylamido-octadecen-4-ene (83) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-
benzyloxy-2-hexacosanoylamido-octadecen-4-ene (83) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-
hexacosanoylamido-octadec-4-ene (84) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(2,6-Di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-
hexacosanoylamido-octadec-4-ene (84) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-
hexacosanoylamido-octadec-4-ene (73) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-
hexacosanoylamido-octadec-4-ene (73) 13C NMR, CDCl3, 125 MHz 
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6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (88) 1H NMR, CDCl3, 500 MHz 
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6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (88) 13C NMR, CDCl3, 125 MHz 
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1,2,3,4-Tetra-O-acetyl-6-deoxy-α/β-D-galactopyranose (86) 1H NMR, CDCl3, 500 MHz 
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1,2,3,4-Tetra-O-acetyl-6-deoxy-α/β-D-galactopyranose (86) 13C NMR, CDCl3, 125 MHz 
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Ethyl 2,3,4-tri-O-acetyl-6-deoxy-1-thio-β-D-galactopyranoside (89) 1H NMR, CDCl3, 500 MHz 
 
SEt
O
AcO
CH3AcO
AcO
89
 lv 
 
 
 
 
 
Ethyl 2,3,4-tri-O-acetyl-6-deoxy-1-thio-β-D-galactopyranoside (89) 13C NMR, CDCl3, 125 MHz 
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Ethyl 2,3,4-tri-O-benzyl-6-deoxy-1-thio-β-D-galactopyranoside (90) 1H NMR, CDCl3, 500 MHz 
 
SEt
O
BnO
CH3BnO
BnO
90
 lvii 
 
 
 
 
 
Ethyl 2,3,4-tri-O-benzyl-6-deoxy-1-thio-β-D-galactopyranoside (90) 13C NMR, CDCl3, 125 MHz 
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2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranose (91) 1H NMR, CDCl3, 500 MHz 
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2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranose (91) 13C NMR, CDCl3, 125 MHz 
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O-(2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranosyl) trichloroacetimidate (72) 1H NMR, CDCl3, 500 MHz 
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O-(2,3,4-Tri-O-benzyl-6-deoxy-α/β-D-galactopyranosyl) trichloroacetimidate (72) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-hexacosanoylamido-octadec-4-ene (71) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-
2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-hexacosanoylamido-octadec-4-ene (71) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-
hydroxy-octadec-4-ene (5) 1H NMR, pyridine-d5, 500 MHz 
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(2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-
hydroxy-octadec-4-ene (5) 13C NMR, pyridine-d5, 125 MHz 
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(2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-
hydroxy-octadecane (6) 1H NMR, pyridine-d5, 500 MHz 
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(2S,3R,4E)-1-(4-O-(3-O-(6-Deoxy-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-2-hexacosanoylamido-3-
hydroxy-octadecane (6) 13C NMR, pyridine-d5, 125 MHz 
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(2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy- 
octadec-4-ene (98) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-2-Azido-1-(4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy- 
octadec-4-ene (98) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-2-azido-3-
benzyloxy-octadec-4-ene (94) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-2-azido-3-
benzyloxy-octadec-4-ene (94) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-2-azido-3-benzyloxy-octadec-4-ene (92) 1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-2-azido-3-benzyloxy-octadec-4-ene (92) 13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-dodecanoylamido-octadec-4-ene (100) 
1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-dodecanoylamido-octadec-4-ene (100) 
13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-2-Dodecanoylamido-1-(4-O-(3-O-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-3-hydroxy-
octadec-4-ene (7) 1H NMR, pyridine-d5, 600 MHz 
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(2S,3R,4E)-2-Dodecanoylamido-1-(4-O-(3-O-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-3-hydroxy-
octadec-4-ene (7) 13C NMR, pyridine-d5, 125 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-
galactopyranosyl)-2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-(11Z,14Z-eicosadienoylamido)-octadec-4-ene (101) 
1H NMR, CDCl3, 500 MHz 
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(2S,3R,4E)-1-(4-O-(4-O-Acetyl-2,6-di-O-benzoyl-3-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-β-D-galactopyranosyl)-
2,3,6-tri-O-benzoyl-β-D-glucopyranosyloxy)-3-benzyloxy-2-(11Z,14Z-eicosadienoylamido)-octadec-4-ene (101)  
13C NMR, CDCl3, 125 MHz 
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(2S,3R,4E)-2-(11Z,14Z-Eicosadienoylamido)-1-(4-O-(3-O-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-3-
hydroxy-octadec-4-ene (8) 1H NMR, pyridine-d5, 600 MHz 
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(2S,3R,4E)-2-(11Z,14Z-Eicosadienoylamido)-1-(4-O-(3-O-α-D-galactopyranosyl)-β-D-galactopyranosyl)-β-D-glucopyranosyloxy)-3-
hydroxy-octadec-4-ene (8) 13C NMR, pyridine-d5, 150 MHz 
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